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Abstract  
 
Asthma is a significant public health burden with 5.4 million people in the UK 
currently receiving treatment for the condition. Exercise induced bronchoconstriction 
(EIB) is a term used to describe an acute asthmatic episode following exercise and is 
highly prevalent amongst asthma sufferers. Traditional treatment involves the use of 
pharmacological interventions, the long-term use of which can have significant side 
effects and reduced efficacy in athletic populations. The purpose of this thesis was to 
initially establish a reproducible means of measuring bronchoconstriction in asthmatics 
through an experimental model of EIB termed hyperpnoea induced bronchoconstriction 
(HIB), and then investigate the use of dietary supplements to treat HIB and suppress 
markers of airway inflammation.  
Accordingly this thesis investigated: (i) the test-retest reproducibility of the 
bronchoconstrictive response to eucapnic voluntary hyperpnoea in physically active 
asthmatics and non-asthmatics, (ii) the effects of omega 3 polyunsaturated fatty acid 
supplementation dose level (6.2 g·d
-1
 vs 3.1 g·d
-1
) on the severity of hyperpnoea 
induced bronchoconstriction, and (iii) the effects of prebiotic trans-
galactooligosaccharide (B-GOS) supplementation on severity of hyperpnoea induced 
bronchoconstriction and inflammatory markers in physically active asthmatics. 
It was found that eucapnic voluntary hyperpnoea incorporating real-time visual 
feedback of minute ventilation  V̇E) and end-tidal PCO2 yielded a smallest meaningful 
change of 88 mL highlighting a highly reproducible bronchoconstrictive response over 
both short- term (21 days) and long-term (70 days) periods, in physically active 
asthmatics with HIB. No between-day differences in the bronchoconstrictive response 
xx 
 
as measured by both absolute drop in forced expiratory volume in one second (FEV1, 
mL) and the percentage change in FEV1 (%ΔFEV1) following the eucapnic voluntary 
hyperpnoea protocol in the asthmatic participants were evident. Subsequently EVH was 
deemed a suitable technique for monitoring the effectiveness of treatment interventions.  
This thesis shows for the first time that lower doses of ω3-PUFA (3.1 g·d-1) are 
equally as effective as higher doses (6.2 g·d
-1
) in reducing the severity of hyperpnoea 
induced bronchoconstriction in recreational athletes.  Maximum reductions in FEV1 at 
day 0 of 28 ± 87%, and -27 ± 17%, had improved to -19 ± 15%; and -18 ± 14% for the 
6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions respectively. Both ω3-PUFA 
interventions resulted in equal reductions of up to 30% in resting levels of exhaled nitric 
oxide, and equal suppression up to 44% in inflammatory maker urinary 9α, 11β-PGF2 
concentration following the eucapnic voluntary hyperpnoea challenge. These data 
highlight that lower ω3-PUFA doses represent a potentially beneficial treatment for 
physically active asthmatics suffering with HIB whilst reducing the burden of cost, 
compliance and potential for gastrointestinal distress.  
A highly novel finding of this thesis was that a 21 day intervention of a prebiotic 
galactooligosaccharide (B-GOS) markedly improved the severity of 
bronchoconstriction in HIB participants, with %ΔFEV1 improving by up to ~40%. This 
occurred in conjunction with reduced markers of airway inflammation including serum 
concentrations of TNF-α (reduced by 36%), CCL17 (reduced by 22%), and C-reactive 
protein (reduced by 11%) in the HIB participants. For the first time this suggests that 
favourable manipulation of the commensal bacteria within the gut by B-GOS will 
influence immune regulation and inflammatory responses and could prove to be a novel 
therapeutic target for asthma and HIB.  
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It is attractive to speculate that combinations of ω3-PUFA, prebiotics, and 
probiotics could prove to be novel therapies for a range of asthma phenotypes and other 
respiratory diseases. Furthermore there is scope to develop a greater understanding into 
the mechanisms behind the effectiveness of the gut microflora as a therapeutic 
treatment option for inflammatory airway diseases.  
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1. Chapter 1 – General Introduction 
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1.1. Introduction and Rationale 
 
Asthma is a highly prevalent chronic inflammatory disorder of the airways that 
affects both adults and children of all ages. It is the most common chronic disease 
among children and young adults, with one in four developing asthma before the age of 
40 (To, et al. 2012, To, et al. 2010). The condition results in variable airflow 
obstruction in susceptible individuals but can be reversed with appropriate therapy or 
spontaneously. Individuals will suffer from symptoms that include, wheezing, 
breathlessness, coughing, and tightness in the chest (Sears 2008). There is a high 
heterogeneity in asthma symptoms and severity, and individuals will respond 
differently to the variety of possible triggers such as dry cold air, exercise, pollen, upper 
respiratory tract infections, pollution, cigarette smoke, and respiratory allergens 
(Douglas, et al. 2008). Asthma has a considerable health cost associated with it and, in 
the UK, the NHS spends £1 billion each year on asthma treatment for 1.1 million 
children (1 in 11) and 4.3 million adults (1 in 12) (Asthma UK Accessed on 
12.06.2013). The prevalence of asthma has increased considerably over recent decades; 
the World Health Organisation suggests that there are 300 million patients with asthma 
globally, and this is expected to increase to 400 million by 2025 (Pawankar, et al. 
2011). The rise in prevalence has been suggested to be in line with changes in 
environment and lifestyle associated with western living rather than genetic alterations 
(Beasley, et al. 2000, Platts‐Mills, et al. 2005, Daley 2014).  
There is high heterogeneity in asthma severity which has led to the recent 
concept that there are multiple phenotypes of asthma or groupings of characterisation 
(Wenzel 2013). Due to these varying phenotypes, difficulty remains in defining the 
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pathophysiology of asthma. It is commonly thought that a combination of airway 
smooth muscle (ASM) contraction, excess mucous production, and inflammation are 
the main symptoms associated with exacerbations (Anderson and Daviskas 2000, 
Anderson and Kippelen 2005b, Anderson and Kippelen 2005a). Airway inflammation is 
associated with a variety of leukocytes including eosinophils, mast cells, macrophages, 
neutrophils, and lymphocytes including B cells, T cells and natural killer cells. These 
inflammatory cells produce a number of inflammatory mediators that are thought to be 
key contributors to asthma. These include prostaglandins, leukotrienes, cytokines, 
histamine, and eicosanoids (Anderson and Kippelen 2005a).  
Exercise induced bronchoconstriction (EIB) is a phenotype of asthma that is 
characterized by a transient narrowing of the airways during or on the cessation of 
exercise (McFadden Jr and Gilbert 1994, Anderson and Holzer 2000, Suman, et al. 
1999). It is estimated that up to 90% of individuals with asthma and 10 to 50% of a 
given elite athletic population can experience EIB (Naguwa, Afrasiabi and Chang 
2012). With such a high prevalence in the asthmatic population there is a clinical, 
quality of life and economic need to understand the best methods for managing EIB. 
Standard management techniques for EIB are pharmacological with the use of short 
acting and long acting bronchodilators (β2-agonists), inhaled corticosteroids and 
leukotriene modifiers. For the elite athlete, there are number of restrictions imposed by 
the World Anti-Doping Agency (WADA). The 2012 prohibited list states that all β2-
agonists (including both optical isomers where relevant) are prohibited except 
salbutamol, a short-acting β2-adrenergic receptor agonist (limited to maximum of 1600 
micrograms over 24 hr), and formoterol a long-acting β2 agonist (maximum 36 
micrograms over 24 hr). All oral or intravenous glucocorticosteroids are prohibited and 
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a therapeutic use exemption certificate is required for these. In addition to the WADA 
restrictions, another limitation is that the chronic use of these drugs can cause systemic 
side effects (reduced bone mineral density, increased airway hyper responsiveness) 
along with degenerative changes to the respiratory system (Dahl 2006, Anderson, et al. 
2006). Research has also shown that EIB in some athletes may not respond well to 
pharmacologic prophylaxis (Sue-Chu, et al. 2000) and over 50% of asthmatics are 
poorly controlled due to poor adherence (Barnes 2010). Furthermore, traditional 
pharmacological treatment such as β2-agonists only target symptoms rather than 
treatment of the underlying disease and inflammation. The limitations of the current 
treatments for asthma highlight the importance of novel therapeutic strategies to target 
underlying asthmatic and immune responses to help improve disease control and 
efficacy.  
Over the past 15 years research has been reported to support the concept that 
diet is a contributory environmental factor to the increase in asthma prevalence (Allan 
and Devereux 2011). Adverse changes in diet have been shown to contribute to both an 
increase in prevalence and severity of asthma (Smit, Grievink and Tabak 1999, 
Shaheen, et al. 2001, McKeever and Britton 2004, Devereux and Seaton 2005). It has 
been hypothesised, for example, that the rise in asthma prevalence over the latter half of 
the 20
th
 century could be related to decreasing omega-3 polyunsaturated fatty acid (ω3-
PUFA) intake, and increased consumption of dietary omega-6 PUFA (ω6-PUFA) 
(Devereux and Seaton 2005). Consequently it seems plausible that favourable dietary 
manipulation may influence asthma and EIB severity.  
Further to these dietary influences, a reduction in the microbial diversity of the 
human microbiome in western societies as a result of changes in diet, reduced exposure 
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to infections and pathogens, and increased antibiotic use may also be involved (Wills-
Karp, Santeliz and Karp 2001). Both the human gastrointestinal tract and airways are 
home to unique colonies of commensal bacteria, the composition of which can 
influence inflammation and immune homeostasis. Murine models and human studies of 
airway diseases such as asthma and cystic fibrosis show sufferers of these diseases have 
altered airway and gut microflora when compared to healthy controls (Madan, et al. 
2012, Sagar, et al. 2014). Evidence is now accumulating that favourable manipulation 
of the gut microflora through dietary interventions of pre- and probiotics can influence 
immune function (Lomax and Calder 2009, Roberfroid, et al. 2010), and consequently 
affect airway inflammation associated with asthma (Sagar, et al. 2014). Furthermore, 
manipulation of the gut microflora through a combination of dietary pre- and probiotics 
has been shown to alter the commensal bacteria of the airways in cystic fibrosis 
(Madan, et al. 2012).  
In relation to asthmatics suffering with EIB, a number of studies have shown 
that manipulation of diet through supplementation with ω3-PUFA can attenuate the 
characteristic reduction in pulmonary function, and increase in airway inflammation 
following bronchial provocation challenges (Mickleborough, et al. 2003, 
Mickleborough, et al. 2006, Tecklenburg-Lund, et al. 2010). In addition, a number of 
research studies suggest that favourable manipulation of the gastrointestinal microbiota 
through pre- and probiotics can improve lung function and reduce asthmatic episodes 
during the course of supplementation (Gutkowski, et al. 2010). These research findings 
highlight the need to gain a greater understanding into the use of dietary supplements 
for managing EIB in active asthmatic individuals. 
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1.2. Research aims  
The purpose of the series of studies was to investigate the following research questions  
 
I. What is the reproducibility of the bronchoconstrictive response to eucapnic 
voluntary hyperpnoea (EVH) in physically active asthmatics and non-
asthmatic controls? 
The research aims were to:  
 Determine the test-retest reproducibility of the bronchoconstrictive response to 
EVH in physically active asthmatics. 
This will allow for greater confidence when tracking changes in the 
management of hyperpnoea induced bronchoconstriction in response to 
treatment interventions. 
 
II. Previous research has demonstrated the effects of very high ω3-PUFA doses 
on EIB; it is of interest therefore to understand how effective a lower dose 
may be in managing EIB. A randomised, double blind, placebo controlled 
cross-over study was conducted to compare the effectiveness of two doses (6.2 
g·d
-1
 vs 3.1 g·d
-1
) of omega-3 polyunsaturated fatty acid (ω3-PUFA) on 
hyperpnoea induced bronchoconstriction and markers of airway 
inflammation in physically active asthmatics. 
The research aims were to evaluate: 
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 The effectiveness of a lower ω3-PUFA dose on hyperpnoea induced 
bronchoconstriction in physically active asthmatics when compared to a 
previously documented higher dose. 
 Establish the immunomodulatory effects of 6.2 g·d-1 and 3.1 g·d-1doses of ω3-
PUFA by assessing markers of airway inflammation in physically active 
asthmatics. 
 
III. A novel management approach for influencing airway inflammation 
associated with hyperpnoea induced bronchoconstriction in asthmatics may be 
through favourable manipulation of the gut microflora. A randomised, double 
blind, placebo controlled cross-over study to establish the effectiveness of 
prebiotic trans-galactooligosaccharide (B-GOS) on HIB and markers of 
airway inflammation was conducted.  
The research aims were to evaluate: 
 The use of B-GOS in managing the severity of hyperpnoea induced 
bronchoconstriction in physically active asthmatics. 
 If B-GOS can favourably alter the levels of inflammatory markers associated 
with airway inflammation in physically active asthmatics. 
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2. Chapter 2 – Review of Literature 
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2.1. Exercise Induced Asthma  
The first record of exercise induced asthma was reported in ~120-200 AD by Aretaeus, 
who noted that physical exertion could provoke airway obstruction (Adams 1856). Exercise 
induced asthma (EIA) refers to the transient narrowing of the airways that occurs after 
vigorous exercise in up to 80% of asthmatics (Anderson and Daviskas 1997) and is 
characterised by symptoms of coughing, wheezing, shortness of breath and chest tightness 
primarily on the cessation of exercise. It is associated with airway obstruction and reduced 
pulmonary function. There are two common terms used to describe airway narrowing 
associated with exercise: EIA and exercise induced bronchoconstriction (EIB). EIA is used 
to describe the exacerbation of an individual’s asthma when they exercise (Storms 2003) 
whereas the term exercise induced bronchoconstriction is used to describe the airway 
narrowing occurring after exercise in individuals with and without a clinical diagnosis of 
asthma (Anderson and Henriksen 1999). It has been stated that the term EIA should no 
longer be used because exercise does not induce asthma, but rather it is a trigger of 
bronchoconstriction (Weiler, et al. 2007).  For the purpose of this thesis the term EIB will 
encompass both of these definitions.   
 
2.1.1. Prevalence of Exercise Induced Bronchoconstriction  
Exercise induced bronchoconstriction is a condition that can affect people at any level 
of exercise, from children to Olympic athletes (Mahler 1993). Bronchoconstriction 
following exercise has been documented since the second century (Rundell and Jenkinson 
2002) and exercise will trigger asthma in most individuals with chronic asthma and in some 
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individuals who do not have asthma (Weiler 1996). Asthma has been an increasing public 
health issue over the past 40 years and affects a significant proportion of the global 
population. The World Health Survey states that on a global scale the prevalence rate of 
doctor diagnosed asthma is 4.3% (To, et al. 2012). In 2004, the Global Initiative for 
Asthma (GIBA) combined data from the Phase 1 International Study of Asthma and 
Allergies (ISAAC) collected from 1992-1996 and the European Community Respiratory 
Health Survey (ECRHS) from 1988-1994 to generate a global estimate of asthma burden. 
The report estimated that 300 million people worldwide have asthma, and projected that 
this number would increase to 400 million by 2025, as countries develop. In the UK, 5.4 
million people are currently receiving treatment for asthma this amounts to 1.1 million 
children (1 in 11) and 4.3 million adults (1 in 12) (Asthma UK Accessed on 12.06.2013). 
The data highlight the global burden of asthma and the increase in prevalence in western 
societies. Thus if the occurrence of asthma is increasing, there will be an associated rise in 
the prevalence of EIB.  
Asthma and airway hyperreposnsiveness are amongst the most common chronic 
medical conditions reported by Olympic athletes with a prevalence of 7-8% (Kippelen, et 
al. 2012) although large variations exist between sports (Fitch 2012). In the general 
population up to 80% of clinically recognised asthmatics can experience EIB (Anderson 
and Holzer 2000). The prevalence of EIB has been reported in a non-elite population of 
230 middle and high school athletes (11 – 18 years old) from a range of sports (Rupp, Guill 
and Brudno 1992). Following the completion of an exercise challenge, 29% of the athletes 
were identified as EIB positive based on a post-exercise drop in FEV1 of greater than 15%; 
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all had been previously undiagnosed (Rupp, Guill and Brudno 1992). This study documents 
the prevalence in sub-elite athletes however with greater training loads associated with elite 
level sport it may predispose a greater risk of EIB in this population. Elite athletes have 
been shown to have a greater prevalence of airway hyper-responsiveness compared to a 
control population (Langdeau, et al. 2000). The athletes had a 49% prevalence of airway 
hyperresponsiveness compared with 28% of the sedentary participants (P = 0.009).  
Within elite sportsmen and women there has been a steady increase in the number of 
athletes reporting symptoms associated with EIB. Reports from a screening programme 
organised by the US Olympic Committee found that 57 out of 597 (9.5%) American 
Olympic Athletes in the 1984 summer games reported suffering from EIB or asthma (Voy 
1986). A high prevalence of asthma was also reported at the 1996 Olympic Games. Six 
hundred and ninety nine athletes completed a medical history questionnaire, 107 reported 
(15.3%) a previous diagnosis of asthma, 97 (13.9%) recorded the use of asthma medication 
at some time in the past, and 73 (10.4%) of the athletes were currently taking medication. 
One hundred and seventeen (16.7%) reported the use of asthma medication, a diagnosis of 
asthma, or both (Weiler, Layton and Hunt 1998). These studies show both prevalence and 
medication usage amongst elite athletes is high. Critically these two studies are solely 
questionnaire based, and no attempts were made to verify or assess EIB by any other forms 
other than symptoms alone. A diagnosis of EIB through symptoms alone has been shown 
to be unreliable (Rundell, et al. 2001a, Holzer, Anderson and Douglass 2002) and likely 
result in both false-positive and false-negative results. Many elite athletes have high 
thresholds for pain, and often view pain and discomfort as a normal part of training. 
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Therefore many may neither consider EIB as abnormal nor realise it can be detrimental to 
performance (Rundell, Wilber and Lemanske Jr 2002).  This suggests that elite athletes 
should be routinely screened for EIB using a suitable bronchial provocation challenge (See 
section  2.4).  
Using the bronchial provocation challenge of methacholine, 49% of 100 competitive 
athletes exhibited airway hyper-responsiveness compared to 28% of sedentary subjects 
(Langdeau, et al. 2000), highlighting the greater risk of EIB within an athletic population. 
The bronchial provocation challenge of eucapnic voluntary hyperventilation (EVH) has 
been shown to diagnose previously undiagnosed athletes (Dickinson, McConnell and 
Whyte 2011). With high prevalence rates amongst elite athletes this has led to a 
concomitant rise in the use of β2-agonist medication. Of all the athletes competing in the 
2002 winter Olympic Games, 5.2% used inhaled β2-agonists and 4.2% in the 2004 Olympic 
Games (Anderson, et al. 2006, Anderson, et al. 2003, Fitch 2006). See section  2.5 for more 
details on pharmacological therapy.  
High prevalence’s of EIB have been reported in the Great Britain Olympic Teams at the 
2000 and 2004 Olympic Games.  Prior to the IOC requirement for bronchial provocation 
testing as evidence for asthma and EIB medical forms of the 2000 Team GB squad (152 
Male, 120 Female) assessed prevalence. 21.2% of the squad reported as suffering from 
asthma (Dickinson, et al. 2005). Prior to the 2004 Olympic Games, British athletes selected 
to compete in Team GB (165 men, and 106 women) were recruited for bronchial 
provocation testing. Athletes were only tested for asthma if they had a previous diagnosis 
of EIB, reported symptoms of EIB or were referred for testing by a team medical officer. 
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Diagnosis was made in accordance with the International Olympic Committee – Medical 
Commission requirements of a positive bronchodilator (increase in FEV1 of ≥ 15% 
following 200 µg of short-acting β2-agonist) or bronchoprovocation test (decrease in FEV1 
≥ 10% from the pre challenge value). Fifty six of the 271 (20.7%) athlete’s tested from the 
2004 Team GB received a positive diagnosis. Sixty two athletes had previously been 
diagnosed with asthma and were prescribed asthma medication; 13 of the 62 (21%) then 
failed to produce a positive test for asthma. The results show prevalence in elite-athletes is 
likely to be sport and environment dependent (Table 2. 1) with the highest rates reported 
amongst swimmers and cyclists, these studies highlight the need for continued monitoring 
and accurate diagnosis so correct support and medication can be offered to our elite 
athletes.  
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Table 2. 1 Prevalence of asthma in the British squads at the 2000 and 2004 Olympic Games. Reproduced 
with permission from Dickinson, et al. (2005). 
 2000  2004  
 N No (%) as asthmatic N No (%) as asthmatic 
Athletics 28 7 (25) 58 9 (16) 
Badminton 13 2 (15) 11 1 (9) 
Canoe/Kayak 12 1 (8) 9 1 (11) 
Cycling 27 12 (44) 23 9 (39) 
Diving 7 3 (43) 7 1 (14) 
Gymnastics 14 0 9 0 
Hockey 31 3 (10) 16 5 (31) 
Judo 10 2 (20) 8 1 (13) 
Rowing 41 8 (20) 36 7 (19) 
Sailing 17 0 18 0 
Shooting 6 0 6 1 (17) 
Swimming 41 17 (41) 36 16 (44) 
Triathlon 8 0 6 0 
Other 19 3 (16) 28 5 (18) 
Overall     
Men 152 29 (19.1) 165 34 (20.6) 
Women 122 29 (23.8) 106 22 (20.8) 
Total 274 58 (21.2) 271 56 (20.7) 
 
 
Some of the highest rates of EIB are found among winter sports athletes who may 
be chronically exposed to dry, cold air. Following assessment of medical history data and a 
methacholine challenge, plus two symptoms identified via medical history, asthma was 
found to be prevalent in 33 of 47 (70%) Swedish cross country skiers, compared to just 1 of 
29 non-skiing controls (Larsson, et al. 1993).  Sue-Chu et al. (1996) provided further 
evidence of the high prevalence of EIB in cross country skiers. Self-reported symptoms of 
asthma were prevalent in 46% of 118 Norwegian skiers, and 51% of 53 Swedish skiers. 
Following methacholine testing, 14% of the Norwegian skiers, and 43% of Swedish skiers 
suffered with airway hyperresponsiveness (Sue-Chu, Larsson and Bjermer 1996). The 
differences in bronchial hyperresponsiveness between the Norwegian and Swedish skiers 
   15 
 
were attributed to the differing geographical locations and subsequently greater exposure to 
cold air in the Swedish skiers. It has been suggested that the combination of demanding 
training at low temperatures and repeated inhalation of cold air may be a pathogenic factor 
in asthma in this population of athletes (Larsson, et al. 1993); it has been termed “ski 
asthma” and could be a normal physiological response to extreme environmental stimuli 
(Bjermer and Larsson 1996, Sue-Chu, et al. 1999). It has been suggested that cross country 
skiers are an extreme subtype of exercise induced asthmatics, and chronic exposure to cold 
dry air at high ventilation rates can lead to significant thickening of the bronchial sub-
epithelial basement membrane, which is similar to that seen in chronic asthmatics 
(Karjalainen, et al. 2000) 
Indoor winter sports competitors also experience a high prevalence of EIB and 
asthma like symptoms, and have been shown to have a great degree of small airway 
dysfunction (Rundell, et al. 2001a, Rundell, et al. 2001b). This high prevalence has been 
attributed to the inhalation of cold dry air and the high-emissions of pollutants from the ice 
resurfacing machines.  
Studies of endurance based summer sports also show a high prevalence of EIB. A 
prevalence of 15-23% has been reported in endurance and distance runners and has been 
associated with atopy, allergy, and asthma (Tikkanen and Helenius 1994, Helenius, et al. 
1998). Elite male and female distance runners who were initially classified as atopic (n=39) 
or non-atopic (n=19) based on skin prick tests of 10 airborne allergens were assessed for 
EIB. Lung function was assessed following an outdoor 2000 m run at 85% of their 
individual maximum heart rate during the winter season (mean temperature −6.6°C) and 
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during the summer pollen season (Helenius, Tikkanen and Haahtela 1998). FEV1 was 
measured immediately post, and at 4, 10, and 20 minutes post exercise. EIB (defined as a 
post exercise drop in FEV1 of 10%) was observed in 9% of the runners in either summer or 
winter. When the group’s mean change in FEV1 minus 2 standard deviations was taken as 
lower limit (a reduction of 6.5% or more in FEV1) 26% of runners had probable EIB in 
either the winter or pollen season.  A high proportion of long distance runners have been 
shown to suffer from asthma; 17% of long distance runners reported physician diagnosed 
asthma compared to 8% of speed and power athletes, and 3% of controls (Helenius, 
Tikkanen and Haahtela 1997).  For athletes competing and training in indoor swimming 
pools, the prevalence of EIB is also high, attributed to the chlorine compounds in 
swimming pools (Helenius and Haahtela 2000). In a sample of 738 swimmers, overall 
prevalence of EIB was 13.4%, in 165 competing at international level, 21% had EIB. The 
prevalence was less amongst the 537 lower level swimmers at 11.2% (Potts 1996), and 
therefore could be dependent upon training and competition intensity.  
It is clear that exercise induced asthma is highly prevalent amongst asthmatics and 
elite athletes. The increase in asthma prevalence over the last 30 years has been linked to 
environmental changes and improved hygiene with fewer children experiencing childhood 
infections (Umetsu, et al. 2002). However the specific early life infections that limit T-
helper type 2 (Th-2)-biased inflammation and asthma are not fully understood. Asthma can 
result from aeroallergen induced inflammation driven by Th-2 response and mediated by 
the cytokines IL-4, IL-5, and IL-13, as opposed to T-helper 1 cells which secrete IL-2 and 
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interferon-γ (Woodruff, et al. 2009, Barnes 2001). The airway cells and their mediators are 
discussed in section  2.2.2.  
Advances in optimal diagnosis and novel treatment methods aimed at athletic 
populations may help to reduce the burden of the condition and improve the management 
for these individuals.  
 
2.1.2. Theories for the pathogenesis of EIB 
There is still active debate on the acute mechanisms and pathogenesis of EIB. EIB has 
been described as an exaggerated airway response to airway dehydration in the presence of 
inflammatory cells and mediators. However, since the late 1970’s there has been 
considerable debate about the mechanisms involved and how exercise provokes airway 
narrowing in both asthmatic and non-atopic individuals. Two main hypotheses have been 
proposed; the ‘thermal hypothesis’ and the ‘osmotic hypothesis’. 
 
2.1.2.1. The Thermal Hypothesis as a mechanism for EIB 
The Thermal Hypothesis was a development of the earlier Airway Cooling Theory 
(Deal Jr, et al. 1979).  The authors of the Airway Cooling Theory concluded that the 
magnitude of EIB was directly proportional to the thermal load placed on the airways, and 
it was the level of heat loss that determined the severity of bronchoconstriction. The Airway 
Cooling Theory was revised to the Thermal Hypothesis that developed over two main 
studies (McFadden Jr 1990, Gilbert and McFadden Jr 1992).  The revision of the cooling 
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theory to thermal hypothesis considers that airway cooling alone is insufficient to produce 
bronchial narrowing and that rapid rewarming is essential for obstruction to develop. It 
suggests that a thermal gradient must be present at the end of exercise. According to the 
thermal hypothesis, EIB is a vascular event involving vasoconstriction resulting from 
airway cooling during exercise, followed by a reactive hyperaemia when the airways re-
warm on the cessation of exercise resulting in airway wall oedema (McFadden Jr 1990, 
McFadden Jr, Lenner and Strohl 1986). The subsequent narrowing of the airways is a direct 
response to these vascular events. The evidence came from a study that showed by 
preventing the airways from re-warming following exercise (breathing in cold air) the 
reduction in FEV1 was reduced from 25% to less than 10% in asthmatic participants 
(McFadden Jr, Lenner and Strohl 1986). McFadden and colleagues looked to strengthen the 
thermal theory in 1999 by comparing FEV1 before and after hyperventilation with either a 
warm or cold dry air to determine whether mucosal dehydration causes thermally induced 
asthma. Eight atopic-asthmatics performed isocapnic hyperventilation while breathing 
either dry cold (12.5 ± 2.7°C) or dry warm air (24.3 ± 0.7°C). FEV1 was measured pre and 
post each challenge, expired temperatures were continuously measured and water loss from 
the intrathoracic airways was calculated (Equation 1).  
WL = ([Wci – Wce] 
.
 VE 
.
 time) 
.
 0.5  
Equation 1. Water loss from the intrathoracic airways calculation Where WL is the volume of water lost to the 
environment in mg·L
-1
 air; Wci is the inspired water content in mg·L
-1
 air; Wce is the expired water content 
in mg·L
-1
; VE is minute ventilation in L·min
-1
; Time is the duration of the hyperventilation in minutes; and 
0.5 is the percentage of water lost from the intrathoracic airways.  
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The researchers reported that the decrement in FEV1 was significantly greater when 
breathing cold air compared to warm air (%∆ FEV1 cold at 8 min post = 30.0 ± 4.7%, 
warm = 16.0 ± 4.7%; p = 0.01). Despite greater reductions in FEV1 during the cold 
condition, water loss was significantly less when compared to the warm condition (WL cold 
at 8 min = 4.8 ± 0.4 g, warm at 8 min = 7.1 ± g; p = 0.001), suggesting the decrement in 
FEV1 was temperature dependent. The authors stated that during the cold condition FEV1 
decreased as water losses rose. However, the largest intrathoracic losses were associated 
with the smallest obstructive response (%∆ FEV1 cold at 8 min post = 30%, water loss = 
4.7 mg; %∆ FEV1 warm at 8 min post = 16%, water loss = 7.1 mg; p = 0.002). The authors 
concluded that the water loss associated with hyperpnoea may promote EIB through an 
effect on the cooling-rewarming gradient rather than through airway dehydration. These 
conclusions supported previous work into the thermal hypothesis (McFadden Jr, Lenner 
and Strohl 1986, Gilbert, Fouke and McFadden Jr 1987). Early work by Gilbert and 
colleagues in 1987, found that after participants had cycled for 4 minutes breathing cold air 
(−16 ± 2°C), on cessation the airstream temperature increased rapidly, rising twice as fast 
in asthmatics when compared to non-asthmatic controls. They concluded that a reaction 
sequence consisting of vasoconstriction and airway cooling during exercise followed by a 
rapid re-supply of heat when exercise ceases was occurring, suggesting that a rebound 
hyperaemia may lead to airway oedema and EIB.  
The thermal hypothesis assumes that an increase in the intra-airway temperature 
reflects an increase in the blood flow of the airways and that this provides a significant 
source of heat to the airways in rewarming them on cessation of exercise (Gilbert, Fouke 
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and McFadden Jr 1987). This theory has been challenged, with reports that changes in 
airway temperature are the result of a prolonged warming of the air in the alveoli as a 
consequence of flow limitations in asthmatics (Anderson and Daviskas 2000). Further, 
bronchial circulation is a very limited source of heat replenishment for the airways (Solway 
1990), and represents only 1% of total cardiac output. Fundamental to the thermal 
hypothesis is the concept of vasoconstriction causing a reduction in bronchial blood flow. 
Vasoconstriction is an unlikely response to inhaling hot dry air, and data from animal 
studies (Baile, et al. 1987) and humans (Agostoni, et al. 1990) demonstrate that there is an 
increase in blood flow, rather than a reduction when dry air is inspired. Those that 
developed the initial cooling and thermal theories (McFadden Jr, Lenner and Strohl 1986, 
McFadden Jr, et al. 1999, McFadden 1983) have acknowledged that bronchial blood flow 
increases with dry air hyperpnoea and have formally revised the thermal hypothesis. The 
theory now recognises that airway cooling associated with hyperpnoea will provoke an 
increase in bronchial blood flow in humans and is thought to regulate thermal losses and 
prevent tissue damage (McFadden Jr, et al. 1999, Kim, et al. 1996).  
Bronchial circulation cannot be ruled out, and it has the potential to contribute to 
the pathogenesis of EIB. Bronchial circulation is an important source of water for the 
airways, and increases in osmolality of the airways causes an increase in circulation 
(Zimmerman and Pisarri 2000). The increase in bronchial circulation would not just 
increase the delivery of water to dehydrated airways in response to an osmotic stimulus, 
but would also aid in the clearance of bronchoconstrictive mediators (See section  2.2.1).  
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Previous research has produced findings that may not be explained by the Thermal 
Hypothesis. Severe EIB has still occurred whilst individuals have been inspiring hot dry air 
(Aitken and Marini 1985, Anderson, et al. 1985) for example. Twenty out of twenty two 
asthmatic children recorded EIB after cycling for 8 minutes whilst inspiring hot (32-40°C) 
and dry (3-10 mg H20
.
L-
1
) air (Anderson, et al. 1985). Ten asthmatic adults exercised and 
recovered whilst breathing air at 36°C in an environmental chamber, yet they still had a 
mean fall in peak expiratory flow of 43% ± 18% (Hahn, et al. 1984). In another study, ten 
asthmatics and 10 control participants were exposed to 7 air conditions varying in 
temperature (−2 to 49°C) and relative humidity (10 to 100%). The authors concluded that 
dehydration and changing osmolality of the airways determined the level of 
bronchoconstriction as opposed to the thermal exchange (Aitken and Marini 1985).  
Inhalation of hot dry gases has been shown to facilitate airway cooling too. It is 
thought that heat loss of the airways will always occur as a normal part of respiration and 
develops whenever the inhaled air requires transfer of heat and moisture to condition it 
(Zawadski, Lenner and McFadden Jr 1988).  The Thermal Hypothesis cannot explain early 
findings that EIB severity was greatest when cold air (-10°C) was inspired both during and 
importantly for 4 minutes after exercise (Deal Jr, et al. 1979). In addition the Thermal 
Hypothesis does not implicate any involvement of the release of pro-inflammatory 
mediators in EIB. If pro-inflammatory mediators were not involved then pharmacological 
treatments (see section  2.5) that reduce inflammation would be of no benefit.  These 
findings are not compatible with the concept that the development of obstruction occurs 
due to cooling and rapid rewarming as proposed by the Thermal Hypothesis. In summary, 
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the weaknesses in the Thermal Hypothesis are that it does not include a role for bronchial 
smooth muscle, or inflammatory mediators in the mechanism of EIB. 
In reviewing the Thermal Hypothesis literature there may be a number of errors in 
the research. The McFadden studies may have underestimated the level of water loss 
occurring within the airway so misjudged the importance of airway dehydration in EIB. 
Moreover, the authors assumed that the expired air was fully saturated at its exiting 
temperature. Such assumptions have been questioned. Eschenbacher and Sheppard (1985) 
undertook studies of asthmatic subjects performing hyperpnoea of dry air at -20°C and 
+39°C. They found difficulties when measuring the expired air temperature when it was 
inspired at -20°C, as at -20°C, expirate would freeze and then condense on the 
thermocouple dampening the response time of the thermocouple. To overcome this, the 
authors completely separated the inspired and expired airstreams and measured both water 
and temperature during cold air hyperpnoea. The technical difficulties associated with 
measuring expired air temperature and water loss are likely to result in the very low 
expired air temperatures reported in the McFadden et al (1999) paper (Freed, et al. 2000). 
The alternative hypothesis is the Osmotic Hypothesis. This was proposed as a result of the 
failures of the thermal hypothesis to fully elucidate the mechanisms behind EIB. 
 
2.1.2.2. The Osmotic Hypothesis as a mechanism for EIB 
The Osmotic Hypothesis was developed after the finding that subjects with EIB 
were sensitive to inhalation of hypertonic saline solutions (Schoeffel, Anderson and 
Altounyan 1981). A fall in FEV1 of 20% or more in response to inhalation of 3.6% saline 
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and distilled water was observed in patients with asthma, but no response observed in non-
asthmatics (Schoeffel, Anderson and Altounyan 1981). Importantly it was found that 
varying the temperature of the inhaled solution from 22°C to 30°C did not change the 
response (Schoeffel, Anderson and Altounyan 1981). More recently, it has been supported 
by the findings that cold air inhalation does not influence the severity of EIB after exercise 
or eucapnic voluntary hyperpnoea (Evans, et al. 2005). The authors suggested that cold air 
inhalation or rapid rewarming was not necessary to elicit bronchoconstriction. The 
similarities in the response to these challenges are consistent with the hypothesis that 
hyperventilating dry isocapnic/eucapnic air induces asthma via alterations in the osmolality 
of the airway surface liquid. Further development arose after marked similarities were 
reported in the airway response to both hyperpnoea of dry air and hypertonic aerosols 
(Smith and Anderson 1986, Smith and Anderson 1989). The lowest FEV1 as a percentage 
of predicted after isocapnic hyperventilation was 45% ± 16% and after inhalation of 
hypertonic saline was 51% ± 18% (r = 0.93) (Smith and Anderson 1989). More recently, 
hyperosmolarity has been shown to release inflammatory mediators from eosinophils and 
mast cells contributing to the development of EIB (Broide, et al. 1992, O'Sullivan, et al. 
1998, Moloney, et al. 2003). 
The osmotic hypothesis first proposed in 1984 (Anderson 1984) has changed little 
since, with the exception of the addition of the involvement of the epithelial cells in 1989 
(Anderson, Daviskas and Smith 1989), and the inclusion of the submucosa in signalling 
bronchial blood flow (Anderson and Daviskas 1992). Initial evidence showed that the 
severity of EIB was directly proportional to the water content of the inspired air  (Strauss, 
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et al. 1978) and that when water loss is prevented by inhalation of humid air at body 
conditions, even severe EIB could be prevented (Strauss, et al. 1978, Anderson, et al. 
1982). Anderson et al (1982) suggested that bronchoconstriction induced by water loss 
from the airways during exercise may be due to changes in the osmolality of the surface 
liquid in the respiratory tract. With the calculation of the airway surface liquid (ASL) 
volume to be less than 1 mL in the first 10 generations of airways, it gave further support 
and focus for the Osmotic Hypothesis (Anderson 1984) (Figure 2. 1). This very low volume 
causes the osmolality of the ASL to change rapidly in response to water loss and 
dehydration through exercise hyperpnoea and evaporation or deposition of hypertonic 
aerosol particles.  
 
Figure 2. 1 Generation of airways adapted from (Anderson 1984) 
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Following this research, additional evidence from canine models showed that 
vasodilation of the tracheal circulation occurred as a result of hypertonic solutions 
perfusing into the trachea (Deffebach, et al. 1989). This indicates that vasodilation and an 
increase in blood flow can occur independently of thermal events, but as a direct response 
to increased osmolality of the ASL. Data from human studies highlight the inability of the 
human airways to maintain a fluid balance during the breathing of warm air (Tabka, et al. 
1988). Tabka et al (1988) showed that whilst exercising and breathing warm dry air, the 
expired air de-saturates to 80% and the water content falls to 29 mg·L
-1
 when measured by 
mass spectrometry. They suggested that this shows both dehydration of the airway mucosa 
and importantly an increase in osmolality of the ASL. Accurate collection and 
measurement of the ASL in terms of both volume and osmolality is difficult and has not 
been achieved. The development of the hypothesis would serve to explain several 
observations about EIB, namely why both intensity and duration of hyperpnoea are 
important determinants of the response.  
Measurements of the intra-airway temperature have been reported (Gilbert, Fouke 
and McFadden Jr 1987) and were then subsequently used to analyse the magnitude of water 
lost from the trachea down to the fifth generation of airways (Anderson, Daviskas and 
Smith 1989). This analysis showed that the airway surface could become dehydrated within 
a few minutes even if the water loss is low (1 mg·L
-1
). Dehydration of the trachea could 
occur very rapidly as it has been shown that there is less than 68 mg of ASL to cover it, 
causing the epithelial cells to become dehydrated within five minutes (Anderson and 
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Daviskas 1992). Mathematical models highlight the possibility there may be significant 
dehydration of the airway epithelial cells due to water moving from them to restore the 
ASL in response to changes in the osmotic gradient (Daviskas, Gonda and Anderson 1990, 
Daviskas, Gonda and Anderson 1991). This has been supported in human epithelial cells in 
vitro in response to hyperosmotic stimulus (Matsui, et al. 2000). The authors state that 
normal epithelial cells have relatively high water permeability and thus have a capacity to 
restore water on the airway surface that may be lost from dehydration.  
The osmotic hypothesis is often favoured because it enables an explanation for 
many of the established facts about EIB, including contributions from inflammatory 
mediators and airway smooth muscle contraction. Data has accumulated in support of the 
osmotic hypothesis and it is of interest to note that only one study to date has refuted the 
osmotic hypothesis (McFadden Jr, et al. 1999) (See section  2.1.2.1).   
 
2.1.2.3. Reconciling the hypotheses for mechanism for EIB 
An attempt was made to reconcile these two theories in 2000 by Anderson and 
Daviskas. They concluded that inspiration of cold and dry air during intense exercise 
causes not only cooling of the airway, but also increases the hyperosmolar area and 
dehydrates the airway surface (Anderson and Daviskas 2000). It is clear from the above 
research that there is a high prevalence of EIB respiratory symptoms in elite athletes that 
can be explained by the dehydrating effects of intense exercise on the small airways. 
During moderate exercise only 10 to 12 generations of airways are needed to condition the 
inspired air. However, during intense exercise or when breathing cold air, the smaller 
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airways (< 1.0 mm in diameter) are recruited in an attempt to condition the air (Anderson 
and Daviskas 2000). The recruitment of these small airways may be the critical determinant 
for the vasculature to contribute to airway narrowing. The involvement of the small 
airways may be necessary for some subjects to achieve a clinically positive airway 
response to exercise (>10% fall in FEV1) (Anderson and Kippelen 2005a); for others it will 
just enhance their response.  
These small airways may actually undergo injury due to the significant dehydration 
and increases in osmolality that can occur in subjects who exercise intensely for prolonged 
periods breathing dry and/or cold air. In addition, airway injury may also result from 
repeated and prolonged exposure to pharmacologic and physical agents and irritants 
(Anderson and Holzer 2000). As a result of the airways being exposed to these conditions, 
they may become inflamed, and airway smooth muscle can become more sensitive, also 
leading to airway injury and remodelling; these events are likely to lead to an exaggerated 
response to dehydration in asthmatic athletes. There is a wealth of research to suggest that a 
cooling of the airways followed by a rapid re-warming may not be essential for the 
development of EIB (Deal Jr, et al. 1979, Aitken and Marini 1985, Anderson, et al. 1985, 
Hahn, et al. 1984, Evans, et al. 2005, Sheppard and Eschenbacher 1984). It seems essential 
that sufficient water loss must occur to cause the airway surface to become dehydrated. The 
thermal theory and osmolality theory merge with the proposal that cold air breathing may 
enhance the airway response to exercise because the surface area involved in the air 
conditioning process increases and as a results, very small airways could be subjected to 
injury from dehydration (Anderson and Kippelen 2008).  
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In the past 10 years, the focus of the literature has moved away from understanding 
the acute effects of exercise on the mechanisms of EIB and shifted to gaining a greater 
understanding of the overall pathogenesis of EIB and airway injury. The shift in focus is 
concurrent with an increase in the number of individuals reporting EIB, who are otherwise 
healthy, and exercise regularly both competitively and non-competitively (Anderson and 
Kippelen 2005a).  This greater frequency is even more evident in athletes performing 
endurance sports especially in challenging environmental conditions (Rundell, et al. 2001a, 
Langdeau and Boulet 2001, Fitch, et al. 2008). This increased prevalence concurs with a 
notable rise (320%) in the notification of use of inhaled β2-adrenoceptor agonists before 
exercise in athletes between the 1984 and 2000 summer Olympic Games (Anderson, et al. 
2003).  
The acute events that lead to EIB, in both classic asthma and the athlete are 
depicted below (Figure 2. 2). EIB is most commonly reported in people with clinically 
recognized asthma shown on the left in yellow. In clinically diagnosed asthmatics EIB 
stems predominantly from airway dehydration and increases in osmolality associated with 
the Osmotic Hypothesis. The right of the diagram (green area) highlights the multifactorial 
events that can lead to EIB in athletes, including non-atopic athletes. The severity of EIB in 
the non-atopic athletes on the right is determined by the ventilation reached and sustained 
during exercise, and the water content of the air inspired during exercise. The diagram 
reconciles the Osmotic and Thermal Hypotheses with the presence of the airway 
dehydration (red), and cooling (blue), with the addition of airway injury in the athlete 
(orange).   
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Figure 2. 2 Flow chart depicting acute events leading to EIB, in classic asthmatic (yellow) (left) and progression in the athlete (green) (right). Orange 
shows the role of the osmotic hypothesis, and blue the role of the thermal hypothesis. Adapted from (Anderson and Kippelen 2005a). 
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2.2. Pathophysiology of Asthma and EIB 
Understanding of the pathogenesis of asthma has changed dramatically with 
time. Records dating back to 1500BC, indicate that asthma was considered to be a 
disease caused by “spirits” (Salvi, Suresh Babu and Holgate 2001). It wasn’t until 1678 
that asthma was first described as a disease rather than purely a symptom, when 
Thomas Willis (17th century English Physician) described asthma to be due to 
“obstruction of bronchi by thick humors, swelling of their walls and obstruction.” The 
role of contraction and spasm of the bronchial smooth muscle was first suggested by Sir 
John Floyer in 1698 (Sakula 1984). With the advent of fiberoptic bronchoscopy in the 
1970s and the use of modern molecular biology, it became clear that asthma was a 
chronic inflammatory disorder mediated by a multitude of cell types and inflammatory 
mediators (Salvi, Suresh Babu and Holgate 2001). Figure 2. 3 depict the structural 
changes occurring in the airways during an asthma exacerbation. It is characterised by 
airway narrowing with constriction of the bronchial smooth muscle, increased mucus 
production, and inflammation resulting in decreased lumen diameter.  
 
Figure 2. 3 Structure and physiological changes characteristic of an asthma exacerbation (NHLBI) 
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Figure 2. 4  a) normal lung tissue; b) lung tissue with characteristics during an asthma exacerbation, 
showing increased mucus production from goblet cells, infiltration of mast cells, macrophages, 
eosinophils, and neutrophils into the lamina propria, and increased thickness of the basement membrane 
and smooth muscle. Adapted from OpenStax College (07/08/2013). 
 
Asthma and EIB are now well recognised as inflammatory borne conditions, 
with significant contributions from inflammatory cells of the immune system that 
infiltrate the walls of the bronchi and bronchioles during an asthma exacerbation 
(Figure 2. 4) these include eosinophils, mast cells, and macrophages. As described by 
Rundell and Jenkinson (2002) the symptoms of EIB are merely the ‘tip of the iceberg’ 
and reflect remodelling and inflammation of the airways (Figure 2. 5).  
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Figure 2. 5 The ‘asthma iceberg’ schematically illustrates airway inflammation and remodelling as 
underlying cause of AHR, airflow limitation and symptoms presented by EIB (Rundell and Jenkinson 
2002). 
 
Exercising individuals have a need to humidify and warm a high volume of 
inspired air. The dehydrating and osmotic effects of this respiratory water loss are 
thought to stimulate the release of a number of pro-inflammatory mediators.  It has been 
proposed that it is the regulatory volume increase, after cell shrinkage that is the key 
event leading to the release of pro-inflammatory mediators (Anderson and Daviskas 
2000). There is potential that all cells could be subjected to cell volume loss including 
the epithelial cells, mast cells, eosinophils, macrophages, and sensory nerve cells. The 
airways are narrowed by contraction of bronchial smooth muscle in response to the 
mediators; the effect will be amplified if airway oedema is present (Anderson and 
Daviskas 2000).  The influx of mediators leads to airway inflammation, with EIB 
regarded as an inappropriate inflammatory response.  
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2.2.1. The immune system and inflammation 
The immune system is comprised of a network of cells, proteins, tissues, and 
organs that coordinate to defend the body against attacks from foreign elements. The 
immune system can be viewed as a series of organs that are distributed throughout the 
body to provide the human with defence against pathogens wherever these may enter or 
spread (Janeway, et al. 2001). An immune response is generally divided into innate and 
adaptive immunity. Innate immunity occurs immediately, when circulating innate cells 
recognize a problem. Adaptive immunity occurs later, as it relies on the coordination 
and expansion of specific adaptive immune cells. Immune memory follows the adaptive 
response, when mature adaptive cells, highly specific to the original pathogen, are 
retained for later use. An important part of the adaptive immune system aside from the 
lymphatic system and spleen is the mucosal immune system, termed the mucosal 
associated lymphoid tissue (MALT) (Janeway, et al. 2001). The mucosal surfaces of the 
body are located at sites that make them particularly vulnerable to infection. They are 
thin permeable barriers between the exterior and interior of the body, and include the 
lungs, the gut, eyes, nose, mouth and throat, and uterus and vagina. The primary 
function of the immune system is to maintain homeostasis (see section  2.3 for specific 
details on the intestinal immune system).  
Homeostasis is achieved through the recognition and then elimination of 
harmful stimuli such as pathogens followed by the repair and removal of damaged or 
abnormal tissue. When the cellular elements of the immune system are challenged by 
harmful stimuli there is the local response of inflammation.   
Inflammation is generally manifested by the accumulation of fluids and blood 
cells at the point of tissue damage, and is largely a reaction of blood vessels (Horwitz 
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and Busse 1995). Acute inflammation is a short-term response that usually results in the 
infiltration of leukocytes to the damaged region, removal of the stimulus, and repairing 
of the damaged tissue. In contrast, chronic inflammation is a prolonged, deregulated 
and defective response that involves active inflammation, tissue destruction and 
attempts at tissue repair (Weiss 2008). Persistent inflammation is associated with 
chronic conditions and diseases such as allergy and asthma.  
While a controlled inflammatory response is thought to be beneficial in 
providing protection against infection for example, it can become detrimental if 
dysregulated (e.g. septic shock). At a basic level, the acute inflammatory response is 
coordinated by the delivery of blood components (plasma and leukocytes) to the site of 
injury and inflammation (Robbins, Kumar and Cotran 2003). This response is triggered 
by receptors of the innate immune system, such as Toll-like receptors (TLRs) and NOD 
(nucleotide-binding oligomerization-domain protein)-like receptors (NLRs) (Barton 
2008). This initial recognition is mediated by tissue-resident macrophages and mast 
cells, leading to the production of a variety of inflammatory mediators (Medzhitov 
2008), including cytokines (see section  2.2.3), eicosanoids (see section  2.2.5) and 
chemokines (see section  2.2.4), all of which have been implicated in asthma and EIB.  
The main and most immediate effect of these mediators is to elicit a local inflammatory 
exudate of plasma proteins and leukocytes (primarily neutrophils). These are normally 
restricted to the blood vessels but the exudates components now gain access to the 
extravascular tissues at the site of infection or injury through the post-capillary venules. 
The activated endothelium of the blood vessels allows selective extravasation of 
neutrophils while preventing the exit of erythrocytes (Medzhitov 2008). This selectivity 
is afforded in part by chemokine receptors on leukocytes, which occurs at the 
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endothelial surface, as well as in the extravascular spaces (Pober and Sessa 2007). 
When the leukocytes reach the afflicted site, the neutrophils become activated either by 
direct contact with pathogens, or through the actions of cytokines secreted by tissue-
resident cells.  
A successful acute inflammatory response results in the elimination of the 
infectious agent, or successful repair of the physical damage. The switch in lipid 
mediators from pro-inflammatory prostaglandins (section  2.2.5.2) to lipoxins which are 
anti-inflammatory is crucial for the transition from inflammation to resolution 
(Medzhitov 2008). Lipoxins inhibit the recruitment of neutrophils, and instead, promote 
the recruitment of monocytes which remove dead cells and initiate tissue remodelling 
(Serhan and Savill 2005). Resolvins and protectins (see section  2.2.5.3), which 
constitute another class of lipid mediator, transform growth factors produced by 
macrophages, and play a crucial role in the resolution of inflammation, including the 
initiation of tissue repair (Serhan and Savill 2005, Serhan, Yacoubian and Yang 2008).  
If the acute inflammatory response fails to eliminate the pathogen or repair the 
damaged tissue, the inflammatory process persists. Neutrophil infiltration is replaced 
with macrophages, and in some instances T cells. If the combined effect of these cells is 
still insufficient, a chronic inflammatory state can occur (Medzhitov 2008). Persistent 
asthma is characterised by chronic inflammation of the bronchial mucosa, with high 
levels of circulating T cells and eosinophils (Corrigan and Kay 1990).  
The view of asthma has changed from one primarily involving smooth muscle 
contraction to one of complex interactions between inflammatory mediators and 
effector cells (Horwitz and Busse 1995).  Pathologic evidence for inflammation in 
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asthma was observed in early autopsy specimens of patients who died from ‘status 
astmaticus’ (a prolonged and severe asthma attack that does not respond to treatment) 
(Ellis 1908, Huber and Koessler 1922, Messer, Peters and Bennett 1960). These 
included hypertrophy of the airway smooth muscle, thickening of basement membrane, 
mucous deposition in the terminal bronchioles with glandular hyperplasia, and the 
presence of inflammatory cells. The inflammatory infiltrate was shown to compose of 
mainly eosinophils as well as neutrophils, lymphocytes, and mononuclear cells (Messer, 
Peters and Bennett 1960).  These early autopsy studies led to the belief that 
inflammation represented a terminal event in severe asthma, however more recent 
understanding is that inflammation is not restricted to severe asthma, but rather is a 
general characteristic of asthma (Horwitz and Busse 1995). Bronchoalveolar lavage 
(BAL) collections give further insights into the inflammatory basis of asthma, with 
increased percentages of eosinophils, mast cells, and epithelial cells in asthmatics 
compare to non-atopic non-asthmatic controls. In addition increases in activated T-cell 
populations have been consistently noted in asthma (Salvi, Suresh Babu and Holgate 
2001). 
T helper cells (Th cells) are critical to coordinating the activity of the immune 
and inflammatory response; they orchestrate the immune response by controlling T-cell 
subsets, B-cells and innate immune responses. The T helper cell response is defined by 
two distinct pathways involving two subtypes of Th cells; Th-1 and Th-2 cells. It is 
thought that immune regulation involves a homeostasis between Th-1 and Th-2 cells. 
Th-1 cells drive cellular immunity to fight viruses and other intracellular pathogens, 
eliminate cancerous cells, and stimulate delayed hypersensitivity skin reactions.  
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It is known that a deregulated Th-2 response overwhelms the protective 
mechanisms that normally develop to prevent asthma, with an increased production of 
pro-inflammatory cytokines (see section  2.2.3). This inappropriate Th-2 response 
causes pulmonary inflammation, airway eosinophilia, mucus hypersecretion and airway 
hyperreactivity to a variety of stimuli (including allergens and airway dehydration) 
(Umetsu, et al. 2002). Cytokines play an integral role in the coordination of the 
inflammatory processes associated with asthma. Solely Th-2 mediated cytokines is an 
oversimplification of the pathogenesis of asthma and EIB. There are additional 
mediators in the form of lipid derived eicosanoids, including prostaglandins (PGs), 
leukotrienes (LTs), and lipoxins (LXs), which have important roles in the 
pathophysiology of asthma (Drazen 1998) (see section  2.2.5).  
Th-2 cells drive humoral immunity and up-regulate antibody production (Kidd 
2003). Over-expression of either can cause disease and either pathway can down-
regulate the other. The Th-2 pathway is often thought to underlie allergy, atopy and 
immunoglobulin-E based diseases (Kidd 2003). However, the specific conditions and 
changing environments that are responsible for driving the development of Th-2 
immune responses are not clear. 
One of the main key effector cells in asthma are eosniophils, but their role in 
EIB remains less clear. Eosinophilic granulocytes are attracted and activated at the site 
of inflammation by chemokines which are proteins of the cytokine family, and these 
play another mediating role in asthma (Lukacs, Oliveira and Hogaboam 1999, Lukacs 
2001) (see section  2.2.4). Synthesis of leukotrienes occurs in mast cells, eosinophils, 
basophils, monocytes, macrophages, and other airway cells. There is strong evidence 
that mast cells release the mediators histamine, cysteinyl leukotrienes and 
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prostaglandins following exercise and are released into the airways during EIB (Rundell 
and Jenkinson 2002, Mickleborough, Lindley and Ray 2005, Hallstrand, et al. 2005).  
 
2.2.2. Airway Cells and Inflammation in EIB 
Many different inflammatory cells are involved in asthma, although the precise 
role of each cell type is not certain (Barnes 1996), and a number are associated with 
EIB. Mast cells are purported to be the most important in regards to mediator release 
within the airways; in addition, elevated cell counts of T-lymphocytes, macrophages, 
neutrophils and eosinophils have been made and thus increase eicosanoid and cytokine 
release into the airways during EIB of asthmatic individuals (Rundell and Jenkinson 
2002, Hallstrand, et al. 2005). The issue is whether these cells are merely markers of 
chronic airway inflammation, or if they have a relationship with the acute response 
associated with EIB. The significance of mast cells is that they are likely to be 
important in the pathogenesis of EIB in both asthmatic and non-asthmatic EIB 
individuals. Mast cell mediator release can occur by immuno-globulin (Ig) E-allergen-
induced activation as well as by non-IgE-dependent stimuli such as dry cold air (Togias, 
et al. 1985, Togias, et al. 1988). This is an important point if mast cells are involved in 
airway hyperresponsivenes (AHR) in both asthmatics and non-atopic EIB sufferers.  
Induced sputum collected from EIB positive asthmatics and EIB negative 
asthmatics has been compared for its cellular constituents (Hallstrand, et al. 2005). The 
total volume of the induced sputum was higher for the EIB positive group, compared to 
the EIB negative group (7.7 vs 3.4 mL, p = 0.003). The concentrations of eosinophils, 
and columnar epithelial cells were found to be greater in the EIB positive group 
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compared to the EIB negative group (Table 2. 2 ). Alterations in epithelial permeability 
may be responsible for the higher volume of induced sputum in positive EIB 
asthmatics. Disruption of the airway epithelium also increases the transit of 
granulocytes into the airways (Erjefält, et al. 2004).  Significantly higher percentages of 
eosinophils and higher levels of serum eosinophilic cationic protein have been found in 
EIB-positive asthmatics than in non-EIB controls (Yoshikawa, et al. 1998). 
 
Table 2. 2 Cellular findings in induced sputum from EIB positive and EIB negative asthmatics data 
expressed as median (interquartile ranges). ¥ Mann-Whitney U Test; ‡Inflammatory cells and columnar 
epithelial cells expressed as % of nonsquamous epithelial cells; § squamous epithelial cells expressed as 
percentage of total cells; ¤ unclassified cells Adapted from Hallstrand, et al. (2005) 
 
 
Asthma 
 P Value ¥ 
EIB Positive (n=10)  EIB Negative (n=10) 
Percentage      
Eosinophils ‡ 2.07 (0.58-3.49)  0.44 (0.00-1.49)  0.123 
Lymphocytes ‡ 1.50 (0.78-4.36)  1.20 (0.88-1.74)  0.353 
Macrophages ‡ 36.89 (26.02-51.44)  43.80 (16.14-52.22)  1.000 
Neutrophils ‡ 36.20 (24.40-56.41)  35.29 (28.50-64.86)  0.579 
Columnar epithelial cells ‡ 7.07(3.65-14.35)  2.43 (1.40-10.16)  0.143 
Squamous epithelial cells § 18.51 (10.41-25.70)  34.99 (14.46-46.49)  0.19 
Other cells ¤ 4.77 (3.15-8.42)  7.226 (3.56-10.14)  0.393 
Concentration (X 10
4
)      
Eosinophils ‡ 3.58 (12.06-68.71)  0.49 (0.00-1.10)  0.043 
Lymphocytes‡ 2.73 (0.90-7.38)  0.99 (0.63-2.27)  0.105 
Macrophages ‡ 49.63 (23.18-119.01)  22.59 (15.05-65.88)  0.123 
Neutrophils ‡ 45.33 (23.60-127.58)  44.03 (14.35-69.73)  0.247 
Columnar epithelial cells ‡ 13.70 (5.91-20.13)  2.91 (1.78-7.65)  0.011 
Squamous epithelial cells 32.42 (20.43-62.47)  38.62 (15.15-70.03)  0.912 
Other cells ¤ 6.68 (3.52-17.62)  5.60 (3.67-10.05)  0.579 
 
 
The bronchial epithelium is favourably situated where gene-environment and 
environment-environment interactions can occur. The airway epithelium acts as the 
barrier between the external environment and the internal body and airways. It is 
continuously exposed to gases and particulates from the external environment and as 
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such is involved in many of the reactions that lead to airway inflammation and smooth 
muscle contraction. When the airways are exposed to infectious agents, inhaled 
pollutants, and particulates the epithelium acts as the protective barrier. During 
exercise, in an attempt to equilibrate the inspired air to a humidity and temperature of 
the lower airways, heat and water are transferred out of the airways. At the airway 
epithelium there is a transfer of water from osmotically sensitive epithelial cells; these 
osmotic stimuli are known to directly activate inflammatory mast cells (Gulliksson, et 
al. 2006). In addition, the stimulus of exercise or hyperpnoea is also sensed by the 
airway epithelium leading to the activation of inflammatory mediator release from 
leukocytes in close contact to the epithelium (Hallstrand 2012). Induced sputum 
suggests that asthmatics who suffer from EIB have a disrupted epithelium with 
increased shredding of epithelial cells into the airway lumen (Hallstrand, et al. 2005, 
Hallstrand and Henderson 2009). In addition, the intensity of cellular airway 
inflammation and the generation of the inflammatory eicosanoids and cytokines have 
been associated with susceptibility to EIB. Increased urinary eicosanoid and serum 
cytokine concentrations are associated with a more severe EIB response to an exercise 
challenge in asthmatics (Mickleborough, et al. 2003, Mickleborough, et al. 2006).  
Airway inflammation associated with asthma, and allergic asthma is 
multifaceted but Th-2 cells are important in driving the processes and are mediated by 
the inflammatory cytokines IL-4, IL-5, and IL-13. The “Th2 hypothesis for asthma” 
was first suggested by Mosmann in 1989 (Mosmann and Coffman 1989), who earlier 
had discovered the presence of two distinct subtypes of helper T cells called Th-1 and 
Th-2 (Mosmann, et al. 1986). The two subclasses of helper T cells differ in their 
production of cytokines and are reciprocally inhibitory. Th-2 lymphocytes produce IL-
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4, IL-5, IL-9, and IL-13, which are active in allergic airway inflammation whereas Th-1 
produce interferon γ (IFN- γ) and IL-2 which activate mechanisms important in defence 
against viruses and bacteria (Mosmann and Coffman 1989). The Th-2 hypothesis 
suggests that asthma is caused by a relative increase in Th-2 cellular response in 
combination with a decrease in Th-1 response. The subsequent alterations in cytokine 
milieu within the lung with excess Th-2 products in conjunction with decreased Th-1 
products are predicted to drive the asthma phenotype (von Hertzen and Haahtela 2000).  
Additional cells of both the adaptive and innate immune systems are the 
dendritic cells (DCs). DCs primarily initiate and maintain adaptive Th-2 cell responses 
to inhaled allergens in asthma (Lambrecht and Hammad 2009). They are antigen 
presenting cells as part of the adaptive immune system, and immature dendritic cells, or 
dendritic cell precursors are key components of the innate immune system. DCs bridge 
the innate and adaptive immunity (Hammad and Lambrecht 2008) associated with 
asthma, but physical stimuli (exercise and dry air) can modify and exacerbate the 
disease. These exacerbating factors interfere with the innate immune system and 
homeostasis of the lung structural cells. Subsequently it is increasingly appreciated that 
asthma is more than a disorder of the adaptive immune response, but is influenced by 
pattern recognition of the innate immune cells such as the bronchial epithelial cells, 
mast cells, and basophils. The lung possess an elaborate network of DCs found 
throughout the conducting airways, lung interstitium, vasculature, pleura, and bronchial 
lymph nodes (GeurtsvanKessel and Lambrecht 2008). DCs perform a unique function 
in the pulmonary immune response recognizing inhaled antigens through expression of 
pattern-recognition receptors such as Toll-like receptors and NOD-like receptors. These 
recognise virtually any inhaled pathogen, allergen, or substance to produce the cascade 
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of immune response (Barrett, et al. 2009). Additionally lung DCs express numerous 
receptors for inflammatory mediators that are released upon damage or trauma to the 
airways to further enhance the immune response. DCs are primarily associated with 
allergen induced asthma, with little research to suggest a direct link to the onset of EIB 
following exercise in asthmatics. However, DCs are shown to respond and be recruited 
into inflamed airways in response to a variety of stimuli (McWilliam, et al. 1996).  The 
drying of the airway surface liquid and changes in osmolality of the airways that is 
characteristic of EIB (see section  2.1.2.2) results in a cascade of inflammatory 
mediators that may too be interacting with the DCs.  
 
2.2.3. Cytokines in Asthma and EIB 
The word ‘cytokine’ originates from the Greek word ‘cyto’ meaning cell and 
‘kine’ meaning movement. They are simple peptides, proteins or glycoproteins (Akira 
et al. 1993). Cytokines are regarded as a catalyst for cell-cell communication, which can 
also include growth factors, and cytokines with chemoattractant properties 
(chemokines) (see section  2.2.4). They act on target cells to cause a wide array of 
cellular functions including activation, proliferation, chemotaxis, immunomodulation, 
release of other cytokines or mediators, growth and cell differentiation, and apoptosis 
(Chung and Barnes 1999).  
When cytokines are produced they influence target cells. The type of target cell 
provoked by a particular cytokine is determined by the type of specific receptor on its 
surface. The term ‘autocrine regulation’ is used when the receptor is present on the 
surface of the same cell that produces the cytokine (Figure 2.6A). Alternatively, the 
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target receptor may be present only on the surface of another cell. If the target cell 
resides close to the producer cell this is termed ‘paracrine regulation’ (Figure 2.6B). 
Also, a producer cell can exert its actions on target cells that reside in distant parts of 
the body or in other tissues or organs; this is termed ‘endocrine regulations’ (Figure 
2.6C).  
 
Figure 2. 6 Cytokine regulation, (A) autocrine regulation; (B) paracrine regulation; (C) endocrine 
regulation. Reproduced with permission from (Mills 2013).  
 
The airway inflammation underlying asthma is regulated in part by a network of 
mutually interacting cytokines. The exact functional role of each individual cytokine in 
the pathogenesis of asthma remains to be fully established. The effect of an individual 
   44 
 
cytokine in the context of disease may not be easy to predict because it can be 
influenced by other cytokines released simultaneously by the same cell or from other 
target cells. Many cytokines play an integral role in the coordination and persistence of 
the inflammation process within the airways in asthma and they are capable of inducing 
many pro-inflammatory effects characteristic of the disease (Chung and Barnes 1999). 
Ultimately they contribute to the release of mediators such as cys-LTs, airway 
remodelling, bronchoconstriction, and bronchial hyperresponsiveness. Each cytokine 
will have varying roles in the development of these processes and can be evaluated by 
studying their properties, presence in the airway walls, and secretions in patients 
suffering from asthma. Cytokines such as tumour necrosis factor-α (TNF-α) are 
increased in response to exercise (Mickleborough, et al. 2003), with TNF-α specifically 
involved in inducing airway hyperresponsiveness (Anderson and Kippelen 2005a). 
Within the range of cytokines produced as part of airway inflammation associated with 
EIB, TNF-α has specifically received attention when assessing EIB in athletes in 
response to dietary interventions. In addition to this, recent evidence also suggests a key 
component to the initialisation of pro-inflammatory states is interleukin-33 (IL-33).    
 
2.2.2.1. Tumour necrosis factor-alpha (TNF-α) 
The cytokine tumour necrosis factor-alpha (TNF-α) has been implicated in both 
asthma and EIB (Mickleborough, et al. 2003, Mickleborough, et al. 2006, Bradding, et 
al. 1994). Bronchial mucosal biopsies taken from asthmatic individuals have shown a 
seven fold increase in the number of mast cells staining for TNF-α compared to non-
asthmatic controls, suggesting that TNF-α is up-regulated in asthma (Bradding, et al. 
1994). Circulating concentrations of TNF-α were assessed prior to, and following an 
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exercise challenge test in ten clinically diagnosed EIB participants, and ten controls. 
Within the EIB group, there was a significant increase in plasma concentrations of 
TNF-α following the exercise challenge, peaking 60 minutes after the challenge 
compared to no increases in the control group (Mickleborough, et al. 2003). 
Importantly, TNF-α concentration was significantly reduced following dietary 
intervention of high dose omega-3 polyunsaturated fatty acids in these EIB participants, 
and was associated with improvements in pulmonary function following an exercise 
challenge compared to placebo (Mickleborough, et al. 2003).  
 
2.2.2.2. Interleukin-33 (IL-33) 
Classically, T cell derived Th-2 cytokines such as IL-4 and IL-5 have been 
implicated in asthma (Bradding, et al. 1994, Doucet, et al. 1998, Shi, et al. 1998); in 
addition it is now recognised that IL-33 also plays an important contribution to allergic 
responses and asthma (Prefontaine, et al. 2009). IL-33 is a recently described member 
of the interleukin-1 family of cytokines, and is expressed by many cells following a 
pro-inflammatory stimulation. It is widely expressed by T helper 2 cells and mast cells, 
both of which have been implicated in the pathogenesis of EIB (Wenzel 2013) 
(Section  2.2.2). It is thought to function as an alarm following cell necrosis to alert the 
immune system to tissue damage or stress (Miller 2011). It mediates its biological 
effects via interaction with receptors (ST2 and IL-1RAcP), which are widely expressed 
by innate immune cells and Th2 cells.  Importantly IL-33 strongly induces Th2 cytokine 
production and can promote the pathogenesis of Th2 diseases such as asthma (Miller 
2011). The gut and the lungs appear to be prominent IL-33 expressing organs and IL-33 
mRNA expression is found in multiple tissue related cells. Importantly initial gene 
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expression studies in a range of tissues revealed expression of IL-33 in lung tissue and 
high expression in bronchial smooth muscle cells (Schmitz, et al. 2005, Smith 2010). 
Further studies to investigate which cells are the main IL-33 responsive cells in the lung 
demonstrated that bronchial epithelial and endothelial cells were important (Yagami, et 
al. 2010). Released IL-33 from these tissue cells could provide a local signal to sustain 
the accumulation and effector function of innate inflammatory mediators to exacerbate 
conditions further.  
IL-33 exerts its cytokine activity through a signalling receptor known as ST2. 
ST2 is expressed predominantly on immune cells that are associated with allergic and 
asthmatic inflammation (Section  2.2.2). The concentration of serum ST2 is significantly 
increased in asthmatics following an exacerbation (Oshikawa, et al. 2001). Furthermore, 
the serum ST2 levels during the asthma exacerbations were statistically correlated with 
the percentage predicted peak expiratory flow. The results highlight that serum ST2 (as 
a marker of IL-33 activity) may be related to Th2 mediated inflammation during acute 
exacerbations in atopic asthmatics (Oshikawa, et al. 2001). Research is beginning to 
show that IL-33 mediates its biological effects via ST2 and subsequently drives the 
production of Th2 associated cytokines both in vitro and in vivo, this leads to 
pathological changes in mucosal organs such as the lungs (Schmitz, et al. 2005).  
In a murine model of ovalbumin induced airway inflammation, intranasal 
administration of IL-33 induces antigen specific IL-5 T cells, furthermore it also 
increases airway hyper-responsiveness, goblet cell hyperplasia, eosinophilia, and 
accumulation of IL-4, IL5, and IL-13 in the airways (Kondo, et al. 2008, Stolarski, et al. 
2010)  
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Bronchial biopsies from asthmatics have been reported to have an increased IL-
33 expression when compared to controls and further supporting the importance of 
TNF-α, this cytokine has been shown to increase up-regulation of IL-33 in vitro 
(Prefontaine, et al. 2009). Furthermore, traditional asthma treatment of inhaled 
corticosteroid has been shown to completely suppress some inflammatory cytokines, 
but not IL-33 (Yagami, et al. 2010). This suggests that additional treatment methods 
that influence IL-33 activity are warranted considering the role of IL-33 in asthma. 
 
2.2.4. Chemokines in Asthma and EIB 
Chemokines are a large family of peptide chemotactic mediators that control 
leukocyte migration to the site of inflammation and subsequent activation. As described 
in section  2.2.2, asthma is characterized by an infiltration of primarily mononuclear 
cells (lymphocytes and macrophages) and eosinophils. The ability to control leukocyte 
infiltration into the lungs is viewed as a key regulator of disease severity (Lukacs 2001), 
and so the expressions of chemokines are a key marker of asthma severity (Lukacs, 
Oliveira and Hogaboam 1999).  The expression of distinct chemokines within the 
airways raises the prospect that specific profiles of chemokines may mediate various 
stages or phenotypes of asthma; no specific chemokine profile of EIB is currently 
known. Chemokines bind to G-protein coupled serpentine receptors and are divided into 
two main groups on the basis of their sequence homology and the position of the first 
two cysteine residues, CxC (alpha), and CC (beta) (Rossi and Zlotnik 2000). There are 
6 known CXC chemokine receptors and ten known CC chemokine receptors. To date, 
16 CxC ligands (CxCL1-16) and 28 CC ligands (CCL1-28) have been identified (Table 
2. 3).   
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Table 2. 3 Chemokines and their receptors – recreated from (Lukacs 2001) 
Chemokine Receptor Ligands (CCL or CxCL) Cellular expression of receptor 
CC Family   
CCR1 CCL3, 7, 9, 15, 16, 23 D, DC, E, M, N, NK, MC, T 
CCR2 CCL2, 7, 8, 12, 13 BA, DC, EC, F, M, MC, NK, N, 
SM, T 
CCR3 CCL5, 7, 8, 11, 13, 24, 26 BA, E, EP, T 
CCR4 CCL17, 22 BA, DC, M, T 
CCR5 CCL3, 4, 5 DC, M , NK, T 
CCR6 CCL20 B, DC, N, NK, T 
CCR7 CCL19, 21 B, NK, T 
CCR8 CCL1, 16, 17 N, NK, T 
CCR9 CCL25 T 
CCR10 CCL27, 28 B, M, T 
CxC Family   
CxCR1 CxCL1, 7, 8 E, EC, MC, N, NK 
CxCR2 CxCL1, 2, 3, 5, 6, 7, 8 E, EC, MC, N 
CxCR3 CxCL9, 10, 11 E, EC, NK, T 
CxCR4 CxCL12 DC, NK, M, T 
CxCR5 CxCL13 B, M, T 
CxCR6 CxCL16 T 
B, B Cell; BA, basophil; DC, dendritic cell; E, eosinophil; EC, endothelial cell; EP epithelial cell; F, fibroblast; M, 
monocyte/macrophage; MC, mast cell; N, neutrophil; NK, natural killer cell; SM, smooth muscle; T, T cell.  
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Many of the CC ligands, and CxC ligands had multiple names, but their 
nomenclature has now been standardised (Table 2. 4) (Rossi and Zlotnik 2000, Zlotnik 
and Yoshie 2000). As eosinophils are implicated in the pathophysiology of asthma, 
research has tended to focus primarily on chemokines that have chemotactic activity for 
eosinophils.  Chemokines such as CCL5 (RANTES), CCL7 (MCP-3), and CCL13 
(MCP-4), have been identified in the airways of asthmatics. These three chemokines are 
associated with eosinophil recruitment through the CCR3 receptor which is highly 
expressed in eosinophils (Powell, et al. 1996, Stellato, et al. 1997). The airway 
epithelium also produces high levels of chemokines namely CCL5, CCL11, and CCL13 
(Stellato, et al. 1997, Wang, et al. 1996, Taha, et al. 1999). This high level of 
chemokine expression may favourably signal eosinophils to the asthmatic airways. 
Subsequent degranulation of these cells will lead to the release of mediators at the site 
of inflammation. These same chemokines can also influence other asthma related 
leukocyte cells such as basophils and Th2 lymphocytes (Lukacs 2001).  
Lymphocytes that are activated in the lymph node are recruited into the 
asthmatic airways. The T helper cells produce an array of Th2 cytokines (IL-4, IL-5, 
and Il-13), see section  2.2.3 for further details. The Th2 mediated cell response results 
in the production of a characteristic subset of chemokines that include CCL11, CCL13, 
CCL22, CCL1, and CCL17 (Sekiya, et al. 2000, Andrew, et al. 1998) and induces Th2 
lymphocyte migration through specific receptors (CCR4, CCR8, and CCR3). The 
continued activation of these cells induces pathophysiological dysfunctions associated 
with asthma such as excess mucous production (Lukacs 2001).  
  
   50 
 
Table 2. 4 Standardised nomenclature for chemokines and their receptors. Adapted from (Zlotnik and 
Yoshie 2000).  
New 
nomenclature 
Abbreviation Common (full) name Receptors 
CCL1 TCA3 T-cell activation-3 CCR8 
CCL2 MCP-1 Monocyte chemotactic protein-1 CCR2 
CCL3 MIP-1α Macrophage inflammatory protein-1α CCR1, CCR5 
CCL5 RANTES Regulated on activation, normal T cell 
expressed and secreted 
CCR1, CCR3, 
CCR5 
CCL7 MCP-3 Monocyte chemotactic protein-3 CCR1, CCR2, 
CCR3 
CCL11  Eotaxin CCR3 
CCL13 MCP-4 Monocyte chemotactic protein-4 CCR2, CCR3 
CCL17 TARC Thymus and activation-regulated chemokine CCR4, CCR8 
CCL22 MDC Macrophage-derived chemoattractant CCR4 
CCL24  Eotaxin-2 CCR3 
CCL26  Eotaxin-3 CCR3 
CxCL8 Il-8 Interleukin-8 CxCr1, CxCr2 
CxCL12 SDF-1 Stromal-derived factor-1 CxCr4 
 
With evidence of EIB in asthmatic individuals being associated with 
eosinophilic airway inflammation (Lee, et al. 2006), it highlights the potential role of 
eosinophil chemo attractant chemokines in the manifestation of the condition. Research 
suggests that local and systemic expression of the CC ligand chemokines such as 
CCL11 (eotaxin), CCL5 (RANTES), and CCL17 (TARC), are increased in patients 
with asthma (Lilly, et al. 1999, Kalayci, et al. 2004). Research also shows a significant 
rise in chemokine levels following marathon running (Ostrowski, et al. 2001).  Plasma 
concentrations of CCL3 and CxCL8  peaked 0.5 h after the run and where 3.5-fold, and 
4.1-fold higher than pre marathon levels. Although the authors did not investigate EIB, 
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it suggests that following exercise there is an increase in circulating levels of 
chemokines which could contribute to the exacerbation of EIB post exercise in 
asthmatics. In support of a potential role of chemokines in EIB; in vitro hyperosmolar 
challenges which cause changes in osmolality of the airways similar to that seen in 
exercise result in an increased release of CxCL8 from human bronchial epithelial cells 
(Gon, et al. 1998, Hashimoto, et al. 1999). Therefore this suggests that the osmotic 
changes that occur in asthmatic airways following exercise can result in increased 
chemokine release from the bronchial epithelial cells.  
The exact role of individual chemokines in EIB has not been fully elucidated. 
The chemokine response of CCL5, CCL11, and IP-10 to a standardised exercise 
challenge in asthmatic children (aged 6 – 17 years) have been assessed (Tahan, et al. 
2006). The authors found that the exercise challenge did not induce any significant 
changes in plasma chemokine levels despite a positive reduction in FEV1 (> 10% 
reduction) in 50% of the children. Correlation analysis showed that in children with a 
positive exercise response (> 10% reduction in FEV1 post exercise) there was a weak 
inverse correlation between eosinophil counts and CCL11 levels (r = −0.616; P = 0.01), 
and a stronger inverse correlation between FEV1 and CCL17 (r = −0.865; P = 0.001). 
This suggests that systemic CCL17 values may be one factor in determining the 
severity of EIB in children with asthma, with an association to the reduction in FEV1. It 
is possible that the level of bronchoconstriction exhibited by the children in Tahan et al. 
(2006) (maximum Δ%FEV1 of −17.9%) was too little to see a significant increase in 
circulating systemic chemokines and may not reflect changes taking place in the local 
environment of the lung following exercise.  Taking measurements directly from the 
lung in the form of exhaled breath condensate (EBC) has provided more robust 
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evidence for the role of CCL5 and CCL11 in EIB (Zietkowski, et al. 2009, Zietkowski, 
et al. 2011).  
Asthmatics with EIB had significantly higher CCL5 concentration in EBC 
collected during the first 24 h after an exercise challenge. Additionally there was a 
significant correlation between the maximum increase in CCL5 concentration following 
exercise with baseline FeNO, bronchial hyperreactivity to histamine, and also an 
increase in serum eosinophil cationic protein or FeNO 24 h after the exercise in the EIB 
asthmatics (Zietkowski, et al. 2009). The increased expression of CCL5 in EIB 
asthmatics, signifies greater levels of migration and activation of inflammatory cells 
including eoisnophils to the inflamed airways in asthmatics with EIB.  
Similar results were found when investigating CCL11. Twenty seven asthmatics 
(17 with EIB, 17 without EIB) cycled for 9 minutes at an intensity of 85% of age 
predicted heart rate maximum; spirometery, EBC, and FeNO were assessed pre and 
post the exercise challenge. Bronchial provocation with a histamine challenge was also 
performed 24 h before and 24 h after the exercise test. In the asthmatics with EIB a 
statistically significant increase in CCL11 concentrations in EBC collected during the 
first 24 h after the exercise test with a maximum increase at 6 h was reported 
(Zietkowski, et al. 2011). Significant correlations between maximum increase in 
CCL11 concentrations in EBC after exercise, and an increase in both eosinophil 
cationic protein and FeNO 24 h after exercise in asthmatic EIB group was seen. These 
results highlight the connection between EIB and increased expression of chemokines 
associated with eosinophil migration; and as such are a potential marker for EIB 
severity.  
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2.2.5. Eicosanoids  
The discovery of the eicosanoids dates back to the 1930s, when they were first 
isolated from human seminal plasma (Goldblatt 1935), and the prostate gland (Von 
Euler and Bergstrom). Eicosa means twenty in Greek, and the eicosanoids are lipid 
derived signalling molecules that are generated primarily through an oxidative pathway 
from arachidonic acid (AA), but also from the pathways originating from 
eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) (Harizi, Corcuff and 
Gualde 2008) (Figure 2.7).  At sites of inflammation the production of eicosanoids are 
considerably increased, and their biosynthetic pathways are of particular clinical 
relevance because their products are involved in the pathology of diseases related to 
immune function and inflammatory conditions including asthma (Wan and Wu 2007, 
Wang and DuBois 2010). Eicosanoids generated from AA are generally considered to 
be pro-inflammatory, where as those generated from EPA and DHA are considered to 
be less pro-inflammatory, even anti-inflammatory, and possess inflammatory resolving 
properties (see section  2.2.5.3).  
The generation of inflammatory based eicosanoids are dependent upon the 
availability of free arachidonic which is associated with dietary intake of omega-6 
polyunsaturated fatty acids (see section  2.6.1.3). When tissues are exposed to 
physiological and pathological stimuli such as growth factors and hormones, 
arachidonic acid is liberated from membrane phospholipids by the action of 
phospholipase A2 (PLA2) and can then be converted into different eicosanoids (Harizi, 
Corcuff and Gualde 2008). Arachidonic acid derived eicosanoids exert complex control 
over a wide range of physiological processes. Arachidonic derived eicosanoids have 
been associated with a vast number of inflammatory disorders such as arthritis, 
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(Sperling 1995) and risk factors associated with atherosclerosis and cancer (Wang and 
DuBois 2010, Thiemermann, Mitchell and Ferns 1993) and importantly asthma (Boyce 
2008). 
 
2.2.5.1. Eicosanoids in Asthma and EIB 
Asthma is recognized as a mediator driven inflammatory process within the lung. 
The arachadonic acid derived eicosanoids cysteinyl leukotrienes and prostaglandins 
have been implicated in the inflammatory cascade that occurs in asthmatic airways. The 
cyclooxygenase pathway that results in the generation of prostaglandins is involved in 
maintaining a balance in the airways with both PGD2 and thromboxane A2 causing 
bronchoconstriction, whereas PGE2 is bronchoprotective (Wenzel 1997). The 
leukotrienes are exclusively proinflammatory in nature and are potent 
bronchoconstrictors. LTB4 may play an important role in attracting neutrophils and 
eosinophils into the airways whereas the cysteinyl leukotrienes (LTC4, LTD4, and 
LTE4) are active in the development of airway inflammation and lead directly to 
bronchoconstriction through effects on vascular permeability, mucus secretion, and 
smooth muscle constriction (Hallstrand and Henderson 2009). LTD4 is the most potent, 
and LTE4 the least potent (Hallstrand and Henderson 2009) (figure 2.5). A direct 
association between an increase in urinary excretion of cysteinyl leukotrienes and EIB 
is suggested by the findings of Mickleborough et al. (2003). They report significant 
increases in urinary excretion of 9α-11β, PGF2 and LTE4, and circulating cytokines 
TNF-α and interleukin 1-β as an acute response to exercise to the volitional point of 
exhaustion in subjects with mild EIB (Mickleborough, et al. 2003).  
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Figure 2. 7 Generation of eicosanoids. DHA, docosahexanoic acid; EPA, eicosapentanoic acid; AA, 
arachadonic acid; COX, cyclooxygenase enzymatic pathway; 5-LOX, 5 lipoxygenase enzymatic 
pathway; TXA, thromboxane; PG, prostaglandin, LT, leukotriene 
 
 
2.2.5.2. Leukotrienes and Prostaglandins in Asthma and EIB 
The leukotrienes are pro-inflammatory lipid mediators that were first discovered 
after challenging animal lungs with snake venom (Feldberg and Kellaway 1938). The 
authors found that cobra venom caused the release of histamine from perfused lungs 
and this observation has since been explained by leukotriene synthesis induced by the 
enzyme phospholipase A2 which is a major component of snake venom. The 
leukotrienes are formed from AA by the 5-lipoxygenase (5-LO) pathway in the 
presence of 5-LO-activating protein (FLAP). The intermediate LTA4 is then converted 
to LTB4 via LTA4 hydrolase. The formation of the cysteinyl LTs (LTs C4, D4, and E4) is 
initiated by the action of LTC4 synthase (Figure 2.8). The cysLTs play an important role 
in propagating airway inflammation, causing mucus production, smooth muscle 
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contraction, increased vascular permeability, and have been shown to contribute to 
airway remodelling in murine models of asthma (Hallstrand and Henderson 2009, 
Henderson Jr, et al. 2002). The inflammatory cells responsible for the synthesis of LTs 
are eosinophils, mast cells, basophils, monocytes, and macrophages.  
 
 
Figure 2. 8 The formation of leukotrienes (LTs) from arachadonic acid metabolism through the 5-
lipoxygenase pathway. Ovals indicate the enzymes involved in leukotriene biosynthesis; phospholipase 
A2 (PLA2), 5-lipoxygenase (5-LO) with its activating protein (FLAP), LTA4 hydrolase (LTA4H), 
and LTC4synthase (LTC4S). 
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Hallstrand et al (2005) studied two asthmatic groups, one group with moderate 
to severe EIB (≥ 30% fall in FEV1 after exercise challenge) and one without EIB, and 
showed that both the concentration of cysLTs (727.7 vs 151.9 pg/mL, P = 0.01) and the 
ratio of cysLTs to PGE2 (1.85 vs 1.04, P = 0.002) within the airways were increased in 
the asthmatics with EIB. PGE2 is a bronchoprotective eicosanoid produced in large 
amounts from the epithelium, whereas the cysLTs are the products of inflammatory 
cells. The altered ratio of these in the EIB asthmatic group and higher concentrations of 
cycLTs suggest that airway epithelium injury and influx of inflammatory cells may be 
an underling basis of EIB (Hallstrand and Henderson 2009). Pharmacologic inhibition 
of the cysLT1 receptor through cysteinyl leukotriene antagonist (montelukast) along 
with antihistamines (loratadine) can reduce both EIB severity and release of 
inflammatory mediators (Hallstrand, et al. 2005). However, just inhibiting the release of 
cysLTs alone does not completely reduce EIB highlighting that there is further 
eicosanoid action in bronchoconstriction in the form of the prostaglandins. 
The production of inflammatory prostaglandins begins with the liberation of AA 
from the membrane phospholipids by phospholipase A2 in response to inflammatory 
stimuli. AA is converted to PGH2 by the cyclooxygenase enzymes (COX-1, COX-2); 
COX-1 is expressed in most tissues of the body and acts to maintain homeostasis of 
processes such as mucus secretion. COX-2 is mainly an inducible enzyme primarily 
involved in the regulation of inflammation (Harris, et al. 2002). Cell specific 
prostaglandin-synthases convert PGH2 into a series of prostaglandins (PGI2, PGF2α, 
PGD2, and PGE2) (Figure 2. 9). Prostaglandins have been shown to have both 
bronchoprotective and bronchoconstrictive mechanisms. PGE2 is a bronchoprotective 
eicosanoid produced in large amounts from the epithelium, whereas PGF2α and PGD2 
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mediate bronchoconstriction in asthmatics (Pang, et al. 1998). PGD2 is the major 
eicosanoid released from stimulated mast cells. PGD2 is unstable and rapidly 
metabolised and eliminated from circulation, as such quantification of PGD2 is an 
unreliable indicator of in vivo production. 9α-11β-PGF2α is the primary metabolite of 
PGD2 in vivo and can be reliably quantified in human urine, the concentration of which 
is increased nearly three-fold upon exposure to allergens in asthmatics (O'Sullivan, et 
al. 1996).  
Increased urinary concentrations of 9α-11β-PGF2α have been found in response 
to acute episodes of asthma and EIB (Mickleborough, et al. 2003, Kumlin, et al. 1992, 
Nagakura, et al. 1998). Furthermore the In vivo production of TXA2 and cys-LTs 
responses to specific aeroallergens have been studied (Kumlin, et al. 1992). TXA2 is a 
2-series prostanoid generated from AA via the cyclooxygenase enzymatic pathway, and 
the cys-LTS are generated from AA via the 5-lipoxygenase pathway and both are pro-
inflammatory eicosanoids (Figure 2. 9). Bronchoprovocation with aeroallergen in the 
atopic asthmatics caused significant increases in urinary concentrations of cys-LT LTE4 
(34 ± 6 before, versus 56 ± 7 ng·mmol
-1
 creatinine after allergen challenge; n=5) and 
the TXA2 urinary metabolite 11-dehydro-TXB2 (164 ± 29 versus 238 ± 25 ng·mmol
-1
 
creatinine) (p < 0.05). Following administration of a leukotriene-antagonist the 
provocative dose to cause a 20% reduction in FEV1 (PD20) was significantly increased 
(p < 0.05), suggesting a direct role for AA derived leukotrienes in airway narrowing.  
These findings support that notation that the cys-LTs from the 5 lipoxygenase pathway 
are mediators for allergen induced asthma and the release of LTE4 into the urine 
appears to be direct and dose dependent (Kumlin, et al. 1992).  
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In addition to the 5-lipoxygenase derived eicosanoids, those derived from 
cyclooxygenase (Figure 2. 9) are also raised in asthmatics.  Urinary levels of the PGD2 
metabolite 9α, 11β-PGF2 were measured in 30 asthmatic children admitted to hospital, 
14 children with EIB, and 14 without EIB following an exercise challenge (Nagakura, 
et al. 1998). Increased urinary levels of 9α, 11β-PGF2 observed on the first day of 
hospital treatment, gradually decreased on the third (p < 0.05) and on the sixth day (p < 
0.01). In EIB, there was a significant increase in urinary levels at 1 h (p < 0.01) and at 5 
h (p < 0.01) after the exercise challenge, but no change in children without EIB 
(Nagakura, et al. 1998). This further highlights the role of AA derived eicosanoids not 
only in asthma but specifically in EIB. The pro-inflammatory eicosanoids of the COX 
and 5-LOX pathways are inextricably associated with the pathogenesis of both asthma 
and EIB. Symptoms of asthma and allergies can be significantly improved with long 
term treatment of leukotriene-antagonists (Wood, et al. 1999, Horwitz, McGILL and 
Busse 1998) further supporting the role of leukotrienes in pathogenesis of asthma. 
These AA derived eicosanoids are lipid derived mediators from ω6-PUFA. It supports 
the notion that modulation could occur through dietary supplementation with higher 
levels of EPA and DHA competitively inhibiting the formation of arachidonic acid 
derived eicosanoids and having a therapeutic effect (see section  2.6.1.4).  
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Figure 2. 9 The formation of prostanoids from arachadonic acid metabolism through the cyclooxygenase 
pathway. Ovals indicate the enzymes involved in prostanoid biosynthesis; Phospholipase A2 (PLA2), 
cyclooxygenase (COX), Prostaglandin H2 Synthase (PGH2S), Thromboxane A Synthase (TXAS), 
Prostacyclin I2 Synthase (PGI2S), Prostaglandin D Synthase (PGDS), Prostaglandin E Synthase (PGES). 
 
 
2.2.5.3. Resolvins and Protectins in Asthma and EIB 
As highlighted in section  2.2.1, acute inflammation is essential in the response 
to dangerous stimuli such as potential infection, or tissue injury. The magnitude and 
duration of inflammation is dependent upon mechanisms that amplify inflammation, 
and endogenous braking programs that control the resolution of inflammation (Serhan 
2007). Resolution of inflammation is an active coordinated process controlled by 
endogenously generated autacoids at sites of inflammation (Serhan and Savill 2005, 
Serhan 2007, Serhan, et al. 2000). During inflammation, it is the enzymatic 
transformation of polyunsaturated fatty acids (PUFAs) that lead to the generation of the 
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recently discovered inflammation-dampening and resolution promoting ω-3 PUFA-
derived lipid mediators called resolvins and protectins (Weylandt, et al. 2012). 
Chemically, these compounds are hydroxylated derivatives of the parent ω-3 PUFA 
eicosapentanoic acid (EPA) for the E-series resolvins, and docosahexanoic acid (DHA) 
for the D-series resolvins and protectin D1 (Figure 2. 10). These pro-resolving 
mediators that are enzymatically generated from ω3-PUFA act as agonists to specific 
receptors for chemokines, cytokines and eicosanoids. Resolvins exert counter-
regulatory effects on leukocyte function, preventing uncontrollable neutrophil 
infiltration, decreasing cytokine, chemokine, and reactive oxygen species generation, 
and promoting the clearance of apoptotic neutrophils from sites of inflammation (Uddin 
and Levy 2010). Protectin is generated from DHA and is a protective anti-inflammatory 
molecule that can counter leukocyte action to promote the resolution of inflammation 
(Levy, et al. 2007).  Levels of protectin D1 (PD1) have been shown to be significantly 
lower in the exhaled breath of asthmatics (Levy, et al. 2007). In a murine model of 
asthma, when PD1 was administered before a methacholine challenge, airway 
eosinophil and T lymphocyte recruitment was decreased, as were levels of 
proinflammatory mediators, cytokine IL-13, cysteinyl leukotrienes, and PGD2, and 
airway hyperresponsiveness and mucous production (Levy, et al. 2007). The formation 
of resolvins and protectins from EPA and DHA may offer an important new concept in 
establishing the protective effects of ω-3 PUFA in inflammatory disease. 
To date, research has focused primarily on murine models of asthma and the 
influence of PD1 and resolvin E1 (RvE1) on airway inflammation and allergic asthma 
(Aoki, et al. 2008, Haworth, et al. 2008). Intraperitonetal administration of RvE1 caused 
subsequent reductions in eosinophil and lymphocyte recruitment, Th2 cytokine 
   62 
 
concentration and airway hyperresponsiveness to methacholine (Aoki, et al. 2008), and 
reduces the production of IL-23, and IL-6 (Haworth, et al. 2008). Furthermore, RvE1 
treated mice have been shown to have lower mucous production from goblet cells 
compared to non-treated mice (Aoki, et al. 2008). In a murine model of allergic asthma 
in vivo, RvE1 administered intravenously inhibited the development of allergic airway 
inflammation and when given during the resolution phase of inflammation, RvE1 
accelerated the resolution of airway inflammation, (Haworth, et al. 2008). The 
bronchoprotective effects of RvE1 during resolution were attributed to the inhibition of 
Th17 effector lymphocytes and increased generation of interferon-gamma (IFN-γ) and 
lipoxin A4 (Haworth, et al. 2008). There is potential that RvE1 can prevent the 
development of bronchial hyperresponsiveness, mucus eosinophil accumulation and 
Th2 cytokine mediator release (Aoki, et al. 2008). As RvE1 is a ω-3 PUFA derived 
mediator, it highlights a potential therapeutic use of ω-3 PUFA in EIB (See 
section  2.6.1.4). 
As stated previously, the pathogenesis of asthma is associated with excess 
generation of pro-inflammatory cytokines, chemokines, and eicosanoids (section  2.2). 
Due to the multitude of pro-inflammatory mediators and their numerous interactions 
with inflammatory cell types, an anti-inflammatory therapy designed to target a single 
pro-inflammatory mediator is unlikely to be successful (Uddin and Levy 2010) . No 
current pharmacologic asthma therapies are designed to selectively promote resolution 
of pulmonary inflammation. Also of interest, is that airway mucosal epithelial cells 
from individuals with asthma or cystic fibrosis have depleted stores of ω-3 DHA 
compared with healthy controls (Freedman, et al. 2004). This further suggests an 
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additional role to support the incorporation of ω3-PUFA in diets of asthmatic 
individuals. 
 
 
Figure 2. 10 (A) Formation of D-series resolvins and protectins from DHA, through the 15-lipoxygenase 
(15-LOX), and acetylated cyclooxygenase-2 (COX-2) pathways. Leads to 17S or 17R-H(p)DHA, and 
subsequent processing through epoxide intermediates and lipoxygenase action. Final products are the 
aspirin triggered 17R resolvins D1-D4, and the 15-LOX dependent 17S-resolvins D1-D4. 17S and 17R 
protectin D1’s are also formed. (B) Formation of E-series resolvins from EPA, through acetylated 
cyclooxygenase-2 (COX-2) pathway to form 18S and 18R-H(p) EPE. Subsequently 5-LOX, enzymatic 
epoxidation or reduction lead to resolving E1 or E2. Each compound can exist as 18S or 18S-epimer 
which is dependent upon its precursor molecule.  
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2.3. The gut, the immune system and inflammation 
The immune system as described in section  2.2.1 is comprised of a network of 
cells, proteins, tissues, and organs that coordinate to defend the body against attacks 
from foreign elements. An important part of the adaptive immune system is the mucosal 
immune system, termed the mucosal associated lymphoid tissue (MALT), which 
includes the gut associated lymphoid tissue (GALT). The human intestine represents the 
largest mass of lymphoid tissue in the body. Figure 2. 11 depicts the anatomy of the 
intestinal immune system and it’s interaction with the commensal bacteria. A single 
layer of intestinal epithelial cells (IECs) provide a physical barrier that separates the 
trillions of commensal bacteria in the intestinal lumen from the underlying lamina 
propria. The IECs were once considered to just provide a simple barrier but are a crucial 
cell lineage for maintaining intestinal immune homeostasis (Artis 2008). The IECs are 
continually exposed to substances in the intestinal lumen (nutrients, commensal 
bacteria, immunoglobulin, and mucous from goblet cells) in response to this exposure a 
cascade of events occurs associated with immune function. Epithelial stem cells 
proliferate and give rise to daughter cells with the further potential to proliferate. These 
IECs differentiate into villous or colonic enterocytes, which are able to absorb nutrients 
(small intestine) and water (colon) thus influencing systemic metabolism. In addition to 
differentiated enterocytes and goblet cells, progenitor IECs differentiate into both 
enteroendocrine cells, which secrete enteric hormones, and Paneth cells at the base of 
the small intestinal crypts. Beneath the IECs, the lamina propria is made up of stromal 
cells (myofibroblasts), B cells (especially IgA-producing plasma cells), T cells, 
macrophages and dendritic cells which cab regulate humoral and cellular gut immunity 
through a number of toll like receptors (Denning, et al. 2007, Uematsu, et al. 2008). 
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Certain subsets of T cells and dendritic cells localize between the IECs (Artis 
2008, Abreu 2010). Dendritic cells, with their dendrites are localised between the tight 
junctions of IECs and are in a unique position to sample and respond to environmental 
cues in the lumen of the intestine (alterations in commensal bacteria) and select 
appropriate immune responses (Coombes and Powrie 2008).  As such, dendritic cells 
can have a subsequent influence on tolerance and immunity in the intestine through 
alterations in inflammatory cell and mediator production (Coombes and Powrie 2008, 
Varol, et al. 2009). Furthermore, the small intestine has regions of specialized 
epithelium termed follicle-associated epithelium cells and microfold (M) cells that 
overlie the Peyer's patches and sample the intestinal lumen (Abreu 2010). These cells 
secrete a number of chemokines that are important in the recruitment of inflammatory 
cells and dendritic cells in the Peyer’s patches (Mowat 2003, Zhao, et al. 2003)  
 
 
Figure 2. 11. Anatomy of the intestinal immune system (Abreu 2010). IEL, intraepithelial lymphocyte 
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In combination with the GALT, the intestinal immune system also comprises of 
resident microbiota with the human gastrointestinal tract (GI tract) colonized by over a 
1000 species of microbes known as the commensal bacteria. The GALT and 
commensal bacteria comprise a complex ecosystem that functions to significantly 
contribute to systemic metabolism and immune function. As a result they can impact 
significantly on health and disease (McCracken and Lorenz 2001). Presently a total of 
1057 intestinal species of Eukaraya (92), Archaea (8), and Bacteria (957) have been 
identified (Rajilić‐Stojanović and Vos 2014). This microbial colonisation of the GI tract 
affects the GALT for example; the commensal bacteria in the GI tract cause the 
intraepithelial lymphocytes to greatly increase in number, potentially impacting on 
immune and inflammatory function.  
The adult gastrointestinal immune system comprises of a stable alliance among 
the commensal microbiota, immune mediators, and the epithelial barrier (McCracken 
and Lorenz 2001). All three components are essential for function and maintenance of a 
stable and mature intestinal immune system. There is a complex relationship between 
the intestinal immune system and the GI microbiota. The Intestinal epithelial cells are 
capable of detecting differences in the local environment and will respond to exposure 
to regulate both innate and adaptive immune responses. Signals from, and alterations in 
the gut microbiota can be transmitted to adjacent immune cells such as macrophages, 
dendritic cells, and lymphocytes through molecules expressed on the epithelial cell 
surface known as toll-like receptors (TLRs). The epithelial cells of the GI tract are in 
constant contact with the gut microbiota, and the expression of TLRs must be down-
regulated in order to avoid over-stimulation. It is important for the intestinal epithelial 
cells and the mucosal immune system to be able to distinguish between pathogenic and 
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non-pathogenic agents. Intestinal epithelial cells protect the host by providing a 
physical barrier and produce a variety of innate antimicrobial substance (McCracken 
and Lorenz 2001). 
 
2.3.1. The gut microbiota and disease 
The intestinal immune system must elicit a robust immune response to harmful 
pathogens whilst also restraining immune responses to commensal microbes and dietary 
antigens. There is a delicate balance in this dichotomy and imbalances in either the 
intestinal immune system or gut microbiota can contribute towards a number of 
diseases. Dysregulation of the intestinal immune response to normal bacterial flora has 
been suggested to play a crucial role in several inflammatory and autoimmune diseases 
including asthma (Elson and Cong 2002). 
To support the notion that the gut microbiota plays an integral role in immune 
and inflammatory responses a number of murine based studies of human diseases such 
as inflammatory bowel disease have been completed under germ-free conditions. 
Humans and host animals are highly adapted to have a synbiotic relationship with the 
commensal intestinal bacteria. Experimental procedures now mean it is possible to keep 
experimental mice entirely germ-free with no colonization of commensal bacteria in the 
gut. This is achieved by initially delivering the offspring under sterile caesarean section 
and hand rearing then aseptically (Macpherson and Harris 2004). Germ-free mice have 
no bacteria in the intestine or other body surfaces, and comparing these mice to 
specific-pathogen-free (SPF) mice of the same strain which contain a simple flora 
produces evidence for the importance of the microflora and the intestinal immune 
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system in specific diseases.  Germ-free mice do not develop a full mucosal intestinal 
immune system and also exhibit poorly developed spleen and lymph nodes 
(Macpherson and Harris 2004). Furthermore, the gene expression of the IECs is altered 
in the absence of commensal bacteria. This under development of the mucosal immune 
system in germ free mice highlights the importance of commensal bacteria in ensuring 
an adequate immune response can occur in response to disease.  
Germ-free mice are shown to exhibit high numbers of pro inflammatory 
cytokine secreting cells termed invariant natural killer cells (iNKT) (Olszak, et al. 
2012). iNKT cells play an important role in the pathogenesis of ulcerative colitis, 
irritable bowel disease (IBD), and asthma and are shown to accumulate in high amounts 
in the lamina propria of the both the colon and airways (Olszak, et al. 2012). This 
increased accumulation of iNKT cells resulted in increased morbidity in models of IBD 
and allergic asthma when compared to specific pathogen free mice. It was also 
associated with increased intestinal and pulmonary chemokine expression (Olszak, et al. 
2012). In contrast, colonization of neonatal germ-free mice with a conventional 
microbiota protected the mice from mucosal iNKT accumulation and related pathology. 
Interestingly this was not evident when adult germ-free mice were exposed to 
conventional microbiota suggesting that microbial exposure during early life was 
important. This had persistent effects on natural killer T cell function which are one 
component of the innate immune system and have the ability to both lyse target cells 
and provide an early source of immunoregulatory cytokines, and influence subsequent 
immune function in later life (Olszak, et al. 2012).  
There is growing evidence that children suffering from autoimmune and atopic 
conditions have reduced diversity of the intestinal microbiota. Reduced diversity of the 
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microbiota in infants has been shown to increase the risk of allergic disease, atopic 
eczema, and asthma in later life (Wang, et al. 2008, Sjögren, et al. 2009, Bisgaard, et al. 
2011, Hansen, et al. 2012, Abrahamsson, et al. 2014). Epidemiological studies and 
clinical reports over the last 15 years have revealed dramatic increases in the incidence 
of several immune disorders including IBD, asthma and allergies, primarily in Western 
societies (Bach 2002). According to the ‘Hygiene Hypothesis’ (Strachan 1989), smaller 
family sizes and increased hygienic living standards have caused a reduction in the 
incidences of infections in both Western and recently developing countries occurring 
simultaneously with increased prevalence of autoimmune and allergic diseases 
(Strachan 1989). The Hygiene Hypothesis was based upon epidemiological data and 
migration studies highlighting that individuals migrating from a low-incidence country 
to a high-incidence country become susceptible to immune disorders within the first 
generation (Okada, et al. 2010). This is too quick for any alterations in genetic makeup 
and therefore suggests a cause could be due to changes in environment. A weakness of 
epidemiological studies such as these is that they demonstrate a relationship between 
disease incidence and socio-economic status but do not provide a cause and effect 
between infections and immune disorders (Okada, et al. 2010). Animal models, and to a 
lesser extent some intervention trials in humans, do provide some proof of principle of 
the Hygiene Hypothesis, but the mechanisms are likely to be multiple and complex.  
Western lifestyles can result in disturbances in the gastrointestinal microbiota as 
a result of reduced early life exposure to microorganisms, increased antibiotic use and 
dietary changes. This may subsequently disrupt the immunological and inflammatory 
responses to triggers. The research to support this altered microbiota includes 
correlations between asthma prevalence and antibiotic use in industrialised countries, 
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and association between altered faecal microbiota and allergic disease (Wickens, et al. 
1999, Kirjavainen, et al. 2001, Kalliomäki, et al. 2001) . Children living on farms have 
been shown to have a lower prevalence of asthma and atopy, and are exposed to a 
greater variety of environmental microorganisms compared to a reference population 
during their childhood (Ege, et al. 2011). Early life (children <1 years of age) exposure 
to stables and consumption of farm milk has been associated with lower frequencies of 
asthma, hay fever and atopic sensitisation compared to those aged 1-5 years (Riedler, et 
al. 2001). In addition to early life microorganism exposure impacting on the GI 
microbiota and atopic risk, is the influence of early life antibiotic use. Antibiotic 
treatment has been shown to result in a long term decrease in beneficial anaerobic 
bacteria (Bifidobacterium, Lactobacillus, Bacteroides) and increases in potentially 
harmful microbes (Clostridium difficile). Antibiotic treatment can also result in reduced 
levels of short-chain fatty acids and changes in the 16s rRNA microbiota patterns long 
after antibiotic therapy and this reflects changes in the gut microbiota composition 
(Nord 1993, Sullivan, Edlund and Nord 2001). The use of antibiotics in the first year of 
life has been associated with asthma, hay fever, and eczema (Droste, et al. 2000) 
suggesting early life disturbances in the maturation of the immune system can influence 
asthma susceptibility. The susceptibility of an individual to suffer with asthma and 
allergic disease is complex but will involve genetic variants and environmental 
exposures (bacteria, viruses), alteration of our microbiome and potentially large-scale 
manipulation of our environment over the past century (Daley 2014).  
It is clear that appropriate development of the microbiome during early life is 
necessary for a strong immune system and reduced risk of autoimmune and 
inflammatory conditions. These studies support the concept that the gut microflora and 
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inflammatory conditions are pathogenically closely related, and that the commensal 
bacteria play an important role in the pathogenesis of certain inflammatory borne 
diseases. Recent advances in genomic technologies have shown that the human 
microbiome comprise of 100 trillion bacteria (Human Microbiome Project Consortium 
2012). There is evidence that alterations in gut microbiota may influence immune 
regulation outside of the gut affecting asthma and atopic disease (Noverr and Huffnagle 
2004) moreover, dysbiosis of the gut may well be a critical factor in autoimmune 
diseases such asthma and allergies. 
 
2.3.2. Diet, gut microbiota and asthma 
In recent years it has been clearly demonstrated that diet has a considerable 
effect on the composition of the gut microbiota (Turnbaugh, et al. 2009, De Filippo, et 
al. 2010). Comparisons of dietary intake and microbiota composition have been made 
between children from rural Africa with low incidences of asthma and atopy and 
Europe where there are high incidences (De Filippo, et al. 2010). The diet of children 
from rural Africa has high fibre content similar to that of early humans at the time of 
the birth of agriculture. Rural African children showed a significantly richer and more 
diverse microbiota with greater numbers of beneficial Bacteroidetes, and depletion of 
harmful bacteria Firmicutes (p < 0.001) compared to European children. In addition 
rural African children had significantly greater amount of faecal short-chain fatty acids 
compared to European children (p < 0.001). The authors hypothesise from these 
findings that the diverse gut microbiota in rural African children coevolved with a 
polysaccharide-rich diet allowing them to maximise energy intake from fibres and 
benefit inflammatory and immune function (De Filippo, et al. 2010). The study suggests 
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that development of western diets away from traditional early human diets can have a 
significant impact on the composition and diversity of the gut microbiota, and a 
relationship was inferred that it may impact on immune function and susceptibility to 
atopic diseases.  
It is has been frequently proposed in the literature that changes in diet and 
associated changes in gut microbiota are contributing to increased incidences of 
inflammatory conditions in western society including asthma (Maslowski and Mackay 
2011). Figure 2.12 is a model proposed by Maslowski and Mackay in 2011 in which 
they suggest that balanced microbial composition results in symbiosis; this provides 
regulation of immune and inflammatory responses through anti-inflammatory and/or 
immunomodulatory products such as short chain fatty acids (SCFA), polysaccharide A 
(PSA) and peptidoglycan (PTGN), which help maintain homeostasis. In contrast, 
dysbiosis leads to dysregulation of the immune system through lack of beneficial 
microbial products and an increase in virulence factors, which could leave the host 
susceptible to inflammation. Dysbiosis may occur through poor dietary intake, as well 
as through changes induced by factors such as host genetics, maternal transfer and 
antibiotic use (Maslowski and Mackay 2011).  
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Figure 2.12 Diet, microbial composition and regulation of the immune system. Diet and other 
environmental and host factors have a major effect on gut microbial composition (Maslowski and 
Mackay 2011).  
 
 
 
Childhood diet has been implicated in the development of asthma (Willers, et al. 
2011). Fruit consumption at early age is associated with reduced asthma symptoms, and 
long-term fruit intake was inversely associated with symptoms and sensitisation to 
inhaled allergens (Willers, et al. 2011). Studies have also compared children of families 
with an anthroposophic lifestyle to non-anthroposophic children. Anthroposophic 
lifestyle means children often abstain from antibiotic use and ingest larger quantities of 
fermented foods containing probiotic organisms. Rates of allergy and asthma amongst 
these children were found to be significantly lower than that in control children (Alm, et 
al. 1999). In addition, the microbiota of anthroposophic children was found to have 
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greater numbers of beneficial lactic acid bacteria compared to controls correlating to 
reduced asthma and allergy prevalence (Alm, et al. 2002).  
Ingestion of food by the human host will influence the GI microbiota, and the 
type of breakdown products they generate such as vitamins, and short-chain fatty acids 
and polysaccharides; thus a poor diet can have a detrimental impact on the gut 
microbiota. For example in a murine model, feeding mice a high fat/high sugar western 
diet altered the structure of the microbiota within a single day (Turnbaugh, et al. 2009).  
This association between disturbances in the gastrointestinal microbiota and 
susceptibility to inflammatory conditions including asthma raises the possibility that 
favourable manipulation of the microbiota could be a novel therapeutic target 
(Chapter  6). Rather than developing new anti-inflammatory drugs, it might be more 
cost-effective to devote more effort to new approaches, such as monitoring the human 
intestinal microbiota and manipulating it if required through the use of probiotics and/or 
prebiotics that stimulate the growth and/or activity of bacteria (Maslowski and Mackay 
2011). Recent research has focused on the effect of specific carbohydrates known as 
prebiotics. These are non-digestible carbohydrates that stimulate the growth of 
beneficial probiotic bacteria such as bifidobacteria (See section  2.6.2). 
The exact mechanisms by which manipulation of the gut microflora can 
positively impact on inflammatory conditions beyond the gut including airway 
inflammatory disorders in humans are still poorly understood. In 2004, Noverr and 
Huffnagle proposed a model for how the gastrointestinal microbiota might regulate 
immune responses in the airways (Figure 2. 13). The model depicts that antigens are 
inhaled and are captured by cells of the innate immune system causing stimulation of 
the adaptive immune responses in the secondary lymphoid organs including the lymph 
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nodes and spleen. Antigen-specific T cells are then recruited into the lungs upon 
subsequent antigen exposure. Regulatory T-cell networks are needed to down regulate 
the development of over stimulated Th2 responses in the airways to alterations in the 
airway environment bought about from innocuous inhaled and swallowed antigens (i.e. 
pollen). These swallowed antigens are then acquired by dendritic cells in the GI tract. 
Under non-inflammatory conditions, these DCs promote the development of a 
regulatory T-cell response to the antigens. Dietary changes and increased antibiotic use 
alter the bacterial microbiota, which alter the developmental environment for regulatory 
T cell responses and impact on immune and inflammatory function. A limitation with 
this model is it solely looks at pulmonary immune responses to inhaled antigens. As 
stated in section  2.2.2, EIB develops as a result of an increasing osmotic environment 
within the airways following exercise causing mucous production and airway smooth 
muscle contraction, thereby ruling out a role for antigen inhalation and digestion into 
the GI tract in EIB.  However, it may be argued that the airway epithelial cells and 
dendritic cells respond to the changing osmolality to produce a cascade of inflammatory 
events. This cascade in turn may be modulated by alterations in inflammatory and 
immune function from the gut microbiota.  
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Figure 2. 13 Proposed model for how the gastrointestinal microbiota might be involved in the 
regulation of pulmonary immune responses (Noverr and Huffnagle 2004) 
 
2.3.3. The concept of the gut microbiota as a therapeutic target for airway 
inflammation 
Beneficially altering the gut microbiota with a pre/probiotic supplement will 
influence the intestinal epithelial cells and dendritic cells within the gut associated 
lymphoid tissue (see  2.3 for more details). Figure 2. 14 depicts the interaction of 
probiotic bacteria with the intestinal epithelial cells (IECs) and intestinal DCs. It shows 
that probiotic bacteria can encounter DCs through two routes. DCs residing in the 
lamina propria sample luminal bacteria by passing their dendrites between IECs into the 
gut lumen (Rescigno, et al. 2001), and DCs can also interact directly with bacteria that 
have gained access to the dome region of the GALT through specialised epithelial cells 
termed microfold cells (M cells) (Artis 2008). The interaction of these host cells with 
microorganism-associated molecular patterns (MAMPs) that are on the surface of the 
probiotic bacteria will induce a certain molecular response. The host pattern recognition 
receptors (PRRs) on the dendrites can perceive probiotic signals that include toll-like 
receptors (TLRs) and DC- specific intracellular adhesion molecule 3-grabbing non-
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integrin (DC-SIGN) (Lebeer, Vanderleyden and De Keersmaecker 2010). The 
molecular response of some IECs will depend upon the subtype of cell, e.g. Paneth cells 
will produce defensins whereas goblet cells will produce mucous. The important 
response of DCs to probiotics that may influence systemic inflammation is the 
production of cytokines, and co-stimulatory molecules to polarize T cells into T helper 
or T regulatory cells in the mesenteric lymph nodes (MLNs) of the subepithelial dome 
of the GALT (Lebeer, Vanderleyden and De Keersmaecker 2010). Altering the T helper 
to T regulatory cell ratio is likely to impact upon systemic immune and inflammatory 
function which may in turn alter the inflammatory response associated with EIB.  
 
Figure 2. 14 Interaction of probiotic bacteria with intestinal epithelial cells and dendritic cells in the gut 
associated lymphoid tissue and subsequent influence of T cell expression and cytokine production. 
MAMPs, microorganism-associated molecular patterns; TLR, toll like receptors; IEC, intestinal epithelial 
cell; DC, dendritic cell; SIGN, specific intracellular adhesion molecule 3-grabbing non-integrin; IFNγ, 
interferon-γ; IL, interleukin; TGFβ, transforming growth factor-β; MLNs, mesenteric lymph nodes. 
Adapted from (Lebeer, Vanderleyden and De Keersmaecker 2010).  
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2.3.4. The airway microbiota and asthma 
The human respiratory tract traditionally viewed as a sterile environment, has 
now recently shown to actually harbour its own local microbiota (Charlson, et al. 2011) 
Advances in sequencing technologies have made it possible to identify strains of 
bacteria that colonise the airways.  Contrasting the gut microbiota, the amount of 
bacteria in healthy lungs is lower, but comprises a relatively diverse number of species 
(Gollwitzer and Marsland 2014). The most prevalent phyla identified in the airways are 
Proteobacteria, Firmicutes, and Bacteroidetes. Studies at the genus level confirmed the 
predominant presence of Pseudomonas, Streptococcus, Prevotella, Fusobacteria, 
Veillonella, Haemophilus as well as Neisseria (Hilty, et al. 2010, Erb-Downward, et al. 
2011). To date, the exact initial source of the airway microbiota is unknown, but there is 
evidence to suggest it is determined, not only from the environment but also from the 
gut microbiota and diet (Madan, et al. 2012, Gollwitzer and Marsland 2014).  
A landmark paper in 2010 was the first to describe the existence of a microbiota 
in the lower airways, and showed clear differences in the composition of healthy 
airways compared to asthmatics (Hilty, et al. 2010). Asthmatic airways showed 
significant increased levels of Proteobacteria, with potentially pathogenic strains; and 
reduced levels of beneficial Bacteroidetes when compared to healthy controls (Hilty, et 
al. 2010). This has since been supported by Huang et al. (2011) who showed that total 
bacteria burden and bacterial diversity where much higher in asthmatic patients with 
airway hyperresponsiveness compared to healthy controls, although the exact cause and 
relationship still remains to be established. With evidence to suggest that the gut 
microbiota and diet could influence the airway microbiota (Madan, et al. 2012), it 
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highlights a possible novel treatment target and option for airway diseases that may 
influence the airway microbiome (Hilty, et al. 2010). 
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2.4. Methods to diagnose exercise induced bronchoconstriction 
EIB is usually diagnosed by a ≥10% reduction in forced expiratory volume in 1 
second (FEV1) over the first 20 minutes from the pre-exercise or pre-bronchial 
challenge value. Exposing exercising asthmatics to allergens may also increase the 
exacerbation and airway responsiveness (Anderson and Kippelen 2005a). This 
increased responsiveness is termed “airway hyper-responsiveness (AHR)”. The severity 
of AHR and bronchoconstriction in EIB sufferers is determined by the ventilation 
reached and sustained during exercise, and the water content of the inspired air during 
exercise (Anderson and Daviskas 1997).  
The need for objective testing to identify EIB is supported by the knowledge 
that, in athletes, respiratory symptoms alone do not predict EIB(Rundell, et al. 2001a) 
and may not reliably monitor the condition and responses to interventions and 
medication. Bronchial provocation challenges have been developed to diagnose and 
track management strategies for EIB more accurately. There are two distinct types of 
tests which are termed direct and indirect bronchial provocation challenges. Direct 
challenges involve the inhalation of methacholine or histamine as a provocative 
stimulus, and these cause bronchoconstriction predominantly via their direct effect on 
the airway smooth muscle. In contrast, indirect challenges induce bronchoconstriction 
by acting on inflammatory cells, epithelial cells and nerves which, upon stimulation, 
release mediators or neurotransmitters that provoke smooth muscle contraction (Joos 
and O'Connor 2003).  
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2.4.1. Indirect Challenges 
Indirect challenges have been defined as a challenge that act by causing the 
release of endogenous mediators that cause the airway smooth muscle to contract, with 
or without inducing microvascular leakage. Because the responses to these challenges 
are modified or even completely inhibited by inhaled steroids, the airway response to 
these challenges may be a close reflection of active airway inflammation (Joos and 
O'Connor 2003).  
Indirect measures include, exercise testing, eucapnic voluntary hyperventilation, 
inhaled mannitol, and hypertonic saline (Anderson 2011). Indirect measures have been 
suggested to be a preferred strategy for monitoring the progression of interventions as 
they provoke bronchoconstriction and airway hyperresponsiveness associated with 
increased airway inflammation (Rundell and Slee 2008, Brannan, et al. 1998).  
 
2.4.1.1. Exercise Challenges 
Recommendations for conducting an exercise challenge test (ECT) have been 
described by both the European Respiratory Society(Sterk, et al. 1993) and American 
Thoracic Society(American Thoracic Society 2000). The guidelines state that 
participants should exercise for six (children under 12 years) to eight minutes (adult) 
breathing temperate dry air (< 25°C and <50% relative humidity or < 10 mg H2O·L
-1
) at 
an intensity to raise minute ventilation (V̇E) up to 21 times the FEV1 for the last 4 min 
of exercise (60% maximum voluntary ventilation) (American Thoracic Society 2000). 
In the absence of a measure of ventilation the heart rate should achieve 90% of age 
predicted maximum in the last 4 minutes(Sterk, et al. 1993, American Thoracic Society 
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2000). Pulmonary function testing is performed pre and post the exercise and a 
reduction in FEV1 of 10% of the pre-exercise values is widely accepted as the 
diagnostic criteria (Sterk, et al. 1993, American Thoracic Society 2000).  
Exercise challenges have been compared to direct challenges of histamine and 
methacholine research has shown a weak but statistically significant correlation 
between ECT and log histamine or methacholine PC20 (Anderton, et al. 1979, Eggleston 
1979). ECT is less sensitive, but more specific than the direct challenges in 
differentiating asthmatics from non-asthmatics (Eggleston 1979, Eliasson, et al. 1992). 
There are many asthmatics with mild bronchial hyperresponsiveness to a direct 
challenge who are negative to an ECT, but there are individuals who have a positive 
ECT and a negative direct test (Holzer, Anderson and Douglass 2002). The poor 
relationship between ECT and direct challenges are indicative of the differing 
mechanisms involved. In addition to laboratory based protocols on treadmills and cycle 
ergometers, it is relatively easy to perform a test outside where the participant 
experiences their symptoms and therefore may be more informative for swimmers and 
skiers. However, it is usually easier to have the correct inspired air conditions to 
provoke a response within a laboratory, and the appropriate equipment to measure the 
intensity of exercise by measuring ventilation rather than heart rate. The severity of the 
EIB response will be dependent upon the ventilation reached and sustained during the 
exercise protocol. Severity is related to the rate of water lost from the lower airways 
which is why ventilation and not heart rate is the primary determinant and why the 
inspired air needs to be dry. With increasing ventilation rates and dryer air there is a 
greater recruitment in the number of airways used in an attempt to condition the air this 
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increases the chances of identifying EIB (Anderson and Daviskas 2000, Anderson and 
Kippelen 2010).  
The limitation with ECTs is that there are many other factors that can affect the 
response to exercise. Research highlights that prior exercise or intermittent warm up 
exercise can cause a protective refractory period to develop(Stickland, et al. 2012) 
increasing the likelihood of a false negative response. In contrast, recent exposure to 
inhaled or ingested allergens may increase the participant’s normal response. In 
addition studies show there is inherent variability in the EIB response to ECTs with a 
25-50% variation in the % fall of FEV1 so a diagnosis may be missed if only one test is 
performed (Anderson, et al. 2010). As such, exercise is not the best indirect challenge to 
identify and monitor EIB.  
 
2.4.1.2. Eucapnic Voluntary Hyperpnoea (EVH) 
Eucapnic voluntary hyperpnoea is an alternative to laboratory/field based 
exercise challenge tests to identify EIB. The EVH test was originally developed, 
standardised, and validated by members of the US army (Eliasson, et al. 1992, Argyros, 
et al. 1995, Argyros, et al. 1996) and later adopted to identify EIB in elite athletes 
(Anderson, et al. 2001). A stepped protocol is used in individuals with severe and/or 
unstable asthma. In stable asthmatics and athletes, a standard single-step 6-minute 
uninterrupted EVH challenge is commonly used. This requires participants to 
hyperventilate a dry gas (<5% rH) at room temperature that contains ~5% carbon 
dioxide (to maintain eucapnia), 21% oxygen and balance of nitrogen. The target V̇E is 
calculated as 30 x baseline forced expiratory volume in 1 second (FEV1) and equals 
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approximately 85% of maximal voluntary ventilation (MVV) (Anderson, et al. 2001). 
This is only a target rate and most high level athletes should achieve at least 25 x FEV1 
with some asthmatics responding to a level of 21 x FEV1 (Anderson, et al. 2001).  Post 
EVH FEV1 is then measured in duplicate at set time points (~5, 10, 15 and 20 minutes) 
to determine the percentage drop in FEV1.  A drop of 10% or more is determined as 
diagnostic of EIB.  
EVH is recommended by the International Olympic Committee-Medical 
Commission for diagnosing EIB (Argyros, et al. 1996, Rundell, et al. 2004). It has been 
shown to be a highly diagnostic challenge for provoking bronchoconstriction in 
clinically recognised asthmatics that are responsive to exercise, and produces symptoms 
that are comparable to those associated with exercise
229
.  The advantage of EVH over 
an ECT is that participants can often sustain a higher ventilation rate over the 6 minutes. 
The “square wave” nature of the ventilatory response during EVH allows the participant 
to rapidly achieve their target V̇E. The total pulmonary ventilation over the 6 min EVH 
period is therefore likely to be higher than that achieved during an exercise protocol 
where V̇E increases progressively over time (Anderson, et al. 2001). EVH has been 
shown to have greater sensitivity than a methacholine challenge (Holley, et al. 2012), 
particularly in athletes and military personnel (Dickinson, McConnell and Whyte 2011, 
Argyros, et al. 1996); results in fewer false-negative EIB diagnoses than exercise 
challenges (Rundell, et al. 2004, Mannix, Manfredi and Farber 1999), and can diagnose 
EIB in previously undiagnosed athletes (Dickinson, McConnell and Whyte 2011, 
Molphy, et al. 2013). 
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2.4.1.3. Hypertonic saline and inhaled mannitol 
In 1981 Schoeffel and colleagues demonstrated that airways of asthmatic 
individuals respond with bronchoconstriction following the inhalation of nonisotonic 
aerosols(Schoeffel, Anderson and Altounyan 1981). These findings were later 
confirmed, highlighting that increases in the osmolality of the airway is responsible for 
causing the airway narrowing in asthmatic individuals (Sheppard and Eschenbacher 
1984, Eschenbacher, Boushey and Sheppard 1984). Subsequently a bronchial 
provocation test with a hypertonic (4.5%) saline was developed and standardised 
(Riedler, et al. 1994, Anderson, et al. 1995) followed by the development of Inhaled 
mannitol (Brannan, et al. 1998). Mannitol inhalation is an osmotic challenge that is used 
as an alternative surrogate test to identify EIB in clinically recognised asthmatics 
(Brannan, et al. 1998). The mechanism by which osmotic challenge causes airway 
narrowing is thought to involve both an increase in osmolality and release of mediators 
from mast cells and sensory nerves. In vitro, human lung mast cells have been shown to 
release histamine in response to increases in osmolality (Eggleston, Kagey-Sobotka and 
Lichtenstein 1987). In vitro, mannitol was shown to be more potent than sodium 
chloride at the same level of osmolality in causing a release of mast-cell histamine 
(Eggleston, Kagey-Sobotka and Lichtenstein 1987).  
 
2.4.2. Direct Challenges 
Many earlier studies used a direct airway challenge as a means of diagnosis. The 
most commonly used direct airway challenges are histamine and methacholine. The 
histamine challenge directly activates smooth muscle and secretory receptors, whereas 
the methacholine challenge acts as a non-specific cholinergic agonist to cause 
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bronchoconstriction. The sensitivity and/or specificity of these methods have been 
questioned within the literature. Holzer et al. (2002) screened 50 athletes for EIB 
through both methacholine and EVH challenges. The authors found only 9 (18%) of 
athletes were positive to methacholine, whereas 25 (50%) athletes, which included the 9 
positive methacholine athletes, positive to the EVH challenge. This highlights the 
increased sensitivity and specificity of EVH over methacholine in diagnosing EIB. This 
study supports previous research suggesting that indirect challenges such as EVH are 
the most sensitive and specific bronchial provocation challenges (Haby, et al. 1994, 
Clough, et al. 1991).  
 
2.5. Pharmacological methods to treat exercise induced 
bronchoconstriction 
At present there is no known cure for asthma, or exercise induced 
bronchoconstriction, however there are a range of both pharmacological and non-
pharmacological methods available to manage symptoms. Athletes commonly use 
pharmacologic medication to attenuate EIB with asthma medication amongst the most 
commonly reported medication used by elite level athletes (Helenius and Haahtela 
2000). The British Thoracic Society (BTS) has a 5 step guideline (Table 2. 5) for 
asthma treatment in the general population (BTS 2004). There is a lack of randomised 
control trials for treatment for EIB however despite this the BTS currently recommends 
inhaled corticosteroids and inhaled β2-agonists as the first line of treatment for 
individuals with EIB. The step guidelines show that, for mild EIB, short acting β2-
agonists should be used in the first instance (step 1). If symptoms persist and are not 
controlled then inhaled corticosteroids should be added to the treatment (step 2), 
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followed by long-acting β2-agonists (step 3) if symptoms remain and are not controlled 
by the combination of short-acting β2-agonists and corticosteroids.  
 
Table 2. 5 The British Thoracic Society 5-step asthma medication guidelines (British Thoracic Society 
Scottish Intercollegiate Guidelines Network 2008) 
Step Level Medication 
1 – Mild intermittent asthma Inhaled short-acting β2-agonist 
2 – Introduction of regular preventative 
corticosteroid therapy 
Corticosteroids 
3 – Add on therapy  Increase current medication, Inhaled long 
acting β2-agonists, theophylines, 
leukotriene receptor antagonists, 
antihistamines 
4 – Poor control on moderate dose of 
corticosteroid and add on therapy 
Add forth drug from list above 
5 – Continuous or frequent use of oral 
corticosteroids 
Oral corticosteroids 
 
2.5.1. Inhaled β2-Agonists 
Inhaled β2-agonists are commonly used for an acute asthmatic episode (short 
acting) often during or after exercise in EIB sufferers, with corticosteroids ineffective in 
the acute term. In addition to their use following an acute exacerbation, it is 
recommended that asthmatic athletes inhale short acting β2-agonists 30 minutes before 
a period of exercise. Ninety percent of those with EIB will have a successful reduction 
in EIB with the prophylactic use of inhaled β2-agonists (Anderson, et al. 1979). β2-
agonist medication act by relaxing the smooth muscle so increasing airflow, decreasing 
vascular permeability, and moderately inhibiting mediator release (Johnson 2001).  
The degree of reduction in EIB that is observed following inhalation of short 
acting β2-agonists has ranged from 50-100% in clinical trials in both adults and 
children (Anderson, et al. 1979, Boulet, Turcotte and Tennina 1989, Woolley, Anderson 
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and Quigley 1990). However, short acting β2-agonists are not recommended as the only 
source of medication for chronic asthma and EIB if they are inhaled more than 3 times a 
week (British Thoracic Society Scottish Intercollegiate Guidelines Network 2008). 
 
2.5.2. Inhaled corticosteroids 
Chronic asthmatics, and EIB sufferers who exercise regularly can achieve better 
control using inhaled corticosteroids (ICS). ICS control underlying inflammation, by 
reducing the number of inflammatory cells including mast cells, eosinophils and 
lymphocytes. ICS not only reduce bronchial hyper-reactivity, but also improve the 
diurnal variation that occurs in lung function in asthmatic patients. Asthmatic airways 
are associated with an increased number of goblet cells producing increased amounts of 
mucin, and a reduction in the ciliated epithelium. ICS therapy is associated with 
normalisation of the ciliated epithelium to goblet cell ratio, and reduces inflammatory 
cell infiltrate. Primarily this is a reduction in eosinophils within the lamina propria of 
the airways and respiratory epithelium. It is suggested that combination treatment of 
inhaled β2-agonsits and ICS are used for greatest treatment efficacy (Laitinen and 
Laitinen 1995).  
 
2.5.3. Leukotriene Modifiers 
With evidence that the cysteinyl leukotrienes are important mediators for EIB, 
there are a number of anti-leukotriene medications. A study in 64 asthmatic children 
with EIB found that those who received leukotrienes antagonist montelukast (5 mg·d
-1
) 
for 8 weeks showed significant improvements in symptoms and maximum percent fall 
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in FEV1 following exercise when compared to the control group. Short-term acute 
doses of montelukast have also been used in treating EIB. Six hours prior to either an 
exercise or EVH challenge participants ingested 10mg of montelukast or placebo 
(Rundell, et al. 2005). Reductions in FEV1 after the bronchial provocation challenges 
where shown to be significantly less following montelukast when compared to placebo 
(p < 0.05), and was effective in up to 59% of the asthmatic participants (Rundell, et al. 
2005).    
 
2.5.4. Side effects of pharmacological treatment of exercise induced 
bronchoconstriction 
Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, and have 
been used in ever increasing dosages. However, there is evidence that long term use of 
inhaled corticosteroids can result in reduced bone mineral density (BMD). Thirty seven 
asthmatics who had taken ICS for 18 months where shown to have reduced urinary 
phosphorus levels and serum osteocalcin, although BMD was unchanged compared to 
control population (Boulet, et al. 1994). Others have shown significant reductions in 
BMD, bone turnover markers, and adrenal steroid hormones (Hanania, et al. 1995, 
Wong, et al. 2000).  
Chronic use of β2-agonists can also cause systemic side effects such as 
increased airway hyper responsiveness along with degenerative changes to the 
respiratory system (Dahl 2006, Anderson, et al. 2006). Daily use of β2-agonists can 
increase hyper responsiveness within the airways and contribute to the development of 
EIB, plus a greater frequency of exacerbations. In cross country skiers, regarded as an 
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extreme subset of EIB sufferers, research has shown no beneficial effect of inhaled 
corticosteroid on symptoms, bronchial hyperresponsiveness, or airway inflammation 
(Sue-Chu, et al. 2000). Further, Anderson and Brannan (2004) suggested three clear 
adverse effects. 1) Daily use of inhaled β2-agonists can result in the development of 
tolerance and a reduction in the duration of their protective effect, 2) the severity of EIB 
can increase when exercise is performed 8-12 hours following the last inhaled dose and 
3) prolonged recovery of lung function after an asthma attack. The responses occur due 
to desensitization of β2-receptors on mast cells making them more sensitive to changes 
in osmolality increasing pro-inflammatory mediator release (Simons, Gerstner and 
Cheang 1997). These adverse effects highlight the need and significance for research 
into alternatively therapeutic strategies.  
The NHS currently spends £1 billion each year on asthma treatment (Asthma 
UK Accessed on 12.06.2013), couple this with potential complications of 
pharmacological interventions and the continued scrutiny of their use from governing 
bodies in elite sport, it provides a strong rationale to establish novel ways to treat EIB in 
both athletes and the general public. One potential area for therapy is the use of dietary 
manipulation to aid in the management of EIB.  
In summary, although the majority of asthma patients’ symptoms are well 
controlled with β2-agonsits and inhaled corticosteroids, over 50% of asthmatics exhibit 
poor control largely down to poor adherence (Barnes 2010). These pharmacological 
interventions, specifically β2-agonists, are primarily aimed at relieving symptoms rather 
than treatment of the disease. These limitations of the current treatments for asthma and 
EIB highlight the need for novel therapeutic interventions that target the underlying 
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allergy, inflammation, and immune responses to increase the disease control and have 
greater clinical effect.  
2.6. Dietary methods to treat exercise induced bronchoconstriction 
There are a number of non-pharmacological methods that could be implemented 
in the management of EIB; these include altering the training environment, warming up 
for a refractory period, breathing exercise, and inspiratory muscle training. However, 
the focus of the present thesis is on the use of nutritional interventions to aid in the 
management of EIB. Research suggests that increased prevalence of atopy and asthma 
have been preceded by parallel changes in western diets (Devereux and Seaton 2005).  
For example it has been suggested that reduced consumption of fruit and vegetables has 
left the western diet increasingly deficient of antioxidants. A proposed mechanism 
relates dietary antioxidant intake to reduced lung antioxidant defences so increasing 
airway susceptibility to oxidant damage resulting in airway inflammation and asthma 
(Devereux and Seaton 2005). In addition, western diets have seen changes in dietary fat 
consumption paralleled with increased levels of asthma and atopy. Specifically, there 
has been a fall in the consumption of saturated fat and an increase in the amount of 
omega-6 polyunsaturated fatty acids (principally linoleic acid) from vegetable oils and 
margarine, coupled with a reduction in consumption of omega-3 polyunsaturated fatty 
acids from fatty fish (Black and Sharpe 1997).  
Previous research highlights the effectiveness and possibilities of a number of 
dietary manipulation strategies. Dietary salt intake has increased in western and 
developing societies and there is evidence to suggest a causal relationship between salt 
intake and asthma severity.  A review of the available data showed that adopting a low 
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sodium diet for 2-5 weeks can lead to an improvement in lung function and reduced 
bronchial reactivity (Mickleborough and Fogarty 2006). In contrast, sodium loading had 
the opposite effects (Mickleborough, Lindley and Ray 2005, Mickleborough and 
Fogarty 2006).  The precise mechanism by which dietary salt may influence EIB is 
unknown. In asthma, sodium transport across the smooth muscle cells has been 
implicated in the regulation of airway smooth muscle tone (Tribe, et al. 1994) 
furthermore increased dietary salt intake may increase bronchial reactivity thereby 
increasing the likelihood of exacerbations when asthmatics are exposed to triggers 
(Burney, et al. 1989).  Tribe et al (1994) suggested that a serum-borne factor found in 
asthmatics caused an increase in cell membrane permeability stimulating sodium influx 
into cells; consequently, dietary sodium intake would further increase this influx. The 
increased sodium influx may alter the intracellular calcium concentration in murine 
mast cells increasing smooth muscle contractility and inflammatory mediator release 
(Cabado, Vieytes and Botana 1998, Franzius, Hoth and Penner 1994) . 
A number of studies suggest a link between increased maternal intakes of 
vitamin D and reduced risk of childhood asthma (Devereux, et al. 2007, Camargo, et al. 
2007, Erkkola, et al. 2009). Children with reduced serum vitamin D in Costa Rica had 
increased markers of allergy and asthma (Brehm, et al. 2009). As deficiency leads to 
reduced levels of antimicrobial peptide (Ginde, Mansbach and Camargo 2009), which is 
important in host defence, this could link vitamin D deficiency to increased risk of 
respiratory tract infections. Increased respiratory tract infections are associated with 
wheeze in children and increased asthma exacerbations in adults (Ginde, Mansbach and 
Camargo 2009).  
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Furthermore, asthmatic children with a positive response to an exercise 
challenge (%∆FEV1 >10%) presented with lower serum levels of 25-hydroxyvitamin D 
compared to children who did not respond to exercise (Chinellato, et al. 2011). The 
precise mechanism linking vitamin D deficiency to increased severity of EIB is 
unknown.  In vitro animal studies suggest that vitamin D deficiency is associated with 
increased mast cells in connective tissue. In addition 1,25-dihydroxyvitamin D3 (an 
active vitamin D metabolite) promotes apoptosis and inhibits bone marrow derived 
mast cell precursors and histamine release from mast cells. These in vitro studies 
suggest a role for vitamin D in moderating mast cell derived inflammatory mediators. 
Recently, 1,25-dihydroxyvitamin D3 has been shown to be a potent regulator of 
immune response in Th1-cell driven diseases and has a role in controlling transcription 
factors and co-regulatory molecules to suppress gene transcription in lung inflammation 
(Sundar and Rahman 2011) potentially enhancing immunoregulation in asthma.  
Similarly, vitamin C at a dose of 1500 mg·day
-1
 for two weeks has been shown 
to significantly reduce maximum fall in post exercise FEV1 to non-diagnostic levels in 
eight adult asthmatics, along with improved symptom scores, and reduced inflammatory 
markers in urine (Tecklenburg, et al. 2007). Reductions in urinary inflammatory 
prostaglandin and leukotriene levels following the vitamin C intervention again 
suggested a role for suppressed mast cell activation. 
This thesis focuses on two other dietary components which may have 
therapeutic potential for asthma. A number of studies highlight that modulating the ratio 
between dietary omega 6 and omega 3 fatty acids can result in an improvement in 
asthma symptoms (Oddy, et al. 2004) and reduced inflammatory markers (Hodge, et al. 
1998). In addition, a novel dietary approach may be to manipulate the gut microflora 
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though feeding of prebiotic carbohydrate. Prebiotic carbohydrate has the potential to 
modify the gut microflora which may impact on the systemic inflammation associated 
with asthma and EIB.  
2.6.1. Omega 3 polyunsaturated fatty acids (ω3-PUFA) 
Omega 3 polyunsaturated fatty acids (ω3-PUFA) are generally termed essential 
fatty acids and must be supplied through the diet. The term ω3 is a structural descriptor 
for a family of PUFA, and it describes the position of the first double bond that is 
closest to the methyl terminus of the acyl chain. In all ω3-PUFA, this first double bond 
is on carbon 3, and this differs to ω6-PUFA where the first double bond is on carbon 6 
(Figure 2. 15). The simplest ω3-PUFA is alpha-linolenic acid [18:3(ω-3)] and it is 
synthesized from linoleic acid [18:2(ω-6)] catalysed by Δ15-desaturase. However, 
humans do not possess the enzyme Δ15-desaturase and so cannot synthesise alpha-
linolenic acid, thus it is classed as an essential fatty acid. Humans can however 
metabolize alpha-linolenic acid into other longer chain, more unsaturated ω3-PUFAs 
such as eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:5) 
(Figure 2. 16). The conversion rate of long chain ω3-PUFA (EPA and DHA) from 
alpha-linolenic acid is ineffective and therefore intervention studies commonly 
supplement directly with EPA and DHA (Galli and Calder 2009).  
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Figure 2. 15 Structure of ω-6 and ω-3 PUFA. Highlight shows location of first double bond 
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Figure 2. 16 The biosynthesis of the ω3 PUFA family from α-linolenic acid and the formation of 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
 
2.6.1.1. Dietary sources and typical intakes of ω3-PUFA 
α-Linolenic acid is a common component of green leaves, comprising over 50% 
of their fatty acids, but as green leaves are low in fat they are not usually a major 
dietary source of α-linolenic acid (Calder 2012). Linseeds (flaxseeds) and their oil 
typically contain 45-55% of fatty acid in the form of α-linolenic acid, whereas soybean, 
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rapeseed, and walnuts typically contain ~10% α-linolenic acid (Simopoulos 2002a). 
There is very little α-linolenic acid in corn, sunflower, or safflower oil all of which are 
high in linoleic acid (ω6-PUFA) and are key contributors to the rise of ω6-PUFA intake 
in western diets (Simopoulos 2002a). ω3-PUFA consumption among Western 
populations is low, and estimated to be ~0.15-0.25 g·d
-1
 (Calder 2012), whereas ω6-
PUFA is the main PUFA typically consumed in 5 to 20 fold greater amounts than α-
linolenic acid which can have implications in health and disease (Burdge and Calder 
2006, British Nutrition Foundation 2000, Blasbalg, et al. 2011).  
Fish and other seafood are much better sources of very long ω3-PUFA than 
green leafy vegetables (British Nutrition Foundation 2000). Lean fish, like cod or 
haddock, store lipids in their liver whereas oily fish like salmon, tuna, and sardines 
store lipids in their flesh/muscle in higher quantities, although it is important to note 
that different types of fish contain varying amounts of ω3-PUFA with differing ratios of 
EPA:DHA. This is because the ω3-PUFA content and type is influenced by the 
metabolic characteristics of the fish, their diet, the temperature of the water in which 
they live, and the season (Calder 2012). A single serving of a lean fish could typically 
provide 0.2-0.3 g ω3-PUFA, whereas a single oily fish portion could provide 1.5-3.5 g 
of ω3-PUFA (Calder 2012). ω-3 PUFA, specifically the biologically active EPA and 
DHA, possess the most immunomodulatory action, and are more biologically potent 
that α-linolenic acid (Simopoulos 2002b). The ω6 and ω3 PUFAs are metabolically 
distinct, and have opposing physiological functions, as such the increased ω6:ω3 ratio 
in Western diets likely contributes to an increased incidence of disease and 
inflammatory disorders such as asthma (Simopoulos 2002b).  
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2.6.1.2. Anti-inflammatory actions of ω3-PUFA 
Polyunsaturated fatty acids (PUFAs) are important constituents of the 
phospholipids of all cell membranes. In animal studies, increasing the dietary intake of 
ω3 EPA and DHA results in higher concentrations of these fatty acids in inflammatory 
cells including lymphocytes, macrophages, and neutrophils (Yaqoob, Newsholme and 
Calder 1995, Brouard and Pascaud 1990, Palombo, et al. 1999). Typically the increase 
in EPA and DHA in cell membranes is at the expense of ω6 arachidonic acid (Calder 
2010). The anti-inflammatory actions of ω3-PUFA are likely to be multifactoral, and 
due to this complexity, it has made elucidating the exact actions of PUFAs within 
inflammatory processes difficult (Calder 2010). This difficulty has been further 
compounded by the variety of experimental approaches that have been used, including 
the method of presentation of PUFAs of interest to inflammatory cells in order to study 
their effects. For example, many in vitro studies have exposed cells to non-esterified 
fatty acids, often at concentrations that might not be achieved physiologically (Calder 
2010). Despite these difficulties there is a wealth of evidence that the consumption of 
oily fish or fish oils can have a multitude of anti-inflammatory effects (Simopoulos 
2002a) (Table 2. 6). Many experimental studies have provided evidence that 
incorporating ω3-PUFAs into tissues may modify the inflammatory and immune 
reactions meaning that they have the potential to be a therapeutic agent for 
inflammatory diseases.  
The most commonly reported anti-inflammatory action of ω3-PUFA within the 
literature is their influence on the lipid derived mediators eicosanoids (section  2.2.5). 
Relatively high amounts of ω6 arachidonic acid are present in the phospholipid 
membranes of inflammatory cells and this fatty acid is the major precursor for 
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eicosanoids which are produced in greatly increased amounts upon cellular stimulation 
(Calder 2010). In general, the eicosanoids produced from arachidonic acid act in a pro-
inflammatory way, although this is a slight over-simplification as it is now recognised 
that arachidonic acid derived eicosanoid PGE2 can be both pro- and anti-inflammatory 
(Levy, et al. 2007, Vachier, et al. 2002). Increasing dietary intake of EPA and DHA can 
decrease the production of pro-inflammatory arachidonic acid derived eicosanoids 
cysteinyl leukotrienes, and prostaglandins. Like arachidonic acid, EPA is a substrate for 
the cyclooxygenase and lipoxygenase enzymatic pathways; as such, increases in EPA 
within the phospholipid membranes of inflammatory cells can competitively inhibit the 
use of arachidonic acid as a substrate for eicosanoid production. The EPA derived 
mediators are much less biologically active than those produced from arachidonic acid. 
For example, EPA-derived LTB5 is 10- to 100-fold less potent as a neutrophil 
chemoattractant compared with LTB4 (Lee, et al. 1984). Supplementing the diet with 
high dosages of ω3-PUFA (3.2 g EPA and 2.2 g DHA, per day) in normal subjects can 
increase the EPA content in neutrophils and monocytes more than sevenfold (Lee, et al. 
1985). The anti-inflammatory effects of fish oils are partly mediated by inhibiting the 5-
lipoxygenase pathway in neutrophils and monocytes and inhibiting the leukotriene B4 
(LTB4)-mediated function of LTB5 (Lee, et al. 1985). ω3-PUFAs influence cytokine 
production specifically interleukin metabolism such as TNF-α, IL-6 and IL-1β (Endres, 
et al. 1989, Khalfoun, et al. 1996, Kremer, Lawrence and Jubiz 1989). With 
leukotrienes and prostaglandins produced from the metabolism of arachidonic acid, and 
pro-inflammatory cytokines implicated in the pathogenesis of asthma and EIB, the ratio 
of ω6:ω3 may be an important determining factor in the severity of symptoms and the 
disease.  
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As described in section  2.2.5.3 EPA and DHA also give rise to resolvins and 
protectin compounds through the cyclooxygenase and lipoxygenase pathways. These 
mediators have been demonstrated in cell culture and animal feeding studies to be anti-
inflammatory and inflammation resolving (Calder 2010). Resolvin E1, D1, and 
protectin D1 have been shown to prevent neutrophilic infiltration at sites of 
inflammation, and protectin D1 inhibits TNF-α and IL-1β production. As such, the role 
of resolvins and protectins from ω3-PUFA may be important in the resolution of 
inflammation and stopping ongoing inflammatory processes to limit tissue damage 
(Calder 2012, Calder 2010).  
Table 2. 6 Effects of omega-3 PUFAs on factors involved in the pathophysiology of inflammation, 
recreated from (Simopoulos 2002a, Simopoulos 2002b).  
Factor Function Effects of 
ω3-PUFA 
Arachidonic Acid 
Eicosanoid precursor, aggregates platelets, stimulates 
leukocytes 
Decreases 
Thromboxane 
Platelet aggregation, vasoconstriction, increase of 
intracellular Ca
++
 
Decreases 
Prostacyclin (PGI2/2) Prevents platelet aggregation, vasodilation, increase CAMP Increases 
Leukotriene (LTB4) Neutrophil chemoattractant, increases  intracellular Ca
++
 Decreases 
Fibrinogen A member of the acute phase response, blood clotting factor Decreases 
Tissue plasminogen 
factor 
Increases endogenous fibrinolysis Increases 
Platelet activating 
factor (PAF) 
Activates platelets and leukocytes Decreases 
PDGF Chemoattractant Decreases 
Oxygen free radicals 
Cellular damage, enhances LDL uptake by macrophages, 
stimulates arachidonic acid metabolism 
Decreases 
Lipid hydro peroxides Stimulates eicosanoid formation Decreases 
IL-1 and TNF 
Stimulate neutrophil O2 free radical formation, stimulate 
lymphocyte proliferation, express intracellular adhesion 
molecule-1 on endothelial cells, inhibit plasminogen 
activator 
Decreases 
IL-6 
Stimulates the synthesis of all acute phase proteins involved 
in the inflammatory response: C reactive protein, serum 
amyloid A, fibrinogen, α1-chymotrypsin, and heptoglobin 
Decreases 
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2.6.1.3. Importance of the ω3:ω6-PUFA ratio in health 
Mammalian cells lack the enzyme ω3-desaturase so subsequently cannot 
convert ω6 to ω3 fatty acids. The balance of essential fatty acids, and thus the ratio of 
ω6:ω3 is important for good health and normal development. When humans consume 
fish or fish oil, the quantities of EPA and DHA partly replace the ω6-PUFA, primarily 
arachidonic acid, in the membranes of almost all cells, especially in the membranes of 
platelets, erythrocytes, neutrophils, monocytes, and liver cells (Simopoulos 1994). As 
described in section  2.2.5, arachidonic acid derived from ω6-PUFA, and EPA, DHA 
derived from ω3-PUFA are the parent compounds for the production of eicosanoids.  
With the increased intake of ω6 PUFA in western diets, the eicosanoids derived 
from arachidonic acid, specifically prostaglandins, thromboxanes, and leukotrienes, are 
formed in larger quantities than those formed from EPA and DHA. Only small 
quantities of arachidonic acid are required to produce highly biologically active 
eicosanoids and if they are formed in large amounts they contribute to the formation of 
allergic and inflammatory disorders particularly in susceptible people (Simopoulos 
2002a, Simopoulos 2002b). Therefore, modern Western diets rich in ω6 PUFA can shift 
homeostasis to one of a greater pro-inflammatory state. 
There is a lack of understanding into the optimal therapeutic dose or ratio of 
ω6:ω3 with recommendations varying from 1:1, to 4:1 depending on the disease which 
is expected due to the multifactorial nature of many Western chronic diseases 
(Simopoulos 2002a). The research highlights that altering the ratio in favour of ω3 can 
decrease drug dose in chronic inflammation (James and Cleland 1997), and reduce 
levels of pro-inflammatory mediators associated with airway inflammatory (Broughton, 
et al. 1997, Mickleborough 2005). The research supports the rationale that the 
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manipulation of the ω6:ω3 ratio through ω3-PUFA feeding maybe a therapeutic option 
for asthma, EIB and airway inflammation. 
 
2.6.1.4. ω3-PUFA as a therapeutic intervention in asthma 
In western diets 20-25 fold more ω6-PUFA are typically consumed than ω3-
PUFA which can result in a greater liberation of pro-inflammatory arachidonic acid 
metabolites (Simopoulos 2002a).  It has been previously hypothesized that the low 
prevalence of lung disease among Eskimos is a result of their diet high in ω3-PUFA 
(Horrobin and Manku 1987). This was attributed to the anti-inflammatory role of ω3-
PUFA in reducing leukotriene generation. Observational research highlights a 
relationship between fish intake and decreased risk of asthma (Wong 2005). Despite 
this, the results from intervention studies have yielded conflicting data. 
Significant improvements in daytime wheezing, reductions in concentration of 
exhaled hydrogen peroxide (marker of airway inflammation), and increase in peak 
expiratory flow were observed in mild adult asthmatics  following 2 months of 
200mg·d
-1
 of an EPA/DHA mix when compared to a placebo (150 mg·d
-1
 of olive oil) 
(Emelyanov, et al. 2002). However no significant changes in FEV1 were noted which 
may be attributed to mild level of asthma exhibited in the participants, and the relatively 
low daily dose of EPA/DHA. Furthermore the improvements that did occur could not 
be solely attributed to EPA and DHA as the supplements also contained carotenoids, 
which can act as antioxidants.  As asthma is regarded as a long-term irreversible 
condition a longitudinal ω3-PUFA supplementation study was conducted over a 12 
month period by Dry and Vincent (1991). Twelve asthmatics were randomized to 
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receive 1000 mg·d
-1
 of an EPA/DHA supplement, or placebo under double-blind 
conditions. In the ω3-PUFA group FEV1 reportedly increased by 23%, significantly 
greater than that seen in the placebo group (p < 0.005) (Dry and Vincent 1991). This 
improvement did not however translate to a reduction in medication usage and in 
addition the authors failed to report the constituents of the placebo. Both of these 
studies also failed to tightly control for the individuals long-term dietary intake which 
will likely impact on the habitual ω3:ω6 ratio.  
The effects of consuming two different ω3:ω6 ratios (0.1:1 and 0.5:1) each for 
four weeks in an asthmatic population has been investigated by Broughton et al., 
(1997). Pulmonary function and urinary 5-series leukotriene excretion were used to 
assess treatment efficacy following a standard methacholine challenge and baseline 
saline challenge. The ω3:ω6 ratio of 0.1:1 resulted in a greater bronchoconstrictive 
response to the methacholine challenges compared to baseline, with a reduction in the 
provocative dose to induce a fall of ≥ 20% in FEV1 of 89%.  Increasing the ω3 PUFA 
intake to a ratio of 0.5:1, resulted in a reduction in drop in FEV1 in response to the 
methacholine challenge compared to baseline and 9 of the 19 participants actually 
improved. Those showing no reduction in respiratory measures to the methacholine 
challenge after the period of increased ω3-PUFA intake where referred to as ω3-PUFA 
responders (Broughton, et al. 1997).  
The lower ratio of ω3:ω6 caused an increase in pro-inflammatory 4-series 
leukotrienes of 13.3 ± 4.5 ng, (p<0.05) in all participants following the methacholine 
challenge. In contrast, following the higher ω3:ω6 ratio there was no increase in the 4-
series leukotrienes. Comparing high and low ω6:ω3 ratios, overall 4-series leukotriene 
excretion were significantly lower (p<0.05) with the high ω3-PUFA intake compared to 
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the low. Leukotriene E5 was markedly increased following the high ω3-PUFA diet, 
compared with baseline in both responders and non-responders although it was 230% 
greater in responders (p<0.05). Higher levels of LTE5 are associated with reduced levels 
of airway inflammation. With a urinary ratio of LTE4 to LTE5 of <1 following the 
higher ω3 intake, it may help to elucidate the positive mechanisms for alleviating 
respiratory symptoms (Broughton, et al. 1997). The research highlights the pro-
inflammatory nature of skewed ω3:ω6 PUFA in favour of ω6 PUFA can have a 
significant impact upon inflammation associated with asthma. As such detailed 
intervention studies that can increase ω3-PUFA intake are warranted in inflammatory 
conditions such as asthma. Chapter  5 highlights the use of ω3-PUFA as a treatment 
intervention in asthmatics with EIB.  
 
2.6.2. Prebiotics 
Prior to the 1990’s there had been a widespread belief that while food intake 
may regulate certain metabolic activities associated with micro-organisms, changing the 
diet had little effect on the overall composition and structure of the microbial 
communities in the human gut (Macfarlane and Macfarlane 2003, Macfarlane, Steed 
and Macfarlane 2008). However, it is now recognised that the species composition of 
the microbiota, as well as many physiological consequences can be modified by small 
changes in food consumption that includes the introduction of prebiotics into the diet 
(Macfarlane, Steed and Macfarlane 2008).  
The original definition of a prebiotic was proposed by Gibson and Roberfroid 
(1995) as ‘a non-digestible food ingredient that beneficially affects the host by 
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selectively stimulating the growth and/or activity of one or a limited number of bacteria 
in the colon and thus improves health’. More recently, this has been amended to ‘a 
prebiotic is a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microbiota that confers benefits upon 
host well-being and health’ (Gibson, et al. 2004).  
Prebiotic oligosaccharides can be classified according to their chemical 
constituents and degree of polymerisation. In addition to be classified as a dietary 
prebiotic the ingredient must: 
 Resist gastric acidity, hydrolysis by mammalian enzymes and 
gastrointestinal absorption; 
 Be  fermented by the intestinal microflora; 
 Stimulate selectively the growth and/or activity of the intestinal bacteria 
associated with health and wellbeing (Gibson, et al. 2004).  
 
Any food ingredient that escapes digestion in the upper gastrointestinal tract has 
the potential to be prebiotic, but only certain carbohydrates have shown convincing 
evidence of prebiotic action. A review of the literature (Macfarlane, Macfarlane and 
Cummings 2006) highlights that the majority of prebiotic research has focused on 
inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS). FOS and 
GOS are not sensitive to gastric acid, and do not serve as substrates for hydrolytic 
enzymes in the upper digestive tract; as such they are capable of stimulating the growth 
and activity of intestinal bacteria within the lower gut. FOS and GOS have been 
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assessed and achieve all of the above classification criteria (Gibson, et al. 2004, 
Bouhnik, et al. 2004). Bouhnik et al (2004) compared the prebiotic characteristics of a 
number of candidate prebiotics in vivo. Following 7 days of consumption, GOS showed 
the greatest prebiotic effect with a stronger bifidogenic effect than short chain FOS 
(Bouhnik, et al. 2004). Although this is a rapidly growing research area, the evidence 
for prebiotic status of other non-digestible carbohydrates (glucooligosaccharides, 
isomaltooligosaccharides, lactosucrose, polydextrose, soybean oligosaccharides, and 
xylooligosaccharides) offer preliminary promising data but currently are not sufficient 
to classify them as prebiotics according to the stated criteria (Bandyopadhyay and 
Mandal 2014) . 
Unlike probiotics where the microbes are introduced to the gut, and actually have 
to compete against the established colonic communities, an advantage of prebiotics is 
that they target probiotic bacteria that are already commensal to the large intestine. As 
such, prebiotics are arguably a more practical and efficient way to manipulate the gut 
microflora than probiotics. Conversely, if the gut microflora are not present due to 
disease, ageing, antibiotics, or drug therapy the prebiotic is unlikely to be of benefit and 
a synbiotic (combined prebiotic and probiotic) approach may be more beneficial 
(Macfarlane, Steed and Macfarlane 2008).  
 
2.6.2.1. Prebiotic – Trans-galactooligosaccharide (B-GOS)  
Galactooligosaccharides are very stable carbohydrates at high temperatures and 
acidic environments and with a low calorific value of 1.7 kcal·g-1 it makes them of 
particular interest to the food industry.  A number of health benefits have been 
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attributed to the ingestion of prebiotics mainly with the use of FOS, and less so GOS 
although GOS has the potential to have a greater bifidogenic effect within the gut 
(Bouhnik, et al. 2004).  
GOS is principally formed by enzymatic treatment of lactose by β-galactosidase 
to produce several oligomers of different chain lengths (Prenosil, Stuker and Bourne 
1987). GOS is an inclusive term referring to oligosaccharides with 2 to 6 sugars that 
have galactose as their main component. It can be produced from lactose in cow’s milk, 
but the main raw material for its production is usually from whey-derived lactose. GOS 
is then produced by β-galactosidases that have transgalactosylation activities, which 
results in the formation of 4- or 6-galactosylactose, oligosaccharides, 
transgalactosylated disaccharides and non-reducing oligosaccharides (Figure 2. 17) 
(Angus, Smart and Shortt 2005).  
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Figure 2. 17 Schematic showing production of GOS from lactose adapted from Angus, Smart and 
Shortt., (2005).  
One way of increasing the specificity of the products and interaction with 
prebiotic bacteria in the gut may be by using β-GOS synthesized by bifidobacteria when 
manufacturing the product (Macfarlane, Steed and Macfarlane 2008). The prebiotic 
used in the current thesis was produced this way. A novel strain of Bifidobacterium 
bifidum NCIMB 41171 isolated from a faecal sample from a healthy human volunteer 
with an ability to express β-galactosidase activity was used in synthesis reactions for the 
production of GOS from lactose (Tzortzis, Goulas and Gibson 2005). Synthetic 
prebiotic mixtures produced by enzymes from initial probiotic organisms potentially 
confer greater selectivity on those organisms when ingested and then fermented by the 
colonic microflora (Depeint, et al. 2008). This product is now commercially available 
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as a prebiotic powder marketed as BiMUNO by Clasado and referred to as a trans-
galactooligosaccharide (B-GOS). 
The bifidogenic properties of B-GOS have been studied under a number of 
conditions. The prebiotic potential of B-GOS was initially assessed in vitro and in pigs 
in vivo. The in vitro study was a model of the gut whereby physicochemical conditions 
of the colon were replicated in a 3-stage fermenter representing the proximal, 
transverse, and distal colon (Tzortzis, et al. 2005). Following the addition of the B-GOS 
mixture the bifidobacterial numbers in the first two vessels representing the proximal 
and transverse colon increased (p < 0.05). In addition the study showed that the B-GOS 
mixture may also have potential therapeutic effects by reducing Salmonella and E.coli 
associated infections.  Addition of B-GOS in vivo to the commercial diets of pigs 
increased the number of bifidobacteria (p < 0.001) and acetate concentration (p < 0.001) 
and decreased the pH (p < 0.001) compared to a control diet, and control diet with 
inulin. These data suggest that B-GOS has a greater prebiotic potential than inulin 
(Tzortzis, et al. 2005).  
The prebiotic potential of this novel B-GOS mixture (BiMUNO) was studied in 
30 healthy human volunteers. Participants were assigned to a sequence of 7 day 
treatments differing in the quantity of B-GOS received (0, 3.6, or 7g·d
-1
) with a 7 day 
washout between treatments. Stool samples were collected before and after each 
intervention, and bacteria numbers were determined by fluorescent in situ hybridization. 
The novel B-GOS supplement significantly increased the bifidobacterial population 
ratio compared to the placebo (p < 0.05), and 7g·d
-1
 was shown to significantly increase 
bifidobacteria numbers greater than a previous commercial GOS supplement (p < 0.05). 
Furthermore a dose dependent response between the bifidobacteria proportion and 
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novel B-GOS dose was observed (p < 0.01). This study showed that the novel B-GOS 
mixture had greater bifidogenic properties than previously commercially available 
supplements, and increased the bifidobacteria in a dose dependent response from 3.6 to 
7.0 g·d
-1
. This study highlighted the bifidogenic properties of B-GOS in humans for the 
first time but the subsequent potential therapeutic impact of B-GOS on immune 
function and inflammation remained to be elucidated.  
Consequently the effects of B-GOS on immune function and faecal microflora 
composition were assessed in a healthy elderly population (Vulevic, et al. 2008). Aging 
is associated with a reduced number of bifidobacteria within the gut and weakened 
immunity. Forty four elderly participants (age 69.3 ± 4.0 y) were randomly assigned to 
receive either a placebo or B-GOS treatment (5.5 g·d
-1
) for 10 weeks with a 4 week 
washout period between treatments under double-blind, cross-over conditions. Blood 
and faecal samples were collected prior to, during (5 week), and at the end of the 
treatment periods. The study showed that B-GOS significantly increased the numbers of 
beneficial bacteria, primarily bifidobacteria (p < 0.01) at the expense of less beneficial 
bacteria compared to baseline and placebo. Significant increases in phagocytosis, 
natural killer cell activity, and the production of anti-inflammatory cytokine IL-10, and 
reduction in pro-inflammatory cytokines IL-6, IL-1β, and TNF-α were observed. These 
data suggest that B-GOS administration in the elderly can positively alter the gut 
microflora and subsequently affect immune function (Vulevic, et al. 2008). The 
influence of B-GOS on asthma and airway inflammation remains to be elucidated. The 
proposed rationale for B-GOS supplementation in asthma is discussed in more detail in 
Chapter 6.  
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2.7. General Summary 
Hyperpnoea through exercise or volitional breathing involving dry/cold air is an 
important trigger of EIB. Increased airflow will cause dehydration of the airway surface 
liquid, mucosal cooling, and epithelial disruption resulting in airway inflammation 
(Anderson and Kippelen 2005a). Airway inflammation is associated with an increase in 
chemokine activity with subsequently greater leukocyte migration to the site of 
inflammation. This results in the significant release of a number of pro-inflammatory 
mediators from a range of leukocytes. These include lipid derived eicosanoids from 
arachidonic acid metabolism (leukotrienes and prostaglandins) and a number of pro-
inflammatory cytokines (TNF-α, IL-33 amongst others). These pro-inflammatory 
mediators are known to cause bronchial smooth muscle contraction, airway obstruction, 
and increased mucous production (Anderson and Daviskas 2000).  
Conventional pharmacological treatment for EIB primarily involves the 
suppression of airway inflammation with chronic treatment involving inhaled 
corticosteroids and acute relief of symptoms with bronchodilators. However, these 
therapies do not consistently relieve symptoms in all individuals and long term use can 
lead to systemic side effects. Traditional treatment typically targets symptoms and 
therefore therapeutic strategies which target the underlying inflammation are warranted. 
Research has highlighted the effectiveness of high dose omega 3 polyunsaturated fatty 
acids (ω3-PUFA) in reducing airway obstruction and eicosanoid accumulation 
associated with EIB (Mickleborough, et al. 2003, Mickleborough, et al. 2006, 
Tecklenburg-Lund, et al. 2010) but further research is warranted to establish more 
achievable dose levels.  
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Furthermore epidemiological research has highlighted that an increase in asthma 
prevalence has run parallel with alterations in Western lifestyles (Bach 2002) (Hygiene 
hypothesis), which has recently been expanded to include alterations in the gut 
microbiome. Significant levels of dysbiosis of the gut microbiota have been found in 
asthmatic individuals and this highlights the potential that the gut microbiota may be a 
significant therapeutic target in the treatment of asthma and EIB (Noverr and Huffnagle 
2004). Beneficial manipulation of the gut microbiota can be achieved through the 
feeding of pre- and probiotics and this area warrants further investigation to establish if 
this manipulation can have a systematic benefit for adult sufferers of asthma and EIB.   
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3. Chapter 3 – General Methods 
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3.1. Participants 
Participants were recruited through adverts placed in the Nottingham Trent 
University, local sports clubs, leisure centres and running shops; and online postings on 
relevant forums (Runners World, Cycling Weekly, and TriTalk).  All participants 
provided written informed consent for each experimental study (Appendix 3, Appendix 
5, and Appendix 7) following approval from the Nottingham Trent University Human 
Research Ethics Committee. A self-reporting medical questionnaire (Appendix 1) 
confirmed participants were non-smokers, free from illness (excluding asthma), and 
injury, and where not taking medication other than asthma related medication detailed 
in section  3.1.1. All participants completed a 48 h estimated diet record prior to their 
first laboratory visit which was then replicated on all subsequent conditions. 
Participants were instructed to adhere to their habitual training programme and not 
undergo any dramatic changes in their training schedule throughout the duration of the 
studies, and were asked not to partake in strenuous exercise 48 h prior to testing days. 
On test days participants abstained from caffeine (8 h prior) and alcohol (24 h prior) 
and arrived at the laboratory at least 2 h post-prandial.  
 
3.1.1. Participant medication requirements 
Asthma and HIB diagnosis was performed through spirometery (section  3.3) and 
eucapnic voluntary hyperpnoea (EVH) (section  3.4). In preparation for this testing 
participants using asthma medication were instructed to cease their medication prior to 
each EVH challenge (inhaled corticosteroids and leukotriene modifiers: 4 days 
(American Thoracic Society 2000); inhaled long acting β2 agonists: 2 days (Cockcroft 
and Swystun 1997); anti-histamines: 2 days; inhaled short acting β2 agonists: the day of 
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the test (Ahrens, et al. 1984, Greenspon and Morrissey 1986); and were tested at least 2 
weeks following recovery from any chest or upper respiratory tract infection 
(Dickinson, McConnell and Whyte 2011, Anderson, et al. 2001).  
3.2. Anthropometric Measurements 
Body mass was measured using a calibrated electronic scale (SECA 877 Scale, 
SECA, Birmingham, UK) to the nearest 0.1 kg, whilst participants wore lightweight 
clothing and were barefoot (Roger, Eston and Reilly 2009). Height was measured with 
a portable stadiometer (SECA stadiometer, SECA, Birmingham, UK) with participants 
standing barefoot, with heels together, looking straight ahead, and arms relaxed by their 
sides (Roger, Eston and Reilly 2009).  
3.3. Pulmonary Function – Dynamic Spirometery 
Pulmonary function was conducted in accordance with ERS guidelines (Miller, et 
al. 2005, Wanger, et al. 2005) using a pneumotrac spirometer (Vitalograph, 
Buckinghamshire, UK) calibrated with a 3 L syringe.  Participants performed lung 
function manoeuvres standing upright and wearing a nose clip. Measures were taken 
from three flow-volume loops, to determine forced vital capacity (FVC) and forced 
expiratory volume in one second (FEV1), with the two highest values being within 
0.100 L of each other, and the highest taken for subsequent analysis (Miller, et al. 
2005). Baseline FEV1 had to be within 65% of predicted based on normative predictive 
equations (Knudson, et al. 1983), for participants to undergo the EVH challenge 
(Argyros, et al. 1996). Following the EVH challenge two reproducible flow-volume 
loops were measured, with the highest acceptable value recorded at each interval.  
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3.4. Bronchial Provocation Test – Eucapnic Voluntary Hyperpnoea 
The EVH challenge is used as alternative for exercise challenges to identify 
exercise induced bronchoconstriction in athletes and recreationally active individuals 
(Anderson, et al. 2001). The bronchoconstriction associated with EVH is commonly 
termed hyperpnoea induced bronchoconstriction (HIB).  EVH is the method of 
bronchoprovocation used within this series of studies subsequently the term HIB will be 
used for the experimental chapters’  4,  5, and  6.  
The EVH challenge required participants to maintain a target V̇  of 30 x 
baseline FEV1 for 6 min, equivalent to 85% of an individual’s maximal voluntary 
ventilation (Argyros, et al. 1996, Hurwitz, et al. 1995) (Figure 3. 1). Participants 
breathed through a flanged mouthpiece (Series 9060, Hans Rudolph, Missouri, USA) 
connected to a flow sensor (ZAN variable orifice pneumotach; Nspire Health, 
Oberthulba, Germany) that was calibrated using a 3 L syringe. Gas concentrations were 
measured using fast responding laser diode absorption spectroscopy sensors, which 
were calibrated using gases of known (5% CO2, 15% O2, balance N2) concentration 
(BOC, Guilford, UK), and ventilatory and pulmonary gas exchange variables were 
determined breath-by-breath (ZAN 600USB; Nspire Health, Oberthulba, Germany). A 
two-way non-rebreathing valve (2700 Series, Hans Rudolph) was connected distally to 
the flow sensor and the inspiratory port was connected via a 1.2 m length of corrugated 
tubing (internal diameter = 35 mm) to a 150 L capacity Douglas bag. Participants 
inspired from the Douglas bag, which was continuously filled with gases of known 
concentration (21% O2, 5% CO2, balance N2). The inspired gas was at room 
temperature (19-21°C) and of low humidity (<3%). Participants received real-time 
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visual feedback of their V̇E throughout EVH and continuous monitoring of end-tidal 
CO2 confirmed that eucapnia (end-tidal CO2 between 35-45 mmHg) was maintained. 
Following the EVH challenge participants remained in the laboratory until their FEV1 
was within 10% of their baseline measurement. The test-retest reproducibility of the 
bronchoconstrictive response to EVH in asthmatic individuals was assessed.  
 
Figure 3. 1 Eucapnic voluntary hyperpnoea testing set up. 
 
3.5. Fraction of Exhaled Nitric Oxide (FENO) – Aerocrine NIOX Mino 
Measurement of fractional nitric oxide in exhaled breath (FENO) is a simple non-
invasive method of quantifying airway inflammation, and provides a complementary 
Breath-by-breath 
analyser with visual 
V̇E feedback
Dry gas inhalation –
5% CO2, 21% O2, 
balance N
Flow meter to 
match target V̇E
Douglas Bag dry 
gas inhalation 
reservoir
Non-rebreathing 
valve and 
pneumotach
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measure to the assessment of asthma (Dweik et al. 2011) and was conducted for the 
studies in Chapter 5 and 6. FENO was measured at baseline prior to the EVH challenge 
on all visits to the laboratory in the asthmatic participants only using a handheld 
monitor (Niox MINO, Aerocrine, Sweden). Participants were instructed to inhale 
through the machine to maximum inhalation, and then an exhalation of 50 mL·s-1 was 
maintained for 6 seconds using a visual target (Dweik, et al. 2011). Previous research 
has established the reliability of the handheld Niox MINO comparing it to the standard 
stationary chemiluminescence unit (Khalili, Boggs and Bahna 2007). One hundred and 
ten patients (6-86 years) completed three exhalations with the standard unit and NIOX 
MINO. Intrasubject FENO levels showed no significant difference between the 
measurements (p >0.05); with a strong correlation between FENO measurements by the 
standard unit and the NIOX MINO (r = 0.98,p < 0.0001).  The intrasubject FENO 
difference between the standard and the MINO was -0.5 ppb, which was not statistically 
significant (p > 0.01) (Khalili, Boggs and Bahna 2007).  
3.6. Blood sampling 
Venous blood was drawn from a vein in the antecubital fossa region of the forearm, 
via a 21 gauge needle (BD value-set, BD, Plymouth, UK). Chapter 5 required the 
collection of 20 mL drawn into plain syringes (no anticoagulant) of whole blood prior 
to the EVH testing protocol for the determination of neutrophil fatty acid phospholipid 
profiles. Chapter 6 required the collection of 20 mL of whole blood prior to EVH and at 
15 min, 60 min, and 24 h post EVH for the determination of cytokine and chemokine 
concentrations. Upon completion of each blood sample, the needle was removed and 
medical tissue was applied under firm pressure to avoid any superficial haematoma.  
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3.7. Enzyme linked immunosorbant assay (ELISA) 
The ELISA has become the ‘gold standard’ in measuring systemic cytokine and 
eicosanoid concentrations from human serum, plasma or urine. ELISA is a biochemical 
technique that detects the presence of an antigen (cytokine or eicosanoid) in a sample 
(Figure 3. 2). The technique of running an ELISA is simple and reliable, and with the 
development of many commercially available kits it allows for the measurement of 
many systemic cytokines and eicosanoids. ELISAs were used for the determination of 
urinary eicosanoid 9α, 11β-PGF2 and serum cytokine TNF-α, and serum CRP and IgE 
in chapters 5 and 6.  
 
Figure 3. 2 Sandwich enzyme linked immunosorbant assay (ELISA). 1) Surface is prepared to which a 
known quantity of capture antibody (specific for metabolite being measured) is bound; 2) the antigen 
containing sample (e.g., serum) us added to the plate; 3) a specific antibody is added and binds to the 
antigen (sandwich); 4) enzyme-linked secondary antibodies are applied; and 5) a chemical is added to be 
converted by the enzyme into a colour of fluorescent signal and the absorbency signal of the plate wells is 
measured to determine the quantity of the metabolite. 
 
.  
 
1 2 3 4 5
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4. Chapter 4 – Reproducibility of the bronchoconstrictive response to 
eucapnic voluntary hyperpnoea 
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4.1. Introduction 
Asthma is a significant public health issue and affects a large proportion of the 
population (Section  2.1.1). It’s estimated that up to 90% of individuals with asthma and 10 
to 50% of a given elite athlete population can experience EIB (Naguwa, Afrasiabi and 
Chang 2012), and asthma is the most common chronic medical condition reported among 
Olympic athletes (prevalence of 7-8%) (Kippelen, et al. 2012). Exercise induced 
bronchoconstriction (EIB) is a phenotype of asthma that is characterized by a transient 
airway narrowing during or on the cessation of exercise (McFadden Jr and Gilbert 1994, 
Anderson and Holzer 2000, Suman, et al. 1999), and it is generally accepted that airway 
drying and changes in airway osmolality trigger the response (Rundell and Jenkinson 
2002). For more details on the pathophysiology of EIB see section  2.2. Whilst EIB is 
prevalent amongst physically active asthmatics and competitive sportsmen and women, the 
risk of acute bronchoconstriction in those undertaking exercise can be reduced through 
early detection and suitable treatment along with reproducible monitoring of the condition 
(Carlsen, et al. 2008).   
Despite EIB’s high prevalence rates there still remains a significant problem with 
diagnosis. The largest issue is forming an accurate diagnosis of EIB from exercise induced 
respiratory symptoms without any confirmatory objective testing. EIB typically presents 
itself with a variety of nonspecific symptoms such as, shortness of breath, wheeze, and 
tightness in the chest. In athletes, EIB was historically assessed by self-reported symptoms 
and clinical history (Larsson, et al. 1993, Heir and Oseid 1994). The lack of specificity and 
sensitivity of symptoms make diagnosis using this information alone extremely inaccurate 
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and can result in either false positive or false negative results (Rundell, et al. 2001a, 
Holzer, Anderson and Douglass 2002, Parsons 2009).  Previous research has shown that 
only 35% of participants who presented with suggestive symptoms of EIB actually had 
objectively diagnosed EIB using pulmonary function and bronchial provocation challenge 
testing (Parsons, et al. 2007). Similarly it has been documented that 45% of athletes who 
complain of respiratory symptoms during exercise were found to be EIB negative after 
bronchial provocation testing (Rundell, et al. 2001a). These data highlight the need for 
confirmatory objective testing to diagnose EIB; however there is no gold-standard 
bronchoprovocation test. A number of bronchoprovocation methods are available, and this 
in part may explain why so many individuals are diagnosed without any objective testing 
(Parsons 2009).  
Both direct and indirect challenge tests are employed as objective testing 
(section  2.4). Direct challenge tests involve the use of inhaled pharmacological agents such 
as histamine and methacholine to act directly on airway smooth muscle receptors to induce 
a bronchoconstriction. Methacholine is widely used as a screening test for asthma, but its 
value for diagnosing EIB is limited. Methacholine challenge tests have been shown to have 
low sensitivity for confirming EIB in athletes (Holzer, Anderson and Douglass 2002). 
These direct challenge tests asses for nonspecific airway hyperresponsiveness, and are not 
specific for the mechanisms that trigger EIB (Parsons 2009). Indirect bronchial provocation 
challenge tests that mimic the breathing rates and mechanisms associated with EIB may 
have greater sensitivity to diagnosing EIB in physically active asthmatics (Weiler, et al. 
2007); these include exercise tests and eucapnic voluntary hyperpnoea (EVH). EVH is an 
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alternative to laboratory and field based exercise challenge tests (section  2.4.1.1). It was 
originally developed, standardised, and validated by members of the US army (Eliasson, et 
al. 1992, Argyros, et al. 1995, Argyros, et al. 1996) and later adopted to identify EIB in 
elite athletes (Anderson, et al. 2001). 
The EVH challenge is recommended by the International Olympic Committee-
Medical Commission to diagnose EIB in elite athletes (Weiler, et al. 2007, Fitch, et al. 
2008) to allow for certification for the use of World Anti-Doping Agency prohibited 
asthma medication (World Anti-Doping Agency). An EVH challenge test comprises 6 
minutes voluntary hyperpnoea breathing a dry gas (5% CO2, 21% O2, balance N2). This 
hyperpnoea mimics the breathing rates associated with intense aerobic exercise, and the 
hyperpnoea induced bronchoconstriction (HIB) results from a similar pathogenesis as EIB 
(Anderson, et al. 2001).  Following EVH, a reduction in forced expiratory volume in 1 s 
(FEV1) of ≥10% is commonly accepted as a diagnosis of EIB/HIB (Anderson, et al. 2001). 
EVH has been shown to have greater sensitivity than other objective tests such as the 
methacholine challenge (Holley, et al. 2012) particularly in athletes and military personnel 
(Dickinson, McConnell and Whyte 2011, Argyros, et al. 1996), and results in fewer false-
negative EIB diagnoses compared to exercise challenges (Rundell, et al. 2004, Mannix, 
Manfredi and Farber 1999). Furthermore, EVH can diagnose EIB in previously 
undiagnosed and asymptomatic athletes and is the recommended challenge of choice in 
elite athletes (Dickinson, McConnell and Whyte 2011, Molphy, et al. 2013, Dickinson, et 
al. 2006).  
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The target ventilation for the 6 minute EVH challenge is established from baseline 
pulmonary function, and set as 30 x FEV1. Target minute ventilation (V̇E) of 30 x FEV1 is 
maintained for 6 min and has been shown to have high EIB diagnostic sensitivity (Argyros, 
et al. 1996, Hurwitz, et al. 1995). However, the duration and target minute ventilation (V̇E) 
of the EVH challenge can directly impact on the bronchoconstrictive response (Argyros, et 
al. 1996) and, therefore, should be closely controlled. Factors that may influence 
pulmonary function in asthmatics include the level of dependence upon medication, the 
level of asthma control, and exposure to triggers prior to assessment (Borsboom, et al. 
1999, Ryan, et al. 1982, Hruby and Butler 1975). Influencing the pulmonary function 
testing will subsequently impact upon the target V̇E and consequent bronchoconstrictive 
response to EVH. Therefore an understanding of the day-to-day variability in pulmonary 
function testing and EVH response is warranted. In competitive swimmers, EVH has been 
shown to elicit consistent reductions of FEV1 when assessed over 2 consecutive days (95% 
limits of agreement: 6%) (Stadelmann, Stensrud and Carlsen 2011). However, the long-
term reproducibility of the bronchoconstrictive response to EVH has not been documented 
but is important given the variability in symptoms, pulmonary function, and biomarkers 
associated with asthma in response to a variety of triggers (Frey, Maksym and Suki 2011).  
Previous research assessing reproducibility of pulmonary function, and responses to 
dry gas exercise challenges have used intraclass correlation coefficients (ICCs) to establish 
the reliability (Dahlen, et al. 2001, Hofstra, et al. 1997).  ICCs are commonly used to 
evaluate reliability; however these focus on a correlation between measures. Correlations 
can only establish an association between variables, and do not show agreement between 
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two measures. For example a high correlation coefficient may exist when one value is 
almost twice the other (Figure 4. 1a). The strong correlation allows for prediction of one 
measure based on the other, but the actual agreement in the absolute values are non-
existent, whereas if the measured values are similar then you achieve both correlation and 
agreement (Figure 4. 1b). Therefore it is important to understand the level of 
reproducibility in the bronchoprovocation response to EVH and conduct statistical methods 
to ensure confidence can be taken from the results.  
When attempting to monitor changes in severity of EIB it is important to 
understand the clinical significance of methods and therefore statistics that utilise 
reproducibility statistics and the calculation of the smallest measurable change are 
warranted (Bland and Altman 1996, Hopkins 2000). With reductions in FEV1 following 
EVH used to diagnose hyperpnoea induced bronchoconstriction, it is important to ascertain 
the reproducibility of such reductions and the smallest measurable change in these 
reductions. This will allow for greater confidence when assessing interventions that aim to 
reduce the severity of EIB. If changes in post EVH FEV1 exceed the smallest measurable 
change then it is likely to be of physiological importance. Understanding the long-term 
reproducibility of the 6 min EVH test may thus improve the monitoring and evaluation of 
EIB management and intervention strategies.  
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Figure 4. 1. Graphical representations of correlation and agreement 
Thus, the aim of this study was to evaluate the short- (21 days) and long- (70 days) 
term test-retest reproducibility of the bronchoconstrictive response to a 6 min EVH 
protocol in asthmatic EIB sufferers and non-asthmatic-non-EIB controls. It was 
hypothesised that both asthmatic EIB sufferers and non-asthmatic controls would receive 
reproducible diagnoses in response to an EVH challenge over 21, and 70 day periods.   
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4.2. Methods 
4.2.1. Participants 
Initially twenty eight recreationally active (completing 4-6 hours of aerobic exercise 
a week) males (14 asthmatics and 14 non-asthmatics) provided written informed consent 
and were assessed for eligibility (Figure 4. 2). Following eligibility, two cohorts of 16 
participants were deemed suitable to take part in a short-term and/or long-term study of 
EVH reproducibility. Each cohort of 16 participants comprised 8 asthmatic HIB positive 
and 8 non-asthmatic HIB negative controls; 8 participants (4 HIB positive and 4 controls) 
were common to both cohorts (Figure 4. 2). Inclusion criteria for HIB positive participants 
were a ≥10% reduction in FEV1 following EVH (Parsons, et al. 2013) and a GP diagnosis 
of asthma. The studies were approved by the Nottingham Trent University Human Ethics 
Committee, and all procedures were conducted in accordance with the Declaration of 
Helsinki. 
Throughout the study, participants adhered to their usual training regime and were 
asked not to partake in strenuous exercise 48 h prior to testing. On test days, participants 
abstained from caffeine and alcohol and arrived at the laboratory at least 2h post-prandial. 
Asthmatics were instructed to cease their medication prior to each EVH challenge (inhaled 
corticosteroids and leukotriene modifiers: 4 days; inhaled long acting β2 agonists: 2 days; 
anti-histamines: 2 days; inhaled short acting β2 agonists: the day of the test) and were 
tested at least 2 weeks following recovery from any chest or upper respiratory tract 
infection (Dickinson, McConnell and Whyte 2011, Anderson, et al. 2001).  
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Figure 4. 2 Consort diagram – flow of participants through both short-term and long-term studies. 
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4.2.2. Experimental design 
Following familiarization with the EVH protocol, the short-term reproducibility 
study comprised 4 EVH challenge tests each separated by 7 days. The long-term 
reproducibility study comprised 3 EVH challenge tests each separated by 35 days. Tests 
were conducted at the same time of day for each participant.   
4.2.3. Pulmonary function and EVH 
Pulmonary function (forced vital capacity (FVC) and FEV1) and the EVH protocol 
were conducted following the methods outlined in Chapter  3. Following each EVH 
challenge, pulmonary function was re-evaluated in duplicate at 3, 6 and 16 min, and the 
highest values recorded at each interval were used for subsequent analysis (Parsons, et al. 
2013). A reduction in FEV1 of ≥10% following EVH was deemed positive of HIB 
(Anderson, et al. 2001). 
4.2.4. Statistical analysis 
Statistical analyses were performed using SPSS for Windows version 22 (SPSS 
Inc., Chicago, IL, USA). One way repeated measure ANOVAs were performed to assess 
changes in pre-EVH FEV1 and FVC over the course of both short-term and long-term 
studies in HIB and control participants. Between-group comparisons (HIB vs. control) of 
baseline pulmonary function and %∆FEV1 were made using independent samples t-tests. 
To assess changes in FEV1 and FVC as a result of EVH, one-way repeated measures 
ANOVA followed by Bonferroni adjusted t-tests were conducted to compare pre-EVH 
values to the 3, 6, and 16 min time points post EVH for each day in both HIB and control 
participants. Bonferroni adjusted pairwise comparisons assessed differences between the 
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post EVH time points for FEV1 and FVC at day 0 for both short-term and long-term 
studies. If no difference was evident (p > 0.05) the post-EVH values were averaged to 
produce a mean response to EVH which was subsequently followed by the calculation of 
absolute changes (mL). The %∆FEV1 was calculated and a reduction of 10% was deemed 
diagnostic.  
Within participant coefficients of variation (CV) were calculated for pulmonary 
function measures pre and post EVH.  Measurement error otherwise known as the within-
subject standard deviation was calculated as the square root of the within-subjects error 
generated by SPSS repeated measures analysis of variance (Bland and Altman 1996). 
Reproducibility was calculated from measurement error multiplied by 2.77 (√2 x 1.96) 
(Bland and Altman 1996). This states that the difference between two measurements for the 
same participant is expected to be less than 2.77 x measurement error for 95% of a pair of 
measurements (Bland and Altman 1996). Subsequently the smallest measurable change 
was calculated from the reproducibility value divided by 2 (Hopkins 2000). These 
reproducibility statistics were calculated for pre-EVH FVC and FEV1, the post EVH FEV1 
and FVC, and the absolute change in FEV1 and FVC (mL) post EVH. In HIB participants 
only, the area under the curve for %∆FEV1 during the 16 min period after EVH was 
calculated using the trapezoidal rule (AUC0-16%∆FEV1). All data are reported as mean ± 
SD. Statistical significance was set at p < 0.05.  
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4.3. Results 
Participant characteristics and pre-EVH pulmonary function measures are shown in 
Table 4. 1. Baseline FEV1 was always ≥65% of predicted (Knudson, et al. 1983) in all 
participants, who were therefore able to undergo all EVH challenge tests (Argyros, et al. 
1996). HIB participants in the short-term and long-term studies achieved their target V̇E on 
all occasions (120 ± 24 vs 120 ± 20; p >0.05 and 114 ± 24 vs 115 ± 22; p >0.05 
respectively).  The lower baseline FEV1 in the HIB group meant that the target V̇E during 
EVH was lower compared to the control group in both the short- and long-term studies (p < 
0.05). Control participants achieved their target V̇E on all occasions for both short- and 
long-term studies (141 ± 12 vs 139 ± 12; p >0.05 and 139 ± 11 vs 137 ± 9 p >0.05). All 
HIB participants experienced a ≥10% reduction in FEV1 after each EVH challenge test 
receiving a positive diagnosis on each occasion (Figures 4.1 and 4.2).  
Table 4. 1. Participant characteristics for both short- and long-term studies. * significant difference between 
HIB and Control group (p < 0.05). % predicted from (Knudson, et al. 1983) 
 Short-term study Long-term study 
 HIB group Control group HIB group Control group 
Age (yr) 28 ± 7 25 ± 3 31 ± 9 26 ± 4 
Height (m) 1.77 ± 0.06 1.81 ± 0.06 1.75 ± 0.02 1.81 ± 0.05 
Body mass (kg) 75.83 ± 0.90 79.30 ± 7.86 72.75 ± 9.63 77.75 ± 8.58 
Baseline FVC (L) 5.14 ± 0.90 5.56 ± 0.42 4.68 ± 0.69 5.22 ± 0.40 
% predicted 100 ± 12 102 ± 7 94 ± 10 97 ± 6 
Baseline FEV1 (L) 4.03 ± 0.80* 4.71 ± 0.40 3.79 ± 0.80* 4.63 ± 0.39 
% predicted  93 ± 15 103 ± 6 91 ± 14 102 ± 5 
 
In both short- and long-term studies pre-EVH FVC did not differ between HIB and 
control groups, whereas FEV1 was consistently lower in the HIB group when compared to 
the control group (p < 0.05) (Table 4. 1). No difference in pre-EVH FEV1 and FVC were 
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found between days for the short- and long-term studies in either the HIB or control groups 
(p > 0.05).  
HIB participants at day 0 of the short-term study exhibited a significant reduction in 
FVC from pre-EVH to post-EVH (p < 0.05), no difference was evident between the three 
post-EVH time points (p > 0.05) which were averaged for reproducibility statistics (Table 
4.3). Bonferroni pairwise adjusted comparisons in the mean post-EVH FVC between day 0, 
7, 14, and 21 revealed no significant differences (p > 0.05). The absolute fall in FVC did 
not differ between the four short-term days (p > 0.05). In the long-term study a significant 
reduction in FVC from pre-EVH to post-EVH occurred at 3 and 6 minute time points (p < 
0.05) at day 0. The mean of 3 and 6 minute time points did not differ between days 0, 35, 
and 70 (p >0.05). The absolute fall in FVC did not differ across the three long-term days (p 
>0.05).  
In the short term study FEV1 differed significantly from pre-EVH to post-EVH (p < 
0.05) at all-time points in the HIB participants (3, 6 and 16 minutes). Bonferroni pairwise 
adjusted comparisons revealed no difference was evident between these post-EVH time 
points (p >0.05) which were subsequently averaged for each day (Table 4.2). There was no 
difference in post-EVH FEV1 between days (p >0.05). The absolute fall in FEV1 did not 
differ between days (p >0.05). The fall in FEV1 in HIB participants was always greater 
than 10% meaning a consistent diagnosis was achieved through EVH over the 4 short-term 
and three long term days (Figure 4. 3 and Figure 4. 4).  
Control participants exhibited no reductions in FVC following the EVH protocol in 
both the short- and long-term studies (p > 0.05). Post-EVH FVC did not differ over the 
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course of the 4 short-term days (p > 0.05), and the 3 long-term days (p > 0.05). In the short-
term study FEV1 differed from pre-EVH to post-EVH time points (p < 0.05). Bonferroni 
pairwise comparisons revealed post-EVH FEV1 had reduced but no difference was evident 
between the 3, 6, and 16 minute time points (p > 0.05). In the long-term study pre-EVH 
FEV1 differed to the 3, and 6 minute time points (p < 0.05), but not 16 minutes post EVH 
(p >0.05) at day 0. The 3 and 6 minute time points were averaged to establish the post EVH 
absolute change in FEV1.  In both the short- and long-term studies the reductions in post-
EVH FEV1 were below the 10% diagnosis leading to a consistent non-diagnosis in all 
control participants.  Table 4. 2 shows the group means for %∆FEV1 for both short- and 
long-term studies. The severity of the bronchoconstrictive response as assessed by AUC0-
16%∆FEV1 in HIB participants did not differ over the 4 short-term days, and 3 long-term 
days (p > 0.05) (Table 4. 2).   
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Table 4. 2– Bronchoconstrictive response to EVH over both short- and long-term studies for HIB and control groups (mean ± SD).  
 
SHORT –TERM Day 0 Day 7 Day 14 Day 21 Mean of 4 sessions
% change
Absolute 
change (L)
% change
Absolute 
change (L)
% change
Absolute 
change (L)
% change
Absolute 
change (L)
% change
Absolute 
change (L)
EIB Group 
Post EVH 
ΔFEV1
-27 ± 18 -0.97 ± 0.51 -27  20 -1.00 ± 0.62 -27  19 -0.96 ± 0.56 -26 19 -0.94 ± 0.61 -27  18 -0.97 ± 0.55
Control 
Group
Post EVH 
ΔFEV1
-2 ± 1 -0.11 ± 0.06 -2 ± 2 -0.10 ±0.09 -2 ± 2 -0.11 ± 0.09 -2 ± 2 -0.11 ± 0.08 -2 ± 2 -0.11 ±0.08
EIB Group 
Post EVH 
ΔFVC
-11 ± 13 -0.51 ± 0.54 -16 ± 18 -0.74 ± 0.79 -14 ± 15 -0.66 ± 0.66 -14 ± 14 -0.61 ± 0.56 -14 ± 14 -0.63 ± 0.62
Control 
Group
Post EVH 
ΔFVC
-1 ± 1 -0.05 ± 0.07 -1 ± 1 -0.05 ± 0.04 -2 ± 2 -0.09 ± 0.09 0 ± 1 -0.01 ± 0.05 -1 ± 1 0.05 ± 0.07
LONG-TERM Day 0 Day 35 Day 70 Mean of 3 sessions
% change
Absolute 
change (L)
% change
Absolute 
change (L)
% change
Absolute 
change (L)
% change
Absolute 
change (L)
EIB Group 
ΔFEV1 (%)
Post EVH 
ΔFEV1
-25 ± 18 -0.85 ± 065 -25  16 -0.73 ± 0.47 -25  16 -0.74 ± 0.62 -25  16 -0.77 ± 0.56
Control 
Group
Post EVH 
ΔFEV1
-2 ± 2 -0.10 ± 0.08 -2 ± 2 -0.09 ± 0.07 -3 ± 2 -0.13 ± 0.07 -2 ± 2 -0.10 ± 0.07
EIB Group 
Post EVH 
ΔFVC
-19 ± 16 -0.85 ± 0.65 -17 ± 12 -0.73 ± 0.47 -17 ± 15 -0.74 ± 0.62 -18 ± 14 -0.77 ± 0.56
Control 
Group
Post EVH 
ΔFVC
-1 ± 2 -0.04 ± 0.09 -2 ± 2 -0.10 ± 0.10 -1 ± 2 -0.04 ± 0.09 -1 ± 2 -0.06 ± 0.10
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The within-participant CVs and reproducibility of pre-EVH FVC and FEV1 and 
change in FVC and FEV1 post EVH are shown in Table 4. 3. The within participant CV for 
the post EVH change in FEV1 for HIB participants in the short-term was 11.5%, the 
measurement error was 118 mL and the reproducibility was 328 mL, and smallest 
measurable change was 164 mL. The within participant CV was 8.5% in the HIB 
participants over the long term study for post EVH change in FEV1. The measurement 
error was 63 mL, the reproducibility was 175 mL, and smallest measurable change was 88 
mL.  
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Figure 4. 3 Individual (grey dotted lines) and mean (black line) percentage change in FEV1 following EVH for HIB participants over the four short-term 
sessions. No difference was found in %change FEV1over the 21 days (p > 0.05) 
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Figure 4. 4 Individual (grey dotted lines) and mean (black line) percentage change in FEV1 following 
EVH for HIB participants over the three long-term sessions. No difference was found in %change 
FEV1over the 21 days (p > 0.05) 
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Table 4. 3 Reproducibility in pre-EVH pulmonary function, and change in FEV1 post EVH for control 
and HIB participants, and change in FVC for HIB participants over both short- and long-term studies. 
SMC, smallest measurable change.  
 
 
4.4. Discussion 
The main finding of the present study is that EVH incorporating real-time visual 
feedback of  V̇E and end-tidal PCO2 induces a highly reproducible bronchoconstrictive 
response, over both short- term (21 days) and long-term (70 days) periods, in physically 
active asthmatics with HIB. We also show that baseline pulmonary function is 
reproducible in this population of asthmatics, and non-asthmatic controls.  
The present study showed no significant between day differences in the 
bronchoconstrictive response as measured by both absolute drop in FEV1 (mL) and 
%ΔFEV1 following the EVH protocol in the asthmatic participants. The reproducibility 
SHORT-TERM
Mean ± SD Within 
participant CV (%)
Measurement Error 
(mL)
Reproducibility 
(mL)
SMC  (mL)
CTRL Pre-EVH FEV1 2.0 ± 0.9 100 277 139
EIB Pre-EVH FEV1 2.2 ± 1.3 95 263 131
CTRL Change in FEV1 post-EVH 29.0 ± 13.7 45 124 62
EIB Change in FEV1 post-EVH 11.5 ± 4.1 118 328 164
CTRL Pre-EVH FVC 1.3 ± 0.3 77 215 107
EIB Pre-EVH FVC 3.2 ± 3.3 182 503 252
CTRL  Change in FVC post-EVH - - - -
EIB Change in FVC post-EVH 40.5 ± 32.5 130 361 181
LONG-TERM
CTRL Pre-EVH FEV1 1.6 ± 0.8 85 235 118
EIB Pre-EVH FEV1 2.2 ± 1.7 89 246 123
CTRL Change in FEV1 post-EVH 28.3 ± 17.0 32 88 44
EIB Change in FEV1 post-EVH 8.5 ± 4.5 63 175 88
CTRL Pre-EVH FVC 2.0 ± 1.2 115 319 159
EIB Pre-EVH FVC 3.1 ± 2.2 143 395 198
CTRL  Change in FVC post-EVH - - - -
EIB Change in FVC post-EVH 24.1 ± 15.6 164 455 228
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of the change in FEV1 post EVH was 328 mL and 175 mL for the short- and long-term 
studies respectively. This suggests that the fall in FEV1 following EVH over two 
different testing sessions is expected to vary less than 328 mL for 95% of paired of 
observations over a 70 day period (Bland and Altman 1996). This is significant as the 
mean absolute fall in FEV1 in the asthmatics was greater at ~770 – 970 mL highlighting 
the EVH protocol induces a reproducible level of bronchoconstriction. The smallest 
measurable post-EVH change in FEV1 was 164 and 88 mL for the short- and long-term 
studies respectively. To the authors knowledge this is the first time that the smallest 
measurable change in the fall in FEV1 post-EVH has been calculated from repeated 
EVH challenges. With the smallest measurable change at 88 mL it suggests that 
alterations in the post-EVH fall in FEV1 that are greater than this are likely to be of 
physiological significance. The current protocol allows confidence in monitoring 
changes greater than 88 mL to be detected. With the average fall in FEV1 in the HIB 
participants >770 mL it suggest EVH is likely to be sensitive to changes in the 
bronchoconstrictive response that may be a result of treatment interventions. Having an 
understanding of the smallest measurable change in the FEV1 response to EVH allows 
future research to discriminate physiological changes from any inherent variability in 
the EVH protocol. Interventions to treat HIB that show alterations in the fall in FEV1 
above 88 mL could indicate a significant physiological effect in the response to EVH in 
physically active asthmatics.  
The current study has reported reproducibility in applicable values of mL, 
previous research has assessed reproducibility through the use of intraclass correlation 
coefficients (ICCs). Previous research has reported ICCs for the %ΔFEV1 following 
EVH to be 0.72 and 0.57 obtained using a dry-air exercise challenge (Dahlen, et al. 
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2001, Hofstra, et al. 1997). Although not presented, ICCs for the %ΔFEV1 were 
calculated in the current study as ≥0.98, which is higher than those previously reported. 
The data presented in Table 4. 3 suggest that EVH induces a reproducible 
bronchoconstrictive response in physically active asthmatics. The low SMC for post-
EVH change in FEV1 supports previous research that suggests EVH is also more 
sensitive in diagnosing EIB than (non-dry-air) exercise challenges, which are more 
difficult to standardize due to potential variability in exercise intensity and duration, 
and inspirate moisture content (Rundell, et al. 2004, Rundell, et al. 2000). Not 
standardising these factors and/or using an exercise challenge (e.g. an incremental / 
ramp protocol) that evokes inadequate bronchoprovocation (Anderson and Brannan 
2011) may result in false negative EIB diagnoses (Rundell and Slee 2008) due, in part, 
to release of bronchodilating substances (e.g. prostaglandin E2) at low exercise 
intensities (Manning, Watson and O'Byrne 1993, Pavord and Tattersfield 1995). 
Bronchoprovocation tests based on field-based exercise challenges also lack utility due 
to difficulties in standardizing exercise intensity,  V̇E, inspirate temperature, humidity 
and air quality (Anderson 2011, Anderson 2011, Rundell and Slee 2008, Rundell, et al. 
2004). The present study demonstrates that the bronchoconstrictive response to EVH is 
reproducible over both the short- and long-term and therefore may be a more useful 
challenge than exercise when evaluating and monitoring treatment interventions for 
asthma and EIB/HIB.  
The reproducibility of the evoked bronchoconstrictive response in the present 
study may be explained by the “square wave” nature of the ventilatory response during 
EVH, which permits rapid achievement of the target V̇E. The total pulmonary 
ventilation over the 6 min EVH period is therefore likely to be higher than that achieved 
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during an exercise protocol where V̇E increases progressively over time (Anderson, et 
al. 2001). The target V̇E during EVH, which was well tolerated in the present study, 
approximates 85% of maximal voluntary ventilation (Anderson, et al. 2001), which is 
thought to represent that which can be maintained for at least 6 min whilst also 
stimulating a bronchoconstrictive response (Anderson, et al. 2001). Pre-EVH 
pulmonary function showed no differences over the 4 short-term and 3 long-term days, 
the mean within-participant CVs were <3% and exhibited a low measurement error, and 
good reproducibility (Table 4. 3). Consistent pre-EVH pulmonary function tests allows 
for a highly reproducible target V̇E for the EVH challenge. In the present study, two of 
the asthmatics presenting with GP diagnosed EIB experienced a fall in FEV1 of <10% 
and therefore did not meet the EIB group inclusion criterion (Figure 4. 1). This is 
consistent with reported EIB misdiagnosis (inspiratory stridor may, for example, be 
confused with wheeze) (Rundell and Spiering 2003) and highlights the utility of EVH 
in accurately identifying EIB. However, it must be acknowledged that in certain cases 
EVH can fail to diagnose EIB in some athletes (Dickinson, McConnell and Whyte 
2011). EIB is highly heterogeneous and additional factors such as medication and 
asthma control level, or specific activities/environments and triggers can influence the 
diagnosis.  Furthermore some athletes with inspiratory stridor may be diagnosed with 
EIB on symptoms (Rundell and Spiering 2003), but would subsequently be EVH 
negative and non-responsive to β2-agonist medication.  
The use of a breath-by-breath analyser (Figure 3. 1) in the present study 
provided participants with a visual target and real-time feedback of V̇E. Previous EVH 
protocols have used a metronome to pace breathing frequency and a dry gas meter to 
determine cumulative ventilation (Anderson, et al. 2001). Not providing real-time 
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feedback to the participant may compromise standardization of the EVH challenge. 
Additionally, since hypocapnia evokes bronchoconstriction in asthmatics (Suman, et al. 
1999, Sterling 1968), breath-by-breath analysis allows continual monitoring of end tidal 
PCO2 and maintenance of eucapnia (defined as end tidal PCO2 of 35-45 mmHg) all 
EVH challenge tests in the current study maintained end-tidal PCO2 within this range. 
The apparatus used in the present study may have therefore improved validity and 
reproducibility of the EVH challenge and subsequent HIB response. It must be 
acknowledged that EVH causes hyperpnoea induced bronchoconstriction as an 
experimental model of the breathing rates associated with exercise that results in EIB. 
EVH is a relatively severe bronchoprovocation challenge compared to laboratory and 
field exercise tests, and some athletes who are HIB diagnostic from EVH may not 
notice symptoms during training and competition (Dickinson, McConnell and Whyte 
2011). However, the protocol in the current study is highly sensitive and reproducible 
and if an individual does present HIB then it suggests they are at risk of EIB during or 
following exercise and may benefit from pharmacological and non-pharmacological 
treatment options. The effectiveness of subsequent treatment interventions can be 
confidently and effectively monitored by alterations in the bronchoconstrictive response 
through the use of EVH.  
In conclusion, this study confirms the efficacy of a 6 min EVH protocol as a 
bronchoprovocation test. The study has demonstrated excellent within-participant test-
retest reproducibility for EVH and the evoked changes in pulmonary function in HIB 
participants, over both short- (21 days) and long-term (70 days) periods. The EVH 
protocol described in the present study thus provides a valuable tool for monitoring HIB 
and assessing the efficacy of interventions aimed at reducing HIB. 
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5. Chapter 5 – The effects of omega 3 polyunsaturated fatty acid 
supplementation dose level (6.2 g·d
-1
 vs 3.1 g·d
-1
) on the severity of 
hyperpnoea induced bronchoconstriction 
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5.1. Introduction 
Airway inflammation is associated with the release of a number of lipid derived 
pro-inflammatory mediators which include leukotrienes and prostaglandins generated 
from arachidonic acid. These pro-inflammatory eicosanoids are known to cause 
bronchial smooth muscle contraction and airway obstruction (Anderson and Daviskas 
2000) (see section  2.2.5).  
Traditional asthma and EIB treatment with β2-agonists typically targets 
symptoms alone, and long-term use of inhaled corticosteroids can have systemic side 
effects (section  2.5.4). Therefore therapeutic strategies which aim to reduce the release 
of pro-inflammatory mediators such as the arachidonic acid metabolites in an attempt to 
reduce airway inflammation are warranted.  Dietary supplement use is popular in both 
the general and asthmatic populations and a nutritional approach to treating asthma is 
appealing to reduce the reliance upon medication that can have adverse side effects.  A 
recent US National Health and Nutrition Examination Survey revealed that 
approximately 50% of people in both these groups reported using dietary supplements 
in the last 30 days. The survey also found that omega-3 polyunsaturated fatty acid (ω3-
PUFA) supplementation is used by 6.7% of asthmatics as a nutritional therapy (Ma and 
Xiao 2011) . 
The effectiveness of high dose ω3-PUFA supplementation in reducing airway 
obstruction and eicosanoid accumulation associated with EIB has been demonstrated 
previously (Mickleborough, et al. 2003, Mickleborough, et al. 2006, Tecklenburg-Lund, 
et al. 2010, Mickleborough, et al. 2013), however, the optimal dose level of ω3-PUFA 
for alleviating EIB in physically active asthmatics is yet to be determined and warrants 
further investigation.  
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5.1.1. ω3-PUFA and EIB 
The first study to investigate the effects of supplementation with ω3-PUFA on 
symptoms of asthma and response to exercise provided equivocal results (Arm, et al. 
1988). Twenty five mild asthmatics (responsive to exercise and histamine challenge) 
were randomised to receive either ω3-PUFA (3.2 g·d-1 EPA and 2.2 g·d-1 DHA) or 
identical in size and shape placebo capsules (olive oil) for 10 weeks under double blind 
conditions. Airway responsiveness to histamine and exercise, diurnal peak expiratory 
flow, symptom scores, and bronchodilator use were measured. Neutrophil fatty acid 
composition was evaluated by gas chromatography as an indication of compliance to 
the supplementation regime. The ω3-PUFA supplementation produced a greater than 10 
fold increase in the EPA content of the neutrophil phospholipids, and a 50% inhibition 
of total leukotriene B4 generation (p < 0.01) in stimulated neutrophils. Despite the 
changes in phospholipid fatty acid content and suppression of pro-inflammatory 
eicosanoid production, there was no significant change in airway responsiveness 
following either the histamine, or exercise challenge, in the asthmatics. The results 
indicated that neutrophil function could be suppressed in asthmatics following high 
dosages of ω3-PUFA but did not improve the severity of disease. The authors attributed 
the results to the fact that neutrophils may not play a major role in the pathogenesis of 
asthma, or the level of change in neutrophil function was not of a level to alter disease 
severity (Arm, et al. 1988). The study failed to acknowledge additional roles of other 
inflammatory cell types and provide data on the physical activity of their asthmatic 
population.  
In contrast, two key studies have shown improvements in EIB after exercise 
challenge testing following 3 weeks of high doses of ω3-PUFA (3.2 g·d-1 EPA and 2.2 
g·d
-1
), with FEV1 improving to non-diagnostic levels, coupled with reduced 
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inflammatory markers (Mickleborough, et al. 2003, Mickleborough, et al. 2006). In 
2003, Mickleborough and co-workers assessed the effectiveness of 3-weeks 
supplementation of ω3-PUFA on EIB in elite athletes. Ten elite athletes with mild EIB 
(~15% drop in FEV1 post exercise) and 10 non-EIB controls completed the randomised, 
double-blind, placebo-controlled (olive oil) crossover study (normal diet vs placebo vs 
ω3-PUFA) with a two-week washout between interventions. EIB was assessed via 
exercise challenge testing, and a drop in FEV1 of ≥10% was considered diagnostic of 
EIB.  
In participants with EIB, intervention with ω3-PUFA improved post exercise 
pulmonary function compared with participant’s normal diet, and placebo interventions. 
Following the 3 week ω3-PUFA intervention, asthmatic participants exhibited no 
reduction in FEV1 after an exercise challenge -3 ± 2% (p > 0.017, Bonferroni adjusted) 
suggesting participants had become non-diagnostic. However, on the placebo 
intervention and their normal diets they remained diagnostic recording %ΔFEV1, of -
14.5 ± 5% and -17.3% ± 6% respectively (p < 0.017, Bonferroni adjusted) 
(Mickleborough, et al. 2003). Urinary eicosanoids and circulating immunoreactive 
cytokines as markers of airway inflammation were reduced following the ω3-PUFA 
intervention. At day 21 of the ω3-PUFA intervention urinary LTE4 excretion was 
significantly reduced  prior to exercise and 15 minutes post exercise by 19.4 pg·mg
-1
 
creatinine and 13.1 pg·mg
-1
 creatinine respectively (p < 0.017) compared to pre 
supplementation LTE4 concentration of 56.9 ± 13.3 pg·mg
-1
 creatinine (Mickleborough, 
et al. 2003). Day 21 of the ω3-PUFA intervention resulted in reductions of mean 
urinary excretion of 9α, 11β-PGF2α prior to exercise of 16.8 ng·mg
-1
·mmol creatinine
-1
 
and by 13.9 ng·mg
-1
·mmol creatinine
-1
 at 15 minutes post exercise compared with the 
pre supplementation level of 53.2 ± 12.4 ng·mg
-1
·mmol creatinine
-1
 (p < 0.017) 
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(Mickleborough, et al. 2003). Following the ω3-PUFA intervention both TNF-α, and 
IL-1β decreased by 22.6 ± 6.3% (p < 0.017), and 22.5 ± 6.7% (p < 0.001) respectively 
compared to day 0 of the intervention. IL-1β significantly reduced by 15.1 ± 4.7% at 15 
minutes post exercise (p < 0.017) compared with pre-ω3-PUFA diet values 
(Mickleborough, et al. 2003).  
Mickleborough et al. (2003) were the first to show a significant therapeutic 
effect of high dose ω3-PUFA in physically active asthmatics with improvements in 
pulmonary function and attenuation in inflammatory markers.  These findings are in 
contrast to those previously shown by Arm et al. (1988). These conflicting findings are 
surprising considering the longer supplementation period with identical daily dosages 
used by Arm et al. (1988). The differences may be attributed to the participant’s 
activity, and athletic ability levels. Mickleborough et al. (2003) studied collegiate or 
national level athletes (V̇O2max = 61.7 ± 7.9 mL·kg
-1
·min
-1
) compared to non-athletic 
participants in the Arm et al (1988) study (VO2max not reported). It has been suggested 
that higher level athletes are more likely to suffer with EIB than non-athletic asthmatics 
due to inspiring larger quantities of unconditioned air in both competition and training 
which may predispose this population to more severe EIB. There is evidence of airway 
remodelling in athletes with EIB (Sue-Chu, et al. 2000, Sue-Chu, et al. 1999, 
Karjalainen, et al. 2000, Karjalainen, et al. 2000), and some athletes are non-responsive 
to inhaled corticosteroids (Sue-Chu, et al. 2000). This indicates the varying 
pathogenesis of EIB, which may be more severe in physically active and athletic 
asthmatics.   
Mickleborough et al. (2006) were able to support their earlier 2003 findings in a 
study where participants consumed ω3-PUFA intervention (3.2 g EPA and 2.0 g DHA 
daily) and placebo intervention (olive oil) for 3 weeks in a randomised double-blind 
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cross-over study. The authors found similar protective effects of ω3-PUFA in 
recreationally active asthmatics (Mickleborough, et al. 2006). This study continued to 
support the notion of a reduction in pro-inflammatory mediator release as a mechanism 
of action through the collection of induced sputum as a more direct measure of airway 
inflammation. Pulmonary function, induced sputum differential cell count percentage, 
pro-inflammatory eicosanoid metabolites (LTC4 – LTE4 and PGD2) and cytokines (IL-
1β, and TNF-α) were assessed pre and post exercise challenge. All participants 
exhibited EIB on their normal diet and placebo intervention. However, following the 
ω3-PUFA intervention, the mean reduction in FEV1 after the exercise challenge was 
below diagnostic levels (%∆FEV1 -8.1 ± 0.19%) (Mickleborough, et al. 2006). The ω3-
PUFA intervention resulted in large reductions in pre-exercise sputum LTC4-LTC4, 
PGD2, IL-1 and TNF-α by 74%, 93%, 71%, and 95% respectively compared to the 
placebo intervention, this was also observed at 1 h and 24 h after the exercise challenge 
compared to placebo and normal interventions. There were positive correlations 
between the severity of EIB and percentages of post-exercise sputum eosinophils and 
neutrophils when on the placebo intervention and normal diet highlighting their role in 
pathogenesis of EIB (Mickleborough, et al. 2006). These findings corresponded with 
increased neutrophil phospholipid content of EPA (~20 fold increase) and DHA (~4 
fold increase) on the ω3-PUFA (p < 0.05), and reduced content of linoleic acid and 
arachidonic acid (p < 0.05) (Mickleborough, et al. 2006). This study showed for the first 
time that fish oil supplementation reduced airway inflammation in recreationally active 
asthmatics. The mechanisms for this are likely to be related to the reduced production 
of cysteinyl leukotrienes and cytokines. With the cysteinyl leukotrienes thought to be 
the most important pro-inflammatory mediators causing EIB in asthmatics (O'Byrne 
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2000), the two Mickleborough studies highlight a strong rationale for the use of ω3-
PUFA supplementation in the treatment of EIB.  
More recently research has emerged in support of Mickleborough’s previous 
work, showing ω3-PUFA to be as effective in EIB treatment as the pharmacological 
intervention of montelukast, a leukotriene antagonist (Tecklenburg-Lund, et al. 2010). 
In a randomised cross-over design, 3 weeks of 10mg·d-1 montelukast was equally as 
effective in treating EIB when compared to 3 weeks of ω3-PUFA alone (3.2g EPA and 
2.0g DHA per day). Prior to the interventions, post EVH maximum percentage drop in 
FEV1 was -18.4 ± 2.1%. Following interventions, post EVH FEV1 percentage drop had 
improved to -9.3 ± 2.8% on fish oil, and -11.6 ± 2.8% on montelukast; and combination 
treatment was -10.8 ± 1.7% (p < 0.05). This finding suggests that the efficacy of 
montelukast can be met via non-pharmacological means and is likely due to the anti-
leukotriene properties of omega-3 PUFA. Recently, the marine lipid fraction of the 
green-lipped mussel has been shown to reduce airway inflammation and 
bronchoconstriction following an EVH challenge in active asthmatics (Mickleborough, 
et al. 2013). The supplement contained five main lipid classes including sterol esters, 
triglycerides, free fatty acids, sterols and polar lipids so elucidating the actions of solely 
EPA and DHA could not be made, but the findings suggest manipulation of lipid 
derived mediators has a positive effect on asthma.  
Contrasting the consistent findings of Mickleborough et al., (2003; 2006) and 
Tecklenburg-Lund et al., (2010), a recent study has shown no benefit of 3 weeks of ω3-
PUFA (4.0 g·d
-1
 EPA and 2.0 g·d
-1
 DHA) on pulmonary function responses to a 
mannitol test and markers of airway inflammation in physically active asthmatics 
(Brannan, et al. 2014). The difference in the outcomes is likely to be due to the 
bronchial provocation test employed. Inhaled mannitol is a hypertonic challenge and 
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has been suggested as an alternative for EVH (Holzer, et al. 2003). However, it is 
plausible that exercise/EVH and mannitol produce very slightly different 
bronchoconstrictive responses. Although both mannitol and dry-air hyperpnoea are 
known to alter the tonicity and volume of the airway surface liquid and produce 
bronchoconstrictive mediators, the generations of airways recruited and affected may 
differ. Mannitol is known to not cause any disruption to the airway epithelium unlike 
dry-gas hyperpnoea (Romberg, Bjermer and Tufvesson 2011) and EVH and mannitol 
can produce different levels of bronchoconstriction in physically active asthmatics 
(Holzer, et al. 2003, Sue-Chu, et al. 2010).  
Recent research has started to explore the effects of solely EPA or DHA upon 
airway inflammation and EIB. Interestingly, a recent study failed to show any benefit of 
consuming DHA in isolation on the severity of EIB (Head and Mickleborough 2013). 
The randomised, double-blind, placebo controlled crossover trial failed to show any 
improvement of lung function after EVH or markers of airway inflammation following 
3 weeks of 4 g·d
-1
 DHA in nine asthmatics with EIB. This suggests that either a higher 
or longer dose of DHA is needed; or that a combination of EPA and DHA are required; 
or that EPA is solely effective in attenuating EIB in physically active asthmatics. If a 
combination of EPA and DHA is most effective then understanding the effects of a 
lower dose would be beneficial in improving the adherence and uptake of ω-3 PUFA as 
a treatment option for EIB. Despite the latest study findings producing equivocal 
results, the consensus suggests a potential benefit of ω3-PUFA on EIB in physically 
active asthmatics, however a number of questions still remain.  
The previous research (Mickleborough, et al. 2003, Mickleborough, et al. 2006, 
Tecklenburg-Lund, et al. 2010), used very large dosages of ω3-PUFA (5.2g ω3-PUFA; 
3.2 g EPA and 2.0g DHA) equating to ~10 capsules a day. This is significantly higher 
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than the UK recommended daily intake of 0.45 g·d
-1
 (Scientific Advisory Committee on 
Nutrition/Committee on Nutrition/Committee on Toxicity 2004) and there is a large 
cost implication with such a high dose. In addition, there is the potential for problems 
with adherence to these dosages and a potential side effect of gastrointestinal 
discomfort (Van de Rest, et al. 2008). These high doses are likely to have been set as a 
proof of concept, with the high dose saturating the phospholipid membrane of 
inflammatory cells. It is plausible that dose levels could be reduced but still have 
beneficial effects.  
As such the aim of the current study was to investigate the effectiveness of a 
lower omega-3 PUFA dose on hyperpnoea induced bronchoconstriction and markers of 
airway inflammation.   
   152 
5.2. Methods 
5.2.1. Participants 
Twelve male asthmatics and 10 male non-asthmatics (controls) recreationally 
active (completing 6-8 hours of aerobic exercise per week) participants volunteered for 
the study and provided written informed consent (Appendix 5 - Chapter 5 Informed 
Consent Form). Participants with a history of taking ω3-PUFA and antioxidant 
supplements above the RDI, or regularly consuming more than one fish meal a week 
were excluded from the study prior to eligibility assessment in accordance with the 
inclusion criteria outlined in the participant information sheet (Appendix 4 - Chapter 5 
Participant Information Sheet). All volunteers underwent an initial screening session to 
determine the presence of hyperpnoea induced bronchoconstriction as an experimental 
model of EIB. Participants were excluded if resting FEV1 values were less than 65% of 
predicted (Argyros, et al. 1996, Knudson, et al. 1983).  Participants presenting to the 
study with a GP diagnosis of asthma and a history of shortness of breath and wheezing 
after exercise had to have a ≥ 10% reduction in FEV1 following bronchoprovocation 
with eucapnic voluntary hyperpnoea to be diagnostic (Anderson, et al. 2001) and 
included in the study.  Two asthmatics were found to be non-diagnostic with a < 10% 
reduction in FEV1 following EVH and were excluded from the study; two controls 
declined to participate further. Two asthmatic participants withdrew from the study 
during the high dose ω3-PUFA intervention due to gastrointestinal distress leaving a 
total of 8 HIB participants (age 30 ± 9 Yr; height 1.77 ± 0.03 m; body mass 75.6 ± 9.4 
kg) and 8 non asthmatic non-HIB controls (age 25 ± 9 Yr; height 1.81 ± 0.06 m; body 
mass 78.0 ± 9.0) to complete the study (Figure 5. 1). Independent samples t-tests 
revealed no between group differences for age, height, or weight (p > 0.05).  
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Current medication of the eight HIB participants was (n = 5 Salbutamol; n = 2 
Salbutamol, Salmeterol, and Budesonide with Formoterol, n=1 Salbutamol and 
Beclomethasone). All participants had well controlled asthma and were on step 1-3 on 
the stepwise treatment of asthma (National Asthma Education and Prevention Program 
2007). The study was approved by the Nottingham Trent University Human Ethics 
Committee, and all procedures were conducted in accordance with the Declaration of 
Helsinki. 
Throughout the study participants were instructed to adhere to their usual 
training regime and were asked not to partake in strenuous exercise 48 h prior to testing. 
On test days participants abstained from caffeine and alcohol and arrived at the 
laboratory at least 2 h post-prandial. Asthmatics were instructed to cease their 
medication prior to each EVH challenge (inhaled corticosteroids [Budesonide, 
Formoterol, Beclomethasone]: 4 days; inhaled long acting β2 agonists [Salmeterol]: 2 
days; inhaled short acting β2 agonists [Salbutamol]: the day of the test) and were tested 
at least 2 weeks following recovery from any chest or upper respiratory tract infection 
(Dickinson, McConnell and Whyte 2011, Anderson, et al. 2001).  
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Figure 5. 1 CONSORT diagram of participant flow through the study 
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5.2.2. Experimental Design and Protocol 
The study was conducted as a randomised, double-blind, placebo controlled 
cross-over design over fourteen weeks per participant. All participants entered the study 
on their normal diet after which they were randomised to receive in a counter-balanced 
order, one of the following supplement conditions for 21 days: 
• ω3-6.2 g·d-1– 8 ω-3 capsules equalling 6.2 g (3.7 g EPA and 2.5 g DHA) per day 
• ω3-3.1 g·d-1 – 4 ω-3 capsules equalling 3.1 g (1.8 g EPA and 1.3 g DHA) + 4 placebo 
capsules per day 
• Placebo (PLA) – 8 placebo capsules containing medium chain triglyceride GTCC per 
day 
Supplement capsules were identical in size, shape, taste and colour (CRODA 
Europe Ltd, East Yorkshire, UK). Participants followed a 2-week washout period 
(normal diet) between conditions (Mickleborough, et al. 2003, Mickleborough, et al. 
2006). To standardise dietary intake prior to each testing session participants completed 
a food diary for their first intervention that was subsequently repeated prior to each 
session. This was also standardised for the first two days of each intervention.   
At Day 0 and Day 21 of each intervention, participants attended the laboratory 
for the assessment of HIB by eucapnic voluntary hyperpnoea (EVH). Pulmonary 
function was assessed pre-EVH and at 3, 6, 16, 20, and, 30 minutes after EVH. A drop 
in FEV1 following EVH of ≥10% compared to pre EVH values confirmed the presence 
of HIB (Anderson, et al. 2001). Pre EVH at day 0 and day 21 of each intervention a 
venous blood sample was drawn from the antecubital vein for the assessment of 
neutrophil phospholipid fatty acid content. In addition at day 0 and day 21 of each 
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intervention prior to EVH, HIB participants only provided a fraction of exhaled nitric 
oxide (FENO) sample. FENO was not assessed in controls as values are not elevated in 
non-atopic non-asthmatic individuals (Franklin, et al. 2003, Jouaville, et al. 2003). Both 
HIB and control participants provided urine samples before and at 12, 60, and 90 
minutes post EVH for the determination of the urinary concentration of the pro-
inflammatory eicosanoid 9α, 11β-PGF2 (a PGD2 metabolite).  
 
5.2.3. Pulmonary function, EVH challenge, and FENO 
Pulmonary function, EVH, and FENO were conducted in accordance with the 
procedures outlined in Chapter 3. EVH provides a reproducible bronchoconstrictive 
response (Chapter 4) so allows for accurate monitoring of responses to dietary 
interventions. Following the EVH challenge, two reproducible flow-volume loops were 
measured at 3, 6, 16, 20, and 30 min, with the highest acceptable value recorded at each 
interval (Parsons, et al. 2013).  
 
5.2.4. Urinary 9α, 11β-PGF2 Concentration  
Participants were asked to provide ~20 mL urine samples prior to EVH and at 
12, 60, and 90 min post the EVH protocol. Participants were instructed to arrive at the 
laboratory in a euhydrated state having consumed 500 mL of water 60 min prior to 
arrival. Participants drank water ab libitum pre and post the EVH challenge to ensure 
urine samples could be collected. Urine samples were immediately separated into 2 mL 
eppendorf tubes and frozen at −80°C until further analysis.  
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Urinary concentration of 9α, 11β-PGF2 was determined by enzyme-linked 
immunosorbent assay (ELISA) (Caymen Chemicals, Ann Arbor, Michigan, USA). The 
9α, 11β-PGF2 antibody cross-reacted with 2,3 dinor-11β-PGF2 (10%), 11β-13,14-
dihydro-15-ketoPGF2 (0.5%) and below 0.01% for all other primary eicosanoids 
metabolites. Intra-assay coefficient of variation was 4%, and Inter-assay coefficient of 
variation was 5%. No samples were below the lowest level of detection. The 
concentration of 9α, 11β-PGF2 was adjusted for creatinine concentration which is used 
to normalise the concentration of urine samples and account for variable levels of 
hydration amongst samples (Cone, et al. 2009). Urinary creatinine concentration was 
measured using a clinical analyser (ABX Pentra 400; Horiba, Northampton, UK) and 
ABX Pentra creatinine kit using the kinetic Jaffe reaction (Junge, et al. 2004). The 
corrected 9α, 11β-PGF2 was expressed as ng/mg·mmol·g
-1
 creatinine.  
 
5.2.5. Neutrophil phospholipid fatty acid analysis 
The neutrophil isolation protocol is a purification procedure to isolate 
neutrophils from 20 mL of whole human blood and was adapted from previous 
descriptions of the method (Eggleton, Gargan and Fisher 1989, Nauseef 2007). Twenty 
mL of blood was drawn into a syringe from a vein in the antecubital fossa region of the 
forearm and immediately transferred to a 50 mL sized conical tube containing 4 mL 
anticoagulant acid-citrate-dextrose (ACD - 250 mL of ultrapure water containing, 7.36 
g citric acid; 14.71 g sodium citrate; 9.91 g dextrose). The conical tube was gently 
inverted several times to mix. 12 mL of 6% Dextran and 0.9% NaCl solution (250 mL 
of ultrapure water containing, 15.00 g 100,000 molecular weight Dextran and 2.25 g 
NaCl) was pipetted into the ACD/blood mixture and gently inverted several times to 
mix. This mixture was equally distributed between four 15 mL conical tubes and left to 
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stand at room temperature for 60 minutes. This dextran sedimentation stage causes the 
majority of the red blood cells to sediment to the bottom of each 15 mL conical tube 
while the mononuclear cells remain suspended in solution. 
After 60 minutes the yellowish supernatant containing the leukocytes and 
lymphocytes was pipetted from each 15 mL conical tube and transferred to a 50 mL 
conical tube. This was centrifuged (MSE Harrier 18/80, MSE, London, UK) at 1150 
rpm for 12 minutes at 4°C using a low brake. Following centrifugation, hypertonic lysis 
was conducted to remove any remaining red blood cells and platelets. The supernatant 
from the centrifuged solution was discarded. The remaining pellet was re-suspended in 
12 mL of ice-cold ultra-pure water and, after 20 seconds 4 mL of 0.6 M KCl (250 mL 
ultra-pure water containing 11.18 g KCl) was added and mixed several times. This 
solution was diluted to 50 mL with phosphate buffered saline (PBS) and spun at 1300 
rpm for 6 minutes at 4°C using a high brake. This step was repeated until no red blood 
cells remained. The remaining pellet containing the mononuclear cells was re-
suspended in 2.5 mL of PBS. This cell suspension was layered over 3mL of Ficoll-
Hypaque (Sigma-Aldrich, Dorset, UK) solution in a 15 mL conical tube; this then was 
spun at 1500 rpm for 30 minutes at 4°C using a low brake. The Ficoll sedimentation 
allowed the separation of the neutrophil cells (sinking to the bottom of the conical tube) 
from the remaining mononuclear cells which remain suspended in solution. The 
solution was removed and the neutrophil cell pellet was re-suspended in 2 mL of Hanks 
balanced salt solution (HBSS) (Sigma-Aldrich, Dorset, UK). The neutrophil cell 
suspension was stored under nitrogen in 1.5 mL eppendorf tubes at −80°C until further 
analysis by gas chromatography.  
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5.2.5.1 Determination of fatty acid phospholipid profile by gas chromatography 
Phospholipids were extracted from the neutrophils using previously described 
methods (Bligh and Dyer 1959) through collaboration at Reading University. Fatty acid 
composition was analysed by gas chromatography. EPA, DHA, linoleic acid (ω6-
PUFA), and arachidonic acid (ω6-PUFA) were expressed as a percentage of total fatty 
acid content. 
 
5.2.6. Assessment of compliance 
Participant’s received unlabelled pots of supplements that had been randomly 
numbered by a colleague of the investigator. The pots were labelled and the contents of 
each pot was counted and recorded by the colleague of the investigator to ensure 
double-blind conditions were maintained. Participants received the pots and instructions 
to consume a total of 8 capsules a day (4 in the morning, and 4 in the evening) for 21 
days. Participants were contacted several times throughout the duration of the 
interventions to monitor progress. On completion of the intervention participants 
returned the pots and the remaining capsules were counted by the colleague of the 
investigator.  Compliance was expressed as the discrepancy between the expected 
numbers of returned capsules and the actual number used using the following equation: 
%compliance = (actual\expected) x 100. Compliance to all interventions was >85%. In 
addition to this, compliance was also was assessed through the analysis of the 
neutrophil phospholipid fatty acid contents to establish changes in the fatty acid 
phospholipid profiles (section  5.2.5).  
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5.2.7. Statistical analysis 
The severity of the bronchoconstrictive response to EVH was assessed as the 
area under the curve for %∆FEV1 during 30 min post-EVH (AUC0-30%∆FEV1). In 
addition AUC0-30FEV1, and AUC0-30FVC were also calculated using trapezoidal 
integration.  
Data were analysed using the statistical software SPSS for Windows version 
22.00 (SPSS Inc., Chicago, IL, USA). The data were initially assessed for normality 
using Shapiro-Wilks test and assessed for skewness and kurtosis. To confirm the 
presence of HIB, the drop in FEV1 post EVH was assessed through one-way repeated 
measures ANOVA followed by a-priori Bonferroni adjusted post-hoc t-tests to compare 
pre-EVH values to post. Three-way repeated measures ANOVAs were used to analyse 
the effects of intervention (Placebo vs 6.2 g·d-1 vs 3.1 g·d
-1
) and day (Day 0 vs Day 21) 
with a between subject factor of group (HIB v Control) for AUC0-30%∆FEV1, AUC0-
30FEV1, AUC0-30FVC. Within-group changes were further explored by analysing the 
HIB and control groups separately using a two-way repeated measures ANOVA. To 
establish the between intervention differences at Day 0 and Day 21 significant F ratio 
was followed by a-priori Bonferroni adjusted post-hoc t-tests to establish where 
significant differences occurred between conditions (Placebo, 6.2 g·d
-1
, 3.1 g·d
-1
) and 
time points (Day 0 and Day 21).  
The response of urinary concentration 9α, 11β-PGF2 to the EVH test was 
initially assessed by a one-way repeated measures ANOVA for time (Pre-EVH vs, 12 
vs 60 vs 90 min Post–EVH) for each day (Day 0 and Day 21) within each group (HIB 
and Control). Subsequently a four-way repeated measure ANOVA to establish the 
effects of intervention (Placebo vs 6.2 g vs 3.1 g), day (Day 0 vs Day 21) and time (Pre-
EVH vs Post-EVH), with a between subject factor of group (HIB vs Control) was 
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completed. This was followed by  three-way repeated measure ANOVAs for each 
group (HIB and CONTROL) to analyse the effects of  intervention (Placebo vs 6.2 g vs 
3.1 g), day (Day 0 vs Day 21), and time (Pre-EVH vs Post-EVH). In the HIB group 
only two-way ANOVAs for each day (DAY 0 and DAY 21) analysed the effects of 
intervention (Placebo vs 6.2 g vs 3.1 g) and time (Pre-EVH vs Post-EVH). At day 21 in 
HIB group a one-way ANOVA at each time point (Pre-EVH and Post-EVH) assessed 
the effects of intervention (Placebo vs 6.2 g vs 3.1 g) followed by Bonferroni adjusted 
pairwise comparisons.  
A two-way repeated measures ANOVA assessed differences in pre-EVH FENO 
within each condition (Day 0 versus Day 21) for the HIB participants only followed by 
Bonferroni adjusted paired t-tests. Two-way repeated measures ANOVA assessed 
differences in the fatty acid composition within HIB and control groups and to ensure 
complete washout prior to each intervention, followed by post-hoc Bonferroni adjusted 
pairwise comparisons. Independent samples t-test assessed differences in fatty acid 
composition between the asthmatic and control groups at day 0 of each intervention. 
Statistical significance was set as p < 0.05, all data are presented as mean ± SD unless 
otherwise stated. 
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5.3. Results 
5.3.1. Pulmonary Function 
There were no significant differences at Day 0 between each condition for 
pulmonary function, bronchoconstrictive response to EVH, and markers of airway 
inflammation within HIB and control participants (p > 0.05), suggesting there was no 
carry over effect after each two-week washout period (Table 5.1).  Pre-EVH FEV1 and 
FVC, and maximum %∆FEV1 post-EVH at Day 0 for each condition are shown in 
Table 5.1 for HIB and control participants. At Day 0, asthmatic participants 
demonstrated HIB for Placebo, 6.2 g·d
-1
 and 3.1 g·d
-1
 interventions with EVH causing a 
significant reduction in FEV1 (p < 0.01). Maximum reductions in FEV1 of -28 ± 18%, -
28 ± 87%, and -27 ± 17% always occurred at 6 minute post EVH at Day 0 for Placebo, 
6.2 g·d
-1
 and 3.1 g·d
-1
 respectively. At Day 0 of each intervention, the mean post-EVH 
%∆FEV1 was always greater than 10% for up to 30 minutes.  
 
Table 5.1 Participant characteristics for HIB and control groups Mean (±SD). * Significant difference 
between HIB and Control participants (p < 0.05).  
Pulmonary 
Function 
HIB Participants (n=8) Control Participants (n=8) 
Pre-EVH Day 0 Placebo 6.2 g·d
-1
 3.1 g·d
-1
 Placebo 6.2 g·d
-1
 3.1 g·d
-1
 
FEV1 (L) 3.79 ± 0.82 3.76 ± 0.87 3.72 ± 0.84 4.66 ± 0.45* 4.63 ± 0.41* 4.65 ± 0.45* 
% predicted 91.4 ± 13.1 90.8 ± 12.8 89.9 ± 15.1 102.5 ± 5.5 102.2 ± 5.9 102.2 ± 5.5 
FVC (L) 4.66 ± 0.70 4.71 ± 0.66 4.62 ± 0.72 5.25 ± 0.51* 5.20 ± 0.42* 5.20 ± 0.43* 
% predicted 97.4 ± 9.3 96.1 ± 11.4 97.3 ± 6.4 98.7 ± 7.5 97.9 ± 6.6 96.7 ± 6.5 
Post-EVH Day 0       
Maximum % 
ΔFEV1 
-28 ± 18 -28 ± 18 -27 ± 17 -3 ± 2 -3 ± 2 -3 ± 3 
AUC0-30%ΔFEV1 583.0 ± 
447.2 
570.2 ± 
394.2 
528.2 ± 
402.2 
45.6 ± 41.3* 35.2 ± 49.1* 35.2 ± 49.1* 
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The three-way repeated measures ANOVA for AUC0-30%ΔFEV1 revealed a 
significant intervention x day x group interaction, (p < 0.001). Two-way repeated 
measures ANOVA for the control group revealed no main or interaction effects (p > 
0.05). Subsequent two-way repeated measures ANOVA for the HIB group revealed a 
main effect for intervention (p < 0.002), and day (p < 0.001) and an intervention x day 
interaction (p < 0.01). Subsequent one-way repeated measures ANOVA in the HIB 
group revealed that AUC0-30%ΔFEV1 at Day 21 was significantly less following the 6.2 
g·d
-1
 and 3.1 g·d
-1
 interventions when compared to placebo (p < 0.05), but there was no 
difference between 6.2 g·d
-1
 and 3.1 g·d
-1
 (p > 0.05). The greatest reductions in FEV1 at 
6 minutes had improved to -19 ± 15%; and -18 ± 14% following the 6.2 g·d
-1
 and 3.1 
g·d
-1
 interventions respectively (Figure 5.2A). The AUC0-30%FEV1 values for the 
control group were less compared to the HIB group at Day 0 and Day 21 across all 
interventions (p < 0.05) (Figure 5.2B). Individual and mean severities of HIB as 
assessed by AUC0-30%ΔFEV1 are shown in Figure 5.3 for HIB participants. A three-
way repeated measures ANOVA for AUC0-30FVC revealed a significant day x group 
interaction (p < 0.05). Subsequent one-way between group ANOVA found AUC0-
30FVC was significantly greater in the control group compared to the HIB group at both 
Day 0 and Day 21 for all interventions (p < 0.05).  
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Figure 5.2 The percent change in FEV1 from baseline to post EVH A) in HIB participants and B) in 
controls interventions (Mean ± SD). a) Significant reduction in AUC0-30%∆FEV1 at Day 21 6.2 g·d
-1
; b) 
significant reduction in AUC0-30%∆FEV1 at Day for 21 3.1 g·d
-1
 (p < 0.05).
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Figure 5.3 HIB asthmatic participants only, individual severity of HIB measured by AUC0-30%∆FEV1 
from Day 0 to Day 21. Black line indicates mean.  (a) Placebo intervention; (b) 6.2 g·d
-1
 intervention and 
(c) 3.1 g·d
-1
 intervention.   
-1550
-1350
-1150
-950
-750
-550
-350
-150
A
U
C
0
-3
0
%
Δ
FE
V
1
-1550
-1350
-1150
-950
-750
-550
-350
-150
A
U
C
0
-3
0
%
Δ
FE
V
1
-1550
-1350
-1150
-950
-750
-550
-350
-150
DAY 0 DAY 21
A
U
C
0
-3
0
%
Δ
FE
V
1
(a)
(b)
(c)
   166 
5.3.2. Fraction of Exhaled Nitric Oxide (FENO) 
Pre-EVH FENO values are shown in Figure 5. 4.  A two-way repeated measures 
ANOVA revealed a significant intervention x day interaction (p <0.05). One-way 
repeated measures ANOVA for day 0 revealed no differences in FENO between 
interventions (p > 0.05), significant differences were evident at day 21 (p < 0.05). 
Subsequent Bonferroni pairwise comparisons revealed differences between placebo and 
6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions (p < 0.05), but no difference between 
ω3-PUFA interventions. Within intervention paired t-tests were used to establish 
intervention changes in FENO. Both 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions 
resulted in a significant reduction in the level of FENO at Day 21 when compared to 
Day 0 (p < 0.017). No significant changes were evident following the placebo 
intervention.   
 
 
Figure 5. 4. Pre EVH fraction of exhaled nitric oxide in HIB participants (Mean ± SD). a) significant 
reduction in FENO concentration post intervention (p < 0.017).   
0
10
20
30
40
50
60
70
80
90
P
re
-E
V
H
 F
E
N
O
 (
p
p
b
)
HIB 6.2g·d-1 
(Day 0) 
HIB 6.2g·d-1 
(Day 21) 
HIB 3.1g·d-1 
(Day 0) 
HIB 3.1g·d-1 
(Day 21) 
HIB Placebo
(Day 0) 
HIB Placebo
(Day 21) 
a
b
a
b
   167 
5.3.3. Urinary 9α, 11β-PGF2 concentration 
Within-day one-way repeated measures ANOVA revealed a difference in 
urinary 9α, 11β-PGF2 concentrations for pre- to post-EVH in the HIB group (p < 0.05). 
No difference between post EVH values were found which were subsequently averaged 
(Figure 5. 5). Control participants showed no changes in urinary 9α, 11β-PGF2 
concentration over the course of the study. The four-way repeated measures ANOVA 
revealed a number of significant (p < 0.05) interaction effects (intervention x group; 
time x group; intervention x day; intervention x time; day x time). The three-way 
repeated measures ANOVA in the HIB asthmatics revealed significant main effects for 
intervention, day, and time (p < 0.05), and a significant intervention x day x time 
interaction (p < 0.05). Two-way ANOVA for day 0 in the HIB asthmatics revealed a 
main effect for time (p < 0.05), but no interaction x time interaction. For day 21 there 
was a main effect for time and intervention (p < 0.05), and intervention x time 
interaction (p < 0.05). Subsequent one-way ANOVAs at both Day 0 and Day 21, 
followed by Bonferroni adjusted pairwise comparisons revealed a significant (p < 0.05) 
difference for Placebo vs 6.2 g·d-1, Placebo vs 3.1 g·d-1, but no difference for 6.2 g·d-1 
vs 3.1 g·d-1 ω3-PUFA interventions (Figure 5. 5A). Independent samples t-tests 
revealed no difference in the HIB asthmatics urinary 9α, 11β-PGF2 concentration at day 
21 of 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions when compared to the control 
participants.  
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Figure 5. 5 (A) Urinary 9α, 11β-PGF2 concentration in HIB participants (B) Urinary 9α, 11β-PGF2 
concentration in control participants (Mean ± SD). a significant difference Pre-EVH to Post-EVH (p < 
0.05); b significant difference day 0 vs day 21 within the same intervention (p < 0.05); c significant 
difference compared to placebo for same time point (p < 0.05). (Mean ± SD). 
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5.3.4. Neutrophil phospholipid fatty acid content 
The neutrophil phospholipid fatty acid content was assessed in both HIB and 
control participants (Table 5. 2) and expressed as a percentage of total fatty acid 
content. Between group comparisons at day 0 of each intervention revealed HIB 
participants had a greater percentage of arachidonic acid within the neutrophil 
phospholipid membranes compared to the control participants (p < 0.05).  No 
significant differences (p > 0.05) were observed for linoleic acid, arachidonic acid, 
EPA, and DHA, when comparing day 0 to day 21 in the placebo intervention for both 
HIB and control participants. Following the 6.2 g·d
-1
 ω3-PUFA intervention in the HIB 
group the EPA content increased to 1.39 ± 0.38% (p < 0.05), and the DHA content 
increased to 2.39 ± 0.31% (p < 0.05). Conversely the content of AA decreased to 5.37 ± 
0.80% (p < 0.05); there was no change in the content of linoleic acid (p > 0.05). The 
3.1g·d
-1
 ω3-PUFA intervention resulted in a significant increase in the EPA content to 
1.05 ± 0.31% (p < 0.05), with a concurrent reduction in arachidonic acid to 5.26 ± 
0.99% in the HIB participants (p < 0.05). No significant changes (p > 0.05) in DHA, 
and linoleic acid were observed after the 3.1g·d
-1
 ω3-PUFA dose in the HIB group.  In 
the control group, the 6.2 g·d
-1
 ω3-PUFA dose resulted in significant increases in the 
content of EPA and DHA (p < 0.05) and reductions in arachidonic acid (p < 0.05), and 
the 3.1 g·d
-1
 ω3-PUFA dose increased the content of DHA and reduced arachidonic 
acid (p < 0.05).  
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Table 5. 2 Phospholipid fatty acid composition of neutrophil extracts expressed as a percentage of total fatty acid content at day 0 and day 21 of each intervention in 
HIB asthmatics and control participants Mean (±SD). a Significant difference between HIB and Control participants (p < 0.05); b significant difference between day 0 
and day 21 within condition.   
 
Intervention 18:2 ω6 Linoleic Acid 20:4 ω6 Arachidonic Acid
20:5 ω3 Eicosapentaenoic 
Acid 
22:6 ω3 Docosahexaenoic 
Acid
HIB Controls HIB Controls HIB Controls HIB Controls
PLACEBO
Day 0 6.46 ± 0.87 5.14 ± 1.26 6.52 ± 0.82 a 5.18 ± 1.02 0.72 ± 0.17 0.80 ± 0.19 2.15 ± 0.33 1.98 ± 0.31
Day 21 5.78 ± 0.82 5.25 ± 0.66 6.34 ± 0.62 5.09 ± 1.34 0.75 ± 0.19 0.79 ± 0.22 2.20 ± 0.37 2.14 ± 0.45
6.2 g·d-1 ω3-
PUFA 
Day 0 5.76 ± 0.80 5.58 ± 0.97 6.03 ± 0.78 a 5.20 ± 0.63 0.77 ± 0.19 0.70 ± 0.20 2.06 ± 0.33 2.02 ± 0.28
Day 21 5.96 ± 0.61 5.25 ± 0.81 5.37 ± 0.80 b 4.94 ± 0.56 1.39 ± 0.38 b 0.93 ± 0.12 b 2.39 ± 0.31 b 2.30 ± 0.30 b
3.1 g·d-1 ω3-
PUFA 
Day 0 5.99 ± 0.59 6.24 ± 1.88 6.35 ± 0.92 a 5.73 ± 1.29 0.59 ± 0.29 0.73 ± 0.21 2.14 ± 0.40 1.83 ± 1.40
Day 21 5.80 ± 0.53 5.44 ± 0.73 5.26 ± 0.99 b 5.02 ± 1.01 b 1.05 ± 0.31 b 0.84 ± 0.10 2.29 ± 0.35 2.22 ± 0.26 b
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5.3.5. Summary of key findings 
 6.2 g·d-1 ω3-PUFA and 3.1 g·d-1 ω3-PUFA were equal in reducing the severity 
of HIB (AUC0-30%∆FEV1) when compared to placebo.  
 6.2 g·d-1 ω3-PUFA and 3.1 g·d-1 ω3-PUFA were equal in reducing FENO in 
HIB asthmatics as a marker of airway inflammation. 
 6.2 g·d-1 ω3-PUFA and 3.1 g·d-1 ω3-PUFA were equal in reducing the urinary 
concentration of 9α, 11β-PGF2 when compared to placebo.  
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5.4. Discussion 
This study has demonstrated for the first time that lower doses of ω3-PUFA (3.1 
g·d
-1
) are equally as effective in reducing the severity of hyperpnoea induced 
bronchoconstriction in recreational athletes as higher doses (6.2 g·d
-1
).  Changes in the 
severity of HIB assessed by AUC0-30%ΔFEV1 were similar in both the 6.2 g·d
-1
 and 3.1 
g·d
-1
 ω3-PUFA interventions. Both interventions resulted in equal reductions in resting 
levels of exhaled nitric oxide, and equal suppression of urinary 9α, 11β-PGF2 
concentration following the EVH challenge. No changes in pulmonary function and 
urinary 9α, 11β-PGF2 concentration were evident in the control group throughout the 
study. The current findings suggest for the first time that a lower ω3-PUFA dose is 
effective in management of HIB, and could be used as a therapeutic option for 
physically active asthmatics. Furthermore compliance to the lower 3.1 g·d
-1
 could be 
greater due to the reduced cost and risk of gastrointestinal side effects. 
Previously, 21 days treatment with high dose (~6 g·d
-1) ω3-PUFA completely 
prevented the bronchoconstriction exhibited by asthmatics following an exercise 
challenge with mean post exercise %∆FEV1 becoming less than the diagnostic criteria 
of -10% (Mickleborough, et al. 2003, Mickleborough, et al. 2006, Tecklenburg-Lund, et 
al. 2010).  In the current study %∆FEV1, remained diagnostic (≥-10%∆FEV1) after both 
the 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions in HIB participants and this may be 
due to differences in severity of disease and the bronchial provocation challenge used.  
HIB participants in the current study exhibited a greater maximum fall in FEV1 of ~-
30% (maximum range of -13 to -63%) compared to previous cohorts that report mean 
maximum %∆FEV1 of ~-20% in asthmatics prior to ω3-PUFA interventions 
(Mickleborough, et al. 2003, Mickleborough, et al. 2006, Tecklenburg-Lund, et al. 
2010). This suggests that participants in the current study had greater HIB severity with 
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high heterogeneity; furthermore, EVH was used as the bronchial provocation challenge 
as opposed to an exercise challenge. This dry-gas hyperpnoea challenge mimics the 
breathing rates associated with exercise; it has been shown not only to be highly 
diagnostic, but also to elicit a greater bronchoconstrictive response when compared to 
exercise challenges (Rundell, et al. 2004, Mannix, Manfredi and Farber 1999). 
Consequently, the current study protocol may have elicited a greater 
bronchoconstriction accounting for the difference in recovery rate following ω3-PUFA 
between this and the previous research that used exercise as a challenge test 
(Mickleborough, et al. 2003, Mickleborough, et al. 2006).  
Previous research typically shows 50-60% improvements in AUC%ΔFEV1 
following high dose ω3-PUFA (Mickleborough, et al. 2006, Tecklenburg-Lund, et al. 
2010). This is much greater than improvements shown from Day 0 to Day 21 in the 
current study with improvements in AUC0-30%ΔFEV1 of 27.2% and 24.7% for 6.2 g·d
-1
 
and 3.1 g·d
-1
 interventions respectively. Similarly, this may be due to differences in 
severity of the bronchoconstriction induced between studies, and the high heterogeneity 
of response in the current participants. Further differences in the bronchoconstriction 
response of HIB participants between the current study and Mickleborough et al. (2003) 
and Mickleborough et al. (2006) were apparent. The %ΔFEV1 peaked at 6 minutes post 
EVH in the current study whereas, previously, maximum reductions in FEV1 occurred 
at 15 minutes post exercise (Mickleborough, et al. 2003, Mickleborough, et al. 2006). It 
may be that the square-wave nature of V̇E achieved during EVH elicits a more rapid 
bronchoconstrictive response compared to exercise challenges. EVH is likely to 
produce greater cumulative ventilation over 6 minutes compared to exercise 
contributing to the higher levels of severity in bronchoconstriction and therefore 
reduced percentage improvements following the interventions in the current study.   
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The findings of the current study contrast those of the earliest ω3-PUFA 
intervention study by Arm et al (1988). After 10 weeks of 3.2 g·d
-1
 EPA and 2.2 g·d
-1
 
DHA they found no improvements in airway hyperresponsiveness to a histamine 
challenge and no pulmonary function improvements in response to an exercise 
challenge in the asthmatic participants despite a 10-fold increase in neutrophil EPA. 
This increase in EPA is considerably greater than that in the current study and may be 
due to the longer intervention and lower initial dietary intakes of EPA allowing for a 
greater cumulative effect. The discrepancies in pulmonary function responses could be 
attributed to different bronchial provocation challenges and participant groups with 
Arm et al (1988) using a non-athletic population and a histamine challenge for airway 
hyperresponsiveness. Despite this, recent research has emerged in support in of Arm et 
al (1998) and contrasts our current findings (Brannan, et al. 2014). Three weeks of a 
daily dose of 4.0g EPA and 2.0g DHA intervention did not improve bronchial 
hyperresponsiveness to inhaled mannitol or suppress markers of airway inflammation 
(Brannan, et al. 2014).  
The most obvious differences between the current study and that of Brannan et 
al. (2014) are the bronchoprovocation methods used and asthmatic population recruited. 
Inhaled mannitol is a hypertonic challenge and has been suggested as an alternative for 
EVH (Holzer, et al. 2003). The airway response is measured by changes in FEV1 to 
increasing doses of mannitol, a reduction in FEV1 of >15% from the pre challenge 
value is considered an abnormal response. Evidence suggests that inhaled mannitol 
mimics the airway response and components of HIB including the activation of mast 
cells and eosinophils (O'sullivan, et al. 1998, Brannan, et al. 2003), but equally so does 
EVH (Kippelen, et al. 2010a, Kippelen, et al. 2010b). It is plausible that EVH and 
mannitol are producing very slightly different bronchoconstrictive responses. Although 
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both mannitol and dry-air hyperpnoea are known to alter the tonicity and volume of the 
airway surface liquid and produce bronchoconstrictive mediators, the generations of 
airways recruited and subsequent level of inflammation may differ.  
Mannitol powder is delivered from a dry powder inhaler, and in-vitro testing has 
shown 40-70% of the aerosol particles are less than 7μm in diameter which is small 
enough to reach the distal airways (Anderson, et al. 1997). However, it is acknowledged 
that only 13-31% of the dose inhaled is deposited into the lungs, and although this is 
enough to cause a positive test there is a large variation in peripheral to central 
deposition of mannitol into the lungs (Glover, et al. 2006) which could produce 
differing levels of bronchoconstriction when compared to EVH. Dry gas hyperpnoea as 
used in the current study closely mimics the ventilation rates associated with high 
intensity exercise; such high ventilation rates are known to result in the recruitment of 
smaller generations of airways in an attempt to condition the high volumes of inhaled 
air (Anderson and Kippelen 2008). These smaller airways are at increased susceptibility 
to injury and epithelial cell disruption (Anderson and Kippelen 2008, Kippelen and 
Anderson 2012). The high ventilation rates associated with exercise and dry-air 
hypopnoea are known to result in disruption of the airway epithelial cells, whereas 
mannitol does not cause any airway epithelial injury when urinary marker clara cell 16 
was measured as a marker of epithelial airway injury (Romberg, Bjermer and 
Tufvesson 2011). Severe hyperpnoea causes high force generation on the airway 
epithelial surface causing sheer stress and increasing transepithelial pressure gradients 
(Kippelen and Anderson 2012). An injury-repair response may occur in athletes and 
physically active asthmatics causing a disruption in the epithelial cell layer which may 
alter the airway smooth muscle properties increasing hyperresponsiveness in this 
population (Kippelen and Anderson 2012).  Although urinary clara cell 16 was not 
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measured in the current study it is plausible that the physically active asthmatics had a 
level of underlying airway injury which enhanced their susceptibly to the EVH 
challenge. Brannan et al. (2014) failed to provide any physical activity characteristics of 
their participants; this is an important description as the bronchoconstrictive response to 
EVH and mannitol is known to differ in athletic populations compared to non-elite and 
sedentary populations (Holzer, et al. 2003, Sue-Chu, et al. 2010).  
It may be hypothesised that the differences in bronchial provocation challenges 
used, and the physical activity status of participants influences the severity of EIB and 
epithelial disruption, thus altering the subsequent responses to ω3-PUFA interventions. 
Long term physically active asthmatics may have an underlying level of airway injury 
as shown by higher levels of urinary clara cell 16 (Romberg, Bjermer and Tufvesson 
2011, Bolger, et al. 2011); this may subsequently increase their responsiveness to EVH.  
Evidence regarding the ability of EPA and DHA to reduce airway epithelial cell 
inflammation is lacking. However, recent research has shown a significant reduction in 
urinary clara cell 16 following 3 weeks supplementation of an extract from the New 
Zealand Green Lipped mussels which contained 72 mg of EPA, 48 mg of DHA and mix 
of polyphenols (Mickleborough, et al. 2013). It is plausible that 6.2 g·d
-1
 and 3.1 g·d
-1
 
dose ω3-PUFA in the current study may have influenced airway epithelial disruption to 
reduce the bronchoconstriction caused by EVH. Future research should include 
measures of urinary clara cell 16 in response to different ω3-PUFA doses in physically 
active asthmatics; this may prove to be a novel mechanism of therapeutic action.  
Two participants in the current study dropped out having complained of 
gastrointestinal distress, following un-blinding of the study it was found they were on 
the higher 6.2 g·d
-1
 intervention, this further supports a rationale for reducing the 
effective dose of ω3-PUFA on asthma and HIB. Compliance to the interventions was 
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measured by assessing the fatty acid composition of neutrophil phospholipid cell 
membranes. Dietary intervention of the 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA resulted in 
significant increases in the content of EPA, and the 6.2 g·d
-1
 dose increased the content 
of DHA at day 21 when compared to day 0 verifying compliance to the 
supplementation regimes.  
The increases in EPA and DHA were in accordance with a reduction in the 
content of ω6-PUFA arachidonic acid following the 6.2 g·d-1 and 3.1 g·d-1 interventions 
in the HIB group. Interestingly, the current study has shown that the HIB asthmatics 
had significantly greater levels of arachidonic acid at day 0 of the interventions 
compared to the control group.  This is important because the arachidonic acid derived 
pro-inflammatory eicosanoids have consistently been associated with the pathogenesis 
of asthma and EIB (Hallstrand, et al. 2013). The pro-inflammatory eicosanoids of 
arachidonic acid are leukotriene B4 (LTB4) which is a potent neutrophil chemoattractant 
and pro-inflammatory mediator, and the cysteinyl series leukotrienes (LTC4, LTD4, and 
LTE4), which produce smooth muscle contraction and bronchoconstriction (Manning, et 
al. 1990). Dietary intake influences arachidonic acid content and it may suggest 
discrepancies in lifestyles between the HIB asthmatics and control participants or the 
increase could be due to genetic variations in arachidonic acid metabolism although this 
remains to be fully understood in specific disease states (Simopoulos 2006, Lattka, et al. 
2010). The dietary intervention of ω3-PUFA modifies the fatty acid profiles of 
phospholipid membranes of inflammatory cells such as neutrophil cells in the present 
study. The incorporation of EPA and DHA occurs in a dose response fashion at the 
expense of arachidonic acid (Calder 2012).  The increase in EPA and DHA can then 
cause inhibition of the cyclooxygenase-2 and 5-lipoxygenase pathways from 
arachidonic acid to reduce the production of pro-inflammatory eicosanoids.  
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Following both the 6.2 g·d
-1
 and 3.1 g·d
-1
 doses, arachidonic acid content was 
reduced in neutrophils phospholipids of the HIB participants. This is the first study to 
report a reduction in arachidonic acid content following a 3.1 g·d
-1
 (1.8g EPA and 1.3g 
DHA) dose of ω3-PUFA in HIB asthmatics. The phospholipid fatty acid composition of 
the neutrophil extracts presented in the current study differ considerably from those 
reported previously (Mickleborough, et al. 2003, Mickleborough, et al. 2006). The >6% 
arachidonic acid content in the current study at day 0 is lower than ~15-20% reported 
previously (Mickleborough, et al. 2003, Mickleborough, et al. 2006). These studies 
found a ~35-45% reduction in arachidonic acid which is greater than the 12-27% 
reductions reported in our current study.  The differences suggest that the participants in 
current study had a lower dietary intake of arachidonic acid, subsequently, the response 
to the ω3-PUFA interventions in lowering the percentage of arachidonic is diminished 
slightly. Despite this it still shows significant increases in EPA and DHA content at the 
expense of arachidonic acid.   
 The 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions significantly reduced the 
urinary concentration of PGD2 metabolite 9α,11β-PGF2  at Day 21 compared to Day 0 
post EVH. The increase in urinary 9α,11β-PGF2 following EVH on the placebo, and at 
Day 0 of the 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions is similar to that shown 
previously in response to exercise challenges in asthmatics, rising from a baseline of 
~30-40 ng·mmol
-1
 creatinine up to ~80 ng·mmol
-1
 creatinine (Mickleborough, et al. 
2003). The 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions significantly attenuated the 
rise in post EVH 9α, 11β-PGF2 urinary concentration at Day 21 when compared to Day 
0 and Day 21 of the placebo intervention, the concentrations were subsequently similar 
to the control participants.  
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Urinary 9α,11β-PGF2 is the primary metabolite of PGD2 and has been reported 
to increase after exercise, hyperpnoea induced, and allergen induced 
bronchoconstriction (Mickleborough, et al. 2003, Tecklenburg-Lund, et al. 2010, 
Brannan, et al. 2003, Kippelen, et al. 2010b, Bochenek, et al. 2004). PGD2 is a potent 
bronchoconstrictor that is primarily produced by activated mast cells and in smaller 
amounts by inflammatory eosinophil cells (O'Sullivan, et al. 1998, Dahlen and Kumlin 
2004).  Mast cell activation is significantly increased in asthmatics (O'Sullivan, et al. 
1998), and the numbers of mast cells present in sputum samples of asthmatics is raised 
after exercise (Mickleborough, et al. 2006). The ω3-PUFA interventions reduced the 
9α,11β-PGF2 urinary concentration at Day 21 suggesting less degranulation of mast 
cells, thereby causing a reduction in PGD2 and a suppressed inflammatory response to 
HIB.   Despite this reduction in 9α,11β-PGF2, there was not a complete inhibition of 
HIB in the asthmatic participants which supports the notion that the pathogenesis of 
asthma and EIB is multifaceted, suggesting PGD2 suppression alone does not explain 
the full reduction in bronchoconstriction. This may be due to a time lag between urinary 
9α,11β-PGF2 and that occurring in the airways. Mickleborough et al., (2003) showed a 
steady increase in urinary 9α,11β-PGF2 concentration following an exercise challenge 
in asthmatics receiving no dietary interventions, peaking at 120 minutes post challenge.  
It makes sense that PGD2 alone does not explain the full benefits of ω3-PUFA 
as there are numerous arachidonic acid derived eicosanoids, and pro-inflammatory 
cytokines implicated in its pathogenesis (Hallstrand and Henderson 2009) and these 
may also respond favourably to ω3-PUFA interventions.  Although not measured in the 
current study previous research suggests that increases in EPA and DHA content 
following ω3-PUFA supplementation are sufficient to ameliorate pro-inflammatory 
cysteinyl leukotriene production (Mickleborough, et al. 2003, Mickleborough, et al. 
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2006, Tecklenburg-Lund, et al. 2010). The long chain ω3-PUFAs of EPA and DHA 
competitively inhibit the metabolism of arachidonic acid which is the precursor for 2-
series prostaglandins and 4 series leukotrienes. ω3-PUFA reduces the levels of 
arachidonic by the partial replacement of arachidonic acid in the phospholipid 
membranes of inflammatory cells primarily with EPA that was provided from the 6.2 
g·d
-1
 and 3.1 g·d
-1
 doses. EPA is the preferential substrate of the 5-lipoxygenase 
pathway, therefore increasing the quantity of EPA in the phospholipid membranes of 
inflammatory cells inhibits the release of pro-inflammatory eicosanoids from 
arachidonic acid specifically the 4-series leukotriene’s (Calder 2007). leukotriene B4, is 
a potent neutrophil chemoattractant and proinflammatory mediator, and the cysteinyl 
leukotrienes (LTC4, LTD4, and LTE4) cause smooth muscle contraction and 
bronchoconstriction (Manning, et al. 1990). Urinary leukotriene E4 concentration has 
previously been shown to significantly reduce following high dose ω3-PUFA 
supplementation (Mickleborough, et al. 2003). The EPA derived eicosanoids 5-series 
leukotrienes are much less biologically active than those produced from arachidonic 
acid. For example EPA-derived LTB5 is 10- to 100-fold less potent as a neutrophil 
chemoattractant compared with LTB4 (Lee, et al. 1984).  Furthermore high dose ω3-
PUFA supplementation has been shown to supress pro-inflammatory cytokine 
concentrations (TNF-α and IL-1β) in individuals with EIB (Mickleborough, et al. 2003, 
Mickleborough, et al. 2006, Tecklenburg-Lund, et al. 2010).  
In vitro comparisons of EPA and DHA have shown that EPA is more effective 
in inhibiting pro-inflammatory mediator production and transcription from 
lipolysaccharide stimulated alveolar macrophage cells isolated from human asthmatics. 
EPA significantly suppressed the production of TNF-α, PGD2, IL-1β, and LTB4 
compared to treatment with DHA (Mickleborough, et al. 2009).  In contrast other 
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research showed that DHA can reduce the production of IL-1β, and IL-6 to a greater 
extent than EPA (Weldon, et al. 2007). The contrasting findings may well be due to the 
different cell lines taken from asthmatic individuals. Weldon et al (2007) used human 
THP-1 macrophages from a monocytic leukaemia cell line whereas Mickleborough et al 
(2009) studied a more relevant cell line of asthmatic alveolar macrophages. These 
findings may suggest that the most effective therapeutic benefit of ω3-PUFA may be a 
combination treatment of EPA and DHA for asthma, although further research is 
required on appropriate cell lines.    
The 3.1g·d
-1
 ω3-PUFA intervention provided less EPA and DHA (1.8 g·d-1 EPA 
and 1.3 g·d
-1
 DHA) than previous research studies but still attenuated the reduction in 
lung function following EVH and reduced the PGD2 metabolite urinary 9α,11β-PGF2. 
This is a low level of daily DHA in comparison to previous research (2.0g·d
-1
) 
(Tecklenburg-Lund, et al. 2010, Brannan, et al. 2014) and although DHA may have 
similar immunomodulatory effects as EPA, it does not act by direct inhibition of 
arachidonic acid. In vitro DHA can decrease the release of arachidonic acid from the 
phospholipid membrane of inflammatory cells by decreasing phospholipase A2 activity 
(Martin 1998). In vitro, studies also reveal that DHA can decrease the responsiveness of 
inflammatory cells to toll-like receptors and suppress the activation of nuclear factor 
kappa β (NF-Kβ) and subsequent inflammatory gene transcription (Lee, et al. 2003, Lee, 
et al. 2004).  Further research is required in vivo and in vitro in relevant cell lines to 
establish the immunomodulatory effects of EPA and DHA in isolation in a dose 
response manner.  
There are additional mechanisms of action for ω3-PUFAs that involve specialist 
pro-resolving mediators that are derived from both EPA and DHA and are termed 
resolvins and protectins; these have gained significant interest (Serhan, Yacoubian and 
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Yang 2008, Serhan, et al. 2011). The first identified bioactive pro-resolving mediator 
was termed resolvin E1 (RvE1).  RvE1 is generated from EPA and was initially isolated 
from exudates.  In vivo RvE1 reduces inflammation and in vitro it blocks human 
polymorphonuclear leukocytes migration (Serhan, et al. 2000, Serhan and Chiang 
2008). Intraperitoneal administration of RvE1 has been shown to dampen airway 
inflammation and hyperresponsiveness in a murine model of asthma (Aoki, et al. 2008). 
Subsequently administration of RvE1 to mice intraperitoneally both during sensitisation 
to, and challenge with ovalbumin resulted in a decrease in airway eosinophil and 
lymphocyte recruitment and a reduction in Th2 cytokine and airway 
hyperresponsiveness (Aoki, et al. 2010). In the current study the 6.2 g·d
-1
 and 3.1 g·d
-1
 
ω3-PUFA doses provided 3.7 g·d-1 and 1.8 g·d-1 of EPA respectively which may have 
resulted in significant generation of RvE1 (Seki, Tani and Arita 2009). Previous 
research suggests that RvE1 acts on several phases of asthmatic inflammation and 
modulates its anti-inflammatory and pro-resolving effects on various cell types (Aoki, 
et al. 2008, Aoki, et al. 2010). Further research is required to fully establish the roles of 
EPA derived resolvins in human asthma and HIB. It highlights a more novel role aside 
from arachidonic acid metabolite suppression for the influence of EPA on asthma and 
HIB.  
With EPA key in competitive inhibition of arachidonic acid and formation of 
RvE1, it is of interest to note that many studies have supported the notion that DHA is a 
more potent regulator of resolvin and protectin formation (Levy, et al. 2007, Serhan, et 
al. 2002). The metabolism of DHA can result in the synthesis of protectin D1 (Serhan, 
et al. 2002). Protectin D1 actively resolves inflammation by reducing pro-inflammatory 
signalling (Levy, et al. 2007). In vivo murine studies have shown that protectin D1 
injection significantly decreased subsequent bronchoconstriction during a methacholine 
   183 
challenge (Levy, et al. 2007). Moreover, ex vivo research demonstrates that adding 
DHA to homogenised murine lung tissue resulted in a significant increase in protectin 
D1 concentration, suggesting DHA can be converted to protectins in the respiratory 
tissue (Levy, et al. 2007). Despite these proposed roles of DHA in inflammation, 
supplementation of high dose DHA in isolation has produced equivocal results in 
human asthmatics (Head and Mickleborough 2013).  
Supplementing nine adult asthmatics with 4.0 g·d
-1
 of DHA in isolation for 3 
weeks did not significantly alter pre and post EVH pulmonary function, markers of 
airway inflammation, or DHA metabolite concentration when compared to placebo 
(Head and Mickleborough 2013). This suggests that DHA supplementation taken alone 
cannot improve HIB and there are a number of reasons why DHA taken in isolation 
may not have significantly altered pulmonary function and markers of airway 
inflammation. In the current study the 3.1g·d
-1
 ω3-PUFA dose provided just 1.3g·d-1 of 
DHA, whereas the Head and Mickleborough, (2013) study provided 4.0g·d
-1
. We found 
significant improvements in pulmonary function using a combination of 1.8g·d
-1
 EPA 
and 1.3g·d
-1
 DHA. This suggests that either EPA alone may have greater 
immunomodulatory properties in HIB, or that a combination of EPA and DHA are 
required for maximum effectiveness in physically active asthmatics suffering with EIB. 
There is a wealth of research to support the effectiveness of DHA in reducing 
inflammation, but this is primarily conducted on cellular or murine models of asthma 
(Levy, et al. 2007, Weldon, et al. 2007, Yokoyama, et al. 2000). The Head and 
Mickleborough (2013) study and our current study suggest that further work is required 
to establish the anti-inflammatory and inflammatory resolving properties of EPA and 
DHA in vivo with human asthmatics with EIB and further suggests that a combination 
treatment of EPA and DHA may be the most effective.  
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In the current study, we have shown that both 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA 
doses significantly reduced FENO levels after 21 days of intervention in physically 
active asthmatics with HIB. Fraction of exhaled nitric oxide is now commonly used as a 
marker of asthma control and an objective measure of airway inflammation (Sandrini, 
et al. 2010) with levels shown to be raised in asthmatics (Kharitonov, et al. 1994). In 
asthmatics, FENO is an indicator of eosinophilic airway inflammation, raised IgE levels 
and allergic sensitisation (Strunk, et al. 2003). Exact reference values for FENO are not 
recommended due to confounding factors and overlap between normal and asthmatic 
populations (Dweik, et al. 2011). Despite this, a number of studies show a relationship 
between FENO levels and EIB (Scollo, et al. 2000, ElHalawani, et al. 2003, Buchvald, 
et al. 2005).  The results of the current study support previous findings that high dose 
ω3-PUFA alone and in combination with montelukast can reduce pre-hyperpnoea FENO 
in EIB sufferers from 42.5 ± 6.6  ppb to 25.5 ± 3.9 ppb; and 23.2 ± 3.4 ppb respectively 
(Tecklenburg-Lund, et al. 2010). To the authors knowledge only one other study has 
directly investigated the response of FENO in asthmatics to ω3-PUFA interventions 
(Moreira, et al. 2007). Fourteen days of ω3-PUFA consumption in female asthmatics 
failed to reduce levels of FENO, however the daily ω3-PUFA intake was markedly 
lower than the 3.1 g·d
-1
 dose in the current study (0.91 g EPA and 0.65 g DHA vs 1.8 g 
EPA and 1.3 g DHA). It is likely that this dose was not sufficient to raise levels of EPA 
and DHA in the phospholipid membranes of inflammatory cells to influence FENO 
levels. Additionally no biochemical measure of compliance to the supplementation 
regime was undertaken.  
Nitric oxide is produced in the airway by the conversion of L-arginine to L-
citrulline, which is catalysed by enzymes known as nitric oxide synthases (NOS) 
(Nathan and Xie 1994). Elevated levels of FENO in asthmatics likely results from 
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increased expression of the inducible nitric oxide synthase (iNOS) in T lymphocytes, 
macrophages, airway epithelial cells, and inflammatory cells, and can be induced by 
certain pro-inflammatory cytokines notably TNF-α in vitro (Hamid, et al. 1993, 
Robbins, et al. 1994). The increased expression in response to pro-inflammatory 
cytokines is thought to be via the activation of transcription factor nuclear factor kappa 
β (NF-Kβ) (Barnes 1995), and, importantly, ω3- and ω6-PUFAs are ligands and 
modulators for NF-Kβ. This suggests that ω3-PUFAs influence inflammatory processes 
via modulating cytokine expression and activation of NF-Kβ (Schmitz and Ecker 2008).  
Interestingly, high dose ω3-PUFA has been shown to suppress circulating plasma TNF-
α in EIB sufferers (Mickleborough, et al. 2003) which may in turn influence NF-Kβ 
activity. Consequently a possible mechanism of action of ω3-PUFA on FENO levels 
may be from ω3-PUFA reducing pro-inflammatory cytokine expression resulting in less 
activation of NF-Kβ and lower expression of iNOS. Furthermore, previous research has 
shown ω3-PUFA supplementation to be equal to montelukast in reducing levels of 
FENO (Tecklenburg-Lund, et al. 2010). Montelukast reduces levels of FENO in patients 
with mild chronic asthma and works as a leukotriene receptor antagonist blocking Cyst-
LT receptors (Drazen 2002). This could suggest that ω3-PUFA has a similar anti-
inflammatory role working as a cysteinyl leukotriene antagonist to modify airway 
inflammation and reduce FENO levels.  
6.2 g·d
-1 
and 3.1 g·d
-1
 ω3-PUFAs modulate inflammatory processes via a 
multitude of mechanistic pathways to influence the airway inflammation associated 
with HIB. It is likely that a combination of both EPA and DHA is needed for maximum 
effect, with the current study supporting the notion that lower levels of combined EPA 
and DHA are useful although an exact dose response relationship remains to be 
elucidated.   
   186 
5.5. Conclusion 
In conclusion, this study has shown for the first time that 3.1g·d
-1
 ω3-PUFA 
doses are as effective as higher doses in attenuating HIB in physically active asthmatics. 
It highlights that lower doses represent a potentially beneficial treatment for physically 
active asthmatics suffering with EIB whilst reducing the burden of cost, compliance and 
potential for GI distress.  It is clear that the combination of EPA and DHA can provide 
anti-inflammatory effects to reduce airway inflammation as assessed by FENO and 
urinary 9α,11β-PGF2. Further in vivo research is required to establish an exact dose-
response relationship for EPA and DHA to allow for a greater understanding into their 
individual and synergistic roles in suppressing airway inflammation. This will increase 
current understanding of their individual and dual modulation of the arachidonic acid 
derived eicosanoids. In addition, it will allow for further understanding into their roles 
in serving as pro-resolving agonists and inflammatory antagonists, and their influence 
upon the airway epithelium to restore respiratory homeostasis in asthmatics and EIB 
sufferers.   
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6. Chapter 6 – Prebiotic trans-galactooligosaccharide (B-GOS) 
supplementation reduces the severity of hyperpnoea induced 
bronchoconstriction and inflammatory markers in physically active 
asthmatics 
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6.1. Introduction 
Despite the range of pharmaceutical interventions, asthma remains poorly controlled 
in 50% of asthmatics largely due to poor treatment adherence (Barnes 2010). In addition, β2-
agonists target symptom relief rather than treating the pathogenesis of the disease, and long 
term corticosteroid treatment can have undesirable side effects (section  2.5.4). These 
limitations highlight the need for novel therapeutics which importantly target the underlying 
inflammation and immune response. A novel approach to improve the treatment and 
management of asthma and exercise induced bronchoconstriction (EIB) is to positively 
manipulate the gut microflora through pre- or probiotic supplementation. This may positively 
alter immune responses in asthmatics. As highlighted in section  2.3.1 a dysregulated gut 
microflora increases susceptibility to asthma and inflammatory mediated conditions. Recent 
evidence suggests that the gastrointestinal commensal bacteria could be a therapeutic target to 
influence the immune and inflammatory responses beyond the gastrointestinal tract thereby 
mediating allergy and asthma (Noverr and Huffnagle 2004, McLoughlin and Mills 2011) (see 
section  2.6.2 for more details).   
The gastrointestinal (GI) microbiota includes over 1000 identified bacterial species 
that colonize the mucosal surface of the gut (Human Microbiome Project Consortium 2012) 
and it is involved in host immune system maturation in both a local and systemic manner.  
The intestinal microbiota plays an important role in the development and regulation of gut-
associated lymphoid tissue (GALT), ligands and cells within the GALT regulate T helper 1 
(Th-1), T helper 2 (Th-2) and regulatory T cell (Treg) differentiation. Although expressed by 
different phenotypes, asthma and EIB  are both considered to be driven by activated mast 
cells, eosinophils, and Th-2 lymphocytes that collectively produce pro-inflammatory 
mediators. These mediators, cytokines, chemokines, and eicosanoids contribute to persistent 
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airway inflammation and are implicated in the onset of EIB (Wenzel 2013, Zietkowski, et al. 
2009, Zietkowski, et al. 2011, Wan and Wu 2007, Boyce 2008).  
The increase in prevalence of asthma in western societies could be associated with 
alterations in the GI microbiota as a result of changes in lifestyle, poor diet, and increased 
antibiotic use (De Filippo, et al. 2010, Adlerberth and Wold 2009). Dysbiosis of the 
gastrointestinal and respiratory microbiota can increase the risk of developing asthma in 
childhood (Hilty, et al. 2010, Böttcher, et al. 2000). Modulation of the GI microbiota through 
dietary supplementation may directly or indirectly alter the immune and inflammatory 
response and therefore impact on airway inflammation associated with asthma and EIB. 
There are a number of supplementation methods that can result in positive modulation of the 
GI microbiota, including probiotic, prebiotics and synbiotics.  
The concept that supplementation in sufficient quantities of certain microorganisms 
can confer direct benefit onto the host is described by the term ‘probiotics’ (Marco, Pavan 
and Kleerebezem 2006). Probiotics are broadly defined as living, non-pathogenic 
microorganisms (usually bacteria) that can exert positive health benefits onto the host (Reid 
2005). Only a minority of bacterial species meet this definition and these are primarily from 
the Lactobacillus and Bifidobacterium genera (Howarth and Wang 2013). Within the human 
body the gastrointestinal tract is home to the largest quantities of lactobacilli and 
bifidobacteria, which act as commensal bacteria and contribute to the maintenance of a 
healthy intestinal immune system. A number of studies have now shown the benefits of 
probiotics on health and disease through the maintenance of healthy gut microbiota (Moro-
García, et al. 2013, Demirel, et al. 2013, Whelan and Quigley 2013). Importantly, evidence is 
accumulating for the use of probiotic supplementation in the treatment of allergies and 
asthma (Gutkowski, et al. 2010, Sagar 2014, Rose, et al. 2010, Isolauri, et al. 2000, Forsythe, 
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Inman and Bienenstock 2007). This is discussed in more detail in section  6.1.3. Probiotic 
supplementation can beneficially alter the microbiota composition within the gut from a 
pathogenic predominance towards a more beneficial microbiotic composition (Howarth and 
Wang 2013). However due to the transient nature of probiotic colonization, the microbial 
composition of the microbiota will return to the original state if probiotic supplementation is 
ceased. Furthermore, supplementation with varying strains of probiotic bacteria can have 
varying impacts on the microbiota composition. Probiotics also have to compete against the 
established colonic communities potentially reducing the efficacy of treatment.   
As such, prebiotics are arguably a more effective way to manipulate the gut 
microflora than probiotics (Macfarlane, Steed and Macfarlane 2008). As outlined in 
section  2.6.2 a prebiotic (usually an oligosaccharide) is a selectively fermented ingredient that 
allows specific changes, both in the composition and/or activity of the gastrointestinal 
microbiota, that confers benefits upon host well-being and health (Gibson, et al. 2004).  
The main mechanisms of action of prebiotics is to selectively stimulate the growth of 
commensal probiotic bacteria. The majority of prebiotic research has focused on inulin, 
fructooligosaccharides (FOS), and galactooligosaccharides (GOS) (Macfarlane, Macfarlane 
and Cummings 2006). GOS has been shown to have a greater prebiotic effect (a stronger 
bifidogenic effect) than short chain FOS (Bouhnik, et al. 2004) and sections  6.1.1 and  6.1.2 
provide more detail about GOS supplementation. A combination of pro- and prebiotic 
bacteria is termed a synbiotic (Schrezenmeir and de Vrese 2001), and has been used in the 
management of a number diseases (Kolida and Gibson 2011).  A synbiotic may benefit the 
microbiome of individuals with dysbiosis as it provides both a probiotic (to increase 
beneficial bacteria numbers) and a prebiotic to selectively stimulate the growth of beneficial 
bacteria to positively manipulate the gut microflora (Kolida and Gibson 2011).  
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6.1.1. The use of probiotics, prebiotics, and synbiotics in allergy and asthma 
The health benefits of probiotics in relation to a variety of immune-mediated 
conditions including allergy, asthma and infections of the upper respiratory tract have been 
described previously (Gill and Prasad 2008, Vliagoftis, et al. 2008). In human trials, upper 
respiratory tract infections and the severity of allergic rhinitis is reduced following the use of 
probiotics (Vliagoftis, et al. 2008). This systematic review found nine of the twelve 
randomised control trials showed meaningful improvements in clinical outcomes of allergic 
rhinitis following the use of probiotics (which included Lactobacillus casei, Lactobacillus 
acidophilus, Lactobacillus paracasei, and Bifidobacterium); however, none of the twelve 
showed any positive effects on asthma. This may be due to the small scale nature of the 
studies and diverse asthma heterogeneity. Furthermore, the variety of probiotic strains used 
are likely to have variable effects upon the composition of the GI microbiota and thus the 
immune system.  
Probiotics have been used as a treatment option in a number of research studies 
investigating paediatric asthma. Forty-six children (aged 4-10 years) with mild to moderate 
asthma were randomly allocated into matched groups to receive probiotic Trilac® capsules 
(1.6 x 10
9
 lactic acid bacteria cells: Lactobacillus acidophilus – 37.5%, Bifidobacterium 
bifidum – 37.5% and Lactobacillus delbrueckii subsp. Bulgaricus – 25%) or placebo for 12 
weeks (Gutkowski, et al. 2010). Asthma exacerbations and use of bronchodilators were 
significantly less in the children who received the probiotic capsules compared to those 
receiving placebo.  Immunological parameters studied by flow cytometry differed between 
groups. There was an increase in the expression of HLA-DR, a monocyte activator, in the 
Trilac® group compared with the placebo. Mean percentage (range) of HLA-DR positive 
monocytes increased from baseline to week 12, 90 (72-98)% vs 96 (89-99)% respectively (p 
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= 0.004).  The subset of percentage CD8/CD45RA+ cells (naive cell marker) decreased in 
peripheral blood mononuclear cells from children with atopic asthma after probiotic 
treatment from 28% (visit 1) to 25% (visit 4) (p =0.03). As HLA-DR is considered a marker 
of monocyte activation, and CD45RA is a naive cell marker, the authors suggested that the 
probiotic treatment led to the activation of monocytes and suppression of lymphocyte 
proliferation suggesting a potential immunogenic effect of the probiotic capsules (Gutkowski, 
et al. 2010). Current evidence suggests that asthma is characterised by a relative deficiency in 
Treg cell function, which allows Th-2 cells to proliferate. The Treg cell functioning can be 
measured through examination of Foxp3 expression in isolated PBMCs and with allergic 
asthma characterised by an imbalance in Th1, Th2, and Treg cells, the exact immunological 
effect could have been further explored in the Gutkowski et al. (2010) study through this 
examination of Foxp3 in the PBMCs. Foxp3 expression has been shown to be reduced in 
asthmatics (Provoost, et al. 2009), but may respond to probiotic treatment, as shown in a 
murine model of chronic asthma (Sagar, et al. 2014). Increases in Foxp3 expression allow for 
greater Treg cell functioning which benefits immune function in asthmatics by suppressing 
the dominance of Th2 cell expression and associated inflammation (Sagar, et al. 2014, 
Provoost, et al. 2009).  
The use of synbiotics could confer a greater health benefit through the combination of 
both pro- and prebiotics. To date, two studies have explored the effects of synbiotics on 
allergy. Children with atopic dermatitis (AD) have an increased risk of developing asthma 
with approximately 40% of children with atopic dermatitis developing asthma in later 
childhood (Gustafsson, Sjöberg and Foucard 2000). Early intervention with a synbiotic 
supplement was investigated in ninety infants (<7 months) with AD to investigate the impact 
on asthma symptoms (Van der Aa, et al. 2011). The synbiotic was delivered in a hydrolysed 
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formula and included the combination of Bifidobacterium breve M-16V and a 
galacto/fructooligosaccharide mixture (Immunofortis®); this was compared to the same 
formula without the synbiotic mixture. At a one year follow up the prevalence of ‘frequent 
wheezing’ and ‘wheezy noisy breathing apart from colds’ was significantly lower in the 
synbiotic group compared with the placebo group. Significantly fewer children in the 
synbiotic group compared to the placebo group had started to use asthma medication (5.6% 
vs 25.6%, absolute risk reduction -20.1% CI -35.7% to -4.5%). However, no changes in total 
IgE levels were evident. The results suggest that this symbiotic reduced asthma-like 
symptoms in AD, although further research is needed to elucidate the mechanisms. 
In allergic adult asthmatics receiving 4 weeks of synbiotics (90% short-chain galacto-
oligosaccharides, 10% long-chain fructo-oligosaccharides: Immunofortis® and 
Bifidobacterium breve M-16V), treatment significantly increased (50%) morning and evening 
peak expiratory flow compared to placebo (Van de Pol, et al. 2010). The synbiotic was 
associated with a significantly lower increase in serum IL-5 24h after house dust mite 
challenge compared to the placebo (mean (± SE) increase in serum IL-5 at 24 h after 
challenge: from 2.5 (1.5) to 74.1 (28.4) pg·mL
-1
 after placebo vs from 1.4 (0.4) to 36.3 (18.7) 
pg·mL
-1
 after synbiotics, p = 0.034). Similar reductions were shown in ex vivo allergen-
induced Th2-cytokine (IL-5, IL-4 and IL-13) production by PBMCs (Van de Pol, et al. 2010). 
However, treatment did not reduce bronchial inflammation as assessed by sputum eosinophil 
counts. The treatment with synbiotic was able to significantly reduce systemic production of 
Th-2-cytokines and improve peak expiratory flow. Although no direct reduction in bronchial 
inflammation was found, this suggests that the gut microflora may alter systemic 
inflammation, but not selectively reduce bronchial inflammation. To date, no research has 
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investigated strategies to manipulate the gut microflora in adult asthmatics suffering with 
EIB.  
Since alterations in the gut microbiota can influence immune function and 
inflammation beyond the gastrointestinal tract (Noverr and Huffnagle 2004), it could be a 
novel therapeutic target for asthmatics suffering with EIB. With asthma and EIB known to be 
associated with over expression of Th2 cells, and suppression of Treg cells, therapeutic 
strategies to alter this balance warrant further investigation. Probiotics are known to alter T 
cell function and supress immune disorders (Kwon, et al. 2010), thus administration of a 
prebiotic supplement to increase the quantity of bifidobacteria in the GI tract of asthmatics 
could be a novel treatment option for EIB sufferers.  
 
6.1.2. Prebiotic Trans-Galactooligosaccharide (B-GOS) and its influence on 
immune function and inflammation 
As described in  2.6.2.1 B-GOS is highly bifidogenic favourably altering the 
commensal bacteria within the gut (Depeint, et al. 2008, Vulevic, et al. 2008) which may, in 
turn, have a subsequent impact on immune function. Previous research into the use of B-GOS 
has focused primarily on adult and elderly populations with little evidence for its impact on 
allergy and asthma. In relation to inflammation the effect of B-GOS on cytokine production 
in PBMCs from elderly participants has been investigated. Five weeks of supplementation 
with B-GOS (5.5g·d-1) resulted in decreased production of TNF-α (p < 0.01) and IL-6 (p < 
0.05), and increased production of IL-10 (p < 0.05) compared to baseline and placebo. At 10 
weeks of supplementation B-GOS resulted in reductions of IL-1β (p < 0.01) compared to 
baseline, and TNF-α and IL-6 when compared to baseline and week 5, and when compared to 
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placebo (p < 0.05) (Vulevic, et al. 2008). Increased levels of TNF-α and IL-6, and 
suppression of IL-10 are implicated in the pathogenesis of asthma and EIB (Mickleborough, 
et al. 2003, Mickleborough, et al. 2006, Wong, et al. 2001). If these cytokines can be 
modulated by B-GOS in the elderly it is possible that they may respond favourably in 
asthmatics who consume B-GOS. In addition to the alterations in pro- and anti-inflammatory 
cytokines, from faecal analysis the Vulevic, et al. (2008) study showed that the B-GOS 
supplement was able to significantly increase the number of beneficial probiotic bacteria 
within the gut of healthy elderly volunteers. If B-GOS can increase the number of beneficial 
bacteria in the gut it could be a novel therapeutic strategy for asthmatics. 
The research suggests that prebiotics can increase the growth of probiotic bacteria in 
the gut including lactobacilli and bifidobacteria. These probiotic bacteria then make contact 
with underlying immune tissues and cells and can bring about strain-specific 
immunomodulation (Winkler, et al. 2007), including induced cytokine production in a 
concentration dependent manner (Marin, et al. 1998). This is shown by altered concentrations 
of pro and anti-inflammatory cytokines (Vulevic et al. 2008). Increasing the quantity of 
beneficial probiotic bacteria in response to B-GOS supplementation can help to regulate the 
balance between necessary and excessive immune responses. Prebiotics are fermented to 
varying degrees by the commensal probiotic bacteria (bifidobacteria and lactobacilli) with the 
immunomodulatory properties mainly attributed to specific microflora-dependent effects 
(Vulevic, et al. 2008). Probiotic bacteria can enhance phagocytosis, and alter Th1 responses 
associated with the release of pro-inflammatory cytokines, and simultaneously induce anti-
inflammatory cytokines through regulatory T cells (Winkler, et al. 2007). In elderly 
participants, it appears that B-GOS can have significant immunomodulatory effects, primarily 
resulting in less pro-inflammatory cytokine production and increased anti-inflammatory 
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cytokine production (IL-10). The authors speculate that the mechanism of action for 
increased IL-10 production likely involves the nuclear transcription factor kβ pathway 
(Vulevic, et al. 2008). IL-10 is a significant immunoregulator with potent anti-inflammatory 
and immunosuppressive properties and the suppression of pro-inflammatory cytokines by IL-
10 is regulated by the nuclear transcription factor kβ (Baldwin 1996). Nuclear transcription 
factor kβ can play a critical role in the chronic inflammation that underlies asthma and EIB 
(Barnes 1996) and can be activated by cytokine TNF-α, furthermore it can regulate the 
expression of chemokines CCL17, and CCL11 which are also implicated in asthma (Lukacs 
2001, Berin 2002). If B-GOS can result in reductions in cytokines and chemokines that are 
implicated in asthma, serum levels of TNF- α, CCL17, and CCL11 could be suitable markers 
for establishing alterations in the inflammation associated with EIB and the efficacy of B-
GOS in asthma trials. In addition to their effect on probiotic bacterial numbers in the gut and 
the resulting effect on the immune system some prebiotics are reported to bind to specific 
receptors on cells of the immune system suggesting that a direct interaction between 
prebiotics and the host is also a possibility (Vos, et al. 2007, Hoyles and Vulevic 2008). 
Similar to asthmatic patients, the gut microbiota of overweight individuals has a 
reduced microbial diversity and is accompanied by increased levels of inflammation 
(Abrahamsson, et al. 2014, Vulevic, et al. 2013). A double-blind, randomised, placebo 
controlled cross over study assessed the use of B-GOS in 45 overweight adults through 
markers of metabolic syndrome, immune function, and alterations in the gut microbiota 
(Vulevic, et al. 2013). Participants received 5.5g·d
-1
 B-GOS or placebo maltodextrin for 12 
weeks. B-GOS was shown to increase the number of faecal bifidobacteria at the expense of 
less desirable groups of bacteria. Although the study found no significant changes in cytokine 
production from whole blood cultures, it did find reduced levels of plasma c reactive protein 
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(CRP) at 12 weeks of B-GOS intervention (p < 0.0012) which the authors attributed to a 
positive shift in gut inflammation. C reactive protein can indicate a level of low grade 
inflammation and is an important marker underlying many common diseases. Increases in 
serum CRP have been associated with airflow obstruction and airway inflammation and may 
serve as a surrogate marker of airway inflammation in asthma (Takemura, et al. 2006). 
Therefore if B-GOS treatment can reduce CRP levels in obese patients, and if it is associated 
with asthma it could be a useful marker in assessing the efficacy of B-GOS in EIB patients 
who experience greater levels of airway inflammation.   
In general, the use of B-GOS for the treatment of inflammatory and immune diseases 
is a novel area. Since asthma is described as a chronic inflammatory disorder the use of B-
GOS in the treatment of this disease warrants future investigation.  
 
6.1.3. Rationale for prebiotic use in asthma and EIB 
The research area of pre- and probiotic treatment for airway associated diseases is 
growing. To date it suggests that oral treatment to favourably manipulate the gut microflora 
may prove to be a novel therapeutic strategy to attenuate major characteristics of an asthmatic 
response including airway hyperresponsiveness, local cytokine influx and airway eosinophilia 
in adults and children (Sagar, et al. 2014, Gutkowski, et al. 2010, Vliagoftis, et al. 2008, 
Provoost, et al. 2009, Van de Pol, et al. 2010), and murine models (Sagar, et al. 2014). 
Therefore, it is possible that the gut microflora could be a significant therapeutic target for 
systemic inflammatory airway disorders (Gollwitzer and Marsland 2014, Nagalingam, Cope 
and Lynch 2013).  
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Thus the aims of the study were to investigate a 3 week intervention of a prebiotic 
trans-galactooligosaccharide (B-GOS) on the severity of hyperpnoea induced 
bronchoconstriction (HIB) in physically active asthma sufferers and non-asthmatic controls 
using a randomised double-blind placebo controlled cross-over design. Second it was to 
investigate markers of airway inflammation to gain an understanding into the systemic 
cytokine and chemokine levels of asthma participants with diagnosed HIB and their 
responses to B-GOS. Markers of airway inflammation to be measured included serum TNF-α 
concentration which is implicated in the pathogenesis of EIB, and shown to be supressed in 
response to B-GOS treatment and other nutritional interventions (Mickleborough, et al. 2003, 
Vulevic, et al. 2008, Mickleborough and Rundell 2005). The inflammatory cytokine IL-33 
(section  2.2.2.2) is a newly discovered member of the interleukin-1 family of cytokines and is 
an important contributor to allergic responses and asthma (Prefontaine, et al. 2009).  It is 
expressed by T helper 2 cells and mast cells following a pro-inflammatory stimulation both of 
which have been implicated in the pathogenesis of EIB (Wenzel 2013). To date, no research 
has quantified the serum levels of IL-33 in a cohort of physically active asthmatics with EIB 
and this warrants further investigation. The current study will also aim to measure serum 
chemokine levels CCL11, CCL17, and CCL5 which are previously underreported in this 
population of asthmatics. CCL11 and CCL17 are Th2 cell-specific chemokines, and amplify 
the recruitment of Th2 cells to sites of inflammation to generate a self-sustaining pro-
inflammatory loop (Teran 2000, Bloemen, et al. 2007).  This makes them an important target 
to reduce the airway inflammation associated with asthma and EIB (Garcia, Godot and 
Humbert 2005). Furthermore, serum C-reactive protein (CRP) and immunoglobulin E (IgE) 
will be measured in the asthmatic and control groups as markers of low-grade systemic 
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inflammation. These are known to be raised in asthmatics and CRP can respond favourably to 
B-GOS supplementation (Vulevic, et al. 2008).  
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6.2. Methods 
6.2.1. Participants 
Eleven asthmatic HIB positive (6 male, 5 female) and 11 non-asthmatic non-HIB (4 
male, 5 female) recreationally active participants volunteered for the study and provided 
written informed consent. Prior to the study all participants had to meet the inclusion and 
exclusion criteria outlined in Appendix 6. All volunteers (HIB asthmatics and non-HIB 
controls) underwent an initial screening session to determine the presence of HIB. 
Participants were excluded if resting forced expiratory volume in 1 second (FEV1) was less 
than 65% of predicted (Argyros, et al. 1996, Knudson, et al. 1983).  Participants presenting to 
the study with a GP diagnosis of asthma and a history of shortness of breath and wheezing 
after exercise had to have a ≥ 10% reduction in FEV1 following bronchoprovocation with 
eucapnic voluntary hyperpnoea to be diagnostic (Anderson, et al. 2001) and included in the 
study. One male asthmatic was found to be non-diagnostic (<10% reduction in FEV1) 
following bronchoprovocation and excluded from the study. Two controls declined to 
participate further. The study was approved by the Nottingham Trent University Human 
Ethics Committee, and all procedures were conducted in accordance with the Declaration of 
Helsinki. A total of 19 participants; 10 HIB asthmatics (age 27 ± 9 Yr; height 1.72 ± 0.08 m; 
body mass 69.80 ± 9.0 kg) and 9 non-asthmatic non-HIB controls (age 26 ± 4 Yr; height 1.74 
± 0.10 m; body mass 72.2 ± 12.0 ) completed the study (Figure 6. 1). Independent samples t-
test revealed no differences in age, height, or body mass between groups (p > 0.05).  
Current medication of included HIB participants was n = 5 Salbutamol; n = 3 
Salbutamol and Budesonide; n = 1 Salmeterol and Budesonide; n = 1 Salbutamol, 
Budesonide, and formoterol. All participants had well controlled asthma and were on step 1-3 
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of the stepwise treatment of asthma (National Asthma Education and Prevention Program 
2007). 
Throughout the study, participants were instructed to adhere to their usual training 
regime and were asked not to partake in strenuous exercise 48 h prior to testing. On test days, 
participants abstained from caffeine and alcohol and arrived at the laboratory at least 2 h 
post-prandial. Asthmatics were instructed to cease their medication prior to each EVH 
challenge (inhaled corticosteroids: 4 days; inhaled long acting β2 agonists: 2 days; inhaled 
short acting β2 agonists: the day of the test) and were tested at least 2 weeks following 
recovery from any chest or upper respiratory tract infection (Dickinson, McConnell and 
Whyte 2011, Anderson, et al. 2001).   
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Figure 6. 1. CONSORT diagram of participant flow through the study.  
  
 
Assessed for eligibility (n= 22 
11 asthmatic, 11 controls) 
Excluded Asthmatics (n=1) 
   Not meeting inclusion criteria (n=0) 
   Declined to participate (n=0) 
   Declined to participate (n=0) 
   Other reasons (n= 1) – presented as 
suffering from EIB, but found to be non-
diagnostic 
Excluded Controls (n=2) 
   Not meeting inclusion criteria (n=0) 
   Declined to participate (n=2) 
 
Allocated to PREBIOTIC intervention (n=10) 
 n=5 Controls 
 n=5 Asthmatics 
 Completed intervention (n=10) 
 
Randomised (n=19)                   
[n=10 asthmatics] [n=9 controls] 
Enrollment 
Prebiotic and EIB Study 
Allocated to PLACEBO intervention (n=9) 
 n=4 Controls 
 n=5 Asthmatics 
 Completed intervention (n=9) 
Allocation 
Allocated to PREBIOTIC intervention (n=9) 
 n=4 Controls 
 n=5 Asthmatics 
 Completed intervention (n=9) 
 
Allocated to PLACEBO intervention (n=10) 
 n=5 Controls 
 n=5 Asthmatics 
 Completed intervention (n=10) 
14 day washout 
and crossover 
period 
Analysis 
Completed study and included in analysis 
(n=19) 
 n=9 Controls 
 n=10 Asthmatics 
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6.2.2. Experimental design and protocol 
The study was conducted as a randomised, double-blind, placebo controlled cross-
over design over eight weeks per participant (Figure 6. 1). All participants entered the study 
on their normal diet after which they received in a randomised order one of the following 
interventions for 21 days: 
Prebiotic (B-GOS) –5.5 g·d-1 (48% wt:wt of trans-galactooligosaccharide (B-GOS)) 
(Bi
2
muno, Clasado, Milton Keynes, UK).  
Placebo – Maltodextrin (Clasado, Milton Keynes, UK).  
Placebo and prebiotic sachets were the same in shape, size and colour. Both contained white 
powder that was identical in taste, colour and texture. Participants followed a 2-week 
washout period (normal diet) between conditions.  Prior to and for the first two days of 
supplementation all participants completed a food diary. This was then standardised for each 
condition and prior to every laboratory visit.  
 
6.2.3. Pulmonary function, EVH, and FENO 
Pulmonary function, EVH, and FENO (in EIB participants only) were conducted in 
accordance with the procedures outlined in Chapter 3. Following the EVH challenge, two 
reproducible flow-volume loops were measured at 3, 6, 10, 20, and 30 min, with the highest 
acceptable value recorded at each interval.  
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6.2.4. Collection of blood 
Venous blood was drawn from a vein in the antecubital fossa region of the forearm 
via a 21 gauge needle (BD value-set, BD, Plymouth, UK). 20 mL of whole blood was 
collected at each time point (pre-EVH, 15 min, 60 min, and 24 h post EVH). Once drawn, it 
was immediately transferred into 5 mL serum separation tubes (Sanstedt AG & Co, 
Numbrecht, Germany). Tubes were gently inverted several times before being left to stand 
for 30 min at room temperature then centrifuged (Fisher Scientific Accuspin 1R, Fisher 
Scientific, Loughborough, UK) for 15 minutes at 1000 x g at 4°C. The serum supernatant was 
subsequently removed and stored in eppendorfs at −80°C until further analysis. After blood 
sampling, the needle was removed and medical tissue was applied under firm pressure to 
prevent a superficial haematoma. 
  
6.2.5. Tumour necrosis factor-α (TNF-α) analysis 
The concentration of serum TNF-α was assessed as a measure of systemic 
inflammation. Frozen serum samples were thawed and mixed by vortexing.  Serum TNF-α 
concentration was determined in duplicate by high sensitivity ELISA (R & D Systems 
Europe., LTD, Abingdon, Oxford, UK). This ELISA did not cross-react with human IL-1β, 
IL-1α, IL-2-13, or TNF-β and was specific for the measurement of natural and recombinant 
human TNF-α. The minimum detectable dose of the assay was 0.106 pg·mL-1, intra-assay 
coefficient of variation was 11%, and inter-assay coefficient of variation was 10%, no 
samples were below the level of detection.  
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6.2.6. C-reactive protein (CRP) and Immunoglobulin E (IgE) analysis  
Frozen serum samples were thawed and mixed by vortexing. Concentrations of serum 
CRP and IgE were assessed as measures of systemic inflammation and immune function and 
were determined by ELISA (Universal Biologicals, Cambridge, UK). CRP and IgE ELISAs 
did not cross react with other serum proteins, or immunoglobulins. The minimum detectable 
dose of the assays were 0.25 ng·mL
-1
 and 0.69 ng·mL
-1
 for CRP and IgE respectively. No 
samples were below the level of detection.  
 
6.2.7. IL-33, CCL5, CCL11, and CCL17 analysis 
Frozen serum samples were thawed, mixed by vortexing and spun at 10,000 x g for 5 
min in order to remove any solid particles. Concentrations of serum CCL5, CCL11, CCL17 
and IL-33 were determined through multiplex analysis (Luminex 100, Luminex Europe, 
Oosterhout, Netherlands) and Luminex screening assay plates (R & D Systems Europe., 
LTD, Abingdon, Oxford, UK).  The Luminex multiplex technology allows for multiple 
protein profiling to occur simultaneously from a small volume of sample. The kits utilise 
colour-coded polystyrene microparticles that are coated with specific antibodies to specially 
recognise the analytes. The different analyte-specific beads are mixed and incubated with the 
serum sample. Captured analytes are subsequently detected using biotinylated detection 
antibodies and streptavidin-phycoerythrin conjugate. The Luminex 200 uses one laser to 
determine the colour of each bead, while a second laser determines the magnitude of the PE-
derived signal, which is directly proportional to the amount of analyte bound. Multiplex 
technology has been used for the detection of multiple proteins including enzymes, cytokine, 
chemokines, and antigens in a number of disease states (Carson and Vignali 1999). All IL-33 
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and 53% of serum samples for CCL5 were found to be out of range for detection and so were 
excluded from further analysis.  
 
6.2.8. Assessment of compliance 
Participant’s received two unlabelled bags containing a pre-counted number of 
sachets per intervention. Sachets were the same in shape, size and colour and had been 
blinded by the manufacturer (Clasado Ltd) and labelled L and T. Participants received 2 bags 
of the same labelled sachets and instructions to consume 1 sachet in the morning and 1 sachet 
in the evening dissolved in warm fluid for 21 days. Participants were contacted several times 
throughout the duration of the interventions to monitor progress. On completion of the 
intervention, participants returned the bags and the remaining sachets were counted.  
Compliance was expressed as the discrepancy between the expected numbers of returned 
sachets and the actual number used using the following equation: %compliance = 
(actual\expected) x 100. Compliance to the interventions was >88% indicating good 
compliance. The contents of the L and T sachets were not made available to the investigator 
until completion of the research study.  
 
6.2.9. Statistical analysis 
The area under the curve for pulmonary function measures %∆FEV1, FEV1, and FVC 
(AUC0-30%∆FEV1; AUC0-30FEV1; AUC0-30FVC) were calculated over time for the 30 minute 
period post EVH using trapezoidal integration.  
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Data were analysed using statistical software SPSS for Windows version 22.00 (SPSS 
Inc., Chicago, IL, USA). The data were initially assessed for normality using Shapiro-Wilks 
test, and assessed for skewness and kurtosis. Three-way repeated measures ANOVAs were 
used to analyse the effects of intervention (Prebiotic vs Placebo) and day (Day 0 vs Day 21) 
with a between subject factor of group (HIB v Control) for AUC0-30%∆FEV1, AUC0-30FEV1, 
AUC0-30FVC. Within-group changes were further explored by analysing the HIB and Control 
groups separately using two-way repeated measures ANOVA. Within-group intervention x 
day interactions were analysed using a one-way ANOVA followed by a-priori t-tests to 
establish within intervention differences between Day 0 and Day 21. A significant F ratio (p 
< 0.05) was followed by a-priori paired samples t-tests within each group to establish 
differences between condition (Prebiotic and Placebo) and day (Day 0 and Day 21).  Two-
way repeated measure ANOVA (prebiotic vs placebo) and (Day 0 and Day 21) was used to 
assess differences in %∆FEV1 for each post EVH time point within each group.  
The response of serum TNF-α to the EVH test was initially assessed by a one-way 
repeated measures ANOVA for time (Pre-EVH vs, 12 vs 60 vs 90 min post–EVH) for each 
day (Day 0 and Day 21) within each group (HIB and Control). Subsequently a four-way 
repeated measures ANOVA to establish the effects of intervention (Placebo vs B-GOS), day 
(Day 0 vs Day 21) and time (Pre-EVH vs Post-EVH), with a between subject factor of group 
(HIB vs Control) was completed. This was followed by three-way repeated measures 
ANOVAs for each group (HIB and Control) to analyse the effects of intervention (Placebo vs 
B-GOS), day (Day 0 vs Day 21), and time (Pre-EVH vs Post-EVH). In the HIB group only 
two-way ANOVAs for each day (Day 0 and Day 21) analysed the effects of intervention 
(Placebo vs B-GOS) and time (Pre-EVH vs Post-EVH). At day 21 in HIB group a one-way 
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ANOVA at each time point (Pre-EVH and Post-EVH) assessed the effects of intervention 
(Placebo vs B-GOS) followed by Bonferroni adjusted pairwise comparisons.  
Serum CRP, IgE and chemokines (CCL11, CCL17) were not normally distributed 
(Shapiro-Wilks, p < 0.05). Subsequently, Friedman repeated measures test assessed responses 
in serum chemokine concentration to the EVH test (Pre-EVH vs 15 min vs 60 min vs 24 h). If 
no change was evident in response to EVH this was followed by Friedman repeated measures 
tests to assess the pre-EVH serum concentrations between day 0 and day 21 of the B-GOS 
and placebo interventions. Individual Wilcoxon signed rank tests with Bonferroni adjusted 
alpha level assessed within and between intervention differences. Effect sizes were calculated 
as the Z statistic divided by the square root of the n number where .1 is a small effect size, .3 
is a medium effect size, and >.5 is a large effect size (Cohen 1988). Between groups analysis 
was conducted using a Kruskal-Wallis test and Bonferroni adjusted comparisons.  
A two-way repeated measures ANOVA assessed differences in pre-EVH FENO 
within each condition (Day 0 versus Day 21) for the HIB participants only. Statistical 
significance was set as p < 0.05, all data are presented as mean ± SD unless otherwise stated.  
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6.3. Results 
6.3.1. Pulmonary function and EVH challenge test 
There were no significant differences at day 0 between each condition for pulmonary 
function values, response to EVH, and markers of airway inflammation within each group (p 
> 0.05), suggesting there was no carry over effect from the two-week washout period. 
Control participants had significantly higher pre-EVH FEV1 values, and lower %ΔFEV1, and 
AUC0-30%ΔFEV1 in response to EVH compared to HIB participants (p < 0.05) (Table 6.1).  
The %ΔFEV1 pre-EVH to post-EVH prior (day 0) to either the B-GOS or placebo 
interventions are shown in Table 6. 1. Twenty-one days of B-GOS supplementation in the 
HIB participants significantly improved the %ΔFEV1 after EVH at the 3, 6, and 10 minute 
time points (p < 0.05), corresponding to improvements of 36 ± 17, 36 ± 19, and 43 ± 25% 
respectively (Figure 6. 2A). No significant changes in %ΔFEV1 occurred following the 
placebo intervention (p > 0.05) and no changes were evident in the control group (p > 0.05) 
(Figure 6. 2B).  
 
Table 6. 1 Pre- and post-EVH pulmonary function at day 0 of each intervention, Mean (±SD). *Significant 
difference between HIB and Control participants (p < 0.05).  
Pre- and Post-
EVH Pulmonary 
Function 
HIB Participants (n=10) Control Participants (n=9) 
Pre-EVH Day 0 B-GOS Placebo B-GOS Placebo 
FEV1 (L) 3.43 ± 0.74 3.39 ± 0.70 3.88 ± 0.65* 3.89 ± 0.70* 
% predicted 91.1 ± 13.8 90.2 ± 13.2 97.7 ± 9.2 97.7 ± 9.7 
FVC (L) 4.33 ± 0.76 4.23 ± 0.86 4.72 ± 0.75 4.71 ± 0.83 
% predicted 97 ± 10 95 ± 11 102 ± 8 102 ± 7 
Post-EVH Day 0     
Maximum 
%ΔFEV1, 
-28 ± 14 -26 ± 15 -3 ± 3* -3 ± 3* 
AUC0-30%ΔFEV1 547 ± 385 495 ± 365 49 ± 65* 27 ± 55* 
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Figure 6. 2 A) The %∆FEV1 from Pre-EVH to post-EVH in participants with HIB for B-GOS and placebo 
conditions; B) The %∆FEV1 from baseline to post EVH in control participants for B-GOS and placebo 
conditions (Mean ± SD). a – significant difference within B-GOS intervention day 0 to day 21 (p < 0.05); b – 
significant difference at day 21 B-GOS vs placebo (p < 0.05) in HIB participants; c – significant difference 
between HIB participants and controls (p < 0.05).  
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The three-way repeated measures ANOVA for the AUC0-30%ΔFEV1 revealed a 
significant intervention x day x group interaction (p < 0.01). The AUC0-30%ΔFEV1 in 
the HIB participants differed between the interventions and between the days (two-way 
repeated measure ANOVA, intervention x day interaction, p < 0.01). A paired samples 
t-test revealed a reduction in AUC0-30%ΔFEV1 from day 0 to day 21 following the B-
GOS intervention (582.53 ± 403.52 vs 345.44 ± 267; p < 0.01) equating to a 38 ± 18% 
improvement.  No changes were evident following the placebo intervention (p > 0.05). 
No changes pre- to post-EVH in AUC0-30%ΔFEV1 at day 0 and day 21 for either 
intervention were evident for the control group.  
The three-way repeated measures ANOVA for AUC0-30FVC revealed a 
significant intervention x day x group interaction (p < 0.05). The AUC0-30FVC in the 
HIB participants differed between interventions and days (two-way repeated measure 
ANOVA, intervention x day interaction, p < 0.05). A paired samples t-test revealed an 
increase in AUC0-30FVC from day 0 to day 21 following the B-GOS intervention 
(112.29 ± 24.94 vs 121.39 ± 25.56; p < 0.01) (Table 6. 2) corresponding to a 7% 
improvement in FVC.  No significant changes were evident following the placebo 
intervention (p > 0.05). Control participants showed no differences in AUC0-30FVC (p > 
0.05) on either of the dietary interventions. 
 
Table 6. 2 Severity of HIB measured by AUC0-30%∆FEV1; and AUC0-30FVC in HIB positive participants 
only. Mean ±SD a – significant difference compared to B-GOS day 0; b – significant difference 
compared to placebo day 21 (p < 0.05).  
 B-GOS Day 0 B-GOS Day 21 Placebo Day 0 Placebo Day 21 
AUC0-30%ΔFEV1 582.5 ± 403.5 345.4 ± 267.0 
a, b
 529.5 ± 304.0 543.5 ± 405.5 
 
AUC0-30FVC 
 
112.9 ± 24.9 
 
121.4 ± 25.6 
a ,b 
 
111.0 ± 31.3 
 
110.2 ± 34.0 
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6.3.2. Fraction of exhaled nitric oxide (FENO) 
In the HIB positive participants the two-way repeated measures ANOVA 
revealed no change in FENO after each intervention (p > 0.05) (Figure 6. 3).   
 
 
Figure 6. 3 Pre-EVH FENO in asthmatics only (Mean ± SD).   
 
6.3.3. Serum cytokine concentration (TNF-α and IL-33) 
Serum IL-33 concentrations were below the limit of detection and subsequently 
excluded from analysis. Figure 6. 5 panel A shows the serum TNF-α concentration prior 
to and post-EVH for HIB positive participants and panel B for control participants. 
Within-day one-way repeated measures ANOVAs revealed a difference in TNF-α 
concentration for prior to post-EVH in the HIB group, with no difference between post 
EVH values which were subsequently averaged (Figure 6. 4). Control participants 
showed no changes in TNF-α concentration over the course of the study. TNF-α 
concentration differed over the course of the study between HIB and control 
0
10
20
30
40
50
60
70
80
90
100
Prebiotic (Day 0) Prebiotic (Day 21) Placebo (Day 0) Placebo (Day 21)
P
re
-E
V
H
 F
ra
ct
io
n
 o
f 
Ex
h
al
ed
 N
it
ri
c 
O
xi
d
e 
(p
p
b
)
   213 
participants (four-way repeated measures ANOVA, significant intervention x day x 
time x group interaction, p < 0.05). In HIB participants, serum TNF-α concentration 
differed between the placebo and B-GOS interventions (three-way repeated measures 
ANOVA, intervention x day x time interaction, p < 0.05). There was a significant 
within day effect in the HIB group (p < 0.05). For day 21 serum TNF-α concentration 
differed between interventions and time (intervention x time interaction, p < 0.05).  
Subsequent one-way ANOVAs at both Day 0 and Day 21, followed by Bonferroni 
adjusted pairwise comparisons revealed B-GOS resulted in a significant reduction in 
serum TNF-α concentration at day 21 for pre- and post-EVH, and compared to placebo 
day 21 (p < 0.05) (Figure 6. 5A). The post-EVH increase in TNF-α was suppressed by 
36 ± 18% following the 21 days of B-GOS intervention compared to day 0.  
 
 
Figure 6. 4 Serum TNF-α concentration Pre- and post-EVH for HIB participants (Mean ± SD). a 
Significant difference B-GOS day 21 compared to B-GOS day 0 (p < 0.05). b significant difference B-
GOS day 21 vs placebo day 21 (p < 0.05).   
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Figure 6. 5 Serum TNF-α concentration Pre- and post-EVH for HIB asthmatics (panel A) and controls 
(panel B (Mean ± SD). a – significant difference B-GOS day 21 compared to B-GOS day 0 B-GOS 
intervention (p < 0.05). b – significant difference B-GOS day 21 vs placebo day 21 in HIB asthmatics (p 
< 0.05). c – significant difference HIB asthmatics vs controls (p < 0.05).  
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6.3.4. Serum chemokine concentration  
Friedman repeated measures test revealed no differences in pre- to post-EVH 
serum CCL17 concentrations in both asthmatic and control participants. Pre-EVH 
serum CCL17 concentrations differed over the course of the study (p < 0.05). In the 
HIB asthmatics, serum CCL17 concentration was reduced at day 21 of the B-GOS 
intervention when compared to day 0  (Wilcoxon signed rank tests with Bonferroni 
adjusted alpha level, p < 0.0125, with a large effect size, r = .88; see Figure 6. 6). In the 
HIB asthmatics, there was a trend for CCL17 day 21 in the B-GOS intervention to be 
less compared to day 21 in the placebo but it did not reach significance (p = 0.06), there 
was a large effect size however (r = .61). No changes were evident in the control group 
across the duration of the study. Serum CCL17 concentrations were greater in HIB 
asthmatics compared to controls at day 0 of the B-GOS, and day 0 and day 21 of the 
placebo intervention (Kruskall-Wallis test, p < 0.0125) see Figure 6. 6.  
No changes in serum CCL11 concentrations were evident across the duration of 
the study in both the HIB asthmatics (p > 0.05), and control participants (p > 0.05). 
There was a trend for serum CCL11 to be greater in the asthmatics but this did not 
reach significance (p = 0.07) (Table 6. 3).   
Table 6. 3. Serum CCL11 concentrations pre-EVH in HIB and control participants at day 0 and day 21 of 
each intervention. (Mean ± SD). 
 B-GOS Day 0 B-GOS Day 21 Placebo Day 0 Placebo Day 21 
 HIB CTRL HIB CTRL HIB CTRL HIB CTRL 
Serum 
CCL11 
(pg·mL-1) 
201.02 
±  
48.63 
156.81 
±  
72.58 
201.90 
±  
43.52 
150.17 
±  
58.86 
214.18 
±  
56.96 
153.75 
±  
72.02 
219.84 
±  
55.53 
148.28 
±  
34.67 
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Figure 6. 6 Serum CCL17 concentrations in HIB (Panel A) and control groups (B) mean (± SD). a –
significant difference day 0 to day 21 in HIB asthmatic group following B-GOS intervention; b – 
significant difference within-day between HIB and control group (p < 0.0125).  
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6.3.5. Serum CRP and IgE concentration 
Friedman repeated measures ANOVAs revealed no change in serum CRP in 
response to EVH in both asthmatic and control participants. Pre-EVH serum CRP was 
significantly different between interventions and days in the HIB participants (p < 
0.05). A-priori Wilcoxon signed rank tests revealed serum CRP had significantly 
reduced from day 0 to day 21 (p < 0.0125) in the HIB participants following the B-GOS 
intervention, with a large effect size (r = 0.80) (Figure 6. 7A). There was a trend for this 
reduction to differ from the placebo intervention but it did not reach significance (p = 
0.028; effect size r = 0.70). No change was evident following the placebo intervention 
in the HIB participants (p < 0.05). Similarly, pre-EVH serum CRP was significantly 
different between interventions and days in the control participants (p < 0.05). A-priori 
Wilcoxon signed rank tests revealed serum CRP had significantly reduced from day 0 
to day 21 following the B-GOS intervention in the control participants (p < 0.0125; 
effect size r = 0.71) (Figure 6. 7B). Again, there was a trend for day 21 in the B-GOS 
intervention to be reduced compare to day 21 of the placebo intervention but it did not 
reach significance (p = 0.038; effect size r = 0.69).  
No significant changes in IgE over the course of the study in either the HIB or 
control groups were found. Kruskal-Wallis test revealed pre-EVH serum IgE 
concentrations were significantly greater in the HIB asthmatics when compared to 
control participants (p < 0.0125) see Table 6. 4.  
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Figure 6. 7 Pre-EVH serum CRP concentrations in HIB asthmatics (Panel A) and control participants 
(Panel B) mean (± SD). a – significant difference day 0 to day 21 following B-GOS intervention (p < 
0.0125).  
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Table 6. 4 Pre-EVH serum IgE (mean ± SD) in the HIB participants and control participants at day 0 and 
day 21 of both interventions. a – significant difference between HIB asthmatics and controls (p < 
0.0125).  
 B-GOS Day 0 B-GOS Day 21 Placebo Day 0 Placebo Day 21 
 HIB Control HIB Control HIB Control HIB Control 
Serum 
IgE 
(KU·L-1) 
350 ± 
174
a 
179 ± 
129 
357 ± 
169
a
 
153 ±  
89 
366 ± 
177
a 
164 ± 
105 
364 ± 
172
a
 
174 ± 
106 
 
 
6.3.6. Summary of key findings  
 21 days of prebiotic B-GOS supplementation significantly attenuated the post-
EVH decline in pulmonary function in the HIB participants.  
 B-GOS supplementation reduced the concentration of pre- and post-EVH serum 
TNF-α in the HIB participants suggesting alterations in underlying immune 
function and inflammatory response to bronchoprovocation. 
 B-GOS supplementation reduced the baseline serum concentrations of CCL17 
in the HIB participants, and CRP in the HIB participants and controls. This 
suggests alterations in systemic inflammation and immune function may 
contribute to the reduced bronchoconstriction following EVH at day 21 of the 
B-GOS intervention.   
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6.4. Discussion 
This study has demonstrated for the first time that a 21 day intervention of 
prebiotic galactooligosaccharide (B-GOS) can markedly reduce the severity of HIB in 
physically active asthmatics. The B-GOS intervention almost halved the post EVH 
decline in %∆FEV1 and this occurred in conjunction with reduced serum concentrations 
of TNF-α, CCL17, and CRP in the HIB asthmatics. After 21 days of B-GOS the change 
in the fall in FEV1 in response to EVH from day 0 to day 21 was ~270 mL which is 
considerably greater than the smallest measurable change of 88 mL calculated from 
Chapter  4. Therefore we can be confident that the B-GOS intervention had a genuine 
meaningful impact upon the pulmonary function response to EVH to reduce the severity 
of HIB. This supports previous research whereby improvements in asthma symptoms 
and lung function have occurred in parallel to changes in immunological markers 
(Gutkowski, et al. 2010, Van de Pol, et al. 2010). The gut microbiota is instrumental in 
the development of the gut immune system and gut associated lymphoid tissue to 
establish immune tolerance (McLoughlin and Mills 2011), consequently it is likely to 
play a role in the regulation of allergic and asthmatic inflammatory responses.  The 
microbial communities of both the gut and airways have been shown to be dysregulated 
in patients suffering with respiratory diseases (Madan, et al. 2012, Hilty, et al. 2010, 
Huang, et al. 2011). It is plausible that the bifidogenic properties of B-GOS were able to 
modify the gut microflora and influence the underlying inflammation of asthmatics and 
supress the subsequent inflammatory responses of HIB in response to EVH.   
The dose of B-GOS chosen in the current study has previously been shown to 
significantly modify the faecal microflora profile and immune function in both young 
and elderly populations (Depeint, et al. 2008, Vulevic, et al. 2008). B-GOS is a non-
   221 
digestible carbohydrate, when consumed it is highly bifidogenic significantly increasing 
the numbers of beneficial bacteria, primarily bifidobacteria, at the expense of less 
beneficial bacteria, thereby improving the gut microflora (Depeint, et al. 2008). In 
conjunction with an improved microflora these initial studies found changes in markers 
of immune function showing suppression of pro-inflammatory cytokines (IL-6, IL-1β, 
and TNF-α) and significant increases in phagocytosis and anti-inflammatory cytokine 
IL-10. Our current study extends the research knowledge of B-GOS further suggesting 
it can attenuate the bronchoconstriction associated with HIB and reduce chemokine and 
cytokine markers of airway inflammation in physically active asthmatics. Although not 
measured in the current study it is likely that 21 days treatment of B-GOS had a 
significant bifidogenic effect within the gut microflora similar to the previous research 
(Depeint, et al. 2008). 
 
6.4.1. Pulmonary function response to B-GOS 
The prebiotic B-GOS intervention attenuated the severity of HIB as measured 
by post EVH AUC0-30%ΔFEV1 by 38%. This level of improvement is similar to those 
found following both pharmacological and dietary interventions (Mickleborough, et al. 
2003, Tecklenburg-Lund, et al. 2010, Villaran, et al. 1999). To our knowledge this is 
the first time a prebiotic intervention has been shown to improve the pulmonary 
function response of adult asthmatics to a bronchoprovocation challenge. 
These findings are in broad agreement with the limited number of studies that 
have explored the effects of probiotics and synbiotics on lung function and 
immunological parameters in children with atopic asthma and atopic diseases 
(Gutkowski, et al. 2010, Van der Aa, et al. 2011, Van de Pol, et al. 2010).  In 2010, Van 
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de Pol and colleagues found an increase in peak expiratory flow and inhibition of pro-
inflammatory cytokine IL-5 (both measured at rest) following 4 weeks of synbiotic 
supplementation (90% short-chain galacto-oligosaccharides, 10% long-chain fructo-
oligosaccharides: Immunofortis and Bifidobacterium breve M-16V) in asthmatic 
children. Direct comparisons between the current study and that of previous paediatric 
asthma research have to be made with caution. Adult asthmatics in the current study 
were likely to have more stable pulmonary function as it increases linearly with age up 
to 18 years (Wang, et al. 1993). The adult asthmatics in the current study had well 
controlled stable asthma, subsequently B-GOS is unlikely to offer any benefit on 
baseline pulmonary function in this cohort, but would be of benefit during HIB.  The B-
GOS supplement differed to the synbiotic used in the Van de Pol et al. (2010) study, it 
is possible that combined pre- and probiotics may have a greater therapeutic benefit in 
asthmatics who are likely to have reduced microbial diversity. Future research should 
look to combine B-GOS with bifidobacteria and lactobacilli.  B-GOS is known to 
increase the quantity of bifidobacteria within the gastrointestinal tract, therefore a 
combined prebiotic and probiotic intervention to also include lactobacillus may confer 
a greater therapeutic effect than B-GOS alone.   
A combined probiotic treatment (1.6 × 109 lactic acid bacteria cells: 
Lactobacillus acidophilus – 37.5%, Bifidobacterium bifidum – 37.5% and Lactobacillus 
delbrueckii subsp. bulgaricus – 25%) was shown to reduce asthma exacerbations and 
reliance upon medication in children and improve FEV1 (Gutkowski, et al. 2010). 
However other studies using probiotic treatment in asthmatic children have been less 
clear, with weak effects in 131 asthmatic children (Rose, et al. 2010), or limited only to 
pregnant women with atopic dermatitis treated with 3 strains of Lactobacillus 
(Dotterud, et al. 2010).  Attempting to establish the efficacy of probiotics is complicated 
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by the fact that some probiotic strains have varying immunomodulatory capabilities (De 
Roock, et al. 2010). This variability has been attributed to contrasting capabilities of 
probiotic bacteria to produce T-regulatory cells (Treg cells) and cytokines (Smits, et al. 
2005). It is currently not fully understood if a global gut increase in a specific bacterial 
strain over a specific length of time will be sufficient to induce long-term sustainable 
immunologic effects to influence allergic asthma in all patients (McLoughlin and Mills 
2011). Consequently the use of prebiotics as in the current study can enhance and 
promote the growth of the hosts commensal bacteria and this may represent a more 
applicable approach.  
 
6.4.2. Serum TNF-α concentration response to B-GOS 
Although not measured directly in the current study, previous research suggests 
that B-GOS is able to promote the growth of beneficial commensal bacteria within the 
gut (Depeint, et al. 2008, Vulevic, et al. 2008, Vulevic, et al. 2013). These increases 
may well have occurred within the asthmatics to subsequently impact on 
immunological and inflammatory function associated with asthma and HIB. In addition 
to improving pulmonary function in the HIB asthmatics, B-GOS attenuated 
inflammation, as evident by reductions in serum TNF-α.  
Serum TNF-α concentration at Day 21 of the B-GOS intervention was 
significantly less when compared to day 21 of the placebo intervention in the HIB 
asthmatics. B-GOS has previously been shown to reduce TNF-α in isolated peripheral 
blood mononuclear cells (Vulevic, et al. 2008) from elderly participants after 5 weeks 
of intervention. This study shows for the first time that circulating serum TNF-α can 
also be modulated by B-GOS supplementation.  The suppression of TNF-α by B-GOS 
   224 
is an important indicator of immunological changes occurring within the HIB 
participants. TNF-α is a potent pro-inflammatory cytokine produced by a number of 
inflammatory and epithelial cells that have been implicated in the pathogenesis of 
asthma and HIB (macrophages, mast cells, eoisnophils, airway epithelial cells, CD4
+
 
lymphocytes) (Chung and Barnes 1999, Berry, et al. 2007). Furthermore TNF-α is 
associated with the contraction of airway smooth muscle and development of airway 
hyperresponsiveness (Amrani 2014).  
At rest the HIB asthmatics had greater concentrations of TNF-α compared to the 
control participants, which supports previous reports of raised TNF-α in cross country 
skiers and elite athletes with EIB compared with non-asthmatic counterparts 
(Mickleborough, et al. 2003, Sue-Chu, et al. 1999). Chronic airway inflammation 
associated with asthma is in part maintained by the suppressive action of TNF-α on 
Treg cell function. Treg cells contribute to the maintenance of immune homeostasis in 
the airways by reducing inflammation and controlling immune tolerance. Commonly 
studied Treg cells in the context of pulmonary health and asthma are the natural thymic-
derived CD4+Foxp3+ Treg cells and peripherally antigen-induced adaptive CD4+ Treg 
cells, which comprise both Foxp3-positive and -negative populations (Lloyd and 
Hawrylowicz 2009). Natural Treg cells suppress allergic responses to inhaled antigens 
such as grass or pollen (Ling, et al. 2004, Grindebacke, et al. 2004), and may respond to 
changes in the airway environment associated with dry-gas hyperpnoea. TNF-α plays a 
crucial role in bridging innate and adaptive immunity in chronic inflammation such as 
asthma and crucially it impairs the regulatory activity of natural Treg cells via the TNF-
α receptor 2 (TNFR2) signalling pathway to down modulate Foxp3 expression (Lin, 
Shieh and Wang 2008). The transcription factor Foxp3 is a crucial regulator for Treg 
cell development and function and is currently the most specific Treg marker (Hori, 
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Nomura and Sakaguchi 2003, Fontenot, Gavin and Rudensky 2003). The B-GOS 
mediated reduction in serum TNF-α pre- and post-EVH suggests Treg cell expression 
may be altered (see section  6.5 for more details).  
Future research to investigate the mechanisms by which B-GOS is effective in 
treating HIB should look to measure Foxp3 expression in isolated PBMCs from 
asthmatics. Although previous research suggests there are no differences in the number 
of peripheral blood CD4
+
CD25
high
 cells between asthmatic participants and control 
participants, importantly Foxp3 protein expression within the CD4
+
CD25
high
 Treg cells 
is significantly decreased in asthmatics (Provoost, et al. 2009). This reduction in Foxp3 
protein expression may be linked to an increased TNF-α expression (Valencia, et al. 
2006). Therefore it is attractive to speculate the B-GOS mediated reduction in TNF-α 
resulted in increased Foxp3 expression in this study. This is further supported by anti-
TNF-α treatment (to inhibit TNF receptor signalling) resulting in priming naïve CD4+ T 
cells towards regulatory IL-10
+
 T cells to improved immune regulation and function 
(Boks, et al. 2014).   
The concentratrion of TNF-α is increased in response to exercise in asthmatics 
in both serum and sputum (Mickleborough, et al. 2003, Mickleborough, et al. 2006). In 
support of this we have shown increases in serum TNF-α following the EVH challenge 
suggesting similar pathophysiology in EIB and HIB. These increases were subsequently 
supressed by 36 ± 18% following the 21 days intervention of B-GOS this may indicate 
improved expression of Foxp3 within CD4
+
CD25 Tcells to enhance immune regulation 
in the HIB asthmatics so dampening the bronchoconstrictive response to EVH. Previous 
research has shown Foxp3 mRNA delivered therapeutically can rebalance pulmonary T 
helper cell responses and protect murine models of asthma from allergen-induced 
inflammation and airway hyperresponsiveness (Mays, et al. 2013). Mechanistically 
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Foxp3 induction controls Th2 and Th17 inflammation by regulating innate immune cell 
recruitment through IL-10 dependent pathways. The B-GOS suppression in TNF-α in 
the current study might suggest alterations in Treg cell expression bought about by 
enhanced Foxp3 activity in the HIB asthmatics.  
Although an exact cause and effect relationship cannot be made, the B-GOS 
treatment was able to reduce serum TNF-α concentration. Consequently this may 
indicate less suppression of Foxp3 protein that is commonly seen in asthmatics 
(Provoost, et al. 2009, Valencia, et al. 2006). This in turn will favourably alter the 
priming of naïve Tcells to support CD25
+
 Foxp3 Treg cells to enhance immune 
function and reduce the inflammatory responses to EVH associated with HIB. Future 
research should look to measure serum levels of IL-10, and soluble CD4 as markers of 
altered Treg cell functioning and Foxp3 expression in PBMCs in HIB-asthmatics 
following B-GOS treatment. Commensal bacteria within the gut can regulate Foxp3 
expression and subsequent Treg cell development to impact on immune function 
(Round and Mazmanian 2010)  this could be a novel therapeutic mechanism for the use 
of B-GOSs in HIB. The proposed mechanistic relationship between prebiotic treatment 
and improved immune function to alter the inflammatory response to EVH is discussed 
further in section  6.5.  
 
6.4.3. FENO response to B-GOS 
In addition to altered Treg cell functioning, HIB in asthmatic individuals is 
associated with increased eosinophilic airway inflammation and FENO (Lee, et al. 
2006). FENO is commonly used as marker of eosinophilic airway inflammation and 
levels in the HIB asthmatics in the current study are similar to those previously reported 
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in physically active asthmatics (Tecklenburg-Lund, et al. 2010). However, B-GOS did 
not confer any reduction in the FENO levels unlike the omega-3 PUFA intervention as 
seen in Chapter  5 and previous pharmacological interventions of montelukast 
(Tecklenburg-Lund, et al. 2010). It is possible that a longer duration of B-GOS 
supplementation is required to see a significant reduction in the raised FENO levels. The 
increased eosinophilic airway inflammation in HIB asthmatics highlights the role of 
eosinophil chemoattractant chemokines in the manifestation of the condition. Research 
suggests that local and systemic expression of the CC ligand chemokines such as 
CCL11 (eotaxin), and CCL17 (TARC), are increased in patients with asthma (Lilly, et 
al. 1999, Kalayci, et al. 2004, Zietkowski, et al. 2009, Zietkowski, et al. 2011).  
 
6.4.4. Serum chemokine CCL11 concentration response to B-GOS 
Chemokines can be produced in substantial amounts from structural cells 
including airway epithelial and endothelial cells, not only in response to their 
immunological environment but also as a response to microbial and viral stimuli. There 
was a trend for the HIB asthmatics to have greater serum CCL11 concentrations than 
the control groups, but due to high heterogeneity in this marker the increase did not 
reach significance. Future research should look to include a larger population of 
asthmatics with HIB when assessing CCL11 concentrations. Furthermore the asthmatics 
in the current study had well controlled stable asthma which may indicate no change in 
this chemokine. Despite this previous research shows that the expression of CCL11 is 
increased in the airways of asthmatics and CCL11 is an important attractant for 
eoisnophils which are upregulated in epithelial cells of asthmatics (Smit and Lukacs 
2006). The expression of CCL11 has been found to be increased in the airways of 
asthmatics and the level of CCL11 is proportional to eosinophil infiltration and the 
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severity of bronchial hyperreactivity (Ying, et al. 1997, Lamkhioued, et al. 1997). 
Further to this human airway smooth muscle cells are capable of producing CCL11 
upon stimulation of cytokines including IL-4, IL-5, and TNF-α. CCL11 is then involved 
in further recruitment of inflammatory cells into the airways to maintain an increased 
level of airway hyper-responsiveness which would further exacerbate HIB. As such 
treatments to reduce the activity of chemokines are warranted in asthma.  To our 
knowledge this is the first time serum CCL11 values have been reported in a group of 
physically active asthmatics with documented HIB. The CCL11 serum concentrations 
of ~200 pg·mL
-1
 are similar to those reported in plasma of stable asthmatics (232 ± 188 
pg·mL
-1
) (Tateno, et al. 2004). Despite the trend for raised serum CCL11 at day 0 in the 
HIB asthmatics, the B-GOS intervention did not reduce the concentration at day 21. 
The pathogenesis of HIB and asthma is known to be multifactorial with a number of 
inflammatory cells and mediators involved in its development. It is possible that 
although the B-GOS intervention significantly reduced the level of HIB in the asthmatic 
group this was independent of changes to CCL11. This further supports the finding of 
no reductions in FENO. It is possible that although CCL11 is known to be associated 
with airway inflammation the mechanisms of prebiotic action to induce a clinical 
improvement in HIB are independent of this chemokine. Further to this a limitation of 
the current study was that inflammatory markers were studied from the collection of 
serum, and as such only give an indication of systemic levels. It is possible the 
chemokines are likely to be in higher concentrations at the site of airway inflammation 
and may show more responses to treatment through the collection of sputum or exhaled 
breath condensate (Zietkowski, et al. 2009, Zietkowski, et al. 2011).  
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6.4.5. Serum chemokine CCL17 concentration response to B-GOS 
The HIB asthmatics had significantly higher concentrations of serum CCL17 at 
day 0 of the interventions compared with the control group (408.69 ± 182.53 vs 239.73 
± 80.28 pg·mL
-1
). CCL17 is a key chemokine for attracting Th2 lymphocytes into the 
sites of inflammation (Imai, et al. 1999) it is also preferentially produced in the 
presence of Th2 cytokines to further increase the recruitment of inflammatory T cells 
such as CD4
+
Th2 cells thereby generating a self-sustaining pro-inflammatory loop. 
Consequently chemokines and their receptors are important therapeutic targets in 
asthma because of this central role in cell recruitment and activation during 
inflammation. Plasma and serum CCL17 concentrations are shown to be raised in adults 
and children with asthma (Sekiya, et al. 2002, Leung, et al. 2002). To our knowledge 
this is the first study to report serum CCL17 concentrations in HIB asthmatics and they 
are similar to those found previously in allergic asthmatics (Sekiya, et al. 2002). The 
increased serum CCL17 in the asthmatics supports the notion of increased Th2 
lymphocyte infiltration in the pathogenesis of the condition (Hallstrand, et al. 1998).  
B-GOS supplementation reduced the pre-EVH concentration of serum CCL17 
in the HIB participants which may be due to the bifidogenic properties of B-GOS. 
Manipulating the commensal bacteria through B-GOS supplementation will 
subsequently affect the production and expression of cytokines and chemokines 
associated with inflammatory responses (Wells, et al. 2011). A suppression of CCL17 
concentration may have subsequently reduced the Th2 lymphocyte infiltration into the 
airways of the HIB asthmatics so reducing the inflammatory and bronchoconstrictive 
response to EVH. It should be noted that direct cause and effect relationship of B-GOS 
supplementation and CCL17 cannot be established from the current study and the exact 
mechanisms of how prebiotics influence the inflammatory cascade associated with 
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chemokine expression still remains to be elucidated. Research into the direct effects of 
prebiotic supplementation and probiotic bacteria on chemokine function is limited, but 
probiotic supplementation of Lactobacillus sakei has been shown to reduce serum 
levels of CCL17 in children with atopic eczema-dermatitis syndrome and improve 
severity (Woo, et al. 2010). Atopic dermatitis is similar to asthma in that both are Th2 
driven suggesting that favourable manipulation of the gut microflora either through 
probiotics (Woo, et al. 2010) or B-GOS as in the current study can influence Th2 
infiltration by suppression of CCL17 activity. CCL17 is known to drive Th2 
lymphocyte recruitment into the airways so favourable manipulation of the commensal 
bacteria may supress systemic chemokine expression to reduce this infiltration of pro-
inflammatory Th2 lymphocytes in the airways of HIB asthmatics. With the findings of 
the current study showing for the first time that B-GOS can reduce levels of serum 
CCL17 in asthmatics, more research is warranted to establish the clinical benefit and 
mechanism of action of prebiotic supplementation on chemokine function.  
 
6.4.6. Serum CRP concentration response to B-GOS 
Further to a reduction in serum concentration of TNF-α and CCL17 in the 
asthmatic group, the current study also demonstrates a reduction in serum CRP 
following the 21 day B-GOS intervention. Circulating CRP is an acute phase protein 
that is produced by hepatocytes primarily under the action of inflammatory cytokine IL-
6. Serum CRP is known to be a marker of systemic inflammation in asthmatics and is 
associated with airway inflammation, obstruction, and bronchial hyperresponsiveness 
(Takemura, et al. 2006, Kony, et al. 2004). Increasing levels of CRP correlate with 
worsening FEV1 values (Shaaban, et al. 2006) which supports the greater concentration 
of CRP in the HIB participants compared to the controls in the current study. The 
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reductions in serum-CRP at day 21 in the B-GOS intervention in both the controls and 
HIB participants supports previous observations of reduced plasma CRP following 12 
weeks of B-GOS in obese participants (Vulevic, et al. 2013). The reductions in CRP in 
response to B-GOS highlight the interventions effect on improving immune function, 
and suppression of low-grade inflammation. With prebiotic B-GOS increasing the 
number of beneficial bifidobacteria in parallel with reduced CRP concentrations 
(Vulevic, et al. 2013) it is plausible that changes in the microbiota may significantly 
alter the immune response in the current asthmatic group to reduce the subsequent 
inflammatory response to HIB. Serum CRP is negatively correlated with indices of 
pulmonary function, and positively correlates with the number of sputum eosinophils 
(Takemura, et al. 2006).  Following B-GOS supplementation the opposite was true in 
the current study serum CRP levels were reduced in conjunction with improvements in 
pulmonary function.  
 
6.4.7. Serum IgE concentration response to B-GOS 
The current study showed no alterations in serum IgE following B-GOS 
intervention, although IgE was significantly greater in HIB asthmatics compared to the 
control group. This supports previous research showing serum IgE concentrations are 
related to airway hyperresponsiveness and severity of allergy in children and adults 
with asthma (Sears, et al. 1991, Sunyer, et al. 1996). The improvement in HIB is likely 
to be independent of IgE levels and the current study supports previous human 
intervention studies that found no benefit of symbiotic treatment (Bifidobacterium breve 
M-16V and a galacto/fructooligosaccharide) on IgE levels despite improvements in 
atopic dermatitis (Van der Aa, et al. 2011). In contrast Lactobacillus reuteri 
interventions in infants with atopic diseases have been shown to suppress IgE levels 
   232 
(Abrahamsson, et al. 2007). B-GOS is known to increase the numbers of bifidobacteria 
(Depeint, et al. 2008) to a greater extent than lactobacillus. It is likely that different 
commensal bacteria strains will influence IgE differently and therefore may not respond 
to B-GOS treatment. Future research should look to investigate the use of synbiotics 
that could include B-GOS in combination and lactobacillus reuteri as this may confer a 
greater immunomodulatory benefit and influence IgE levels in asthmatics to further 
improve severity. 
 
6.4.8. Limitations of analysis 
A limitation of the current study was that faecal samples were not obtained to 
analyse the bifidogenic properties of B-GOS and potential alterations in the microbiota 
of the HIB asthmatics as a result of the intervention. Consequently, an exact cause and 
effect relationship of the B-GOS intervention improving the bronchoconstriction and 
reducing airway inflammation has to be made with caution. However, previous research 
has shown B-GOS to have substantial bifidogenic properties (Depeint, et al. 2008) and 
compliance to the current intervention was greater than 88%. There is growing evidence 
that beneficial manipulation of the gut microbiota can influence immune and 
inflammatory responses beyond the gut (Noverr and Huffnagle 2004). The precise 
mechanisms of action for the beneficial effects of prebiotics on airway inflammation 
still remain to be elucidated and are discussed in more detail in section  6.5. In an 
attempt to understand these mechanisms through non-invasive means serum blood 
markers were measured. A limitation of this is relating systemic changes to direct 
changes within the lung, and therefore future research should assess sputum and cellular 
changes from within the airways. In the current study attempts were made to measure 
the inflammatory cytokine IL-33. IL-33 is known to be involved in the development of 
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allergic sensitization and the exacerbation of lung inflammation, to our knowledge this 
is the first study that has attempted to measure serum IL-33 in physically active 
asthmatics with HIB. Upon analysis using a multiplex assay, all samples were below 
the limit of detection. It may suggest that IL-33 is not raised in HIB asthmatics or, as 
some research suggests, IL-33 acts solely as an alarmin to signal further inflammatory 
responses (Besnard, et al. 2011, Sattler, et al. 2013). Therefore systemic measures of 
IL-33 are not an applicable means to establish its activity.  IL-33 activity occurs via its 
ST2 receptor in an ST2-dependent manner, consequently, serum soluble ST2 may be a 
more appropriate measure of IL-33 activity (Mok, et al. 2010, Ho, et al. 2013) and 
should be investigated in future research.      
For the first time, this study has shown that a 3 week intervention of prebiotic B-
GOS can successfully attenuate the bronchoconstriction and airway inflammation 
associated with HIB in physically active asthmatic. As such it may be a novel treatment 
option for asthmatics who suffer with exercise induced asthma. The results add to the 
growing body of evidence that manipulation of the commensal bacteria can influence 
inflammatory responses beyond the gastrointestinal tract. The precise mechanisms and 
exact cause and effect relationships are yet to be fully determined but proposed 
mechanisms and current understandings are discussed in section  6.5.   
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6.5. Proposed mechanism of action of prebiotic bacteria on asthma and 
exercise induced bronchoconstriction 
Asthma was once considered as a single disease, but its high level of 
heterogeneity has given rise to an understanding of numerous phenotypes (Wenzel 
2013). Once such phenotype is exercise induced bronchoconstriction and as outlined by 
Wenzel (2013) it is primarily Th2 derived and overlaps with allergic asthma (Figure 6. 
8).  
 
Figure 6. 8 Theoretical grouping of asthma phenotypes based on distinction between Th2 high asthma 
and non-Th2 asthma. Th2 asthma consists of both early and late onset disease over a range of severities. 
It is likely that majority of early onset allergic asthma is mild but increasing complexity of immune 
responses leads to greater severity and EIA is a milder form of Th2 asthma (Wenzel 2013).  
 
The overlapping phenotypes of allergic asthma and EIB suggest that treatment 
to target underlying immune function and inflammation associated with Th2 type 
diseases is warranted. It is now known that altered gut microbiota composition is 
thought to contribute to various inflammatory diseases including asthma (Noverr and 
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Huffnagle 2004, Kranich, Maslowski and Mackay 2011). We have now shown for the 
first time that potential manipulation of the gut microflora through B-GOS 
supplementation can reduce the severity of HIB and supress markers of airway 
inflammation in physically active asthmatics.  This supports previous research into 
allergic asthma, where different species of probiotic lactobacillus can inhibit the 
allergic airway hyperresponsiveness and preferentially alter the Th1/Th2 balance to 
prevent asthma in murine models (Forsythe, Inman and Bienenstock 2007, Yu, et al. 
2010, Jan, et al. 2011). Supplementation with probiotic or  B-GOS in the current study 
can favourable manipulate the gut microbiome which then interacts with the immune 
system via toll-like receptors, specifically  toll-like receptor 2, toll-like receptor 9, 
human dendritic cells, and intestinal epithelial cells. These have all been reported to be 
involved in the induction of regulatory T cells in response to the intestinal microbiota 
and this may be responsible for the protective effects of pre/probiotics associated with 
asthma and allergy (McLoughlin and Mills 2011, Sagar 2014).  
As described in section ‎2.2 EIB is characterised by airway hyperresponsiveness, 
bronchoconstriction, and excess mucous production to exercise or dry-gas hyperpnoea. 
The pathogenesis of these symptoms is likely due to the thermal and osmotic 
consequences of water loss and evaporation of the airway surface liquid in an attempt to 
humidify and condition large volumes of air in a short time (Anderson and Daviskas 
2000). In response to changes in airway osmolality there is an influx of inflammatory 
cells to the airways of EIB sufferers (Hallstrand, et al. 2005, Hallstrand 2012). The 
current study used an experimental model of EIB through the use of EVH to cause 
hyperpnoea induced bronchoconstriction. This study has shown similar increases in 
inflammatory cytokine TNF-α and similar severity of bronchoconstriction as caused by 
exercise (Mickleborough, et al. 2003) supporting the use of EVH in nutritional 
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intervention studies. Subsequently the pathogenesis of HIB is identical to that of EIB 
and the inflammatory cell infiltration associated with asthmatic airways is depicted in 
Figure 6. 9, with focus on Tcells (Lloyd and Hessel 2010). It highlights that 
inflammatory cells (mast cells, dendritic cells, eosinophils, and neutrophils) infiltrate 
the airways along with T-cells which can promote exacerbations and Th2 can 
specifically promote further mast cell and eosinophil recruitment, mucous production 
and airway hyperresponsiveness. Regulatory T-cells oppose the Th2 cells and are 
important for a maintaining and modulating a balanced immune response (Lloyd and 
Hessel 2010).  
 
 
Figure 6. 9. A number of different T cell subsets are thought to influence the nature and magnitude of the 
allergic immune response by the cytokines that they secrete. T helper 2 (TH2) cells are thought to 
promote eosinophil recruitment, in conjunction with nature killer T (NKT) cells and CD8+ T cells. By 
contrast, TH1 cells and TH17 cells are thought to be associated with severe, steroid-resistant asthma, 
which is often marked by neutrophilic infiltrates. Regulatory T (TReg) cells and subtypes of γδ T cells 
are able to downregulate pulmonary immune responses and are thought to be important for maintenance 
of immune homeostasis in the lungs. The nature and magnitude of allergic inflammation in the lung is 
influenced by external environmental stimuli, such as exposure to allergens and pollution as well as 
infection with pathogens. IFNγ, interferon-γ; IL, interleukin. (Lloyd and Hessel 2010) 
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T-regulatory cells are important in balancing immune responses, and moderating 
inflammatory response. Traditionally the Th2 characterization of asthma was viewed as 
a skewed Th1/Th2 ratio in favour of Th2 inflammation. However, it is now accepted 
that in addition to this a reduced expression of Treg cells is commonly associated with 
asthma (Provoost, et al. 2009, Lloyd and Hawrylowicz 2009, Lloyd and Hessel 2010), 
and murine models of asthma (Sagar, et al. 2014, Feleszko, et al. 2007). Manipulation 
of Treg cell expression through their interaction with the intestinal mucosal immune 
system may be a key therapeutic target for pre- and probiotic treatment. Following the 
B-GOS intervention the serum concentration of TNF-α was reduced at rest, and 
completely attenuated following EVH.  TNF-α suppresses Treg cell function to 
maintain chronic inflammation associate with asthma, a reduction in TNF-α 
concentration suggests that B-GOS may have enhanced Treg cell functioning which is 
essential for the maintenance and balance of immune responses supporting the 
improvement in post-EVH pulmonary function.  Furthermore, in support of the use of 
pre- and probiotics in the treatment of asthma and EIB, beneficial commensal bacteria 
are known to drive the differentiation of naive T-cells in the gut towards Treg cells via 
the action of TGF-β (McLoughlin and Mills 2011).  Increasing Treg cell activation will 
further improve the immune response in asthmatic airways suppressing the post-EVH 
decline in FEV1 in the asthmatic participants.  
Prebiotic B-GOS has been shown to increase the numbers of commensal 
bifidobacteria within the human gut (Depeint, et al. 2008). This increase in beneficial 
bifidobacteria will interact with the intestinal mucosal immune system and have 
subsequent beneficial immunomodulatory effects (Figure 6. 10). With B-GOS 
increasing the growth of beneficial bifidobacteria these probiotic bacteria contain 
specific toll-like receptor ligands and can therefore modulate toll-like receptor-driven 
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responses and attempt to modulate immune responses in favour of Th1 and Treg cells 
(Kalliomaki, et al. 2010). Improving immune responses in favour of Treg cells will 
suppress the inflammation associated with asthma supporting the reductions in TNF-α 
and CRP in the current study this further suggests there may have been reductions in 
Th2 cell infiltration into the airways in response to EVH suppressing the subsequent 
decline in FEV1. Increasing Treg cell function and reducing Th2 infiltration is likely to 
be a key mechanism of B-GOS in modulating HIB in asthmatic individuals. Future 
research should look to investigate this in more detail and this is discussed in 
section  7.4. Furthermore it should be noted that the intestinal mucosal immune system 
is multifaceted and includes the intestinal epithelial cells (IECs), Peyers patches, 
intestinal lamina propria, intraepithelial lymphocytes and microfold cells. Some of these 
areas and antigen presenting cells such as dendritic cells will respond to changes in the 
diversity of the commensal bacteria in response to B-GOS interventions (Figure 6. 10). 
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Figure 6. 10 Immunomodulatory effects of the gut microbiota and subsequent effects on decreasing inflammatory responses. (McLoughlin and Mills 2011).   
IL-9 IL-17
IEL – intraepithelial 
lymphocyte;
IEC – intestinal epithelial cells;
MLN – mesenteric lymph 
nodes;
PP – Peyer Patches;
M Cell – microfold cell;
TLR – toll-like receptor;
NOD – nucleotide-bonding 
oligomerization domain;
DC – dendritic cell;
TCR – T-cell receptor;
RA – retinoic acid; 
TGF-β – transforming growth 
factor beta
MHCII - major 
histocompatibility complex 
class II molecule 
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Intestinal epithelial cells are the first part of the intestinal mucosal immune 
system to encounter the increase in beneficial commensal bacteria (as a result of B-
GOS interventions) (Figure 6. 10 and Figure 6. 11). The intestinal epithelial cells create 
a barrier between the lumen of the intestine and the rest of the body. Despite this 
physical barrier the contents of the intestinal lumen are continually sampled by 
specialized areas of the gut associated lymphoid tissue. These areas include Peyers 
patches in the small intestine and lymphoid follicles embedded in the lamina propria, 
and microfold cells (m cells) throughout the intestinal tract (Figure 6. 10 and Figure 6. 
11). The intestinal epithelial cells play a critical role in distinguishing between 
pathogenic and beneficial commensal bacteria to regulate immune responses 
(McLoughlin and Mills 2011). B-GOS increases the quantity of beneficial probiotic gut 
bacteria with which the intestinal epithelial cells are in direct contact. Intestinal 
epithelial cells then can express various toll-like receptors and nucleotide-binding 
oligomerization domain-like receptors to interact with the probiotic bacteria and 
activate immune defences. Activation of toll-like receptors on the intestinal epithelial 
cells from interaction with beneficial probiotic bacteria can induce synthesis of growth 
factors and cytokines that exert protective and reparative effects on the intestinal 
epithelial cells to help maintain intestinal homeostasis and immune function (Abreu 
2010, Rakoff-Nahoum, et al. 2004) 
In response to their interaction with probiotic bacteria, intestinal epithelial cells 
can also influence the function of antigen presenting cells including dendritic cells. 
Intestinal epithelial cells can activate toll-like receptors on dendritic cells and secretion 
of immunomodulatory molecules such as thymic stromal lymphopotein and TGF-β 
(Iliev, et al. 2009). Thymic stromal lymphopotein can limit the expression of IL-12 by 
dendritic cells and promote the production of IL-10 to enhance T-reg cell differentiation 
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from naïve T-cells (Figure 6. 10), this helps to create a regulatory as opposed to a pro-
inflammatory cytokine response (Iliev, et al. 2009, Rimoldi, et al. 2005). This supports 
the finding of a reduction in TNF-α following B-GOS intervention in asthmatics. 
Furthermore suppression of other Th2 derived pro-inflammatory cytokines (IL-4, IL-5, 
and IL-13) (Figure 6. 10) may explain the improvements in post-EVH %ΔFEV1 in the 
asthmatics following B-GOS supplementation via reduced eosinophil and mast cell 
recruitment to the airways . Dendritic cell pro-inflammatory cytokine production is also 
limited by TGF-β (McLoughlin and Mills 2011). TGF-β in incubated PBMCs increases 
favourably following probiotic supplementation with Lactobacillus acidophilus, 
Bifidobacterium lactis, and Bifidobacterium bifidum in healthy participants (Hepburn, 
et al. 2013). Therefore B-GOS mediated increases in  gut bifidobacteria may increase 
TGF-β in the asthmatics which enabled an improved immune response to the EVH 
challenge. Future research may wish to explore  levels of TGF-β in PBMCs of 
asthmatics pre and post B-GOS interventions as this is likely to be involved in 
improved maintenance of immune function to supress the bronchoconstrictive response 
to EVH. In addition to crosstalk between intestinal epithelial cells and dendritic cells; 
dendritic cells are actively involved in immune regulation in the intestinal immune 
system in their own right and will directly interact with probiotic bacteria within the gut 
lumen (Figure 6. 11) (Lebeer, Vanderleyden and De Keersmaecker 2010).  
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Figure 6. 11 probiotic bacteria interaction with intestinal epithelial cells (IECs) and dendritic cells (DCs) (Lebeer, Vanderleyden and De Keersmaecker 2010).  
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Dendritic cells are able to continually sample the gut lumen content by 
extending their dendrites between tight junctions of IECs (Figure 6. 11). Dendritic cells 
have pathogen recognition receptors on their surface which allows them to respond to 
pathogen and microorganism associated molecular patterns such as toll-like receptors 
and nucleotide-bonding oligomerization like receptors expressed on pathogens and 
commensal bacteria (Lebeer, Vanderleyden and De Keersmaecker 2010). Subsequently 
dendritic cells will positively respond to increases in beneficial probiotic bacteria as a 
result of B-GOS supplementation.  Simultaneously they will present antigens to naïve 
Tcells (Figure 6. 10 and Figure 6. 11). Antigen presentation in conjunction with 
immunomodulatory cytokines directs the development of specific T cell subsets in the 
gut associated lymphoid tissue or mesenteric lymph nodes (Figure 6. 11). In response to 
antigen presentation following increased interaction with beneficial probiotic bacteria 
(as a consequence of B-GOS supplementation), dendritic cells will drive Treg cell 
differentiation (from naïve Tcells) in the gut this is critical in improving or maintaining 
a balanced immune response in asthmatics (McLoughlin and Mills 2011). Improving 
Treg cell differentiation is essential to enhance immune tolerance in asthmatics and 
thereby suppress the inflammatory response in asthmatics to exercise and EVH. Future 
research should look to elucidate this mechanism in more detail in asthmatics with 
EIB/HIB.   
A specific subset of DCs (CD103
+
) is capable of converting naive Tcells to 
inducible FoxP3
+
 Treg cells through a mechanism that is dependent upon TGF-β 
(Round and Mazmanian 2010, Hooper, Littman and Macpherson 2012). It is known that 
asthmatic individuals typically have reduced expression of FoxP3 within CD4
+
CD25
high
 
T cells (Provoost, et al. 2009, Lin, Shieh and Wang 2008). Specific probiotic strains 
(Bifidobacterium infantis, Lactobacillus species, Bacteroides fragilis) have been shown 
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to increase the numbers of CD4
+
CD25
+
FoxP3
+
 cells in the spleen (O'Mahony, et al. 
2008), upregulate FoxP3
+
 expression in CD25
-
 cells in vitro (De Roock, et al. 2010) and 
induce expansion of CD4+ CD25+FoxP3+ T Reg cells (Round and Mazmanian 2010), 
all contributing to improved moderation of immune responses. It is possible that B-
GOS mediated increases in bifidobacteria may have increased numbers of CD4+ 
CD25+FoxP3+ T Reg cells thereby improving immune tolerance and reducing 
inflammation associated with HIB. These proposed mechanisms are supported by work 
showing that a synbiotic supplement (Bifidobacterium breve and non-digestible 
oligosaccharide) had strong anti-inflammatory effects in a murine model of severe 
asthma (Sagar, et al. 2014). The supplement resulted in reduced airway remodelling and 
chronic inflammation which were associated with altered toll-like receptor activity, 
increased expression of anti-inflammatory cytokine IL-10, and increased expression of 
Treg transcription factor FoxP3 (Sagar, et al. 2014). Increased expression of Treg cells 
in the gut associated lymphoid tissue and mesenteric lymph nodes result in greater Treg 
cell counts throughout the lymphatic system. Therefore, beneficial alterations in gut 
bacteria affect, amongst other tissues, the airway mucosal immune system response. In 
this way the balance of Th1, Th2, and Treg cell arriving in the airways upon stimulation 
is positively affected by B-GOS supplementation. Furthermore recent research now 
highlights that the airways are home to their own unique microbiome that is altered in 
individuals suffering from airway diseases (Madan, et al. 2012, Han, et al. 2012). This 
unique lung microbiome can also respond in diversity to dietary interventions (Madan, 
et al. 2012). Consequently it is plausible that in addition to altered immune tolerance 
through the gut microbiota, B-GOS supplementation may be having a direct impact on 
the microbial communities of the asthmatic airways however this remains to be 
elucidated. 
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Consequently feeding pre or probiotic to increase the beneficial commensal 
bacteria being sampled by intestinal epithelial cells and dendritic cells in the gut are 
likely to have a subsequent positive effect on Treg cell differentiation to improve 
immune tolerance and inflammatory function in asthmatics which would support the 
improved pulmonary function responses and reduced inflammatory markers in the 
current study.  
 
6.6. Conclusion 
For the first time this study shows that a 21-day supplementation of prebiotic B-
GOS can significantly reduce the severity of HIB in asthmatics and supress markers of 
airway inflammation. Favourable manipulation of the commensal bacteria by B-GOS 
will influence immune regulation and inflammatory responses via intestinal epithelial 
cells, dendritic cells, Treg cells, and Thelper cells. Favourable increases in beneficial 
commensal bacteria through B-GOS treatment will help to improve the immune 
response in asthmatics towards greater Treg activity to maintain immune modulation 
and suppress inflammatory responses to triggers such as exercise and hyperpnoea.  
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7. Chapter 7 – General Discussion 
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7.1. Introduction 
Asthma has been an increasing public health issue over the past 40 years. In the 
UK, 5.4 million people are currently receiving treatment for asthma, 1.1 million 
children (1 in 11) and 4.3 million adults (1 in 12). The disease has a considerable 
financial burden associated with it costing the NHS £1 billion a year (Asthma UK 
Accessed on 12.06.2013). Eighty percent of clinically recognised asthmatics experience 
exercise induced bronchoconstriction (EIB) (Anderson and Holzer 2000), with asthma 
and airway hyperresponsiveness being amongst the most common chronic medical 
conditions reported by elite athletes with a prevalence of 7-8% (Kippelen, et al. 2012) 
although large variations exist between sports (Fitch 2012). EIB is a phenotype of 
asthma that is characterized by a transient airway narrowing during or on the cessation 
of exercise (McFadden Jr and Gilbert 1994, Anderson and Holzer 2000, Suman, et al. 
1999), and it is generally accepted that airway drying and changes in airway osmolality 
trigger the response (Rundell and Jenkinson 2002). 
Asthma and EIB are traditionally treated with β2-agonists which typically target 
symptoms alone, and long-term use of inhaled corticosteroids can have systemic side 
effects. Furthermore, over 50% of asthmatics are documented to have poorly controlled 
asthma largely due to poor adherence to medication (Barnes 2010). An estimated 75% 
of hospital admissions for asthma are avoidable through improved management 
techniques and as many as 90% of deaths from asthma are preventable (Asthma UK 
Accessed on 12.06.2013).  These striking statistics and limitations with current 
medication provide a strong rationale to develop novel therapeutic strategies which 
encourage adherence and that target the underlying inflammation and immune response. 
In addition, to establish the efficacy of novel treatment options understanding the 
reproducibility of techniques used to measure the severity of EIB was needed. 
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Determining the reproducibility of techniques used to diagnose and monitor EIB allows 
for confidence when assessing changes in the severity of bronchoconstriction in 
response to interventions of ω3-PUFA and B-GOS. Changes in severity can be 
established as a genuine effect if above any inherent variability in the 
bronchoprovocation technique used.  
These questions initiated the rationale for this research thesis. A summary of the 
key findings are detailed below.    
Chapter 4 confirmed the efficacy of a 6 min EVH protocol as a bronchoprovocation 
test. The study demonstrated excellent within-participant test-retest reproducibility for 
EVH and the evoked changes in pulmonary function in HIB participants, over both 
short- (21 days) and long-term (70 days) periods. Reporting reproducibility statistics 
highlighted that the EVH protocol used in the current thesis was a valuable tool for 
assessing the efficacy of interventions aimed at reducing HIB. 
Chapter 5 showed‎for‎the‎first‎time‎that‎a‎lower‎dose‎of‎ω3-PUFA (3.1 g·d-1) was as 
effective as previously used high doses (6.2 g·d
-1
) in suppressing HIB in physically 
active asthmatics. This was in conjunction with equal suppression of FENO, and 
urinary‎9α,‎11β-PGF2 concentration as markers of airway inflammation. It highlights 
that‎lower‎ω3-PUFA doses represent a potentially beneficial treatment for physically 
active asthmatics suffering with EIB whilst reducing the burden of cost, compliance and 
potential for GI distress. 
Chapter 6 showed for the first time that 21 days of prebiotic B-GOS supplementation 
attenuated the post-EVH decline in pulmonary function in physically active HIB 
participants. This was in combination with a reduction in airway inflammatory markers 
including serum TNF-α,‎CCL17,‎and‎CRP.‎This‎suggests‎that‎potentially‎favourable‎
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manipulation of the commensal gut bacteria through B-GOS may alter systemic 
inflammation and immune function to reduce the bronchoconstriction following EVH.  
 
7.2. Experimental findings and recommendations 
Prior to investigating the use of novel dietary interventions in the treatment of 
HIB, a reproducible technique to induce and measure the severity of 
bronchoconstriction needed to be established.  Self-presentation of symptoms by 
asthmatics and EIB sufferers lack specificity and sensitivity which makes diagnosis 
using this information alone extremely inaccurate with a risk of either false positive or 
false negative results (Rundell, et al. 2001a, Holzer, Anderson and Douglass 2002, 
Parsons 2009). Bronchial provocation techniques to induce bronchoconstriction have 
been developed to diagnose and monitor EIB. A number of bronchoprovocation 
techniques have been established but none are generally considered as a gold standard. 
The eucapnic voluntary hyperpnoea challenge is recommended by the International 
Olympic Committee-Medical Commission to diagnose EIB in elite athletes (Weiler, et 
al. 2007, Fitch, et al. 2008), but the reproducibility of the  reduction in pulmonary 
function to EVH was not known. It is important to ascertain the reproducibility of such 
reductions and the smallest measurable change in these reductions as it will allow for 
greater confidence when assessing interventions that aim to reduce the severity of EIB. 
If changes in post-EVH FEV1 exceed the smallest measurable change then it can be 
assumed that the intervention has a genuine effect beyond any inherent variability in the 
bronchoprovocation challenge. Understanding the long-term reproducibility of the 6 
min EVH test may thus improve the monitoring and evaluation of HIB management 
and intervention strategies. 
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In Chapter 4, an EVH method that incorporated real-time visual feedback of  V̇E 
and end-tidal PCO2 through the use of a breath-by-breath analyser was described. It was 
found that this method induced a highly reproducible Broncho constrictive response, 
over both short- term (21 days) and long-term (70 days) periods, in physically active 
asthmatics with HIB. To the author’s knowledge this is the first time that the smallest 
measurable change in the fall in FEV1 post-EVH has been calculated from repeated 
EVH challenges. The smallest measurable change of 88 mL suggests that alterations in 
the post-EVH fall in FEV1 that are greater than this are likely to represent a genuine 
change. The average fall in FEV1 in the HIB participants was >770 mL, this suggests 
that the fall in FEV1 must change by more than 11% to exceed the smallest measurable 
change and this would allow for confidence in monitoring nutritional interventions. The 
low smallest measurable change for post-EVH change in FEV1 supports previous 
research that suggests EVH is also more sensitive in diagnosing HIB than (non-dry-air) 
exercise challenges, which are more difficult to standardize due to potential variability 
in exercise intensity and duration, and inspirate moisture content (Rundell, et al. 2004, 
Rundell, et al. 2000). Furthermore the results in chapter 4 show consistent pre-EVH 
pulmonary function tests in asthmatic HIB sufferers; this allows for a highly 
reproducible target V̇E for the EVH challenge to enhance the reproducibility of the 
bronchoconstrictive response to EVH.  
The outcomes of Chapter 4 allow us to confidently recommend the use of EVH 
utilising real-time visual feedback through a breath-by-breath analyser as a simulation 
of exercise induced bronchoconstriction in the diagnoses and management of HIB. 
Further to this, Chapters  5 and  6 showed increases in pro-inflammatory mediators 
similar to those seen in exercise challenges. This suggests a similar pathogenic pathway 
in HIB as EIB and further supports the use of EVH as an experimental model of EIB.  
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Therapeutic strategies to target the underlying inflammation of EIB/HIB are 
warranted and one area that has received considerable interest is the use of high doses 
of ω3-PUFA (Mickleborough etc.). ω3-PUFA interventions aim to reduce the release of 
pro-inflammatory mediators associated with the metabolism of arachidonic acid and 
increase anti-inflammatory and pro-resolving mediators to suppress inflammation. 
Polyunsaturated fatty acids (PUFAs) are important constituents of the phospholipids of 
all cell membranes. Increasing the dietary intake of the ω3-PUFAs EPA and DHA can 
result in higher concentrations of these fatty acids in inflammatory cells including 
lymphocytes, macrophages, and neutrophils; this can subsequently impact upon 
inflammatory processes (Yaqoob, Newsholme and Calder 1995, Brouard and Pascaud 
1990, Palombo, et al. 1999). Typically the increase in EPA and DHA in cell membranes 
is at the expense of ω6 arachidonic acid (Calder 2010) (Figure 7. 1).  
Previous research (Mickleborough, et al. 2003, Mickleborough, et al. 2006, 
Tecklenburg-Lund, et al. 2010) used very large dosages of ω3-PUFA (5.2g ω3-PUFA; 
3.2 g EPA and 2.0g DHA) equating to ~10 capsules a day. There is a large cost 
implication with such a high dose along with potential for problems with consumption 
adherence and the potential side effect of gastrointestinal discomfort (Van de Rest, et al. 
2008). In Chapter 5 we have shown for the first time that a dose of 3.1g·d
-1
 (1.8 g·d
-1
 
EPA and 1.3 g·d
-1
 DHA) is as effective in treating HIB in physically active asthmatics 
as a higher dose of 6.2 g·d
-1
 (3.7 g·d
-1
 EPA and 2.5 g·d
-1
 DHA). Changes in the severity 
of HIB assessed by AUC0-30%ΔFEV1 were similar in both the 6.2 g·d
-1
 and 3.1g·d
-1
 ω3-
PUFA interventions. The magnitude of the improvement in HIB (30-40%) is 
comparable to previous ω3-PUFA research (Mickleborough, et al. 2003, 
Mickleborough, et al. 2006, Tecklenburg-Lund, et al. 2010) and that which can occur 
from pharmacological interventions (Villaran, et al. 1999). In addition this magnitude of 
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improvement was greater than the smallest measurable change recorded in chapter 4 
highlighting the efficacy of the ω3-PUFA intervention.  Furthermore, both 3.1g·d-1 and 
6.2 g·d
-1
 interventions resulted in equal reductions in resting levels of exhaled nitric 
oxide, and equal suppression of urinary 9α, 11β-PGF2 concentration following the EVH 
challenge. It is also important to note that two participants withdrew from the study due 
to gastrointestinal distress during the higher dose (6.2 g·d
-1
) supporting the rationale for 
understanding the treatment effects of lower doses. Furthermore, on the back of this 
research sports physicians, medical officers, and nutritionists working for the English 
Institute of Sport have expressed an interest in the results. High dose ω3-PUFA 
supplement is widely used in elite sport (personal communication) and this study 
provides evidence to reduce dose levels to improve adherence and reduce costs in this 
cohort of athletes.  
The findings of Chapter 5 suggest that lower doses of ω3-PUFA can 
significantly modulate the inflammatory process associated with HIB. Both ω3-PUFA 
doses resulted in significant increases in the content of EPA and the 6.2 g·d
-1
 dose 
increased the content of DHA in the phospholipid membranes of isolated neutrophils at 
day 21 when compared to day 0. This verified compliance to the supplementation 
regimes and provides evidence to support alterations in the inflammatory responses to 
EVH. The increases in EPA and DHA were in accordance with a reduction in the 
content of ω6-PUFA arachidonic acid following the 6.2 g·d-1 and 3.1 g·d-1 interventions 
in the HIB asthmatics. This is important because the arachidonic acid derived pro-
inflammatory eicosanoids have consistently been associated with the pathogenesis of 
asthma and EIB (Hallstrand, et al. 2013). Both ω3-PUFA interventions significantly 
reduced the urinary concentration of the PGD2 metabolite 9α, 11β-PGF2 at Day 21 
compared to Day 0 post EVH. The increases in urinary 9α, 11β-PGF2 following EVH 
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on all interventions are similar to those shown previously in response to exercise 
challenges in asthmatics, rising from a baseline of ~30-40 ng·mmol
-1
 creatinine up to 
~80 ng·mmol
-1
 creatinine (Mickleborough, et al. 2003). This highlights the utility of 
EVH to cause a hyperpnoea induced bronchoconstriction that is pathologically similar 
to EIB. The 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA interventions significantly attenuated the 
rise in post-EVH 9α, 11β-PGF2 urinary concentration and the concentrations were 
subsequently similar to the control participants suggesting suppression of arachidonic 
acid derived inflammation. Both doses increased the content of EPA in the 
phospholipid membranes of neutrophil cells with a consequential improvement in HIB 
and suppression of 9α, 11β-PGF2. This supports the notion that EPA is key in the 
competitive inhibition of arachidonic acid (Calder. 2010) (Figure 7. 1) and that this is a 
likely mechanism of action for the beneficial effect of ω3-PUFA on HIB. 
 
 
Figure 7. 1 Overview of synthesis and actions of lipid derived mediators (eicosanoids, resolvins and 
protectins) produced from arachidonic acid, EPA, and DHA. Red lines highlight competitive inhibition of 
arachidonic acid enzymatic pathways by EPA (Calder. 2010).  
 
Both 6.2 g·d
-1
 and 3.1 g·d
-1
 ω3-PUFA doses reduced FENO levels after 21 days 
of intervention in the HIB positive participants. Fraction of exhaled nitric oxide is now 
commonly used as a marker of asthma control and an objective measure of airway 
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inflammation (Sandrini, et al. 2010). In asthma sufferers, FENO is an indicator of 
eosinophilic airway inflammation, raised IgE levels and allergic sensitisation (Strunk, et 
al. 2003). The results of the current study support previous findings that high dose ω3-
PUFA alone, and in combination with montelukast, can reduce pre-hyperpnoea FENO 
in HIB sufferers from 42.5 ± 6.6 ppb to 25.5 ± 3.9 ppb; and 23.2 ± 3.4 ppb respectively 
(Tecklenburg-Lund, et al. 2010). To the author’s knowledge, only one other study has 
directly investigated the response of FENO in asthmatics to ω3-PUFA interventions 
(Moreira, et al. 2007). This study found no benefit of daily ω3-PUFA intake on FENO, 
however the intervention dose was markedly lower than the 3.1g·d
-1
 dose in the current 
study (0.91 g EPA and 0.65 g DHA vs 1.8 g EPA and 1.3 g DHA). It is likely that this 
dose was not sufficient to raise levels of EPA and DHA in the phospholipid membranes 
of inflammatory cells to influence FENO levels. The data suggest that there is likely to 
be a minimum effective dose of ω3-PUFA in treating HIB in physically active 
asthmatics, but to date no dose-response studies have elucidated the exact response.  
Recommendations based on the findings of Chapter 5 are that lower ω3-PUFA 
doses are as effective as higher doses in attenuating HIB in physically active asthmatics. 
These data highlight that lower doses represent a potentially beneficial treatment for 
physically active asthmatics suffering with HIB whilst reducing the burden of cost, 
compliance and potential for GI distress. It is clear that the combination of EPA and 
DHA can provide anti-inflammatory effects to reduce airway inflammation as assessed 
by FeNO and urinary 9α, 11β-PGF2.  
The limitations of current pharmacological treatment for asthma and EIB 
provide a strong rationale to develop therapeutic strategies that target underlying 
immune function and inflammation that can be deregulated in asthmatics. Recent 
evidence suggests that the gastrointestinal commensal bacteria could be a therapeutic 
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target to influence the immune and inflammatory responses that mediate allergy and 
asthma (Noverr and Huffnagle 2004, McLoughlin and Mills 2011). Chapter 6 shows for 
the first time that intervention with a prebiotic supplement (trans-
galactooligosaccharide [B-GOS]) can significantly attenuate the bronchoconstriction 
and serum markers of inflammation associated with HIB in physically active 
asthmatics. The use of B-GOS for the management of HIB in physically active 
asthmatics is a new treatment option that currently is not used within sporting 
environments. The efficacy of B-GOS to manage HIB is similar to that shown from 
both ω3-PUFA and pharmacological interventions subsequently sporting bodies such as 
the English Institute of Sport have expressed an interest in these results and are 
currently starting to implement B-GOS supplementation in their athletes suffering with 
asthma. Thus, Chapter 6 presents novel evidence that favourable manipulation of the 
gastrointestinal microflora can be a suitable treatment option for individuals suffering 
from HIB. Twenty-one days of B-GOS intervention significantly improved the 
%ΔFEV1 after EVH at the 3, 6, 10 and 20 minute time points (p < 0.05) in the HIB 
asthmatics by 36 ± 17, 36 ± 19, 43 ± 25%, and 33 ± 24% respectively. This is similar to 
the improvements seen in Chapter 5 and those from previous nutritional intervention 
studies and pharmacological interventions (Mickleborough, et al. 2003, Tecklenburg, et 
al. 2007, Mickleborough 2005). As with chapter 5, the B-GOS supplement was able to 
induce a significant improvement in pulmonary function of the HIB participants. 
Furthermore this was greater than the smallest measureable change from chapter 4, 
indicating that B-GOS was an effective treatment strategy for HIB.   
A limitation of the study in Chapter 6 is that no measurements of faecal 
microflora were taken to support the efficacy of the B-GOS intervention in 
manipulating the gut microflora. However, previous research using the same 
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supplement has shown B-GOS to significantly increase the numbers of beneficial 
bacteria, primarily bifidobacteria, at the expense of less beneficial bacteria to improve 
the microflora of the gut (Depeint, et al. 2008). Coinciding with improvements in the 
gut microflora, previous research showed suppression of pro-inflammatory cytokines 
(IL-6, IL-1β, and TNF-α) (Depeint, et al. 2008). Our current study extends the research 
knowledge of B-GOS further suggesting it can attenuate the bronchoconstriction 
associated with HIB and reduce chemokine and cytokine markers of airway 
inflammation in physically active asthmatics.  
The microbial communities of both the gut and airways have been shown to be 
dysregulated in patients suffering with respiratory diseases (Madan, et al. 2012, Hilty, et 
al. 2010, Huang, et al. 2011). It is plausible that the bifidogenic properties of B-GOS 
were able to modify the gut microflora and influence the underlying inflammation of 
asthmatics to supress the subsequent inflammatory responses of HIB in response to 
EVH. In conjunction with a significant improvement in the level of bronchoconstriction 
caused by EVH, the HIB asthmatics showed reductions in serum concentrations of 
TNF-α, CCL17, and CRP.  
Chronic airway inflammation associated with asthma is in part maintained by 
the action of TNF-α in suppressing Treg cell function which is essential for the 
maintenance and balance of immune responses. The suppression of pre-EVH and post-
EVH serum concentrations of TNF-α suggests that B-GOS intervention enhances Treg 
cell functioning in the HIB asthmatics thus diminishing the level of bronchoconstriction 
associated with HIB. Natural Treg cells are important suppressors of allergic responses 
to inhaled antigens such as grass or pollen (Ling, et al. 2004, Grindebacke, et al. 2004) 
and it may be hypothesised that they could supress the response of HIB asthmatics to 
dry gas hyperpnoea. Importantly, TNF-α impairs the regulatory activity of natural Treg 
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cells via the TNF-α receptor 2 (TNFR2) signalling pathway to down modulate Foxp3 
expression (Lin, Shieh and Wang 2008). The transcription factor Foxp3 is a crucial 
regulator for Treg cell development and function, and asthmatics have a reduced Foxp3 
expression (Provoost, et al. 2009). Twenty-one days intervention of B-GOS reduced 
serum TNF-α by 36 ± 18% in the HIB participants and this may have allowed for 
improved expression of Foxp3 within CD4
+
CD25 Tcells to enhance immune regulation 
in the HIB participants thus dampening the bronchoconstrictive response to EVH. 
Further research is required to elucidate the mechanisms of TNF-α suppression and 
improvements in asthma following B-GOS interventions (see section  7.4 for more 
details).  
Chapter 6 reports serum chemokine concentrations in HIB positive participants 
for the first time along with their subsequent responses to B-GOS intervention. It was 
found that B-GOS reduced the concentration of CCL17, but not CCL11. CCL11 is 
increased in the airways of asthma sufferers and is an important attractant for 
eosinophils which are up-regulated in epithelial cells (Smit and Lukacs 2006). B-GOS 
failed to reduce CCL11 concentration and FENO as markers of eosinophilic airway 
inflammation. Despite this there were still significant clinical improvements in the HIB 
participants. This supports the concept that the pathogenesis of EIB/HIB is multifaceted 
and despite no change in markers of eosinophil recruitment to the airways, a significant 
improvement in post-EVH lung function was still evident. To the authors knowledge 
this is the first study to report serum CCL17 concentrations in HIB participants and they 
are similar to those found previously in allergic asthma sufferers (Sekiya, et al. 2002). 
The increased serum CCL17 in the HIB positive participants supports the notion of 
increased Th2 lymphocyte infiltration in the pathogenesis of the condition (Hallstrand, 
et al. 1998). The HIB asthmatics had significantly higher concentrations of CCL17 at 
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day 0 of the interventions compared with the control group (408.69 ± 182.53 vs 239.73 
± 80.28 pg·mL
-1
). The gut associated lymphoid tissue develops immune responses to 
different stimuli which involve the production of cytokines and chemokines (Sanz and 
De Palma 2009). Manipulating the commensal bacteria may subsequently affect the 
production and expression of cytokines and chemokines associated with inflammatory 
responses (Wells, et al. 2011). The B-GOS intervention successfully reduced the serum 
concentration of CCL17 in the HIB participants. A suppression of CCL17 concentration 
may have subsequently reduced the Th2 lymphocyte infiltration into the airways of the 
HIB participants so reducing the inflammatory and bronchoconstrictive response to 
EVH.  
In support of previous research (Vulevic, et al. 2013), Chapter 6 shows a 
reduction in serum CRP concentrations following the B-GOS intervention. The 
reductions in CRP in response to B-GOS highlight the beneficial effect on immune 
function, and the suppression of low-grade inflammation. With prebiotic B-GOS 
increasing the number of beneficial bifidobacteria in parallel to reduced CRP 
concentrations in Vulevic et al (2013) it is plausible that changes in the microbiota may 
significantly alter the immune response in the HIB positive participants to reduce the 
subsequent inflammatory response to HIB.  
For the first time, Chapter 6 shows that a 3 week intervention of prebiotic B-
GOS can successfully attenuate the bronchoconstriction and airway inflammation 
associated with HIB in physically active asthma sufferers. As such, it may be a novel 
treatment option for asthmatics who suffer with exercise induced asthma. The results 
add to the growing body of evidence that manipulation of the commensal bacteria 
influences inflammatory responses beyond the gastrointestinal tract. The precise 
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mechanisms and exact cause and effect relationships are yet to be fully determined; 
future research directions are discussed in section  7.4.  
7.3. Limitations 
The specific limitations of each study are discussed in the relevant experimental 
chapters. Globally the issues with assessing asthma severity are the high heterogeneity 
in the severity of disease and numerous phenotypes in its manifestation (Wenzel 2013). 
The current studies used relatively small cohorts, but in an attempt to keep the groups as 
homogenous as possible all participants had to be physically active (completing 4-6 
hours of exercise a week), have a previous GP diagnosis of asthma with the severity 
well controlled and prior to the studies all participants were initially screened for HIB 
through EVH. Despite the potential heterogeneity in asthma severity Chapter  4 
documents a high level of reproducibility in baseline FEV1 and FVC values which 
subsequently allows for reproducible EVH tests to be performed. Ideally, a larger 
cohort of asthmatics would be sought to confirm the high level of reproducibility from a 
wider array of asthma phenotypes. 
Chapter’s  5 and  6 show the successful intervention of dietary supplements to 
improve the severity of HIB in a relatively small cohort of physically active asthmatics. 
Larger replication studies should be conducted to support or refute these novel findings.  
Due to the heterogeneity of asthma Chapter  6 found a number of inflammatory markers 
to not be normally distributed; a larger participant number will allow for this 
heterogeneity and develop a better understanding into the effectiveness of these 
interventions.  
A limitation of the studies in Chapters  5 and  6 are that no measures of quality of 
life, and medication usage were taken. Previous research suggests that nutritional 
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interventions do not only result in improvements in clinical measures of pulmonary 
function and markers of inflammation but these coincide with reductions in medication 
usage (Mickleborough, et al. 2003). Future research should look to include 
questionnaires assessing medication usage, asthma severity, and quality of life as 
outcome measure in response to nutritional interventions.     
7.4. Significance of findings and future research direction 
Due to the novelty of the findings in Chapter  5 and  6, there is significant scope 
for the implementation of these protocols to alleviate HIB in physically active 
asthmatics. Well-controlled asthma should not be considered a barrier to physical 
activity and nutritional interventions at the doses currently studied are easy to 
implement and have limited, if any, adverse side effects. This thesis expands the current 
knowledge of effective dose levels of ω3-PUFA in HIB, and shows for the first time 
that treatment with prebiotic B-GOS can significantly attenuate the bronchoconstriction 
associated with HIB in physically active asthmatics. On the back of this novel research 
there are a wealth of future research directions to gain a better understanding into the 
therapeutic and mechanistic benefits of both ω3-PUFA and B-GOS in the treatment of 
asthma and EIB: 
 The 3.1g·d-1 ω3-PUFA dose significantly improved the severity of HIB, and 
reduced urinary markers of airway inflammation and FENO. However 3 
weeks of supplementation at 3.1g·d
-1
 did not elevate the phospholipid content 
of DHA. Therefore a longer duration of supplementation at 3.1 g·d
-1
 should 
be investigated.  This may elicit a significant increase in phospholipid DHA 
content and thus attenuate the severity of HIB further.  
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 Further to this, investigations into an initial high dose similar to 6.2 g·d-1 to 
rapidly increase saturation of the phospholipid membranes followed by a 
lower maintenance dose of 3.1 g·d
-1
 may well be warranted. This would have 
the potential of improving long-term adherence to ω3-PUFA interventions, 
but also allow for an initial increase in EPA and DHA content. Furthermore 
an important development would be to gain an understanding of an exact 
dose-response relationship between ω3-PUFA and HIB/EIB.  
  A greater understanding into the isolated and combined effects of EPA and 
DHA is needed in both in vivo, and in vitro research protocols. To support the 
use of certain dose levels of ω3-PUFA a better understanding into the 
mechanisms by which EPA and DHA regulate inflammation and produce 
pro-resolvins mediators is needed.  
 Site specific markers of airway inflammation such as sputum and 
bronchoalveolar lavage fluid in response to EPA and DHA doses should be 
measured. 
 Furthermore, elite level athletes are known to undergo airway epithelial 
damage and airway injury therefore measures of this through urinary clara 
cell 16 in response to ω3-PUFA interventions are warranted. 
 
We have shown for the first time that a prebiotic B-GOS intervention can 
significantly improve HIB and markers of inflammation in physically active asthmatics, 
however the exact mechanisms of action remain to be elucidated. Future research 
studies should look to focus on: 
 Future research studies should collect faecal samples from asthmatics 
receiving B-GOS to confirm its bifidogenic properties in this population. It 
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would also confirm if this population has a reduced diversity of gut 
microflora that could contribute to the onset of the disease.  
 There is a wealth of potential research studies to follow the initial proof of 
concept described in Chapter 6. A larger scale research study to confirm or 
refute the main outcome of reduced severity of HIB is needed. A larger 
population will also allow for a better understanding into the underlying 
mechanisms.  
 There are a number of methods to try and elucidate the mechanisms of action 
of prebiotic B-GOS on asthma further. The collection of sputum for the 
assessment of site specific inflammation markers would allow for direct 
changes within the airways to be understood.  
 Recent research has also shown that the airways of patients with respiratory 
diseases have a dysregulated microflora which can be manipulated through 
dietary interventions (Madan, et al. 2012). Through the use of epithelial 
brushing technique the lung micro biome could be analysed to establish 
differences in diversity between asthmatics and non-asthmatics and its 
subsequent response to B-GOS treatment.  
 Chapter 6 showed reductions in the serum concentration of TNF-α and this 
may be a marker of, or, as a consequence of alterations in T cell 
differentiation and Foxp3 expression. Peripheral blood mononuclear cells 
(PBMC) from control and asthmatic patients’ pre and post B-GOS 
intervention should be collected in future research. These cells can be 
labelled for CD4, CD25, and intracellular Foxp3 and analysed using flow 
cytometry to establish changes in protein expression in response to B-GOS 
intervention.  
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 Since the mechanisms of action may be different it would be pertinent to 
establish if there is a combination effect of ω3-PUFA and B-GOS on asthma 
and EIB. 
 Furthermore, a combination of B-GOS with strains of lactobacilli and 
bifidobacteria in the form of a synbiotic may enhance the immune regulation 
in asthmatics and suppress markers of inflammation further  
 There is scope for nutritional intervention strategies to be used in other 
phenotypes of asthma such as allergic asthma which is driven by Th2 cell 
which could be suppressed by B-GOS supplementation 
 There is also scope for other populations to be studied such as asthma in the 
elderly and children, and in other respiratory diseases associated with airway 
inflammation such as cystic fibrosis and COPD.  
 
7.5. Conclusion 
In conclusion, this thesis provides novel evidence of the efficacy of two 
nutritional interventions as treatment options for hyperpnoea induced 
bronchoconstriction in physically active asthmatics. We have shown for the first time 
that a lower dose of ω3-PUFA is effective in attenuating the post EVH decline in FEV1 
and suppression of inflammation markers. This reduces the financial and adherence 
burdens of trying to maintain a high dose, and reduces the risk of gastrointestinal side 
effects.  Furthermore, our novel findings show for the first time that potential 
manipulation of the gut microflora through prebiotic B-GOS interventions can 
significantly alter the immune and inflammatory function of asthmatics and reduce the 
severity of bronchoconstriction following EVH. This data adds to the growing body of 
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evidence that the gut microbiome can have a significant impact on immune function 
and inflammation beyond the gastrointestinal tract and as such is a potential therapeutic 
target for future research.  
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Appendix 1 - Self-reporting Health Screen 
Ethical Application 
 
 
Name or Number____________________ 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise Yes      No      
(b) attending your general practitioner  Yes      No      
(c) on a hospital waiting list  Yes      No      
 
2. In the past two years, have you had any illness which require you to: 
(a) consult your GP Yes      No      
(b) attend a hospital outpatient department Yes      No      
(c) be admitted to hospital Yes      No      
 
3. Have you ever had any of the following? 
(a) Convulsions/epilepsy Yes      No      
(b) Asthma Yes      No      
(c) Eczema Yes      No      
(d) Diabetes Yes      No      
(e) A blood disorder Yes      No      
(f) Head injury Yes      No      
(g) Digestive problems Yes      No      
(h) Heart problems Yes      No      
   304 
(i) Problems with bones or joints    Yes      No      
(j) Disturbance of balance / coordination Yes      No      
(k) Numbness in hands or feet Yes      No      
(l) Disturbance of vision Yes      No      
(m) Ear / hearing problems Yes      No      
(n) Thyroid problems Yes      No      
(o) Kidney or liver problems Yes      No      
(p) Allergy to nuts, alcohol etc Yes      No      
(q) Any problems affecting your nose e.g. recurrent nose bleeds 
 Yes     No       
 Any nasal fracture or deviated nasal septum Yes      No      
(r) Are there any reasons why blood sampling may be difficult?   
Yes       No      
(s) Have you had a blood sample taken previously? Yes        No      
(t) Have you had a cold, flu or any flu like symptoms in the last Month?  
Yes       No      
 
4. Has any, otherwise healthy, member of your family under the age of 50 
 died suddenly during or soon after exercise?  Yes      No      
 
5 .Asthma Specific questions: 
 
When was your last asthma exacerbation_________________ 
Have you ever been admitted to hospital for your asthma  Yes      No      
Have you ever been prescribed a course of steroids for your asthma  
Yes     No      
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Do you suffer from asthma symptoms post exercise Yes      No      
Do you suffer from asthma symptoms when exposed to dry/cold air  
Yes     No      
Do you suffer from asthma symptoms when exposed to allergens (pollen, animal 
fur etc)  
Yes     No      
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Appendix 2 - Chapter 4 Participant Information Sheet  
 
Ethical Application 
 
A1 – Participant Information Sheet 
“Reproducibility of diagnosing exercise induced asthma through eucapnic voluntary 
hyperventilation (EVH)” 
 
Introduction 
Exercise induced asthma or sometimes termed exercise induced bronchoconstriction 
(EIB) is a term used to describe a transient narrowing of the airways during or 
following exercise, that can occur in individuals with and without asthma. It is 
generally considered that exercise and high breathing rates are important initiating 
stimuli as they dehydrate and alter the airway surface lining. Exercise induced 
bronchoconstriction presents a significant problem for many elite and recreational 
athletes many of whom have to reduce training loads impacting both their 
performance, and quality of life.  
Eucapnic Voluntary Hyperventilation is an indirect challenge used to identify and 
diagnose exercise induced bronchoconstriction (EIB) in individuals and athletes. It is 
based on the fact that increased ventilation rate causes bronchoconstriction in 
susceptible individuals. This occurs through drying of the airways and increasing its 
osmolality causing the airway smooth muscles to contract. EVH has demonstrated high 
sensitivity to identify those with EIB.  It is currently the International Olympic 
Committee Medical Commissions (IOC-MC) recommended challenge to identify EIB 
among Olympic athletes. EVH requires participants to hyperventilate a dry gas (5% 
CO2, 21% O2, balance Nitrogen) for 6 minutes. Pre and post pulmonary function is 
assessed to diagnose EIB.  
 
Inclusion Criteria 
Aged 18-45 
Body mass index 20-25 kg·m-2 
Physically active (completing 3 or more exercise sessions a week lasting at least 45 
minutes each) 
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Non-smoker 
Asthmatics must have their own clinically prescribed medication (e.g. short acting β2-
agonist) 
 
Exclusion Criteria 
Predicted forced expiratory volume over one second (FEV1) of <65% – this will be 
measured during your assessment visit 
Previously admitted to hospital for asthma or other breathing difficulties 
Previously diagnosed with chronic obstructive pulmonary disease (COPD) emphysema, 
chronic bronchitis or similar respiratory illness 
History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart 
disease 
History of recurrent chest infections 
Smoker 
Acute infection within the last four weeks 
Major operation within the past four months  
Currently taking long term asthma maintenance medications – corticosteroids, and 
leukotriene modifiers that you could not refrain from taking for 4 days prior to 
laboratory session  
 
Requirements 
All subjects will be allowed to continue to use their EIB medication as needed during 
the course of the studies. However, to identify treatment effects subjects will be 
required to refrain from: 
Using short acting β2-agonists for at least 12h before each testing session 
Taking anti-histamines for 48h before testing sessions 
Taking inhaled corticosteroids for 4 days before testing sessions  
Ingesting caffeine for 8h prior to testing sessions 
Physical exercise and alcohol for 24h prior to a testing sessions 
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Consuming food 2h prior to testing sessions 
Female participants must be taking an oral contraceptive, or have a contraceptive 
implant 
These are standardised requirements used in previous EIB, and supplementation 
studies. If your asthma symptoms are exacerbated due to the reduction in medication 
use prior to each testing session then you will be withdrawn from the study. This 
reduction in medication use may also have a very short term impact upon your 
exercise performance, that will be reversed following the testing session and when 
you take your medication again.  
You will perform three initial baseline pulmonary function tests, used to assess the 
function of your lungs. Then you will perform the EVH protocol. The procedure will 
require you to breath dry (<5% relative humidity) hypercapnic air (4.5-5% CO2) at a 
predetermined rate for 6 minutes. Breathing in through a mouthpiece with a nose clip 
on, your target breathing rate will be displayed on a screen to help you maintain this 
ventilation. Following the EVH protocol you will then perform pulmonary function 
tests at 3, 6, and 16 minutes. We then compare your post EVH lung function to your 
baseline, if there is a drop of more than 10% in your forced expiratory volume in 1 
second then this is diagnostic of EIB.  
EVH will induce a bronchoconstrictive response in asthmatic and EIB susceptible 
individuals. Asthmatic individuals may experience symptoms of wheezing, coughing, 
tightness in the chest, and slight shortness of breath. These symptoms although very 
unlikely may result in a slight detriment to exercise performance, immediately 
following the test. If you suffer from asthma or EIB you will not be allowed to 
complete the testing sessions unless you have your own bronchodilator medication to 
hand. There will also be a salbutamol reliever and spacer for treating asthma 
exacerbations. Pulmonary function will be measured pre and post EVH.  
If you have further queries then please don’t hesitate to get in touch.  
Contact 
Neil Williams      Dr Kirsty Hunter  
Nottingham Trent University    Nottingham Trent University 
School of Science and Technology   School of Science and Technology 
Erasmus Darwin, Room 230    Erasmus Darwin Building                      
Clifton, Nottingham     Clifton, Nottingham 
NG11 8NS       NG11 8NS 
Tel : 0115 8483820 
Email: neil.williams2010@my.ntu.ac.uk  Kirsty.hunter@ntu.ac.uk   
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Appendix 3 - Chapter 4 Informed Consent Form  
Ethical Application 
 
A2a – Subject Statement of Consent to Participate in the 
Investigation Entitled: 
 
“Reproducibility of diagnosing exercise induced asthma through eucapnic voluntary 
hyperventilation (EVH)” 
 
1)  I, ________________agree to partake as a subject in the above study. 
 
2)  I understand from the participant information sheet, which I have read in full, 
and from my discussion(s) with Neil Williams that this will involve me: 
Attending the sport Science laboratories at NTU Clifton Campus on four 
occasions over a 21 day period or 3 occasions over a 70 day period, with each 
visit lasting up to 1 hour. I will be required to perform pulmonary function tests 
and undergo eucapnic voluntary hyperventilation (EVH).  
 
3)  It has also been explained to me by Neil Williams that the risks and side effects 
which may result from my participation are as follows: For asthmatic individuals 
mild bronchoconstriction (symptoms similar to mild asthma) will occur from 
completing the EVH protocol. This will be combated by regular measurements of 
pulmonary function and reversed by taking short acting β2 agonist medication. 
 
4)  I confirm that I have had the opportunity to ask questions about the study and, 
where I have asked questions, these have been answered to my satisfaction. 
 
5)  I undertake to abide by University regulations and the advice of researchers 
regarding safety.  
 
6)  I am aware that I can withdraw my consent to participate in the study at any 
time and for any reason, without having to explain my withdrawal. 
 
7) I understand that any personal information regarding me, gained through my 
participation in this study, will be treated as confidential and only handled by 
individuals relevant to the performance of the study and the storing of 
information thereafter.  Where information concerning myself appears within 
published material, my identity will be kept anonymous.  
 
8)  I confirm that I have read the University’s policy relating to the storage and 
subsequent destruction of sensitive information.  I understand that sensitive 
information I have provided through my participation in this study, in the form 
of health and asthma questionnaires, and data relating to the study will be 
handled in accordance with this policy. 
 
9) I understand that as part of this study I will be consuming a supplement. I am 
aware that elite sports people (i.e. international or national standard) may 
undergo either out-of or in-competition (or both) doping tests and appreciate 
that the supplement being studied could be contaminated with a substance that 
appears on the banned lists. 
 
10) I confirm that I have completed the health questionnaire and know of no 
reason, medical or otherwise that would prevent me from partaking in this 
research. 
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Subject signature: …………………………………………………………………    
Date:_____________ 
 
Independent witness signature: ……………………………………………    
Date:_____________ 
 
Primary Researcher signature: …………………………………………….    
Date:______________ 
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Appendix 4 - Chapter 5 Participant Information Sheet  
Ethical Application 
 
 
A1 – Participant Information Sheet – Hand-out for participant 
recruitment 
“A randomised, double blind, placebo controlled, cross-over 
study to compare the effectiveness of two dosages of omega-
3 polyunsaturated fatty acid (ω3-PUFA) for the management 
of exercise induced bronchoconstriction in physically active 
healthy individuals.” 
 
Introduction 
Exercise induced bronchoconstriction (EIB) more commonly known as exercise 
induced asthma is used to describe a narrowing of the airways during or following 
exercise. It presents a significant problem for many elite and recreational athletes 
many of whom have to reduce training loads and have it impact on their performance.  
The common treatment for EIB involves the use of pharmacologic interventions. 
However, some have side effects, and are restricted by the International Olympic 
Committee. There is now evidence that dietary modification has the potential to be 
used in the management of EIB. Omega 3 polyunsaturated fatty acid (ω-3 PUFA) 
supplementation has shown to significantly improve pulmonary function in EIB 
sufferers, reduce markers of inflammation, and the need for bronchodilator 
medication. This study aims to assess the effects of 3 week supplementation periods 
of two different dose levels of ω-3 PUFA on exercise induced bronchoconstriction and 
markers of inflammation in healthy asthmatic and non-asthmatic individuals. 
The protocol and procedures have been reviewed and approved by the Nottingham 
Trent Human Ethics Committee; the protocol and the safeguards that have been put in 
place have been done so in consultation with a respiratory consultant at Nottingham 
City Hospital.   
 
Inclusion Criteria 
 Male 
 Aged 18-45 
 Body mass index 20-25 kg·m-2 
 Physically active (completing 3 or more exercise sessions a week lasting at 
least 45 minutes each) 
 Non-smoker 
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 Non-vegan or vegetarian 
 Asthmatic and EIB sufferers must have their own clinically prescribed 
medication (e.g. short acting β2-agonist) 
 
Exclusion Criteria 
 Predicted forced expiratory volume over one second (FEV1) of <65% – this will 
be measured during visit 1 
 Previously admitted to hospital for asthma or other breathing difficulties 
 Asthma exacerbation within the last month (Course of steroids, or hospital 
visit)  
 Previously diagnosed with chronic obstructive pulmonary disease (COPD) 
emphysema, chronic bronchitis or similar respiratory illness 
 History of heart failure, pulmonary hypertension, embolism, or other 
pulmonary heart disease 
 History of recurrent chest infections 
 Smoker 
 Acute infection within the last four weeks 
 Major operation within the past four months  
 Have a history of taking ω-3 PUFA supplements or supplements with 
antioxidants above recommended intake, or consume more than three fatty 
fish meals per week 
 Take a daily dose of aspirin or other non-steroidal anti-inflammatory drugs 
(NSAIDs) 
 Currently taking a daily dose of anti-histamine 
 Currently taking long term asthma maintenance medications – corticosteroids, 
and leukotriene modifiers that you could not refrain from taking for 4 days 
prior to laboratory session  
 Vegetarian or vegan diet 
 
If you meet the inclusion criteria and consent to take part you will be required to 
attend Nottingham Trent University on 7 occasions You will undergo three different 3-
week dietary supplementation conditions with a two week washout period between 
each (although the wash-out period between supplement conditions can be longer 
and can be worked around your own convenience). The three dietary supplementation 
interventions are: 
• ω3-6.2 g·d-1– 8 ω-3 capsules equalling 6.2 g (3.7 g EPA and 2.5 g DHA) per day 
• ω3-3.1 g·d-1 – 4 ω-3 capsules equalling 3.1 g (1.8 g EPA and 1.3 g DHA) + 4 
placebo capsules per day 
• Placebo (PLA) – 8 placebo capsules containing medium chain triglyceride 
GTCC per day 
All three supplements will be identical in size and appearance. Supplements will be of 
pharmaceutical grade supplied by a reputable manufacturer. 
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Visit one will involve a briefing about the study and familiarisation of the 
measurement techniques to be used during the study. These include pulmonary 
function, fraction of exhaled nitric oxide, and eucapnic voluntary hyperventilation (a 
technique used to diagnose and assess EIB). – EVH is a 6 minute hyperventilation 
challenge that has been shown to elicit a mild but highly diagnostic EIB response and is 
currently the International Olympic Committee-Medical Commissions recommended 
challenge for diagnosing EIB.  
EVH will induce a bronchoconstrictive response in asthmatic and EIB susceptible 
individuals. Asthmatic individuals may experience symptoms of wheezing, coughing, 
tightness in the chest, and slight shortness of breath. These symptoms although very 
unlikely may result in a slight detriment to exercise performance immediately 
following the challenge. Following the testing protocol, you will be free to use your 
own prescribed medication which should alleviate any remaining symptoms.  
During visit two you will have baseline measurements taken, and will also provide a 
urine and blood sample. You will then be provided with your first dietary 
supplementation for three weeks. 
Visits 3-7 will be the same measurements as above pre and post each 3-week 
supplementation period. You will also be required to complete 2 days of food diaries 
at the beginning of each supplementation period, and weekly asthma symptoms and 
control questionnaires.  
You will be chaperoned at all times during all periods of testing and will be closely 
monitored following all tests. You will be allowed to leave when your pulmonary 
function has returned to baseline values.  
Each visit will last up to 2 hours. Total blood taken per visit will be 40 mL which 
amounts to just over one sixth of a normal blood donation. 
If you are an asthmatic and are eligible to participate in this study we will contact your 
GP to inform them of your participation. Your GP will be sent information including a 
copy of the medical questionnaire to inform them that you are taking part in a trial 
that is assessing your management of exercise induced bronchoconstriction. Your GP 
will be asked to contact Mr Neil Williams if they do not deem you fit to participate in 
the study. The GP will be given 2 weeks to respond.  
In addition to this if you report to the study deeming yourself free from asthma and 
are subsequently diagnosed, you will be presented with your results and referred to 
your GP. You will be unable to volunteer for the study until you have visited your GP 
and received any subsequent medication to treat your asthma.   
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Contact 
Neil Williams 
Nottingham Trent University 
School of Science and Technology 
Erasmus Darwin, Room 230 
Clifton, Nottingham 
NG11 8NS 
Tel : 0115 8483820 Mobile.: 07900856252 Email: neil.williams2010@my.ntu.ac.uk  
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Appendix 5 - Chapter 5 Informed Consent Form  
Ethical Application 
A2a – Participant Statement of Consent to Participate in the 
Investigation Entitled: 
 
 
“A randomised, double-blind, placebo-controlled, cross-over 
study to compare the effectiveness of two dosages of omega-
3 polyunsaturated fatty acid (ω3-PUFA) for the management 
of exercise induced bronchoconstriction (EIB) in physically 
active healthy individuals.” 
 
1)  I, ________________agree to partake as a participant  in the above study. 
 
2)  I understand from the participant information sheet, which I have read in full, 
and from my discussion(s) with Neil Williams that this will involve me: 
Attending the sport Science laboratories at NTU Clifton Campus on seven 
occasions over a 13 week period, with each visit lasting up to 90 minutes. I will 
undergo 3 different dietary supplementation conditions, and be required to 
undergo pre and post supplementation period measurements of – Pulmonary 
function, eucapnic voluntary hyperventilation, and fraction of expired nitric 
oxide. I will also be required to provide both urine and blood samples; and 
complete food diaries and asthma symptom questionnaires.  
 
3)  It has also been explained to me by Neil Williams that the risks and side effects 
which may result from my participation are as follows:  EVH will induce a 
bronchoconstrictive response in EIB susceptible individuals. You may experience 
symptoms of wheezing, coughing, tightness in the chest, and slight shortness of 
breath. This will be combated by regular measurements of pulmonary function 
and reversed by taking short acting β2 agonist medication. Some discomfort 
can occur through cannulation although this will be carried out by trained 
members of staff. Some individuals may experience mild gastrointestinal 
discomfort when taken the ω-3 supplements.  
 
4)  I confirm that I have had the opportunity to ask questions about the study and, 
where I have asked questions, these have been answered to my satisfaction. 
 
5)  I undertake to abide by University regulations and the advice of researchers 
regarding safety.  
 
6)  I am aware that I can withdraw my consent to participate in the study at any 
time and for any reason, without having to explain my withdrawal. 
 
7) I understand that any personal information regarding me, gained through my 
participation in this study, will be treated as confidential and only handled by 
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individuals relevant to the performance of the study and the storing of 
information thereafter.  Where information concerning myself appears within 
published material, my identity will be kept anonymous.  
 
8)  I confirm that I have read the University’s policy relating to the storage and 
subsequent destruction of sensitive information.  I understand that sensitive 
information I have provided through my participation in this study, in the form 
of health and asthma questionnaires, and data relating to the study will be 
handled in accordance with this policy. 
 
9) I understand that as part of this study I will be consuming a supplement. I am 
aware that elite sports people (i.e. international or national standard) may 
undergo either out-of or in-competition (or both) doping tests and appreciate 
that the supplement being studied could be contaminated with a substance that 
appears on the banned lists. 
 
10) I confirm that I have completed the health questionnaire and know of no 
reason, medical or otherwise that would prevent me from partaking in this 
research. 
 
Participant signature: …………………………………………………………………    
Date:_____________ 
 
Independent witness signature: ……………………………………………    
Date:_____________ 
 
Primary Researcher signature: …………………………………………….    
Date:______________ 
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Appendix 6 - Chapter 6 Participant Information Sheet  
 
Ethical Application 
 
A1 – Subject Information Sheet – Handout for subject 
recruitment 
“A randomised, double blind, placebo controlled, study to 
establish the effect of 3 weeks of prebiotic supplementation 
on the management of exercise induced bronchoconstriction 
in physically active healthy individuals.” 
 
Introduction 
Exercise induced bronchoconstriction (EIB) more commonly known as exercise 
induced asthma is used to describe a narrowing of the airways during or following 
exercise. It presents a significant problem for many elite and recreational athletes 
many of whom have to reduce training loads and have it impact on their 
performance.  
The common treatment for EIB involves the use of pharmacologic interventions. 
However, some have side effects, and are restricted by the International Olympic 
Committee. There is now evidence that dietary modification has the potential to be 
used in the management of EIB. Omega 3 polyunsaturated fatty acid (ω-3 PUFA) 
supplementation has shown to significantly improve pulmonary function in EIB 
sufferers by reducing markers of inflammation, and the need for bronchodilator 
medication. Recent nutritional research into prebiotics (typically food derived 
carbohydrates) has highlighted their potential to improve gastrointestinal health, 
and reduce incidences of upper respiratory tract infections by increasing the 
numbers of positive microorganisms inside the gut. Research into prebiotics has 
highlighted their effects on the immune system, and the ability to fight infection, 
and inflammatory processes and conditions. In asthmatics and EIB susceptible 
individuals exercise is a trigger for airway inflammation. It could be hypothesised 
that with prebiotics having the potential to reduce airway inflammation they may 
influence the response to exercise in EIB susceptible individuals.  
This study aims to assess the effects of a 3 week supplementation period of a 
prebiotic supplement on exercise induced bronchoconstriction and markers of 
inflammation in healthy asthmatics. 
 
The protocol and procedures have been reviewed and approved by the Nottingham 
Trent Human Ethics Committee; the protocol and the safeguards that have been 
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put in place have been done so in consultation with a respiratory consultant at 
Nottingham City Hospital.   
 
Inclusion Criteria 
 Aged 18-45 
 Body mass index 20-25 kg·m-2 
 Physically active (completing 3 or more exercise sessions a week lasting at 
least 45 minutes each) 
 Non-smoker 
 Female participants must be taking an oral contraceptive or have 
contraceptive implant 
 Asthmatic and EIB sufferers must have their own clinically prescribed 
medication (e.g. short acting β2-agonist) 
 
Exclusion Criteria 
 Predicted forced expiratory volume over one second (FEV1) of <65% – this 
will be measured during visit 1 
 Previously admitted to hospital for asthma or other breathing difficulties 
 Asthma exacerbation within the last month (Course of steroids, or hospital 
visit)  
 Previously diagnosed with chronic obstructive pulmonary disease (COPD) 
emphysema, chronic bronchitis or similar respiratory illness 
 History of heart failure, pulmonary hypertension, embolism, or other 
pulmonary heart disease 
 Previously diagnosed with a bowel disease – ulcerative colitis, Crohn’s 
disease, infectious colitis or similar illness  
 History of  irritable bowel syndrome  
 History of recurrent chest infections 
 Smoker 
 Acute infection within the last four weeks 
 Major operation within the past four months  
 Have a history of taking ω-3 PUFA supplements or supplements with 
antioxidants above recommended intake, or consume more than three fatty 
fish meals per week 
 History of taking probiotic or prebiotic supplements  
 Recent history of taking antibiotics 
 Take a daily dose of aspirin or other non-steroidal anti-inflammatory drugs 
(NSAIDs) 
 Currently taking a daily dose of anti-histamine 
 Currently taking long term asthma maintenance medications – 
corticosteroids, and leukotriene modifiers that you could not refrain from 
taking for 4 days prior to laboratory session  
 
If you meet the inclusion criteria and consent to take part you will be required to 
attend Nottingham Trent University on 5 occasions over an 8 week period. You will 
undergo two, three week supplementation conditions with a two week washout. 
The two dietary supplementation interventions are: 
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The two supplementation conditions will consist of: 
• Prebiotic (PRE) – A Daily dose of 5.5g of GOS, and participants will be required to 
consume this as one dose in the morning. This dose of prebiotic has been shown 
previously to be well tolerated by healthy individuals (Bouhnik, et al. 1999) 
• Placebo (PLA) – The placebo will be identical to the prebiotic but will contain the 
equivalent dose of maltodextrin powder to be consumed in the morning. 
Maltodextrin is a food grade carbohydrate but is not selectively fermented by the 
gut bacteria. It looks and tastes identical to GOS 
Both supplements will be identical in appearance and taste; and will be supplied by 
CLASADO Ltd healthcare. Consumption of other pre- and probiotic supplements or 
foods containing them will not be allowed during the study 
Both supplements will be identical in size and appearance. Supplements will be of 
pharmaceutical grade supplied by a reputable manufacturer. 
 
Laboratory Visits: 
Visit one will involve a briefing about the study and familiarisation of the 
measurement techniques to be used during the study. These include pulmonary 
function, fraction of exhaled nitric oxide, and eucapnic voluntary hyperventilation (a 
technique used to diagnose and assess EIB). – EVH is a 6 minute hyperventilation 
challenge that has been shown to elicit a mild but highly diagnostic EIB response 
and is currently the International Olympic Committee-Medical Commissions 
recommended challenge for diagnosing EIB.  
EVH will induce a bronchoconstrictive response in asthmatic and EIB susceptible 
individuals. Asthmatic individuals may experience symptoms of wheezing, 
coughing, tightness in the chest, and slight shortness of breath. These symptoms 
although very unlikely may result in a slight detriment to exercise performance. 
Following the testing protocol, you will be free to use your own prescribed 
medication which should alleviate any remaining symptoms.  
Visit two will be your first pre supplementation baseline. You will have baseline lung 
function and responses to the EVH test measurements taken, and blood sample 
taken, a further blood sample will be taken 24hr after this visit. You be provided 
with your first dietary supplementation for three weeks. 
Visits 3-5 will be the same measurements as above pre and post each 3-week 
supplementation period. You will also be required to complete 2 days of food diaries 
at the beginning of each supplementation period, and weekly asthma symptoms 
and control questionnaires.  
You will be chaperoned at all times during all periods of testing and will be closely 
monitored following all tests. You will be allowed to leave when your pulmonary 
function has returned to baseline values.  
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Each visit will last up to 1.5 hours. Total blood taken per visit will be 80 mL which 
amounts to just over one sixth of a normal blood donation. 
If you are an asthmatic and are eligible to participate in this study we will contact 
your GP to inform them of your participation. Your GP will be sent information 
including a copy of the medical questionnaire to inform them that you are taking 
part in a trial that is assessing your management of exercise induced 
bronchoconstriction Your GP will be asked to contact Mr Neil Williams if they do not 
deem you fit to participate in the study.  
In addition to this, if you report to the study deeming yourself free of asthma and 
are subsequently diagnosed, you will be presented with your results and are 
strongly advised to see your GP and discuss with them what has been assessed, 
but ultimately, it remains a matter for you the patient to correspond and disclose 
this information with your GP. You would be unable to volunteer for the study until 
you have visited your GP and received any subsequent medication to treat your 
asthma.   
 
Contact 
Neil Williams 
Nottingham Trent University 
School of Science and Technology 
Erasmus Darwin, Room 230 
Clifton, Nottingham 
NG11 8NS 
Tel : 0115 8483820 
Email: neil.williams2010@my.ntu.ac.uk 
 
Dr Kirsty Hunter 
Nottingham Trent University 
School of Science and Technology 
Erasmus Darwin, Room 230 
Clifton, Nottingham 
NG11 8NS 
Tel : 0115 8483069 
Email: Kirsty.hunter@ntu.ac.uk  
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Appendix 7 - Chapter 6 Informed Consent Form  
Ethical Application 
 
A2a – Subject Statement of Consent to Participate in the 
Investigation Entitled: 
 
“A randomised, double blind, placebo controlled, study to 
establish the effectiveness of 3 weeks of prebiotic 
supplementation on the management of exercise induced 
bronchoconstriction in physically active healthy individuals.  .” 
 
1)  I, ________________agree to partake as a subject in the above study. 
 
2)  I understand from the participant information sheet, which I have read in full, 
and from my discussion(s) with Neil Williams that this will involve me: 
Attending the sport Science laboratories at NTU Clifton Campus on five 
occasions over a 8-11 week period, with each visit lasting up to 2 hours. I will 
undergo 2 different dietary supplementation conditions, and be required to 
undergo pre and post supplementation period measurements of – Pulmonary 
function, eucapnic voluntary hyperventilation, and fraction of expired nitric 
oxide. I will also be required to provide both urine and blood samples; and 
complete food diaries and asthma symptom questionnaires.  
 
3)  It has also been explained to me by Neil Williams that the risks and side effects 
which may result from my participation are as follows: For asthmatic individuals 
mild bronchoconstriction (symptoms similar to mild asthma) will occur from 
completing the EVH protocol. This will be combated by regular measurements of 
pulmonary function and reversed by taking short acting β2 agonist medication. 
Some discomfort can occur through cannulation although this will be carried out 
by trained members of staff. Some individuals may experience mild 
gastrointestinal discomfort when taken the prebiotic supplement.  
 
4)  I confirm that I have had the opportunity to ask questions about the study and, 
where I have asked questions, these have been answered to my satisfaction. 
 
5)  I undertake to abide by University regulations and the advice of researchers 
regarding safety.  
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6)  I am aware that I can withdraw my consent to participate in the study at any 
time and for any reason, without having to explain my withdrawal. 
 
7) I understand that any personal information regarding me, gained through my 
participation in this study, will be treated as confidential and only handled by 
individuals relevant to the performance of the study and the storing of 
information thereafter.  Where information concerning myself appears within 
published material, my identity will be kept anonymous.  
 
8)  I confirm that I have read the University’s policy relating to the storage and 
subsequent destruction of sensitive information.  I understand that sensitive 
information I have provided through my participation in this study, in the form 
of health and asthma questionnaires, and data relating to the study will be 
handled in accordance with this policy. 
 
9) I understand that as part of this study I will be consuming a supplement. I am 
aware that elite sports people (i.e. international or national standard) may 
undergo either out-of or in-competition (or both) doping tests and appreciate 
that the supplement being studied could be contaminated with a substance that 
appears on the banned lists. 
 
10) I confirm that I have completed the health questionnaire and know of no 
reason, medical or otherwise that would prevent me from partaking in this 
research. 
 
Subject signature: …………………………………………………………………    
Date:_____________ 
 
Independent witness signature: ……………………………………………    
Date:_____________ 
 
Primary Researcher signature: …………………………………………….    
Date:______________ 
 
 
 
 
